Australian guidelines for the clinical care of people with COVID-19
Contact
National COVID-19 Clinical Evidence Taskforce, National Secretariat
Level 4, 553 St Kilda Rd Melbourne VIC 3004 Australia
guidelines@covid19evidence.net.au
+61 3 9903 0381
www.covid19evidence.net.au

Sponsors/Funding
Development of the Australian guidelines for the clinical care of people with COVID-19 is funded by the Australian Government Department of Health, Victorian Government Department of Health and Human Services, the Ian Potter Foundation and the Walter Cottman Endowment Fund, managed by Equity Trustees

Disclaimer
The consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992. As part of the approval process (and for the lifetime of the guidelines), public consultation is required. We welcome your feedback and suggestions. Comments can be submitted via the feedback function under each recommendation in Magic or by emailing guidelines@covid19evidence.net.au.

These clinical guidelines are a general guide to appropriate practice, to be followed subject to the clinician's judgement and the patient's preference in each individual case. The guidelines are not intended to be proscriptive. They are designed to provide information to assist decision making and have been informed by the highest quality evidence available at the time of compilation. Accordingly, the parties involved in the development of these guidelines shall have no liability to any users of the information contained in this publication for any loss or damage, cost or expense incurred or arising from reliance on the information contained in this publication.
Sections

Summary of recommendations .............................................................................................................. 6

1 - Reading Guide ................................................................................................................................. 36

2 - Introduction .................................................................................................................................. 37

3 - Methods and processes ................................................................................................................... 40

4 - Definition of disease severity ...................................................................................................... 41

   4.1 - Definition of disease severity for adults ................................................................................... 42

   4.2 - Definition of disease severity for children and adolescents .................................................. 43

5 - Monitoring and markers of clinical deterioration ....................................................................... 46

   5.1 - Monitoring and markers of clinical deterioration .................................................................... 46

6 - Disease-modifying treatments ...................................................................................................... 47

   6.1 - Corticosteroids ......................................................................................................................... 47

      6.1.1 - Corticosteroids for adults .................................................................................................. 47

      6.1.2 - Corticosteroids for pregnant or breastfeeding women ................................................... 58

      6.1.3 - Corticosteroids for children or adolescents .................................................................... 68

   6.2 - Remdesivir ............................................................................................................................... 79

      6.2.1 - Remdesivir for adults ........................................................................................................ 79

      6.2.2 - Remdesivir for pregnant or breastfeeding women ............................................................ 96

      6.2.3 - Remdesivir for children or adolescents .......................................................................... 105

   6.3 - Hydroxychloroquine ................................................................................................................ 114

   6.4 - Interferon β-1a ......................................................................................................................... 119

   6.5 - Lopinavir-ritonavir ..................................................................................................................... 123

6.6 - Disease-modifying treatments not recommended outside of clinical trials ............................ 128

      6.6.1 - Aprepitant .......................................................................................................................... 129

      6.6.2 - Azithromycin ..................................................................................................................... 135

      6.6.3 - Baloxavir marboxil ............................................................................................................. 143

      6.6.4 - Bromhexine hydrochloride ............................................................................................... 149

      6.6.5 - Calcifediol .......................................................................................................................... 154

      6.6.6 - Chloroquine ....................................................................................................................... 160

      6.6.7 - Colchicine .......................................................................................................................... 167

      6.6.8 - Convalescent plasma ......................................................................................................... 172

      6.6.9 - Darunavir-cobicistat .......................................................................................................... 182

      6.6.10 - Favipiravir ......................................................................................................................... 188

      6.6.11 - Hydroxychloroquine plus azithromycin ......................................................................... 197

      6.6.12 - Human umbilical cord mesenchymal stem cells ............................................................ 204

      6.6.13 - Immunoglobulin plus methylprednisolone .................................................................... 211

      6.6.14 - Interferon β-1b ................................................................................................................ 217

3 of 418
9.2.2 - Positive end-expiratory pressure (PEEP) ........................................................................................................... 346
9.2.3 - Recruitment manoeuvres ........................................................................................................................................ 347
9.2.4 - Neuromuscular blockers ........................................................................................................................................... 348
9.2.5 - High-frequency oscillatory ventilation (HFOV) ........................................................................................................ 352
9.2.6 - Videolaryngoscopy ...................................................................................................................................................... 353
9.2.7 - Extracorporeal membrane oxygenation (ECMO) ..................................................................................................... 357

10 - Venous thromboembolism (VTE) prophylaxis ..................................................................................................................... 359
   10.1 - VTE prophylaxis for adults ........................................................................................................................................... 359
   10.2 - VTE prophylaxis for pregnant and postpartum women .................................................................................................. 363

11 - Therapies for pre-existing conditions in patients with COVID-19 ....................................................................................... 369
   11.1 - ACEIs/ARBs in patients with COVID-19 ......................................................................................................................... 369
   11.2 - ACEIs in postpartum women ......................................................................................................................................... 371
   11.3 - Steroids for people with asthma or COPD with COVID-19 ............................................................................................ 372

12 - Pregnancy and perinatal care .................................................................................................................................................. 375
   12.1 - Antenatal corticosteroids ............................................................................................................................................... 375
   12.2 - Mode of birth ................................................................................................................................................................. 376
   12.3 - Delayed umbilical cord clamping .................................................................................................................................. 378
   12.4 - Skin-to-skin contact ......................................................................................................................................................... 380
   12.5 - Breastfeeding ................................................................................................................................................................. 382
   12.6 - Rooming-in ..................................................................................................................................................................... 387

13 - Child and adolescent care ....................................................................................................................................................... 390
   13.1 - Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) ............................................................................................. 390
       13.1.1 - Intravenous immunoglobulin ..................................................................................................................................... 393
       13.1.2 - Corticosteroids ............................................................................................................................................................ 394
       13.1.3 - Other immunomodulatory agents ............................................................................................................................ 395
       13.1.4 - Aspirin and antithrombotic agents ............................................................................................................................ 396

14 - Abbreviations and Acronyms ............................................................................................................................................... 398
References ....................................................................................................................................................................................... 400
## Summary of recommendations

### 1 - Reading Guide
### 2 - Introduction
### 3 - Methods and processes
### 4 - Definition of disease severity

#### 4.1 - Definition of disease severity for adults

**Consensus recommendation**

| Mild illness | Adults not presenting any clinical features suggestive of moderate or severe disease or a complicated course of illness.  
Characteristics:  
- no symptoms  
- or mild upper respiratory tract symptoms  
- or cough, new myalgia or asthenia without new shortness of breath or a reduction in oxygen saturation |
| Moderate illness | Stable adult patient presenting with respiratory and/or systemic symptoms or signs. Able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs.  
Characteristics:  
- prostration, severe asthenia, fever > 38°C or persistent cough  
- clinical or radiological signs of lung involvement  
- no clinical or laboratory indicators of clinical severity or respiratory impairment |
| Severe illness | Adult patients meeting any of the following criteria:  
- respiratory rate ≥ 30 breaths/min  
- oxygen saturation ≤ 92% at a rest state  
- arterial partial pressure of oxygen (PaO2)/ inspired oxygen fraction (FiO2) ≤ 300 |
| Critical illness | Adult patient meeting any of the following criteria:  
**Respiratory failure**  
- Occurrence of severe respiratory failure (PaO2/FiO2 < 200), respiratory distress or acute respiratory distress syndrome (ARDS). This includes patients deteriorating despite advanced forms of respiratory support (non-invasive ventilation (NIV), high-flow nasal oxygen (HFNO)) OR patients requiring mechanical ventilation.  
OR other signs of significant deterioration  
- hypotension or shock  
- impairment of consciousness  
- other organ failure |

#### 4.2 - Definition of disease severity for children and adolescents
Consensus recommendation

These definitions apply to children under 16 years of age. Depending on the physical size and/or developmental status of the patient, either the paediatric or adult severity grading can be applied.

Cardiorespiratory and vital parameters must be considered within the normal age-appropriate ranges for neonates and children. If criteria fall across different severity classifications, use the more severe classification to manage illness.

<table>
<thead>
<tr>
<th>Illness Level</th>
<th>Feeding / hydration / conscious state</th>
<th>Respiratory / vital signs</th>
<th>Oxygen requirement[^1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild illness</td>
<td>Normal or mildly reduced feeding</td>
<td>No or mild upper respiratory tract symptoms OR No or mild work of breathing</td>
<td>No supplemental oxygen required to maintain SpO₂ &gt; 92%</td>
</tr>
<tr>
<td>Moderate illness</td>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids AND Normal conscious state</td>
<td>Moderate work of breathing OR Abnormal vital signs for age (tachycardia, tachypnoea) but does not persistently breach Early Warning (e.g. Medical Emergency Team) Criteria[^2] OR Brief self-resolving apnoea (infants)</td>
<td>Requires low-flow oxygen (nasal prongs or mask) to maintain SpO₂ &gt; 92%</td>
</tr>
<tr>
<td>Severe illness</td>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids OR Drowsy / tired but easily rousable</td>
<td>Moderate-severe work of breathing OR Abnormal vital signs for age (tachycardia, tachypnoea) with breaches of Early Warning (e.g. MET) Criteria OR Apnoea needing support / stimulation (infants)</td>
<td>Requires high-flow oxygen at 2 L/kg/min[^3] to maintain SpO₂ &gt; 92%</td>
</tr>
<tr>
<td>Critical illness</td>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids OR Altered conscious state / unconscious</td>
<td>Unable to maintain breathing or prevent apnoea without advanced modes of support OR Abnormal vital signs for age with persistent breaches of Early Warning (e.g. MET) Criteria OR Haemodynamically unstable without inotropic or vasopressor support OR Other organ failure</td>
<td>Requires advanced modes of support to maintain oxygenation High-flow nasal oxygen at &gt; 2 L/kg/min[^3] OR Non-invasive ventilation OR Intubation and mechanical ventilation OR Extracorporeal membrane oxygenation (ECMO)</td>
</tr>
</tbody>
</table>

[^1] Oxygen saturation target should be modified for patients with cyanotic heart disease.

[^2] Temperature instability should be considered an abnormal vital sign in infants. Fever is common in children and does not contribute to determination of illness severity in isolation.

[^3] Infants and neonates < 4 kg may be managed on high-flow nasal cannula oxygen at 2-8 L/min irrespective of weight.

Note: co-morbidities (e.g. preterm infants, oncology, immunosuppressed, etc.) may increase the risk of more severe disease.
5 - Monitoring and markers of clinical deterioration

5.1 - Monitoring and markers of clinical deterioration

Consensus recommendation

For people with COVID-19, monitor markers of clinical progression, such as rapidly progressive respiratory failure and sepsis, especially on days 5 to 10 after onset of symptoms.

6 - Disease-modifying treatments

6.1 - Corticosteroids

6.1.1 - Corticosteroids for adults

Recommended

Use dexamethasone 6 mg daily intravenously or orally for up to 10 days (or acceptable alternative regimen) in adults with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

Remark: The suggested regimen of corticosteroid use is 6 mg of dexamethasone (oral or intravenous) daily for up to 10 days.

In patients for whom dexamethasone is not available, acceptable alternative regimens include:

- hydrocortisone: intravenous (50 mg), every 6 hours for up to 10 days
- prednisolone: oral (50 mg), daily for up to 10 days
- methylprednisolone may also be an acceptable alternative, however the most appropriate dosage is uncertain

Conditional recommendation against

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in adults who do not require oxygen.

Remark: Corticosteroids may still be considered for other evidence-based indications in people who have COVID-19.

6.1.2 - Corticosteroids for pregnant or breastfeeding women

Recommended

Use dexamethasone 6 mg daily intravenously or orally for up to 10 days in pregnant or breastfeeding women with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

Remark: The suggested regimen of corticosteroid use is 6 mg of dexamethasone (oral or intravenous) daily for up to 10 days.

In patients for whom dexamethasone is not available, acceptable alternative regimens include:

- hydrocortisone: intravenous (50 mg), every 6 hours for up to 10 days
- prednisolone: oral (50 mg), daily for up to 10 days
Conditional recommendation against

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in pregnant or breastfeeding women who do not require oxygen.

Remark: Antenatal corticosteroids should still be used for fetal lung maturation in pregnant women at risk of preterm birth who also have COVID-19. Dexamethasone and other corticosteroids should still be used for other evidence-based indications in pregnant and breastfeeding women who have COVID-19.

6.1.3 - Corticosteroids for children or adolescents

Conditional recommendation

Consider using dexamethasone daily intravenously or orally for up to 10 days (or acceptable alternative regimen) in children and adolescents with acute COVID-19 who are receiving oxygen (including mechanically ventilated patients).

Remark: A dose of 6 mg daily is recommended in adults. The RECOVERY trial protocol stated a dose of 0.15 mg/kg/day to a maximum of 6 mg/day for children but it is unclear whether any children were included in the trial. If dexamethasone is not available, an acceptable alternative regimen would be:

- hydrocortisone: intravenous or intramuscular 1 mg/kg/dose, every 6 hours for up to 10 days (to a maximum dose of 50 mg every 6 hours)
- methylprednisolone may also be an acceptable alternative, however the most appropriate dosage is uncertain

For specific recommendations on the use of corticosteroids for PIMS-TS see section.

Conditional recommendation against

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in children or adolescents who do not require oxygen.

Remark: Dexamethasone and other corticosteroids should still be used for other evidence-based indications in children or adolescents who have COVID-19.

For specific recommendations on the use of corticosteroids for PIMS-TS see section.

6.2 - Remdesivir

6.2.1 - Remdesivir for adults
Conditional recommendation

Consider using remdesivir for adults hospitalised with COVID-19 who require oxygen but not ventilation.

Remark: The recommended regimen is daily intravenous infusion (200 mg initial dose, 100 mg maintenance), optimal duration of remdesivir treatment is unclear, however current evidence does not suggest a clear benefit of 10 days over 5 days.

It is unclear whether remdesivir increases or decreases mortality in patients who are hospitalised with COVID-19 and who do not require oxygen. For this population, remdesivir should still be considered for use in randomised trials with appropriate ethical approval.

On 31 July, the Australian Government provided specific criteria that needed to be met in order to access remdesivir for clinical treatment. These included age ≥ 18 years (or 12 to 17 years weighing ≥ 40 kg), an oxygen saturation of SpO2 ≤ 92% on room air and requiring supplemental oxygen, and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) and/or ALT < 3 x ULN and bilirubin < 2 ULN. Patients with evidence of multiorgan failure, renal failure or those receiving mechanical ventilation for > 48 hours at time of application or extracorporeal membrane oxygenation (ECMO) are unable to receive remdesivir.

It is unclear whether older people or those requiring palliative care were included in the studies this recommendation is based on. Until further evidence in these populations is available, the Taskforce does not believe a different recommendation should apply, unless contraindicated.

Due to antagonism observed in vitro, co-administration of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].

Not recommended

Do not start remdesivir in adults hospitalised with COVID-19 who require ventilation.

Remark: Remdesivir should be continued with the appropriate dose and duration, if it was started prior to requiring ventilation.

Within this population, ventilation includes invasive or non-invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO).

Use of remdesivir may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include remdesivir.

6.2.2 - Remdesivir for pregnant or breastfeeding women
Conditional recommendation against

Use of remdesivir for pregnant or breastfeeding women with COVID-19 outside of a trial setting should not be considered routinely.

Remark: As pregnant and breastfeeding women are often excluded from clinical trials, use of remdesivir in this population would be outside a clinical trial setting. Pregnant and breastfeeding women receiving remdesivir should nonetheless be enrolled in national COVID-19 registries. Currently, there is no direct evidence of the effects of remdesivir in pregnant and breastfeeding women.

Due to antagonism observed in vitro, concomitant use of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].

The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMoa2007764). These studies are currently under review by the Pregnancy and Perinatal Care panel and an updated recommendation will be included in a future version of the guideline.

6.2.3 - Remdesivir for children or adolescents

Conditional recommendation against

Use of remdesivir for children or adolescents with COVID-19 outside of a trial setting should not be considered routinely.

Remark: If treatment is considered—in exceptional circumstances—it should be in consultation with a clinical reference group, such as the ANZPID COVID-19 Clinical Reference Group. Informed consent from parents/caregivers should also be obtained. Currently, there is no direct evidence for the use of remdesivir in children or adolescents. Information about the patients and the intervention (dosages, duration) in the trials used for this recommendation can be found in the Practical info tab.

Due to antagonism observed in vitro, concomitant use of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].

The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMoa2007764). These studies are currently under review by the Paediatric and Adolescent Care panel and an updated recommendation will be included in a future version of the guideline.

6.3 - Hydroxychloroquine

Not recommended

Do not use hydroxychloroquine for the treatment of COVID-19.

Remark: This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care.

Use of hydroxychloroquine may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include hydroxychloroquine.

6.4 - Interferon β-1a
6.5 - Lopinavir-ritonavir

Not recommended


Remark: This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care.

Use of lopinavir-ritonavir may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include lopinavir-ritonavir.

6.6 - Disease-modifying treatments not recommended outside of clinical trials

6.6.1 - Aprepitant

Not recommended

Do not use aprepitant for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Aprepitant should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use aprepitant to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.2 - Azithromycin

Not recommended

Do not use azithromycin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Azithromycin should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use azithromycin to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.
6.6.3 - Baloxavir marboxil

Not recommended

Do not use baloxavir marboxil for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Baloxavir marboxil should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use baloxavir marboxil to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.4 - Bromhexine hydrochloride

Not recommended

Do not use bromhexine hydrochloride for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Bromhexine hydrochloride should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use bromhexine hydrochloride for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.5 - Calcifediol

Not recommended

Do not use calcifediol for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Calcifediol should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use calcifediol to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.6 - Chloroquine
Not recommended

Do not use chloroquine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Chloroquine should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use chloroquine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.7 - Colchicine

Not recommended

Do not use colchicine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Colchicine should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use colchicine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.8 - Convalescent plasma

Not recommended

Do not use convalescent plasma for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use convalescent plasma to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.9 - Darunavir-cobicistat

Not recommended

Do not use darunavir-cobicistat for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Darunavir-cobicistat should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use darunavir-cobicistat to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.10 - Favipiravir
Not recommended

Do not use favipiravir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Favipiravir should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use favipiravir to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.11 - Hydroxychloroquine plus azithromycin

Not recommended

Do not use hydroxychloroquine plus azithromycin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Hydroxychloroquine plus azithromycin should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine plus azithromycin for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.12 - Human umbilical cord mesenchymal stem cells

Not recommended

Do not use human umbilical cord mesenchymal stem cells for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Human umbilical cord mesenchymal stem cells should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use human umbilical cord mesenchymal stem cells (hUC-MSCs) to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.13 - Immunoglobulin plus methylprednisolone
Not recommended

Do not use immunoglobulin plus methylprednisolone for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Immunoglobulin plus methylprednisolone should still be considered for other evidence-based indications in people who have COVID-19.

This recommendation does not apply to the use of immunoglobulin plus methylprednisolone in children and adolescents when managing PIMS-TS, Kawasaki disease or toxic shock syndrome related to COVID-19 (see section for specific guidance). The Taskforce is currently developing recommendations for the management of these conditions in children and adolescents with COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use combination immunoglobulin plus methylprednisolone to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.14 - Interferon β-1b

Not recommended

Do not use interferon β-1b for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Interferon β-1b should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use interferon β-1b to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.15 - Interferon gamma

Not recommended

Do not use interferon gamma for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Interferon gamma should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use interferon gamma to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.16 - Interferon kappa plus trefoil factor 2 (IFN-κ plus TFF2)
Not recommended

Do not use IFN-κ plus TFF2 for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: IFN-κ plus TFF2 should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use IFN-κ plus TFF2 to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.17 - Ivermectin

Not recommended

Do not use ivermectin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Ivermectin should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use ivermectin to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.18 - N-acetylcysteine

Not recommended

Do not use N-acetylcysteine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: N-acetylcysteine should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use N-acetylcysteine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.19 - Recombinant human granulocyte colony-stimulating factor (rhG-CSF)

Not recommended

Do not use rhG-CSF for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Recombinant human granulocyte colony-stimulating factor should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use rhG-CSF to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.
6.6.20 - Ruxolitinib

Not recommended

Do not use ruxolitinib for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Ruxolitinib should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use ruxolitinib to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.21 - Sofosbuvir-daclatasvir

Not recommended

Do not use sofosbuvir-daclatasvir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Sofosbuvir-daclatasvir should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use sofosbuvir plus daclatasvir to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.22 - Telmisartan

Not recommended

Do not use telmisartan for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Telmisartan should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use telmisartan to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.23 - Tocilizumab
Not recommended

Do not use tocilizumab for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Tocilizumab should still be considered for other evidence-based indications in people who have COVID-19.

This recommendation does not apply to the use of tocilizumab in children and adolescents when managing paediatric inflammatory multisystem syndrome (PIMS-TS), Kawasaki disease or toxic shock syndrome related to COVID-19. The Taskforce is currently developing recommendations for the management of these conditions in children and adolescents with COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use tocilizumab for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.24 - Triazavirin

Not recommended

Do not use triazavirin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Triazavirin should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use triazavirin for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.25 - Umifenovir

Not recommended

Do not use umifenovir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Remark: Umifenovir should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use umifenovir for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

6.6.26 - Other disease-modifying treatments
Consensus recommendation

For people with COVID-19, do not use other disease-modifying treatments outside of randomised trials with appropriate ethical approval.

Remark: Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use other disease-modifying treatments in these populations unless they are eligible to be enrolled in trials.

6.7 - Disease-modifying treatments under review

6.7.1 - Immunoglobulin

7 - Chemoprophylaxis

7.1 - Hydroxychloroquine for pre-exposure prophylaxis

Not recommended

For healthcare workers with no active COVID-19, do not use hydroxychloroquine for pre-exposure prophylaxis outside of randomised trials with appropriate ethical approval.

Remark: Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine for pre-exposure prophylaxis in these populations unless they are eligible to be enrolled in trials.

7.2 - Hydroxychloroquine for post-exposure prophylaxis

Not recommended

For people exposed to individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, do not use hydroxychloroquine for post-exposure prophylaxis outside of randomised trials with appropriate ethical approval.

Remark: Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine for post-exposure prophylaxis in these populations unless they are eligible to be enrolled in trials.

8 - Respiratory support in adults
Consensus recommendation

Guiding principles of care
For patients with COVID-19 for whom respiratory support (HFNO/NIV) is being considered, decisions should balance likelihood of patient benefit against the risk of infection for healthcare workers. For patients with COVID-19 receiving respiratory support (HFNO/NIV) or requiring intubation, use single rooms or negative pressure rooms wherever possible and ensure contact, droplet and airborne precautions are in place. Closed circuit NIV should be used.

Remark: The relative risk of infection to healthcare workers associated with specific oxygen therapies remains uncertain and may vary from site to site.

8.1 - High-flow nasal oxygen therapy

Info Box
High-flow nasal oxygen (HFNO) therapy is a form of respiratory support where oxygen is delivered, often in conjunction with compressed air and humidification. It delivers high flow oxygen via large diameter nasal cannula that is humidified and heated. Flow rates can be given up to 60 L/min with an oxygen/air blender supplying oxygen at 21-100%.

High-flow humidified oxygen should be considered when unable to maintain \( \text{SaO}_2 \geq 92\% \) despite conventional oxygen delivery at > 6 L/min or an \( \text{FiO}_2 = 0.4 \).

Conditional recommendation
Consider using HFNO therapy for patients with hypoxaemia associated with COVID-19, ensuring it is used with caution and strict attention is paid to staff safety including the use of appropriate personal protective equipment (PPE). If HFNO is being used, ideally this should be in a negative pressure room. If none is available, other alternatives are single rooms, or shared ward spaces with cohorting of confirmed COVID-19 patients only.

Remark: Use the lowest flow necessary to maintain oxygen saturation \( \geq 92\% \).

Not recommended
Do not use HFNO therapy for patients with hypoxaemia associated with COVID-19 in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval.

8.2 - Non-invasive ventilation

Info Box
Non-invasive ventilation (NIV), also known as non-invasive positive pressure ventilation (NIPPV) or bilevel positive pressure support (BiPAP), is a form of respiratory support. Bilevel positive pressure is delivered throughout the respiratory cycle by a firm-fitting nasal-face mask. The patient breathes spontaneously and triggers the device to cycle.

A higher level of pressure is provided during the inspiratory phase to enhance ventilation, while a lower level of continuous positive pressure is delivered during the expiratory phase (also known as positive end-expiratory pressure or PEEP). Supplemental oxygen can also be delivered through the device.

Conditional recommendation
Consider using NIV therapy for patients with hypoxaemia associated with COVID-19, ensuring it is used with caution and strict attention is paid to staff safety including the use of appropriate personal protective equipment (PPE). If NIV is being used, ideally this should be in a negative pressure room. If none is available, other alternatives are single rooms, or shared ward spaces with cohorting of confirmed COVID-19 patients only.
Not recommended

Do not use NIV therapy for patients with hypoxaemia associated with COVID-19 in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval.

Conditional recommendation

In patients with COVID-19 for whom NIV is appropriate for an alternate clinical presentation (e.g. concomitant chronic obstructive pulmonary disease (COPD) with type 2 respiratory failure and hypercapnia, acute pulmonary oedema), ensure airborne and other infection control precautions are optimised.

8.3 - Respiratory management of the deteriorating patient

Consensus recommendation

Do not delay endotracheal intubation and mechanical ventilation in patients with COVID-19 who are deteriorating despite optimised, less invasive respiratory therapies.

Remark: Patients can deteriorate rapidly 5 to 10 days after onset of symptoms.

The net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

8.4 - Videolaryngoscopy

Conditional recommendation

In adults with COVID-19 undergoing endotracheal intubation, consider using videolaryngoscopy over direct laryngoscopy if available and the operator is trained in its use.

8.5 - Neuromuscular blockers

Info Box

Neuromuscular blocking agents (NMBAs) are a pharmaceutical intervention that may facilitate protective lung ventilation in patients who are mechanically ventilated with moderate to severe acute respiratory distress syndrome (ARDS). NMBAs may reduce patient-ventilator dyssynchrony and facilitate improved oxygenation by various mechanisms, including reducing the inspiratory muscle effort and the work of breathing, and reducing ventilator-induced lung injury.

Conditional recommendation against

For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, do not routinely use continuous infusions of neuromuscular blocking agents (NMBAs).

Remark: However, if protective lung ventilation cannot be achieved, consider using NMBAs for up to 48 hours. If indicated, consider cisatracurium as first-line agent, if cisatracurium is not available alternatives include atracurium or vecuronium by infusion.
8.6 - Positive end-expiratory pressure

Consensus recommendation

For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, consider using a higher PEEP strategy (PEEP > 10 cm H2O) over a lower PEEP strategy.

8.7 - Prone positioning

Info Box

Positioning the patient in a face-down (prone) position may help to open up (recruit) collapsed alveoli and improve oxygen levels in the blood.

8.7.1 - Prone positioning for adults

Consensus recommendation

For mechanically ventilated adults with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning for more than 12 hours a day.

Remark: Current reports suggest prone ventilation is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

Net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

Consensus recommendation

For adults with COVID-19 and respiratory symptoms who are receiving any form of supplemental oxygen therapy and have not yet been intubated, consider prone positioning for at least 3 hours per day as tolerated. When positioning a patient in prone, ensure it is used with caution and accompanied by close monitoring of the patient. Use of prone positioning should not delay endotracheal intubation and mechanical ventilation in patients with COVID-19 who are deteriorating despite optimised less invasive respiratory therapies.

Remark: Vulnerable people who are treated outside the ICU, for example people who are older and living with frailty, cognitive impairment or unable to communicate, may particularly be at increased risk of harm from proning. Despite the potential risks of awake proning associated with frailty, there may be benefits for this group. The net clinical benefit for each individual patient should be considered on a case-by-case basis.

Currently, there is limited evidence to suggest prone positioning could be effective in improving oxygenation in patients with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events.

8.7.2 - Prone positioning for pregnant and postpartum women
Consensus recommendation

For mechanically ventilated pregnant women with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning for more than 12 hours a day.

Remark: Current reports suggest prone ventilation in adult patients is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff, and that minimises the risk of adverse events, e.g. accidental extubation.

Proning of a pregnant woman should avoid abdominal compression and ensure a woman's hips and chest are supported. In the absence of specialised equipment, proning can be performed using pillows and blankets.

Proning can be challenging in late gestation and delivery of the baby may be warranted.

Consensus recommendation

For pregnant and postpartum women with COVID-19 and respiratory symptoms who are receiving any form of supplemental oxygen therapy and have not yet been intubated, consider prone positioning. When positioning a pregnant woman in prone, care should be taken to support the gravid uterus to reduce aorta-caval compression. Women who are deteriorating should be considered for early endotracheal intubation and invasive mechanical ventilation. Birth of the baby should be considered when it may enhance maternal resuscitation or be beneficial to the fetus.

Remark: Current reports suggest prone ventilation in adult patients is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

Proning of a pregnant woman should avoid abdominal compression and ensure a woman's hips and chest are supported. In the absence of specialised equipment, it can be performed using pillows and blankets.

Proning can be challenging in late gestation and delivery of the baby may be warranted.

8.8 - Recruitment manoeuvres

Info Box

Patients receiving respiratory support are at an increased risk of lung injury. Recruitment manoeuvres are used to open up ('recruit') collapsed alveoli and are a common element of an 'open lung approach' to protect the lungs during mechanical ventilation. The manoeuvres use a sustained increase in airway pressure to re-open collapsed alveoli.

Types of manoeuvres include: prolonged high continuous positive airway pressure; progressive incremental increases in positive end-expiratory pressure at a constant driving pressure (incremental PEEP, stepwise or staircase); and high driving pressures.

Consensus recommendation

For mechanically ventilated adults with COVID-19 and hypoxaemia despite optimising ventilation, consider using recruitment manoeuvres.

If recruitment manoeuvres are used, do not use staircase or stepwise (incremental PEEP) recruitment manoeuvres.

8.9 - Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO) is a form of life support that removes blood from the body via large cannulae, oxygenates and removes carbon dioxide from the blood external to the patient, and then returns the blood to the body.

Venovenous (VV) ECMO provides oxygenation support for the lungs only, while venoarterial (VA) ECMO supports the heart and lungs.

8.9.1 - ECMO for adults

Conditional recommendation

Consider early referral to an ECMO centre for patients developing refractory respiratory failure in mechanically ventilated adults with COVID-19 (despite optimising ventilation, including proning and neuromuscular blockers).

Remark: Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected patients with COVID-19 and severe ARDS.

Net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

8.9.2 - ECMO for pregnant and postpartum women

Consensus recommendation

Consider referral to an ECMO centre for venovenous ECMO in mechanically ventilated pregnant women with COVID-19 and refractory respiratory failure (despite optimising ventilation, including proning). Delivery of the baby prior to ECMO to enhance maternal resuscitation should be considered on a case-by-case basis.

Remark: Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected pregnant women with COVID-19 and severe ARDS.

The decision on whether to use ECMO should be taken in consultation with the woman's family, as well as obstetric and intensive care specialists. Key considerations include gestational age, fetal viability, fetal well-being and the risks and benefits to mother and baby.

Early referral to an ECMO centre is preferred.

As pregnant and postpartum women may have haemostatic alterations, anticoagulation regimens may need to be modified appropriately.

9 - Respiratory support in neonates, children and adolescents

9.1 - Requiring non-invasive respiratory support
9.1.1 - High-flow nasal oxygen and non-invasive ventilation

**Info Box**

*High-flow nasal oxygen* (HFNO) therapy is a form of respiratory support where warmed, humidified oxygen is delivered at high-flow rates.

*Non-invasive ventilation* (NIV) refers to any type of positive pressure support delivered without an endotracheal tube during spontaneous breathing. Supplemental oxygen can also be delivered through the device.

HFNO or NIV should be considered when low-flow oxygen is unable to maintain target peripheral oxygen saturation and/or to treat respiratory distress. Target peripheral oxygen saturations may vary in neonates, children and adolescents with co-morbid conditions, such as preterm birth, cyanotic congenital heart disease or chronic lung disease.

**Consensus recommendation**

Consider using high-flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) therapy for neonates, children and adolescents with hypoxaemia or respiratory distress associated with COVID-19 and not responding to low-flow oxygen. Use it with caution and pay strict attention to staff safety, including the use of appropriate PPE.

Remark: The preferred location for high-flow nasal oxygen is a negative pressure room or a single room with the door closed. If these locations are not immediately available then HFNO or NIV should not be withheld if indicated. However, it should be recognised that this therapy may pose an aerosol risk to staff and other patients, and appropriate precautions should be used.

In children and adolescents with COVID-19 for whom HFNO or NIV is appropriate for an alternate clinical presentation (e.g. concomitant bronchiolitis or severe asthma), ensure airborne and other infection control precautions are also optimised.

Consider early transfer in the deteriorating neonate, child or adolescent to a specialised paediatric or neonatal critical care unit.

9.1.2 - Prone positioning (non-invasive)

**Consensus recommendation**

For neonates, children and adolescents with COVID-19 and respiratory symptoms who are receiving non-invasive respiratory support, consider prone positioning if patient co-operation is possible. When positioning a patient prone, ensure it is used with caution and close monitoring of the patient.

9.1.3 - Respiratory management of the deteriorating child

**Consensus recommendation**

Consider endotracheal intubation and mechanical ventilation in neonates, children and adolescents with COVID-19 who are deteriorating despite optimised, non-invasive respiratory support.

9.2 - Requiring invasive mechanical ventilation

9.2.1 - Prone positioning (mechanical ventilation)
Consensus recommendation

For mechanically ventilated neonates, children and adolescents with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning if there are no contraindications.

9.2.2 - Positive end-expiratory pressure (PEEP)

Consensus recommendation

For mechanically ventilated neonates, children and adolescents with COVID-19 and moderate to severe ARDS with atelectasis, consider using a higher PEEP strategy over a lower PEEP strategy. The absolute PEEP values that constitute a high and low PEEP strategy will depend on age and patient size.

9.2.3 - Recruitment manoeuvres

Info Box

Neonates, children and adolescents receiving respiratory support are at an increased risk of lung injury. Recruitment manoeuvres are used to open up ('recruit') collapsed alveoli and are a common element of an 'open lung approach' to protect the lungs during mechanical ventilation. The manoeuvres use a sustained increase in airway pressure to re-open collapsed alveoli.

Types of manoeuvres include: prolonged high continuous positive airway pressure; progressive incremental increases in positive end-expiratory pressure at a constant driving pressure, or the use of escalating mean airway pressure during high-frequency oscillatory ventilation (incremental PEEP, stepwise or staircase); and high driving pressures.

Consensus recommendation

For mechanically ventilated neonates, children and adolescents with COVID-19 and hypoxic respiratory failure characterised by severe atelectasis unresponsive to other ventilation strategies, consider using recruitment manoeuvres.

Remark: In neonates and infants, staircase or stepwise incremental recruitment manoeuvres should only be performed using mean airway pressure in a high-frequency oscillatory ventilation mode. Staircase or stepwise (incremental PEEP) recruitment manoeuvres should not be performed during conventional ventilation.

9.2.4 - Neuromuscular blockers

Conditional recommendation against

For intubated neonates, children and adolescents with COVID-19, do not routinely use continuous infusions of neuromuscular blocking agents (NMBAs).

However, if effective lung-protective ventilation cannot be achieved, consider targeted intermittent use of NMBAs. If indicated, the choice of NMBA should be guided by the age group and regional practice.

9.2.5 - High-frequency oscillatory ventilation (HFOV)
Info Box

High-frequency oscillatory ventilation (HFOV) is a specialised mode of respiratory support via an endotracheal tube that delivers very small tidal volumes at a rate much faster than normal breathing rates (> 2 Hz). It is used as a rescue therapy in neonates and children for severe respiratory failure when conventional mechanical ventilation is not effective. In neonates with severe respiratory failure, HFOV reduces need for ECMO. HFOV requires specialist equipment, and nursing and medical expertise.

Consensus recommendation

Do not routinely use HFOV as a first line mode of mechanical ventilation in neonates, children and adolescents with severe COVID-19. HFOV should be limited to a rescue therapy in neonates and children not responding to conventional mechanical ventilation in a specialist centre with experience with HFOV.

HFOV delivers gas at very high flow rates. This may increase the aerosol-generating potential compared to other forms of respiratory support used in intensive care. This may limit the suitability of HFOV in patients with COVID-19 unless strict attention to staff safety and infection control measures can be applied.

9.2.6 - Videolaryngoscopy

Conditional recommendation

In neonates, children and adolescents with COVID-19 undergoing endotracheal intubation, consider using videolaryngoscopy over direct laryngoscopy if available and the operator is trained in its use.

9.2.7 - Extracorporeal membrane oxygenation (ECMO)

Consensus recommendation

Consider early referral to an ECMO centre for venovenous or venoarterial ECMO in mechanically ventilated neonates, children and adolescents with COVID-19 with refractory respiratory or cardiovascular failure despite optimising other critical care interventions.

Remark: Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected neonates, children and adolescents with severe or critical COVID-19 and no contraindications for ECMO, such as severe, irreversible organ dysfunction.

The decision on whether to use ECMO should be taken in consultation with the child's family. Key considerations include pre-existing conditions and the suitability of anticoagulation.

Early referral to an ECMO centre is preferred.

10 - Venous thromboembolism (VTE) prophylaxis

10.1 - VTE prophylaxis for adults
Consensus recommendation

Use prophylactic doses of anticoagulants, preferably low molecular weight heparin (LMWH) (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) in adults with moderate COVID-19 or other indications, unless there is a contraindication, such as risk for major bleeding. Where the estimated glomerular filtration rate (eGFR) (see below) is less than 30 mL/min/1.73m2, unfractionated heparin or clearance-adjusted doses of LMWH may be used (e.g. enoxaparin 20 mg once daily or dalteparin 2500 IU once daily).

Remark: For body weights outside 50-90 kg or heights outside 150-180 cm, calculate the body surface area (BSA) and multiply the eGFR by BSA/1.73.

The Taskforce notes that in critical illness, creatinine-based estimation of kidney function can be unreliable.

Consensus recommendation

Consider using increased prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg twice daily or dalteparin 5000 IU twice daily) in adults with severe or critical COVID-19 or other indications, unless there is a contraindication, such as risk for major bleeding or platelet count \(< 30 \times 10^9/L\). Where eGFR (see below) is less than 30 mL/min/1.73m2, unfractionated heparin or clearance-adjusted doses of LMWH may be used (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily).

Remark: For body weights outside 50-90 kg or heights outside 150-180 cm, calculate the BSA and multiply the eGFR by BSA/1.73.

The Taskforce notes that in critical illness, creatinine-based estimation of kidney function can be unreliable.

10.2 - VTE prophylaxis for pregnant and postpartum women

Info Box

Pregnant women in general are at an increased risk of venous thromboembolism (VTE). Hospitalised pregnant women with an acute infective illness (such as COVID-19) are at even greater risk of VTE. However, the exact duration of increased risk of VTE in association with COVID-19 infection is not yet established.

All pregnant and postpartum women should undergo a documented assessment of risk factors for VTE on admission to hospital, if COVID-19 is diagnosed, if COVID-19 severity changes and postpartum.

The use of pharmacological prophylaxis in women should be accompanied by other measures to prevent VTE, such as anti-embolism stockings and sequential compression devices.
Consensus recommendation

For pregnant or postpartum women who are admitted to hospital (for any indication) and who have COVID-19, use prophylactic doses of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding or imminent birth.

Prophylactic anticoagulants should be continued for at least 14 days after discharge or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

Remark:
- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function.
- For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.

Consensus recommendation

For pregnant women with severe or critical COVID-19, or where there are additional risk factors for VTE, consider using increased prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg twice daily or dalteparin 5000 IU twice daily) unless there is a contraindication, such as risk for major bleeding or platelet count < 30 x 10⁹/L.

Prophylactic anticoagulants should be continued for at least four weeks after discharge or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

Remark:
- Dosing is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
- Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
- In some situations, continuation of LMWH throughout the rest of pregnancy and postpartum may be required. Involvement of specialist obstetricians, obstetric medicine physicians, haematologists or other physicians with expertise in VTE in pregnant women would be warranted.

Consensus recommendation

For pregnant or postpartum women who are self-isolating at home with mild COVID-19 and where additional risk factors for VTE are present, consider using prophylactic doses of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding or imminent birth. Prophylactic anticoagulants should be continued for at least 14 days or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

For pregnant or postpartum women who are self-isolating at home with mild COVID-19 and who have no additional risk factors for VTE, routine pharmacological prophylaxis is not recommended.

Remark:
- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
- Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
Consensus recommendation

For postpartum women who have had COVID-19 during pregnancy, consider using at least 14 days of prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding. Increased duration of six weeks should be considered if severe or critical COVID-19 and/or additional risk factors for VTE are present.

Remark:
- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
- Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.

11 - Therapies for pre-existing conditions in patients with COVID-19

11.1 - ACEIs/ARBs in patients with COVID-19

Recommended

In patients with COVID-19 who are receiving ACEIs/ARBs, there is currently no evidence to deviate from usual care and these medications should be continued unless contraindicated.

Remark: Stopping these medications abruptly can lead to acute heart failure or unstable blood pressure.

11.2 - ACEIs in postpartum women

Consensus recommendation

In postpartum women with COVID-19 who have hypertension requiring treatment with ACE inhibitors, there is currently no evidence to deviate from usual care. These medications should be initiated or continued unless otherwise contraindicated.

Remark: ACE inhibitors are contraindicated in the antenatal period due to risk of fetal and neonatal harm.

11.3 - Steroids for people with asthma or COPD with COVID-19

Consensus recommendation

Use inhaled or oral steroids for the management of people with co-existing asthma or chronic obstructive pulmonary disease (COPD) and COVID-19 as you would normally for viral exacerbation of asthma or COPD. Do not use a nebuliser.

12 - Pregnancy and perinatal care
Info Box

For recommendations on disease modifying treatments, chemoprophylaxis, venous thromboembolism (VTE) prophylaxis and respiratory support in pregnant or breastfeeding women, and ACE inhibitors in postpartum women, please see sections above. We are continually working on updating all recommendations to reflect special populations, including pregnant and breastfeeding women.

12.1 - Antenatal corticosteroids

Consensus recommendation

The use of antenatal corticosteroids for women at risk of preterm birth is supported as part of standard care, independent of the presence of COVID-19.

Remark: There are clear benefits to using antenatal corticosteroids for women at risk of preterm birth at less than 34 weeks gestation. There is currently no evidence to suggest that antenatal corticosteroids cause additional maternal or fetal harm in the setting of COVID-19 when used for this indication. They should therefore be given where indicated.

The Taskforce has separate recommendations regarding the use of dexamethasone as a disease-modifying treatment in pregnant or breastfeeding women for COVID-19. Women with COVID-19 who are on oxygen and receiving dexamethasone do not require additional doses of corticosteroids for fetal lung maturation.

12.2 - Mode of birth

Conditional recommendation

For pregnant women with COVID-19, mode of birth should remain as per usual care.

Remark: There is currently no evidence to indicate that caesarean section for women with COVID-19 reduces the risk of vertical transmission to the newborn. Mode of birth should continue as per usual care. Respiratory deterioration due to COVID-19 may prompt urgent delivery on an individual basis.

12.3 - Delayed umbilical cord clamping

Consensus recommendation

Delayed umbilical cord clamping is supported as part of standard care, independent of the presence of COVID-19.

Remark: There is currently no evidence that delayed umbilical cord clamping affects the risk of vertical transmission of COVID-19.

12.4 - Skin-to-skin contact

Consensus recommendation

Early skin-to-skin contact after birth and during the postnatal period is supported, irrespective of the presence of COVID-19. However, parents with COVID-19 should use infection prevention and control measures (mask and hand hygiene).

Remark: Early skin-to-skin contact refers to placing the naked baby prone on the parent’s bare chest immediately after birth.

Skin-to-skin contact should be encouraged and continue as per usual practice in other postnatal and neonatal settings, such as neonatal ICU and postnatal wards, providing infection prevention and control measures are maintained.
**12.5 - Breastfeeding**

Conditional recommendation

Breastfeeding is supported irrespective of the presence of COVID-19. However, women with COVID-19 who are breastfeeding should use infection prevention and control measures (mask and hand hygiene) while infectious.

Remark: There is currently no evidence to indicate that breastfeeding increases the risk of vertical transmission to the newborn. As there are substantial known benefits for breastfeeding, women should be supported to initiate or continue breastfeeding. If the baby is being fed with expressed breastmilk or formula, these same infection prevention and control measures should be used.

**12.6 - Rooming-in**

Conditional recommendation

For women with COVID-19 who have given birth, support rooming-in of mother and newborn in the birth suite and on the postnatal ward when both mother and baby are well. However, women with COVID-19 should use infection prevention and control measures (mask and hand hygiene).

Remark: There is currently no evidence to indicate that a woman with a known COVID-19 infection should be separated from her newborn to prevent transmission. As there are substantial known benefits for keeping mother and newborn together postpartum, women should be supported to be with their newborn as per usual care.

Women with COVID-19 should be encouraged and supported in using good hand hygiene before and after handling their baby, and using a mask while in close contact with their baby. To the extent possible, these women should practice physical distancing when not feeding or caring for the baby.

**13 - Child and adolescent care**

Info Box

For recommendations on disease-modifying treatments, chemoprophylaxis and respiratory support in children and adolescents please see sections above. We are continually working on updating all recommendations to reflect special populations, including children and adolescents.

**13.1 - Paediatric Inflammatory Multisystem Syndrome (PIMS-TS)**
The Taskforce endorses the PIMS-TS case definition from the Royal College of Paediatrics and Child Health (United Kingdom) [300].

1. A child presenting with persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP) and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features*. This may include children fulfilling full or partial criteria for Kawasaki disease.

2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).

3. SARS-CoV-2 PCR testing may be positive or negative. All stable children should be discussed as soon as possible with specialist services to ensure prompt treatment (paediatric infectious disease / cardiology / rheumatology). There should be a low threshold for referral to paediatric intensive care using normal pathways.

* Additional features include:

**Clinical**
- All: persistent fever > 38.5°C
- Most: oxygen requirement, hypotension
- Some: abdominal pain, confusion, conjunctivitis, cough, diarrhoea, headache, lymphadenopathy, mucus membrane changes, neck swelling, rash, respiratory symptoms, sore throat, swollen hands and feet, syncope, vomiting

**Imaging and electrocardiogram (ECG)**
- Echocardiogram and ECG: myocarditis, valvulitis, pericardial effusion, coronary artery dilatation
- Chest x-ray: patchy symmetrical infiltrates, pleural effusion
- Abdominal ultrasound scan: colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly
- Computed tomography (CT) chest: as for chest x-ray—may demonstrate coronary artery abnormalities if with contrast

**Laboratory**
- All: abnormal fibrinogen, absence of potential causative organisms (other than SARS-CoV-2), high CRP, high D-dimers, high ferritin, hypoalbuminaemia, lymphopaenia, neutrophilia in most – normal neutrophils in some
- Some: acute kidney injury, anaemia, coagulopathy, high IL-10 (if available)**, high IL-6 (if available)**, neutrophilia, proteinuria, raised creatine kinase (CK), raised lactic acid dehydrogenase (LDH), raised triglycerides, raised troponin, thrombocytopenia, transaminitis

**These assays are not widely available. CRP can be used as a surrogate marker for IL-6.

**Consensus recommendation**

Children and adolescents who have suspected or confirmed PIMS-TS should be managed by and discussed with a multidisciplinary team. Because of the potential for rapid deterioration, early consultation with experts and consideration of early transfer to a paediatric hospital with intensive care facilities to manage children are recommended for patients with suspected or confirmed PIMS-TS.

**13.1.1 - Intravenous immunoglobulin**

Consensus recommendation

Consider using intravenous immunoglobulin (2 g/kg per dose) in children and adolescents who meet PIMS-TS criteria or have features of Kawasaki disease related to COVID-19.
13.1.2 - Corticosteroids

Consensus recommendation

Consider using corticosteroids (irrespective of oxygen status) as a second-line agent or as adjuvant therapy for children and adolescents diagnosed with PIMS-TS.

Remark: Intravenous corticosteroids should be considered as the next treatment option for children who remain unwell (tachycardia, need for vasoactive support) 24 hours after infusion of intravenous immunoglobulin, particularly if they have ongoing pyrexia.

In certain cases, Intravenous corticosteroids may be indicated as a first-line option in combination with intravenous immunoglobulin.

13.1.3 - Other immunomodulatory agents

Consensus recommendation

Additional immunomodulatory agents for PIMS-TS (anti IL-1, anti IL-6 or anti-TNF) should be considered as a third-line option in children and adolescents with PIMS-TS who do not respond to intravenous immunoglobulin and corticosteroids.

Remark: Before initiating additional immunomodulatory therapies, all PIMS-TS patients need to be discussed with a multidisciplinary team and interventions carefully considered. Immunomodulatory agents previously used that have an acceptable risk/benefit ratio include:

- Anakinra (IL-1 receptor antagonist)
- Infliximab (TNF inhibitor)
- Tocilizumab (IL-6 receptor antagonist)

Consider testing for infections that may be unmasked by the use of these agents.

13.1.4 - Aspirin and antithrombotic agents

Consensus recommendation

Children who are treated for PIMS-TS with intravenous immunoglobulin or other agents should also be prescribed low-dose aspirin (3-5 mg per kg once daily for at least 6 weeks).

Remark: Additional measures to be considered to prevent venous thrombosis associated with PIMS-TS include:

- Anticoagulation therapy
- Compression stockings (in children older than 12 years of age)

14 - Abbreviations and Acronyms
1 - Reading Guide

Treatment of novel coronavirus disease 2019 (COVID-19) is a rapidly expanding area of research, with an unprecedented global effort underway to combat this disease. As a result, recommendations based on current evidence are likely to become outdated quickly as new primary studies are published. The living evidence approach facilitates rapid updating of recommendations. By frequently incorporating the most up-to-date evidence, these methods ensure that the currency of each recommendation remains high.

It is anticipated that these living recommendations will be updated weekly as and when new evidence is available. This will be reflected in the publication of a new version in which changes made to a specific recommendation or supporting information are highlighted to emphasise the update.

The guideline consists of two layers

1. The Recommendation

Recommendation for (Green)
A strong recommendation is given when there is high-certainty evidence showing that the overall benefits of the intervention are clearly greater than the disadvantages. This means that all, or nearly all, patients will want the recommended intervention.

Recommendation against (Red)
A strong recommendation against the intervention is given when there is high-certainty evidence showing that the overall disadvantages of the intervention are clearly greater than the benefits. A strong recommendation is also used when the examination of the evidence shows that an intervention is not safe.

Conditional Recommendation for (Yellow)
A conditional recommendation is given when it is considered that the benefits of the intervention are greater than the disadvantages, or the available evidence cannot rule out a significant benefit of the intervention while assessing that the adverse effects are few or absent. This recommendation is also used when patient preferences vary.

Conditional Recommendation against (Orange)
A conditional recommendation is given against the intervention when it is judged that the disadvantages of the intervention are greater than the benefits, but where this is not substantiated by strong evidence. This recommendation is also used where there is strong evidence of both beneficial and harmful effects, but where the balance between them is difficult to determine. Likewise, it is also used when patient preferences vary.

Consensus Recommendation (Bluish-Purple)
A consensus recommendation can be given for or against the intervention. This type of recommendation is used when there is not enough evidence to give an evidence-based recommendation, but the panel still regards it as important to give a recommendation.

2. Supporting information

Click on the recommendation to learn more about the basis of the recommendation. Note that early recommendations are primarily adapted from other guidelines and/or based on the consensus of the guideline panel, and supporting information will be limited. Additional information will be added as recommendations are updated in light of new evidence.

Evidence profile: The overall effect estimates and references to the studies.

Summary: Overview and brief review of the underlying evidence.

Certainty of the evidence:

• High: We are very sure that the true effect is close to the estimated effect.
• Moderate: We are moderately sure of the estimated effect. The true effect is probably close to this one, but there is a possibility that it is significantly different.
• Low: We have limited confidence in the estimated effect. The true effect may be significantly different from the estimated effect.
• Very low: We have very little confidence in the estimated effect. The true effect is likely to be significantly different from that estimated effect.

Evidence to decision: Brief description of beneficial and harmful effects, certainty of evidence and considerations of patient preferences.

Rationale: Description of how the above elements were weighted in relation to each other and resulted in the current recommendation direction and strength.

Practical information: Practical information regarding the treatment and information on any special patient considerations.

Adaption: If the recommendation is adapted from another guideline you can find more information here.

Feedback: If you are logged in as a user, you can comment here on specific recommendations. See here for guidance on how to log in.

References: Reference list for the recommendation.

The gradation of evidence quality and recommendation strength used is based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). For a quick and informative introduction to GRADE, the article Understanding GRADE: an introduction by Goldet & Howick is recommended (J Evid Based Med 2013;6(1):50-4). See also http://www.gradeworkinggroup.org.
2 - Introduction

Novel coronavirus disease 2019 (COVID-19) is an infectious disease caused by the newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its identification in December 2019, COVID-19 has spread around the world and was declared a Public Health Emergency of International Concern by the World Health Organization (WHO) on 30 January 2020 [1].

People infected with the COVID-19 virus are most likely to only experience mild symptoms and recover without requiring special treatment. However, some people will experience moderate or severe disease. Older people and those with underlying diseases or medical conditions (such as cardiovascular disease, diabetes, chronic respiratory disease and cancer) are more likely to develop serious illness that require special care and treatment [210].

Clinical guidelines are integral to ensuring that healthcare decisions are based on the best available evidence. Since the emergence of the COVID-19 pandemic, many national and international organisations have released guidelines related to different aspects of the management of people with COVID-19. With the support of the National Health and Medical Research Council (NHMRC), the National COVID-19 Clinical Evidence Taskforce was established to develop (in partnership with a range of national professional societies and organisations) living guidelines for clinical management and care of people with suspected or confirmed COVID-19.

Recommendations within this guideline were developed in collaboration with the organisations listed below. All member organisations are part of the steering committee and formally endorse the guideline. The Steering Committee is governed by a consensus based decision-making process, for more details on the methods and processes of the Taskforce please see the Methods and processes section of this guideline.

- Australian Living Evidence Consortium (Coordinating Lead)
- Cochrane Australia (Secretariat)
- Allied Health Professions Australia
- Australasian Association of Academic Primary Care
- Australasian College for Emergency Medicine
- Australasian College for Infection Prevention and Control
- Australasian College of Paramedicicine
- Australasian Sleep Association
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
- Australasian Society for Infectious Diseases
- Australian Association of Gerontology
- Australian College of Critical Care Nurses
- Australian College of Midwives
- Australian College of Nursing
- Australian College of Rural and Remote Medicine
- Australian COVID-19 Palliative Care Working Group
- Australian and New Zealand College of Anaesthetists
- Australian and New Zealand Intensive Care Society
- Australian and New Zealand Society for Geriatric Medicine
- Australian Primary Health Care Nurses Association
- Australian Resuscitation Council
- Australian Society of Anaesthetists
- College of Emergency Nursing Australasia
- CRANAPlus
- National Aboriginal Community Controlled Health Organisation
- Royal Australasian College of Physicians
- Royal Australasian College of Surgeons
- Royal Australian College of General Practitioners
- Royal Australian and New Zealand College of Obstetricians and Gynaecologists
- Society of Hospital Pharmacists of Australia
- Thoracic Society of Australia and New Zealand
- Thrombosis and Haemostasis Society of Australia and New Zealand

Updating and public consultation

A considerable volume of research related to the care of people with COVID-19 is ongoing and will potentially impact clinical recommendations. To ensure these guidelines are updated rapidly in response to new and important evidence, the underpinning knowledge syntheses and recommendations will be reviewed and updated on an ongoing basis. It is anticipated that these living recommendations will be updated weekly as and when new evidence is available. This will be reflected in the publication of a new version in which changes made to a specific recommendation or supporting information are highlighted in order to emphasise the update.

The consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992. As part of the approval process (and for the lifetime of the guidelines), public consultation is required. We welcome your feedback and suggestions. Comments can be submitted via the feedback function under each recommendation in MAGIC, see the reading guide in the above section for guidance, or by emailing guidelines@covid19evidence.net.au.

Purpose

The purpose of this guideline is to provide health professionals and patients with up-to-date, evidence-based recommendations to guide shared decision-making in the treatment of COVID-19. The guideline contains specific and actionable recommendations for selected, well-defined clinical problems (i.e. what needs to be done and who it is relevant to). It does not define the individuals responsible for providing care, nor does it consider the social or economic implications of guideline adherence.

Scope

This guideline aims to provide specific, patient-focused recommendations on management and care of people with suspected or confirmed COVID-19. With the exception of chemoprophylaxis for the prevention of infection in people exposed to COVID-19, the guideline does not include other interventions used in the prevention of COVID-19 infection or transmission. Within each recommendation, the patient population of interest is specified.

Consumer-centred care in the context of COVID-19

Consumer-centred care is the provision of health care that is respectful of, or responsive to, the needs, preferences and values of consumers. Consumer-centred care “...refrshes the relationships in health care by placing an emphasis on collaborating with people of all ages, at all levels of care, and in all health care settings.” [5][12]

The key principles of consumer-centred care include:
- respect for patients’ preferences and values
- emotional support
- physical comfort
- information, communication and education
- continuity and transition
- coordination of care
• involvement of family and friends
• access to care [6]

In the context of COVID-19, we need to acknowledge the barriers and inequities experienced by consumers. Groups who will face greater barriers and inequities than others include, but are not limited to people with: a disability or cognitive impairment, complex and chronic health needs, stigmatised health conditions and people from culturally or linguistically diverse backgrounds [7].

The Australian Charter of Healthcare Rights (2nd edition) outlines the basic rights that patients and consumers are entitled to receive. These rights are particularly important in the current context. Rights of particular note include:
• access to healthcare services and treatment that meet needs
• safety through safe and high-quality health care in an environment that feels safe
• respect as an individual, with culture, identity, beliefs and choices recognised
• partnership through open and honest communication with healthcare providers
• information about their conditions and the possible benefits and risks of different tests and treatments, waiting times and costs and access to health information to support informed consent
• privacy and security of personal and health information maintained [8]

COVID-19 requires clinical responsiveness to new and emerging treatments, including a significant degree of uncertainty as new treatments emerge. However, consumer preferences and values must remain central in the provision of healthcare and be balanced with the needs of the health service and public health concerns. Health services remain responsible for ensuring that their work remains patient centred. In the context of COVID-19, key concepts include ensuring:
• equity in resource allocation and provision of care
• choice and agency of the consumer
• ethical provision of care at all times

Informed consent is a further component of consumer-centred care and underpins consideration of treatment options for COVID-19 by consumers, families and carers.

**Informed consent**

Informed consent forms an essential component of the moral right of individuals to autonomy over their own bodies [9]. Informed consent is generally understood to be a person's voluntary decision about their health care that is made with knowledge and understanding of the benefits and risks involved [10][11].

In practical terms, informed consent is the process by which a healthcare professional provides appropriate information to a consumer about their treatment options, associated risks and benefits, fees, charges and possible additional costs, and supports them to make a decision about their care. From a legal perspective, informed consent should comply with jurisdictional legislation and best practice and is defined in terms of an agreement or process by which, having provided the relevant information, the rights of individuals to agree or to refuse treatment are upheld. This is particularly important where there are issues relating to impaired capacity of a person to consent [10].

Consent processes help deliver services that are more closely aligned with the priorities and concerns of the community. This has a range of benefits, including improved health outcomes and a more efficient allocation of resources. In this way, informed consent processes are important in developing a genuinely consumer-focused health system.

For ethical decision-making, decisions about whether care is provided and in what form must be informed by the preferences of patients as well as clinical judgement [9]. Any changes affecting the existing plan or access to treatment must be considered with the patient, and the consented plan drafted and followed.

The National Health and Medical Research Council (NHMRC) Guidelines: Communicating with Patients addresses the content of information that should be provided, and states the patient needs to be advised of the possible or likely nature of the procedure or treatment [and] the proposed approach, including:
• what the proposed approach entails
• the expected benefits
• common side effects and material risks
• whether the procedure is conventional or experimental
• who will perform the procedure or treatment
• other options for management of the complaint
• the realistic expectations for the outcome of the procedure or treatment
• the time and cost involved, including any out-of-pocket expenses and any potential costs should further treatment be required [13]

These principles underpin the Australian Health Practitioner Regulation Agency (AHPRA) standards for healthcare professionals, including medical and allied health practitioners, and nurses and midwives to support informed consent by patients about their health care [11].

While in the context of COVID-19, decisions may be being made at greater speed and in more resource-constrained environments than other health care environments, efforts must be made as far as practical to ensure that consumers are involved in their care.

In practical terms, informed consent processes should support the role of consumers as genuine partners in health care and promote consumer involvement in decision-making. Shared decision-making practices as between a treating team and consumer (patients as partners in care) should be standard practice. Consideration must be paid to people with complex communication needs, including those who communicate in ways other than speech and have limited capacity to make decisions about their health care. All consumers should be actively involved in decisions about their treatment and care to the extent they wish to be, and they should be supported to do so [9].

**Note on the language in the pregnancy and perinatal care recommendations**

The Taskforce recognises that individuals have diverse gender identities. Terms such as pregnant person, childbearing people and parent can be used to avoid gendering birth, and those who give birth, as feminine. However, because women are also marginalised and oppressed in most places around the world, we have continued to use the terms woman, mother or maternity. When we use these words, it is not meant to exclude those who give birth and do not identify as women.

**Note on caring for children and adolescents in the context of COVID-19**
The Taskforce regards child- and family-centred care indispensable in managing the health and wellbeing of children and adolescents, and urges continuity of child-centred services, with a particular focus on equity of access. We support efforts to ensure children are able to remain in contact with parents, carers and families despite COVID-19 and recognise this may require specific attention to infection control management practices and may involve adjunctive use of technology such as video-calling. Health facilities should have plans to manage these issues for children and adolescents. We endorse the approach and goals established by the United Nations Policy Brief: the impact of COVID-19 on children [4].

Child-centred services include among others: schooling, nutrition programs, maternal and newborn care, immunisation services, sexual and reproductive health services, HIV treatment, mental health and psychosocial services, birth registration, community-based child protection programs, out-of-home care, and case management for children requiring supplementary personalised care, including those living with long-term medical conditions, disabilities and victims of abuse or family violence [4]. Particularly relevant for the Australian context is to ensure continuity of Aboriginal and Torres Strait Islander child services.

**Note on people requiring palliative care and older people living with frailty or cognitive impairment**

The Taskforce recognises the need for specific recommendations and considerations for older people living with frailty or cognitive impairment. These populations are particularly vulnerable and have been reported as having an increased risk of mortality due to COVID-19 [2]. The Taskforce’s Palliative and Aged Care Panel provides clinical expertise to ensure these populations are appropriately considered in our guidance. The following definitions have been agreed for these populations:

- **Older people with frailty or cognitive impairment and COVID-19**
  This population includes older people (usually over 65 years of age) with impairments of physical, cognitive and/or physiological function, or who have frailty. Frailty is a multifaceted syndrome that includes physical impairments and higher susceptibility to disease [3]. Comorbidities are often present, such as cerebrovascular disease, dementia, heart failure and chronic lung disease [3].
- **People requiring palliative care and COVID-19**
  This population includes people with COVID-19 whose prognosis due to co-existing advanced progressive disease is limited or uncertain, or people with critical COVID-19 illness where recovery is not expected.

**Target audience**

These recommendations are applicable to individuals responsible for the care of people with COVID-19. These include health professionals, individuals providing support and education to people with COVID-19, and people with diagnosed or suspected COVID-19 themselves.

Individuals such as policymakers, practice managers, researchers and students may elect to use or adopt these recommendations for purposes other than the treatment of COVID-19; however these individuals do not represent the target audience. Additional considerations not addressed within this guideline are required when using these recommendations for any purpose other than for the treatment or support of individuals with COVID-19.

**How to cite this guideline**

3 - Methods and processes

Methods and processes
Information about the methods and processes used is described in the technical report. Information about our governance structure and members' details is available here. Our policy on the use of media statements, preprints and other non-peer-reviewed papers in formulating recommendations is available here.

Conflicts of interest
The policy for management of conflicts of interest and the template used for collecting the declarations of interest can be found on the website here and here. A summary of the declarations of interests can be found here.

Public consultation
We welcome feedback and suggestions. Comments can be submitted via the feedback function under each recommendation in MAGIC or by emailing guidelines@covid19evidence.net.au. Feedback and responses to comments received to date is available here.
4 - Definition of disease severity

Definitions of disease severity for adults were developed by the Primary and Chronic Care Panel, Hospital and Acute Care Panel and Critical Care Panel. Definitions of disease severity for children and adolescents were developed by the Paediatric and Adolescent Care Panel. Definitions were reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. In addition, all our definitions are reviewed by the Consumer Panel.
### 4.1 - Definition of disease severity for adults

<table>
<thead>
<tr>
<th>Consensus recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild illness</strong></td>
</tr>
<tr>
<td>Adults not presenting any clinical features suggestive of moderate or severe disease or a complicated course of illness.</td>
</tr>
<tr>
<td>Characteristics:</td>
</tr>
<tr>
<td>• no symptoms</td>
</tr>
<tr>
<td>• or mild upper respiratory tract symptoms</td>
</tr>
<tr>
<td>• or cough, new myalgia or asthenia without new shortness of breath or a reduction in oxygen saturation</td>
</tr>
<tr>
<td><strong>Moderate illness</strong></td>
</tr>
<tr>
<td>Stable adult patient presenting with respiratory and/or systemic symptoms or signs. Able to maintain oxygen saturation above 92% (or above 90% for patients with chronic lung disease) with up to 4 L/min oxygen via nasal prongs.</td>
</tr>
<tr>
<td>Characteristics:</td>
</tr>
<tr>
<td>• prostration, severe asthenia, fever &gt; 38°C or persistent cough</td>
</tr>
<tr>
<td>• clinical or radiological signs of lung involvement</td>
</tr>
<tr>
<td>• no clinical or laboratory indicators of clinical severity or respiratory impairment</td>
</tr>
<tr>
<td><strong>Severe illness</strong></td>
</tr>
<tr>
<td>Adult patients meeting any of the following criteria:</td>
</tr>
<tr>
<td>• respiratory rate ≥ 30 breaths/min</td>
</tr>
<tr>
<td>• oxygen saturation ≤ 92% at a rest state</td>
</tr>
<tr>
<td>• arterial partial pressure of oxygen (PaO2)/ inspired oxygen fraction (FiO2) ≤ 300</td>
</tr>
<tr>
<td><strong>Critical illness</strong></td>
</tr>
<tr>
<td>Adult patient meeting any of the following criteria:</td>
</tr>
<tr>
<td>Respiratory failure</td>
</tr>
<tr>
<td>• Occurrence of severe respiratory failure (PaO2/FiO2 &lt; 200), respiratory distress or acute respiratory distress syndrome (ARDS). This includes patients deteriorating despite advanced forms of respiratory support (non-invasive ventilation (NIV), high-flow nasal oxygen (HFNO)) OR patients requiring mechanical ventilation.</td>
</tr>
<tr>
<td>OR other signs of significant deterioration</td>
</tr>
<tr>
<td>• hypotension or shock</td>
</tr>
<tr>
<td>• impairment of consciousness</td>
</tr>
<tr>
<td>• other organ failure</td>
</tr>
</tbody>
</table>

**Adaptation**
The definitions of disease severity are adapted from published definitions from China [14], Italy [15] and Alfred Health (Melbourne) [16].
4.2 - Definition of disease severity for children and adolescents
These definitions apply to children under 16 years of age. Depending on the physical size and/or developmental status of the patient, either the paediatric or adult severity grading can be applied.

Cardiorespiratory and vital parameters must be considered within the normal age-appropriate ranges for neonates and children. If criteria fall across different severity classifications, use the more severe classification to manage illness.

<table>
<thead>
<tr>
<th>Mild illness</th>
<th>Feeding / hydration / conscious state</th>
<th>Respiratory / vital signs</th>
<th>Oxygen requirement[1]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal or mildly reduced feeding</td>
<td>No or mild upper respiratory tract symptoms OR No or mild work of breathing</td>
<td>No supplemental oxygen required to maintain SpO₂ &gt; 92%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Moderate illness</th>
<th>Feeding / hydration / conscious state</th>
<th>Respiratory / vital signs</th>
<th>Oxygen requirement[1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids AND Normal conscious state</td>
<td>Moderate work of breathing OR Abnormal vital signs for age (tachycardia, tachypnoea) but does not persistently breach Early Warning (e.g. Medical Emergency Team) Criteria² OR Brief self-resolving apnoea (infants)</td>
<td>Requires low-flow oxygen (nasal prongs or mask) to maintain SpO₂ &gt; 92%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Severe illness</th>
<th>Feeding / hydration / conscious state</th>
<th>Respiratory / vital signs</th>
<th>Oxygen requirement[1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids OR Drowsy / tired but easily rousable</td>
<td>Moderate-severe work of breathing OR Abnormal vital signs for age (tachycardia, tachypnoea) with breaches of Early Warning (e.g. MET) Criteria OR Apnoea needing support / stimulation (infants)</td>
<td>Requires high-flow oxygen at 2 L/kg/min³ to maintain SpO₂ &gt; 92%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Critical illness</th>
<th>Feeding / hydration / conscious state</th>
<th>Respiratory / vital signs</th>
<th>Oxygen requirement[1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor feeding, unable to maintain hydration without nasogastric or IV fluids OR Altered conscious state / unconscious</td>
<td>Unable to maintain breathing or prevent apnoea without advanced modes of support OR Abnormal vital signs for age with persistent breaches of Early Warning (e.g. MET) Criteria OR Haemodynamically unstable without inotropic or vasopressor support</td>
<td>Requires advanced modes of support to maintain oxygenation</td>
<td></td>
</tr>
</tbody>
</table>

High-flow nasal oxygen at > 2 L/kg/min³ OR Non-invasive ventilation OR Intubation and mechanical ventilation OR
Oxygen saturation target should be modified for patients with cyanotic heart disease.

Temperature instability should be considered an abnormal vital sign in infants. Fever is common in children and does not contribute to determination of illness severity in isolation.

Infants and neonates < 4 kg may be managed on high-flow nasal cannula oxygen at 2-8 L/min irrespective of weight.

Note: co-morbidities (e.g. preterm infants, oncology, immunosuppressed, etc.) may increase the risk of more severe disease.
5 - Monitoring and markers of clinical deterioration

The primary panel for the recommendation in this section is the Primary and Chronic Care Panel. Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. In addition, all our recommendations are reviewed by the Consumer Panel.

5.1 - Monitoring and markers of clinical deterioration

**Consensus recommendation**

For people with COVID-19, monitor markers of clinical progression, such as rapidly progressive respiratory failure and sepsis, especially on days 5 to 10 after onset of symptoms.

**Adaptation**

The recommendation for monitoring and markers of clinical deterioration is adapted from published recommendations by the World Health Organization [210], National Institute for the Infectious Diseases (Italy) [15] and Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.
6 - Disease-modifying treatments

Several classes of therapies are currently under investigation to determine their effectiveness in treating COVID-19. These include, but are not limited to, antivirals (remdesivir, lopinavir-ritonavir), antimalarials (hydroxychloroquine, chloroquine), interleukin receptor agonists (tocilizumab, anakinra), corticosteroids (dexamethasone) and convalescent plasma. The categories of disease-modifying treatments being considered can be seen in the table below. We are continually monitoring new research for randomised trials that evaluate any disease-modifying treatments for COVID-19.

While national and international guidelines published early in the pandemic did not support the use of disease-modifying therapies in treating people with COVID-19 (except in the context of clinical trials), this is now changing as evidence for certain treatments emerges.

### Disease-modifying treatments

<table>
<thead>
<tr>
<th>Category</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agents that may have activity against SARS-CoV-2</td>
<td>Antimalarials, Antivirals</td>
</tr>
<tr>
<td>Other and ancillary agents</td>
<td>ACE inhibitors, NSAIDs</td>
</tr>
<tr>
<td>Blood purification systems for reducing cytokines in ICU</td>
<td>Cytokine removal</td>
</tr>
</tbody>
</table>

The primary panel for the recommendations in this section is the Disease-Modifying Treatment and Chemoprophylaxis Panel.

Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

6.1 - Corticosteroids

6.1.1 - Corticosteroids for adults

Note: The suggested regimen of corticosteroid use is 6 mg of dexamethasone (oral or intravenous) daily for up to 10 days. In patients for whom dexamethasone is not available, acceptable alternative regimens include:
- Hydrocortisone: intravenous (50 mg), every 6 hours for up to 10 days
- Prednisolone: oral (50 mg), daily for up to 10 days
- Methylprednisolone may also be an acceptable alternative, however the most appropriate dosage is uncertain

**Evidence To Decision**

**Benefits and harms**

In patients receiving oxygen or invasive mechanical ventilation, death is reduced with corticosteroids. Although indirect evidence suggests that corticosteroids may increase the risk of hyperglycaemia, the panel believes the mortality benefit outweighs any potential harms associated with corticosteroid use.

**Certainty of the Evidence**

In patients with severe or critical illness, certainty of the evidence is moderate for all-cause mortality and serious adverse events (due to serious inconsistency in direction of effect), mechanical ventilation or death and discharge from
Due to a reduction in death, along with no important resource implications and the likely acceptability of these drugs, we recommend corticosteroids for adults with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

Preference and values
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there are mortality benefits most patients would opt for corticosteroids.

The NC19CET Consumer Panel believes that most informed patients would agree with the recommendation and opt for this treatment.

Resources
Corticosteroids are widely available and affordable. Use of corticosteroids in adults with COVID-19 who are receiving supplementary oxygen or invasive ventilation is unlikely to have an impact on availability of these drugs for other indications.

Equity
We have no systematically collected evidence regarding impact on equity. Since corticosteroids are widely available and affordable, no negative impact is expected.

Acceptability
Although we have no systematically collected evidence regarding acceptability, corticosteroids are likely to be acceptable to both patients and clinicians.

Feasibility
Corticosteroids are likely to be feasible because they are already widely used for other indications. There are no known issues with availability of these drugs.

Rationale
Due to a reduction in death, along with no important resource implications and the likely acceptability of these drugs, we recommend corticosteroids for adults with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

Clinical Question/ PICO
- **Population:** Patients with COVID-19
- **Intervention:** Corticosteroids
- **Comparator:** Standard care

Summary
Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase...
What is the evidence informing this recommendation?

Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], one study of patients with moderate, severe and critical COVID-19 [33], and one study of patients with severe COVID-19 [35]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics

Three studies compared dexamethasone with standard care [31][29][33], three compared hydrocortisone with standard care [30][28][26] and three compared methylprednisolone with standard care [27][32][35].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO2/FiO2 < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH2O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?

Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 51 more are likely to survive compared with those receiving standard care (RR 0.84 CI 95% 0.73 to 0.98; 5789 patients in 9 studies). Corticosteroids in patients requiring oxygen also probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.

In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

Our confidence in the results

In patients with severe or critical illness, certainty of the evidence is moderate for all-cause mortality and serious adverse events (due to serious inconsistency in direction of effect) and invasive mechanical ventilation or death, and discharge from hospital (due to serious imprecision).

In patients with moderate illness, certainty is low for all outcomes (all-cause mortality, invasive mechanical ventilation or death and discharge from hospital) due to very serious imprecision (reliance on a single study and wide confidence intervals).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), certainty is low due to serious indirectness (evidence from non-COVID-19 patients) and serious imprecision.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Risk</th>
<th>95% CI</th>
<th>Patients</th>
<th>Studies</th>
<th>Comparator</th>
<th>Difference</th>
<th>95% CI</th>
<th>Evidence</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [adults requiring oxygen]</td>
<td>0.84</td>
<td>0.73 - 0.98</td>
<td>5,789</td>
<td>9</td>
<td>Randomized controlled</td>
<td>51 fewer</td>
<td>0.85 fewer - 6 fewer</td>
<td>1</td>
<td>Moderate Due to some inconsistency</td>
</tr>
<tr>
<td>All-cause mortality [adults not requiring oxygen]</td>
<td>1.27</td>
<td>1.16 - 1.61</td>
<td>1,535</td>
<td>1</td>
<td>Randomized controlled</td>
<td>38 more</td>
<td>0.0 fewer - 85 more</td>
<td>10</td>
<td>Moderate Due to only one study</td>
</tr>
<tr>
<td>Serious adverse events [adults requiring oxygen]</td>
<td>0.8</td>
<td>0.53 - 1.19</td>
<td>696</td>
<td>6</td>
<td>Randomized controlled</td>
<td>47 fewer</td>
<td>0.11 fewer - 44 more</td>
<td>3</td>
<td>Moderate Due to serious inconsistency</td>
</tr>
<tr>
<td>Serious adverse events [adults not requiring oxygen]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death [adults requiring oxygen]</td>
<td>0.88</td>
<td>0.79 - 0.97</td>
<td>3,883</td>
<td>1</td>
<td>Randomized controlled</td>
<td>38 fewer</td>
<td>0.67 fewer - 10 fewer</td>
<td>6</td>
<td>Moderate Due to only one study</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death [adults not requiring oxygen]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital [adults requiring oxygen]</td>
<td>1.1</td>
<td>1.06 - 1.15</td>
<td>4,952</td>
<td>2</td>
<td>Randomized controlled</td>
<td>58 more</td>
<td>0.35 more - 87 more</td>
<td>8</td>
<td>Moderate Due to serious inconsistency</td>
</tr>
<tr>
<td>Discharge from hospital [adults not requiring oxygen]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Corticosteroids probably decrease death at day 28 in adults who require oxygen. Corticosteroids probably have little impact on serious adverse events in adults who require oxygen. Corticosteroids probably decrease invasive mechanical ventilation or death in adults who require oxygen. Corticosteroids probably increases discharge from hospital in adults who require oxygen. Corticosteroids probably increase death in adults who do not require oxygen.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Relative Risk</th>
<th>Difference</th>
<th>CI 95%</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive mechanical ventilation or death [adults not requiring oxygen]</td>
<td>1.25</td>
<td>39 more</td>
<td>0-88</td>
<td>Moderate due to only one study [13] Corticosteroids probably increase invasive mechanical ventilation or death in adults who do not require oxygen.</td>
</tr>
<tr>
<td>Discharge from hospital [adults not requiring oxygen]</td>
<td>0.96</td>
<td>32 fewer</td>
<td>8-88</td>
<td>Moderate due to only one study [15] Corticosteroids may have little impact on discharge from hospital in adults who do not require oxygen.</td>
</tr>
<tr>
<td>Gastrointestinal bleeding</td>
<td>1.06</td>
<td>3 more</td>
<td>4-16</td>
<td>Low due to serious indirectness and imprecision Corticosteroids may have little impact on gastrointestinal bleeding.</td>
</tr>
<tr>
<td>Super infections</td>
<td>1.01</td>
<td>2 more</td>
<td>19-24</td>
<td>Low due to serious indirectness and imprecision Corticosteroids may have little impact on number of patients with super infections.</td>
</tr>
<tr>
<td>Hyperglycaemia</td>
<td>1.16</td>
<td>46 more</td>
<td>23-72</td>
<td>Moderate due to serious indirectness Corticosteroids probably increase the risk of hyperglycaemia.</td>
</tr>
<tr>
<td>Neuromuscular weakness</td>
<td>1.09</td>
<td>6 more</td>
<td>10-27</td>
<td>Low due to serious indirectness and imprecision Corticosteroids may have little impact on neuromuscular weakness.</td>
</tr>
<tr>
<td>Neuropsychiatric effects</td>
<td>0.81</td>
<td></td>
<td></td>
<td>Low due to serious indirectness and imprecision Corticosteroids may have little impact on.</td>
</tr>
</tbody>
</table>

2. Inconsistency: Serious. The direction of the effect is not consistent between the included studies.


4. Inconsistency: Serious. The direction of the effect is not consistent between the included studies.

5. The number of patients with severe illness (i.e. who do not require mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days


7. Imprecision: Serious. Only data from one study.


9. Inconsistency: Serious. The confidence interval of some of the studies do not overlap with those of most included studies/ the point estimate of some of the included studies.


11. Imprecision: Serious. Only data from one study, Wide confidence intervals.


13. Imprecision: Serious. Only data from one study.


15. Imprecision: Serious. Only data from one study.


---

**Conditional recommendation against**

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in adults who do not require oxygen.

Corticosteroids may still be considered for other evidence-based indications in people who have COVID-19.

---

**Evidence To Decision**

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Important harms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

52 of 418
In patients who do not require oxygen, death and risk of hypoglycaemia may be higher with dexamethasone and other corticosteroids.

**Certainty of the Evidence**

In patients who do not require oxygen, certainty of the evidence is moderate for all outcomes (mortality, mechanical ventilation or death, and discharge from hospital) due to serious imprecision (reliance on a single study).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

**Preference and values**

We have no systematically collected information regarding patients' preferences and values.

The NC19CET Consumer Panel believes that informed patients may prefer to wait until the available evidence is clearer, and would not agree to this treatment for COVID-19.

**Resources**

There are no identified resource issues as the recommendation reflects usual care.

**Equity**

There are no identified equity issues as the recommendation reflects usual care.

**Acceptability**

We have no systematically collected evidence regarding acceptability.

**Feasibility**

There are no identified feasibility issues as the recommendation reflects usual care.

**Rationale**

Evidence suggests that dexamethasone in patients with COVID-19 who do not require oxygen may increase the risk of death. We therefore recommend against dexamethasone and other corticosteroids in this population unless there is an alternative evidence-based indication for its use.

**Clinical Question/ PICO**

- **Population:** OLD Patients with COVID-19
- **Intervention:** Corticosteroids
- **Comparator:** Standard care
Summary
Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase deaths in patients with moderate COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], and one of patients with moderate, severe and critical COVID-19 [33]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics
Three studies compared dexamethasone to standard care [31][29][33], three compared hydrocortisone to standard care [30][28][26] and two compared methylprednisolone to standard care [27][32].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO2/FiO2 < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH2O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?
Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 44 more are likely to survive compared with those receiving standard care (RR 0.86 CI 95% 0.77 to 0.97; 5727 patients in 8 studies). Corticosteroids in patients requiring oxygen also probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.

In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

Our confidence in the results
In patients with severe or critical illness, certainty of the evidence is moderate for all-cause mortality and serious adverse events (due to serious inconsistency in direction of effect) and invasive mechanical ventilation or death, and discharge from hospital (due to serious imprecision).

In patients with moderate illness, certainty is low for all outcomes (all-cause mortality, invasive mechanical ventilation or death and discharge from hospital) due to very serious imprecision (reliance on a single study and wide confidence intervals).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), certainty is low due to serious indirectness (evidence from non-COVID-19 patients) and serious imprecision.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard care</td>
<td>Corticosteroids</td>
<td></td>
</tr>
</tbody>
</table>

54 of 418
<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference</th>
<th>Quality of Evidence</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [adults requiring oxygen] within 28 days</td>
<td>0.86</td>
<td>0.77 - 0.97</td>
<td>44 fewer</td>
<td>Critical</td>
<td>Corticosteroids probably decrease death at day 28 in adults who require oxygen.</td>
</tr>
<tr>
<td>Serious adverse events [adults requiring oxygen] within 28 days</td>
<td>0.8</td>
<td>0.53 - 1.19</td>
<td>47 fewer</td>
<td>Important</td>
<td>Corticosteroids probably have little impact on serious adverse events in adults who require oxygen.</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death [adults requiring oxygen]</td>
<td>0.88</td>
<td>0.79 - 0.97</td>
<td>38 fewer</td>
<td>Critical</td>
<td>Corticosteroids probably decrease invasive mechanical ventilation or death in adults who require oxygen.</td>
</tr>
<tr>
<td>Discharge from hospital [adults requiring oxygen] within 28 days</td>
<td>1.21</td>
<td>0.91 - 1.61</td>
<td>122 more</td>
<td>Important</td>
<td>Corticosteroids probably increase discharge from hospital in adults who require oxygen.</td>
</tr>
<tr>
<td>All-cause mortality [adults not requiring oxygen] within 28 days</td>
<td>1.27</td>
<td>1 - 1.61</td>
<td>38 more</td>
<td>Moderate</td>
<td>Corticosteroids probably increase death in adults who do not require oxygen.</td>
</tr>
<tr>
<td>Condition</td>
<td>Timeframe</td>
<td>Event</td>
<td>Relative Risk</td>
<td>Confidence Interval</td>
<td>Difference</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Critical Invasive mechanical ventilation or death [adults not requiring oxygen]</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>9 Critical</td>
<td>1.25 (CI 95% 1 - 1.57)</td>
<td>Based on data from 1,535 patients in 1 studies, 12 (Randomized controlled)</td>
<td>155 per 1000</td>
</tr>
<tr>
<td><strong>Discharge from hospital [adults not requiring oxygen]</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>6 Important</td>
<td>0.96 (CI 95% 0.9 - 1.01)</td>
<td>Based on data from 1,535 patients in 1 studies, 14 (Randomized controlled)</td>
<td>804 per 1000</td>
</tr>
<tr>
<td><strong>Gastrointestinal bleeding</strong></td>
<td>End of treatment</td>
<td>6 Important</td>
<td>1.06 (CI 95% 0.85 - 1.33)</td>
<td>Based on data from 5,403 patients in 30 studies, 16</td>
<td>48 per 1000</td>
</tr>
<tr>
<td><strong>Super infections</strong></td>
<td>End of treatment</td>
<td>6 Important</td>
<td>1.01 (CI 95% 0.9 - 1.13)</td>
<td>Based on data from 6,027 patients in 32 studies, 17</td>
<td>186 per 1000</td>
</tr>
<tr>
<td><strong>Hyperglycaemia</strong></td>
<td>End of treatment</td>
<td>6 Important</td>
<td>1.16 (CI 95% 1.08 - 1.25)</td>
<td>Based on data from 8,938 patients in 24 studies, 18</td>
<td>286 per 1000</td>
</tr>
<tr>
<td><strong>Neuromuscular weakness</strong></td>
<td>End of treatment</td>
<td>6 Important</td>
<td>1.09 (CI 95% 0.86 - 1.39)</td>
<td>Based on data from 6,358 patients in 8</td>
<td>69 per 1000</td>
</tr>
</tbody>
</table>

Corticosteroids probably increase the need for invasive mechanical ventilation or death in adults who do not require oxygen.

Corticosteroids may have little impact on discharge from hospital in adults who do not require oxygen.

Corticosteroids may have little impact on gastrointestinal bleeding.

Corticosteroids may have little impact on number of patients with super infections.

Corticosteroids may have little impact on hyperglycaemia.

Corticosteroids may have little impact on neuromuscular weakness.
6 Important studies.  

**Neuropsychiatric effects**

End of treatment  
Relative risk 0.81 (CI 95% 0.41 - 1.63) Based on data from 1,813 patients in 7 studies.  

**Difference:** 6 more per 1000 (CI 95% 10 fewer - 27 more)

**Low**  
Due to serious indirectness and imprecision  
Corticosteroids may have little impact on neuropsychiatric effects.

2. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.
4. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.
5. The number of patients with severe illness (i.e. who do not require invasive mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days
7. **Imprecision:** Serious. Only data from one study.
8. Systematic review [21] with included studies: RECOVERY, RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.
9. **Imprecision:** Serious. Only data from one study.
10. Systematic review [21] with included studies: RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.
11. **Imprecision:** Serious. Only data from one study. Wide confidence intervals.
13. **Imprecision:** Serious. Only data from one study.
15. **Imprecision:** Serious. Only data from one study.
16. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
17. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
18. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
19. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
20. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
### 6.1.2 - Corticosteroids for pregnant or breastfeeding women

**Recommended**

Use dexamethasone 6 mg daily intravenously or orally for up to 10 days in pregnant or breastfeeding women with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

The suggested regimen of corticosteroid use is 6 mg of dexamethasone (oral or intravenous) daily for up to 10 days. In patients for whom dexamethasone is not available, acceptable alternative regimens include:

- hydrocortisone: intravenous (50 mg), every 6 hours for up to 10 days
- prednisolone: oral (50 mg), daily for up to 10 days

**Evidence To Decision**

**Benefits and harms**

Substantial net benefits of the recommended alternative

In patients receiving oxygen or invasive mechanical ventilation, death is reduced with dexamethasone. Although indirect evidence suggests that corticosteroids may increase the risk of hyperglycaemia, the panel believes the mortality benefit outweighs any potential harms associated with corticosteroid use.

Dexamethasone is used for other clinical indications during pregnancy and is considered safe to use [?].

**Certainty of the Evidence**

Low

In patients with severe or critical illness, certainty of the evidence is low for all-cause mortality and serious adverse events (due to serious inconsistency in direction of effect and serious indirectness), mechanical ventilation or death and discharge from hospital (due to serious imprecision and serious indirectness).

For adverse events (gastrointestinal bleeding, super-infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

**Preference and values**

No substantial variability expected

We have no systematically collected information regarding the preferences and values of pregnant or breastfeeding women. The panel believes that since there are mortality benefits most women would opt for dexamethasone.

The NC19CET Consumer Panel believes that most informed pregnant or breastfeeding women would agree with the recommendation.

**Resources**

No important issues with the recommended alternative

Corticosteroids are widely available and affordable. Use of corticosteroids in pregnant and breastfeeding women with COVID-19 who are receiving supplementary oxygen or invasive ventilation is unlikely to have an impact on availability of these drugs for other indications.

**Equity**

No important issues with the recommended alternative

We have no systematically collected evidence regarding impact on equity. Since corticosteroids are widely available and affordable, no negative impact is expected.
Rationale
Due to a reduction in death, along with no important resource implications, and the likely acceptability of corticosteroids and applicability of the evidence to pregnant and breastfeeding women, we recommend corticosteroids for pregnant and breastfeeding women with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

Acceptability
Although we have no systematically collected evidence regarding acceptability, corticosteroids are likely to be acceptable to both patients and clinicians.

Feasibility
Corticosteroids are likely to be feasible because they are already widely used for other indications. There are no known issues with availability of these drugs.

Clinical Question/ PICO
Population: Special populations with COVID-19 [adapted from general adult population]
Intervention: Corticosteroids
Comparator: Standard care

Summary
Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase deaths in patients with moderate COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], one study of patients with moderate, severe and critical COVID-19 [33] and one study of patients with severe COVID-19 [35]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics
Three studies compared dexamethasone with standard care [31][29][33], three compared hydrocortisone with standard care [30][28][26] and three compared methylprednisolone with standard care [27][32][35].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO2/FiO2 < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH2O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?
Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 51 more are likely to survive compared with those receiving standard care (RR 0.84 CI 95% 0.73 to 0.98; 5789 patients in 9 studies). Corticosteroids in patients requiring oxygen also probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.
In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

**Our confidence in the results**

Certainty of the evidence for all outcomes is judged to be low for pregnant and breastfeeding women, and children and adolescents due to serious indirectness. This is in addition to concerns in the adult population about inconsistency in direction of effect and serious imprecision.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality [adults requiring oxygen]</strong></td>
<td>Relative risk 0.84 (CI 95% 0.73 - 0.98) Based on data from 5,789 patients in 9 studies.</td>
<td>316 per 1000 265 per 1000</td>
<td>Low Due to serious inconsistency and serious indirectness</td>
<td>Corticosteroids may decrease death at day 28 in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>(Randomized controlled)</td>
<td>Difference: 51 fewer per 1000 (CI 95% 85 fewer - 6 fewer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events [adults requiring oxygen]</strong></td>
<td>Relative risk 0.8 (CI 95% 0.53 - 1.19) Based on data from 696 patients in 6 studies.</td>
<td>234 per 1000 187 per 1000</td>
<td>Low Due to serious inconsistency and indirectness</td>
<td>Corticosteroids may have little impact on serious adverse events in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>(Randomized controlled)</td>
<td>Difference: 47 fewer per 1000 (CI 95% 110 fewer - 44 more)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation or death [adults requiring oxygen]</strong></td>
<td>Relative risk 0.88 (CI 95% 0.79 - 0.97) Based on data from 3,883 patients in 1 studies.</td>
<td>320 per 1000 282 per 1000</td>
<td>Low Due to only one study and serious indirectness</td>
<td>Corticosteroids may decrease invasive mechanical ventilation or death in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days after commencing treatment</td>
<td>(Randomized controlled)</td>
<td>Difference: 38 fewer per 1000 (CI 95% 67 fewer - 10 fewer)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### All-cause mortality [adults not requiring oxygen] Within 28 days after commencing treatment

Relative risk 1.27 (CI 95% 1 - 1.61) Based on data from 1,535 patients in 1 studies. 8 (Randomized controlled)

<table>
<thead>
<tr>
<th></th>
<th>140</th>
<th>178</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **38 more** per 1000 (CI 95% 0 fewer - 85 more)

**Low**

Due to only one study and serious indirectness 9

Corticosteroids may increase death in patients who do not require oxygen.

### Invasive mechanical ventilation or death [adults not requiring oxygen] Within 28 days after commencing treatment

Relative risk 1.25 (CI 95% 1 - 1.57) Based on data from 1,535 patients in 1 studies. 10 (Randomized controlled)

<table>
<thead>
<tr>
<th></th>
<th>155</th>
<th>194</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **39 more** per 1000 (CI 95% 0 fewer - 88 more)

**Low**

Due to only one study and serious indirectness 11

Corticosteroids may increase invasive mechanical ventilation or death in patients who do not require oxygen.

### Discharge from hospital [adults not requiring oxygen] Within 28 days after commencing treatment

Relative risk 0.96 (CI 95% 0.9 - 1.01) Based on data from 1,535 patients in 1 studies. 12 (Randomized controlled)

<table>
<thead>
<tr>
<th></th>
<th>804</th>
<th>772</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **32 fewer** per 1000 (CI 95% 80 fewer - 8 more)

**Low**

Due to only one study and serious indirectness 13

Corticosteroids may have little impact on discharge from hospital in patients who do not require oxygen.

### Gastrointestinal bleeding End of treatment

Relative risk 1.06 (CI 95% 0.85 - 1.33) Based on data from 5,403 patients in 30 studies. 14

<table>
<thead>
<tr>
<th></th>
<th>48</th>
<th>51</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **3 more** per 1000 (CI 95% 7 fewer - 16 more)

**Low**

Due to serious indirectness and imprecision

Corticosteroids may have little impact on gastrointestinal bleeding.

### Super infections End of treatment

Relative risk 1.01 (CI 95% 0.9 - 1.13) Based on data from 6,027 patients in 32 studies. 15

<table>
<thead>
<tr>
<th></th>
<th>186</th>
<th>188</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **2 more** per 1000 (CI 95% 19 fewer - 24 more)

**Low**

Due to serious indirectness and imprecision

Corticosteroids may have little impact on number of patients with super infections.

### Hyperglycaemia End of treatment

Relative risk 1.16 (CI 95% 1.08 - 1.25) Based on data from 8,938 patients in 24 studies. 16

<table>
<thead>
<tr>
<th></th>
<th>286</th>
<th>332</th>
</tr>
</thead>
<tbody>
<tr>
<td>per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Difference: **46 more** per 1000 (CI 95% 23 more - 72 more)

**Moderate**

Due to serious indirectness

Corticosteroids probably increase the risk of hyperglycaemia.

2. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied.


4. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied.

5. The number of patients with severe illness (i.e. who do not require mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days


7. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study.


9. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study.


11. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study.


13. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study.

**Neuromuscular weakness**
End of treatment

Relative risk 1.09
(CI 95% 0.86 - 1.39)
Based on data from 6,358 patients in 8 studies.

<table>
<thead>
<tr>
<th>69</th>
<th>75</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 more</td>
<td>27 more</td>
</tr>
<tr>
<td>per 1000</td>
<td>per 1000</td>
</tr>
</tbody>
</table>

Low Due to serious indirectness and imprecision
Corticosteroids may have little impact on neuromuscular weakness.

**Neuropsychiatric effects**
End of treatment

Relative risk 0.81
(CI 95% 0.41 - 1.63)
Based on data from 1,813 patients in 7 studies.

<table>
<thead>
<tr>
<th>35</th>
<th>28</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 fewer</td>
<td>22 more</td>
</tr>
<tr>
<td>per 1000</td>
<td>per 1000</td>
</tr>
</tbody>
</table>

Low Due to serious indirectness and imprecision
Corticosteroids may have little impact on neuropsychiatric effects.

**Discharge from hospital [adults requiring oxygen]**
Within 28 days of commencing treatment

Relative risk 1.1
(CI 95% 1.06 - 1.15)
Based on data from 4,952 patients in 2 studies.

<table>
<thead>
<tr>
<th>582</th>
<th>640</th>
</tr>
</thead>
<tbody>
<tr>
<td>58 more</td>
<td>87 more</td>
</tr>
<tr>
<td>per 1000</td>
<td>per 1000</td>
</tr>
</tbody>
</table>

Low Due to serious inconsistency and serious indirectness
Corticosteroids may increase discharge from hospital in patients who require oxygen.
data from one study.

14. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
15. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
16. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
17. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
18. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
20. **Inconsistency:** **Serious.** The direction of the effect is not consistent between the included studies. **Indirectness:** **Serious.** Differences between the population of interest and those studied.

---

**Conditional recommendation against**

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in pregnant or breastfeeding women who do not require oxygen.

Antenatal corticosteroids should still be used for fetal lung maturation in pregnant women at risk of preterm birth who also have COVID-19. Dexamethasone and other corticosteroids should still be used for other evidence-based indications in pregnant and breastfeeding women who have COVID-19.

**Evidence To Decision**

**Benefits and harms**

In pregnant or breastfeeding women who do not require oxygen, there may be more deaths with dexamethasone and other corticosteroids.

**Certainty of the Evidence**

In pregnant or breastfeeding women who do not require oxygen, certainty of the evidence is judged to be low for all outcomes (mortality, mechanical ventilation or death, and discharge from hospital) due to serious imprecision (reliance on a single study and wide confidence intervals) and serious indirectness (results based on the general adult population).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

**Preference and values**

We have no systematically collected information regarding preferences and values of pregnant or breastfeeding women.

The NC19CET Consumer Panel also believes that most informed pregnant or breastfeeding women may prefer to wait until the available evidence is clearer, and would not agree to this treatment for COVID-19.

**Resources**

There are no identified resource issues as the recommendation reflects usual care.
Evidence suggests that dexamethasone in pregnant and breastfeeding women with COVID-19 who do not require oxygen may increase the risk of death. We therefore recommend against dexamethasone and other corticosteroids in this population unless there is an alternative evidence-based indication for their use.

There are no identified equity issues as the recommendation reflects usual care.

There are no identified feasibility issues as the recommendation reflects usual care.

There are no identified acceptability issues as the recommendation reflects usual care.

Rationale
Evidence suggests that dexamethasone in pregnant and breastfeeding women with COVID-19 who do not require oxygen may increase the risk of death. We therefore recommend against dexamethasone and other corticosteroids in this population unless there is an alternative evidence-based indication for their use.

Clinical Question/ PICO
- Population: Special populations with COVID-19 [adapted from general adult population]
- Intervention: Corticosteroids
- Comparator: Standard care

Summary
Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase deaths in patients with moderate COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], one study of patients with moderate, severe and critical COVID-19 [33] and one study of patients with severe COVID-19 [35]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics
Three studies compared dexamethasone with standard care [31][29][33], three compared hydrocortisone with standard care [30][28][26] and three compared methylprednisolone with standard care [27][32][35].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO2/FiO2 < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH2O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?
Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 51 more are likely to survive compared with those receiving standard care (RR 0.84 CI 95% 0.73 to 0.98; 5789 patients in 9 studies). Corticosteroids in patients requiring oxygen also
probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.

In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

**Our confidence in the results**
Certainty of the evidence for all outcomes is judged to be low for pregnant and breastfeeding women, and children and adolescents due to serious indirectness. This is in addition to concerns in the adult population about inconsistency in direction of effect and serious imprecision.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality [adults requiring oxygen]</strong></td>
<td>Relative risk 0.84 (CI 95% 0.73 - 0.98) Based on data from 5,789 patients in 9 studies.</td>
<td><strong>316</strong> per 1000 <strong>265</strong> per 1000</td>
<td>Low</td>
<td>Corticosteroids may decrease death at day 28 in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>9 Critical</td>
<td>Difference: 51 fewer (CI 95% 85 fewer - 6 fewer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events [adults requiring oxygen]</strong></td>
<td>Relative risk 0.8 (CI 95% 0.53 - 1.19) Based on data from 696 patients in 6 studies.</td>
<td><strong>234</strong> per 1000 <strong>187</strong> per 1000</td>
<td>Low</td>
<td>Corticosteroids may have little impact on serious adverse events in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>6 Important</td>
<td>Difference: 47 fewer (CI 95% 110 fewer - 44 more)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation or death [adults requiring oxygen]</strong></td>
<td>Relative risk 0.88 (CI 95% 0.79 - 0.97) Based on data from 3,883 patients in 1 study.</td>
<td><strong>320</strong> per 1000 <strong>282</strong> per 1000</td>
<td>Low</td>
<td>Corticosteroids may decrease invasive mechanical ventilation or death in patients who require oxygen.</td>
</tr>
<tr>
<td>Within 28 days after commencing treatment</td>
<td></td>
<td>Difference: 38 fewer (CI 95% 67 fewer - 10 fewer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Event</td>
<td>Status</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Difference</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>---------------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td>All-cause mortality [adults not requiring oxygen] Within 28 days after commencing treatment</td>
<td>Critical</td>
<td>1.27 (1.01 - 1.61)</td>
<td>178 per 1000</td>
<td>38 more per 1000</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death [adults not requiring oxygen] Within 28 days after commencing treatment</td>
<td>Critical</td>
<td>1.25 (1.01 - 1.57)</td>
<td>194 per 1000</td>
<td>39 more per 1000</td>
</tr>
<tr>
<td>Discharge from hospital [adults not requiring oxygen] Within 28 days after commencing treatment</td>
<td>Important</td>
<td>0.96 (0.9 - 1.01)</td>
<td>772 per 1000</td>
<td>32 fewer per 1000</td>
</tr>
<tr>
<td>Gastrointestinal bleeding End of treatment</td>
<td>Important</td>
<td>1.06 (0.85 - 1.33)</td>
<td>51 per 1000</td>
<td>3 more per 1000</td>
</tr>
<tr>
<td>Super infections End of treatment</td>
<td>Important</td>
<td>1.01 (0.9 - 1.13)</td>
<td>188 per 1000</td>
<td>2 more per 1000</td>
</tr>
</tbody>
</table>
2. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied.
   Baseline/comparator: Control arm of reference used for intervention.
4. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied.
5. The number of patients with severe illness (i.e. who do not require mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days
7. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study.
9. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Only data from one study, Wide confidence intervals.

### Hyperglycaemia

<table>
<thead>
<tr>
<th>End of treatment</th>
<th>Relative risk 1.16 (CI 95% 1.08 - 1.25) Based on data from 8,938 patients in 24 studies.</th>
<th>286/1000</th>
<th>332/1000</th>
<th>Difference: 46 more per 1000 (CI 95% 23 more - 72 more)</th>
</tr>
</thead>
</table>

**Moderate** Due to serious indirectness

Corticosteroids probably increase the risk of hyperglycaemia.

**End of treatment**

6 Important

### Neuromuscular weakness

<table>
<thead>
<tr>
<th>End of treatment</th>
<th>Relative risk 1.09 (CI 95% 0.86 - 1.39) Based on data from 6,358 patients in 8 studies.</th>
<th>69 per 1000</th>
<th>75 per 1000</th>
<th>Difference: 6 more per 1000 (CI 95% 10 fewer - 27 more)</th>
</tr>
</thead>
</table>

**Low** Due to serious indirectness and imprecision

Corticosteroids may have little impact on neuromuscular weakness.

**End of treatment**

6 Important

### Neuropsychiatric effects

<table>
<thead>
<tr>
<th>End of treatment</th>
<th>Relative risk 0.81 (CI 95% 0.41 - 1.63) Based on data from 1,813 patients in 7 studies.</th>
<th>35 per 1000</th>
<th>28 per 1000</th>
<th>Difference: 7 fewer per 1000 (CI 95% 21 fewer - 22 more)</th>
</tr>
</thead>
</table>

**Low** Due to serious indirectness and imprecision

Corticosteroids may have little impact on neuropsychiatric effects.

**End of treatment**

6 Important

### Discharge from hospital [adults requiring oxygen]

<table>
<thead>
<tr>
<th>Within 28 days of commencing treatment</th>
<th>Relative risk 1.1 (CI 95% 1.06 - 1.15) Based on data from 4,952 patients in 2 studies.</th>
<th>582 per 1000</th>
<th>640 per 1000</th>
<th>Difference: 58 more per 1000 (CI 95% 35 more - 87 more)</th>
</tr>
</thead>
</table>

**Low** Due to serious inconsistency and serious indirectness

Corticosteroids may increase discharge from hospital in patients who require oxygen.

**End of treatment**

6 Important
6.1.3 - Corticosteroids for children or adolescents

**Conditional recommendation**

Consider using dexamethasone daily intravenously or orally for up to 10 days (or acceptable alternative regimen) in children and adolescents with acute COVID-19 who are receiving oxygen (including mechanically ventilated patients).

An *dose of 6 mg daily is recommended in adults*. The RECOVERY trial protocol stated a dose of 0.15 mg/kg/day to a maximum of 6 mg/day for children but it is unclear whether any children were included in the trial. If dexamethasone is not available, an acceptable alternative regimen would be:

- hydrocortisone: intravenous or intramuscular 1 mg/kg/dose, every 6 hours for up to 10 days (to a maximum dose of 50 mg every 6 hours)
- methylprednisolone may also be an acceptable alternative, however the most appropriate dosage is uncertain

For specific recommendations on the use of corticosteroids for PIMS-TS see section.

**Evidence To Decision**

**Benefits and harms**

In patients receiving oxygen or invasive mechanical ventilation, death is reduced with corticosteroids. Although indirect evidence suggests that corticosteroids may increase the risk of hypoglycaemia, the panel believes the mortality benefit outweighs any potential harms associated with corticosteroid use.

**Certainty of the Evidence**

In patients with severe or critical illness, certainty of the evidence is low for all-cause mortality and serious adverse events (due to serious inconsistency in direction of effect and serious indirectness), mechanical ventilation or death, and discharge from hospital (due to serious imprecision and serious indirectness).

For adverse events (gastrointestinal bleeding, super-infections, hyperglycaemia, neuromuscular weakness and
neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

### Preference and values

We have no systematically collected information regarding the preferences and values of patients, parents, carers, families and guardians. The panel believes that since there are mortality benefits most patients would opt for corticosteroids.

The NC19CET Consumer Panel believes that some informed patients (and their parents, carers, families and guardians) may prefer to wait until the available evidence is clearer, but most informed patients (and their parents/carers/guardians) would agree to this treatment for COVID-19.

### Resources

Corticosteroids are widely available and affordable. Use of corticosteroids in adults with COVID-19 who are receiving supplementary oxygen or invasive ventilation is unlikely to have an impact on availability of these drugs for other indications.

### Equity

We have no systematically collected evidence regarding impact on equity. Since corticosteroids are widely available and affordable, no negative impact is expected.

### Acceptability

Although we have no systematically collected evidence regarding acceptability, corticosteroids are likely to be acceptable to both patients and clinicians.

### Feasibility

Corticosteroids are likely to be feasible because they are already widely used for other indications. There are no known issues with availability of these drugs.

### Rationale

Due to a reduction in death, along with no important resource implications and the likely acceptability of these drugs, we recommend considering using corticosteroids in children and adolescents with COVID-19 who are receiving oxygen (including mechanically ventilated patients).

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Special populations with COVID-19 [adapted from general adult population]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Corticosteroids</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

### Summary

Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase

What is the evidence informing this recommendation?
Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], one study of patients with moderate, severe and critical COVID-19 [33] and one study of patients with severe COVID-19 [35]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics
Three studies compared dexamethasone with standard care [31][29][33], three compared hydrocortisone with standard care [30][28][26] and three compared methylprednisolone with standard care [27][32][35].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO₂/FiO₂ < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH₂O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?
Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 51 more are likely to survive compared with those receiving standard care (RR 0.84 CI 95% 0.73 to 0.98; 5789 patients in 9 studies). Corticosteroids in patients requiring oxygen also probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.

In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

Our confidence in the results
Certainty of the evidence for all outcomes is judged to be low for pregnant and breastfeeding women, and children and adolescents due to serious indirectness. This is in addition to concerns in the adult population about inconsistency in direction of effect and serious imprecision.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [adults requiring oxygen] Within 28 days of commencing treatment</td>
<td>Relative risk 0.84 (CI 95% 0.73 - 0.98) Based on data from 5,789 patients in 9 studies. 1 (Randomized controlled)</td>
<td>316 per 1000 265 per 1000</td>
<td>Low Due to serious inconsistency and serious indirectness 2</td>
<td>Corticosteroids may decrease death at day 28 in patients who require oxygen.</td>
</tr>
<tr>
<td>Event (Adults requiring oxygen)</td>
<td>Criticality</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Number of Patients</td>
</tr>
<tr>
<td>--------------------------------------------------------------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>--------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Critical Serious adverse events</td>
<td>9</td>
<td>Relative risk 0.8 (CI 95% 0.53 - 1.19)</td>
<td></td>
<td>696 patients in 6 studies</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death</td>
<td>6</td>
<td>Relative risk 0.88 (CI 95% 0.79 - 0.97)</td>
<td></td>
<td>3,883 patients in 1 studies</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>9</td>
<td>Relative risk 1.27 (CI 95% 1 - 1.61)</td>
<td></td>
<td>1,535 patients in 1 studies</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death</td>
<td>9</td>
<td>Relative risk 1.25 (CI 95% 1 - 1.57)</td>
<td></td>
<td>1,535 patients in 1 studies</td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>9</td>
<td>Relative risk 0.96 (CI 95% 0.9 - 1.01)</td>
<td></td>
<td>772</td>
</tr>
</tbody>
</table>
### Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

<table>
<thead>
<tr>
<th>Condition</th>
<th>End of treatment</th>
<th>Relative risk</th>
<th>CI 95%</th>
<th>Difference</th>
<th>CI 95%</th>
<th>Important</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal bleeding</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 1.06</td>
<td>CI 95% 0.85 - 1.33</td>
<td>Based on data from 5,403 patients in 30 studies.</td>
<td>32 fewer</td>
<td>CI 95% 80 fewer - 8 more</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Super infections</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 1.01</td>
<td>CI 95% 0.9 - 1.13</td>
<td>Based on data from 6,027 patients in 32 studies.</td>
<td>3 more</td>
<td>CI 95% 7 fewer - 16 more</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Hyperglycaemia</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 1.16</td>
<td>CI 95% 1.08 - 1.25</td>
<td>Based on data from 8,938 patients in 24 studies.</td>
<td>46 more</td>
<td>CI 95% 23 more - 72 more</td>
<td>Moderate</td>
</tr>
<tr>
<td><strong>Neuromuscular weakness</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 1.09</td>
<td>CI 95% 0.86 - 1.39</td>
<td>Based on data from 6,358 patients in 8 studies.</td>
<td>6 more</td>
<td>CI 95% 10 fewer - 27 more</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Neuropsychiatric effects</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 0.81</td>
<td>CI 95% 0.41 - 1.63</td>
<td>Based on data from 1,813 patients in 7 studies.</td>
<td>7 fewer</td>
<td>CI 95% 21 fewer - 22 more</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Discharge from hospital [adults requiring oxygen]</strong></td>
<td><strong>6 Important</strong></td>
<td>Relative risk 1.1</td>
<td>CI 95% 1.06 - 1.15</td>
<td>Based on data from 4,952 patients in 2 studies.</td>
<td>58 more</td>
<td>CI 95% 35 more - 87 more</td>
<td>Low</td>
</tr>
</tbody>
</table>
   **Baseline/comparator:** Control arm of reference used for intervention.
   2. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.
   4. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.
   5. The number of patients with severe illness (i.e. who do not require mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days.
   7. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.
   8. Systematic review [21] with included studies: RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.
   9. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study, Wide confidence intervals.
   10. Systematic review [21] with included studies: RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.
   11. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.
   13. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.
   14. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
   15. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
   16. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
   17. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
   18. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.
   20. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.

---

**Conditional recommendation against**

Do not routinely use dexamethasone (or other corticosteroids) to treat COVID-19 in children or adolescents who do not require oxygen.

**Dexamethasone and other corticosteroids should still be used for other evidence-based indications in children or adolescents who have COVID-19.**

For specific recommendations on the use of corticosteroids for PIMS-TS see section.
Evidence To Decision

**Benefits and harms**

In adult patients who do not require oxygen, there may be more deaths with dexamethasone and other corticosteroids. It is unclear if any children were included in the trials, therefore there is uncertainty regarding the benefits in this population but there are known potential adverse effects.

**Certainty of the Evidence**

In children and adolescents who do not require oxygen, certainty of the evidence is judged to be low for all outcomes (mortality, mechanical ventilation or death, and discharge from hospital) due to serious imprecision (reliance on a single study and wide confidence intervals) and serious indirectness (results based on the general adult population).

For adverse events (gastrointestinal bleeding, super infections, hyperglycaemia, neuromuscular weakness and neuropsychiatric effects), evidence is generally low due to serious indirectness (evidence comes from non-COVID-19 patients) and serious imprecision.

**Preference and values**

We have no systematically collected information regarding the preferences and values of patients, parents, carers, families and guardians.

The NC19CET Consumer Panel believes that most informed patients (and their parents, carers, families and guardians) may prefer to wait until the available evidence is clearer, and would not agree to this treatment for COVID-19.

**Resources**

There are no identified resource issues as the recommendation reflects usual care.

**Equity**

There are no identified equity issues as the recommendation reflects usual care.

**Acceptability**

We have no systematically collected evidence regarding acceptability.

**Feasibility**

There are no identified feasibility issues as the recommendation reflects usual care.

**Rationale**

Evidence from an adult population suggests that dexamethasone and other corticosteroids in people with COVID-19 who do not require oxygen may increase the risk of death. We therefore recommend against dexamethasone and other corticosteroids in children or adolescents unless there is an alternative evidence-based indication for its use.

**Clinical Question/ PICO**

- **Population:** Special populations with COVID-19 [adapted from general adult population]
- **Intervention:** Corticosteroids
Comparator: Standard care

Summary
Evidence indicates that corticosteroids reduce deaths in patients with critical or severe COVID-19, but may increase deaths in patients with moderate COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a recent meta-analysis and associated living guidance [22] of seven randomised trials of patients with critical COVID-19 [26][27][28][29][30][31][32], one study of patients with moderate, severe and critical COVID-19 [33] and one study of patients with severe COVID-19 [35]. Over 5700 patients are included in the meta-analysis. All trials compared corticosteroids plus standard care with standard care alone.

In addition, two meta-analyses of corticosteroids for other conditions—other coronavirus infections, influenza, community-acquired pneumonia, acute respiratory distress [23] and sepsis [24]—provided indirect evidence for serious adverse events.

Study characteristics
Three studies compared dexamethasone with standard care [31][29][33], three compared hydrocortisone with standard care [30][28][26] and three compared methylprednisolone with standard care [27][32][35].

Disease severity was reported independently for each trial. Definitions included patients who required mechanical ventilation or NIV, PaO2/FiO2 < 200, positive end-expiratory pressure (PEEP) ≥ 5 cmH2O, and the presence of pneumonia or infiltrates on chest imaging.

Mean or median age ranged from 57 to 67 years in the corticosteroid groups and from 60 to 66 years in the standard care groups. The proportion of women was 32% (range 13% to 43%) in the corticosteroid groups and 29% (range 21% to 36%) in the standard care groups.

What are the main results?
Compared with standard care, corticosteroids probably reduce death in patients with severe and critical COVID-19. For every 1000 patients given corticosteroids, 51 more are likely to survive compared with those receiving standard care (RR 0.84 CI 95% 0.73 to 0.98; 5789 patients in 9 studies). Corticosteroids in patients requiring oxygen also probably reduce the composite outcome of requirement for invasive mechanical ventilation or death, and time to discharge from hospital.

In patients who do not require oxygen, corticosteroids probably increase death (RR 1.27 CI 95% 1.00 to 1.61; 1535 patients in 1 study) and the composite outcome of invasive mechanical ventilation or death.

Indirect evidence of corticosteroid use in patients with other, similar indications shows no difference in the incidence of gastrointestinal bleeding, superinfections, neuromuscular weakness and neuropsychiatric effects. However, corticosteroid use was associated with an increase in hyperglycaemia (RR 1.16 CI 95% 1.08 to 1.25; 8938 patients in 8 studies).

Our confidence in the results
Certainty of the evidence for all outcomes is judged to be low for pregnant and breastfeeding women, and children and adolescents due to serious indirectness. This is in addition to concerns in the adult population about inconsistency in direction of effect and serious imprecision.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [adults]</td>
<td>Relative risk 0.84 (CI 95% 0.73 - 0.98)</td>
<td>316 265</td>
<td>Low Due to serious</td>
<td>Corticosteroids may decrease death at day</td>
</tr>
</tbody>
</table>
**Serious adverse events [adults requiring oxygen]**

Within 28 days of commencing treatment

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>95% CI</th>
<th>Study Details</th>
<th>Pooled Difference</th>
<th>95% CI</th>
<th>Study Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious adverse events</td>
<td>0.8</td>
<td>0.53 - 1.19</td>
<td>9,789 patients in 9 studies</td>
<td>51 fewer per 1,000</td>
<td>85 fewer - 6 fewer</td>
<td>28 in patients who require oxygen</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death</td>
<td>0.88</td>
<td>0.56 - 0.97</td>
<td>696 patients in 6 studies</td>
<td>47 fewer per 1,000</td>
<td>110 fewer - 44 more</td>
<td>Due to serious inconsistency and indirectness</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>1.27</td>
<td>0.95 - 1.71</td>
<td>1,535 patients in 1 study</td>
<td>38 more per 1,000</td>
<td>0 fewer - 85 more</td>
<td>Due to only one study and serious indirectness</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or death</td>
<td>1.25</td>
<td>0.95 - 1.61</td>
<td>1,535 patients in 1 study</td>
<td>39 more per 1,000</td>
<td>0 fewer - 88 more</td>
<td>Due to only one study and serious indirectness</td>
</tr>
</tbody>
</table>

Corticosteroids may have little impact on serious adverse events in patients who require oxygen.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference</th>
<th>P Value</th>
<th>Risk Level</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharge from hospital [adults not requiring oxygen]</strong></td>
<td>Within 28 days after commencing treatment</td>
<td>0.96</td>
<td>0.90 - 1.01</td>
<td>Lower than 1.00</td>
<td>Low</td>
<td>Corticosteroids may have little impact on discharge from hospital in patients who do not require oxygen.</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal bleeding</strong></td>
<td>End of treatment</td>
<td>1.06</td>
<td>0.85 - 1.33</td>
<td>Higher than 1.00</td>
<td>Low</td>
<td>Corticosteroids may have little impact on gastrointestinal bleeding.</td>
<td></td>
</tr>
<tr>
<td><strong>Super infections</strong></td>
<td>End of treatment</td>
<td>1.01</td>
<td>0.90 - 1.13</td>
<td>Higher than 1.00</td>
<td>Low</td>
<td>Corticosteroids may have little impact on number of patients with super infections.</td>
<td></td>
</tr>
<tr>
<td><strong>Hyperglycaemia</strong></td>
<td>End of treatment</td>
<td>1.16</td>
<td>1.08 - 1.25</td>
<td>Higher than 1.00</td>
<td>Moderate</td>
<td>Corticosteroids probably increase the risk of hyperglycaemia.</td>
<td></td>
</tr>
<tr>
<td><strong>Neuromuscular weakness</strong></td>
<td>End of treatment</td>
<td>1.09</td>
<td>0.86 - 1.39</td>
<td>Higher than 1.00</td>
<td>Low</td>
<td>Corticosteroids may have little impact on neuromuscular weakness.</td>
<td></td>
</tr>
<tr>
<td><strong>Neuropsychiatric effects</strong></td>
<td>End of treatment</td>
<td>0.81</td>
<td>0.41 - 1.63</td>
<td>Lower than 1.00</td>
<td>Low</td>
<td>Corticosteroids may have little impact on neuropsychiatric effects.</td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital [adults requiring oxygen]</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>1.10</td>
<td>1.06 - 1.15</td>
<td>Higher than 1.00</td>
<td>Low</td>
<td>Corticosteroids may increase discharge from hospital in patients who require oxygen.</td>
<td></td>
</tr>
</tbody>
</table>

2. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.


4. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.

5. The number of patients with severe illness (i.e. who do not require mechanical ventilation at enrolment) that progress to requiring invasive mechanical ventilation or death within 28 days


7. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.

8. Systematic review [21] with included studies: RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.

9. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study, Wide confidence intervals.

10. Systematic review [21] with included studies: RECOVERY. **Baseline/comparator:** Control arm of reference used for intervention.

11. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.


13. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.

14. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.

15. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.

16. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.

17. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.

18. Systematic review [22]. **Baseline/comparator:** Control arm of reference used for intervention.


20. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.
6.2 - Remdesivir

6.2.1 - Remdesivir for adults

**Conditional recommendation**

Consider using remdesivir for adults hospitalised with COVID-19 who require oxygen but not ventilation.

The recommended regimen is daily intravenous infusion (200 mg initial dose, 100 mg maintenance), optimal duration of remdesivir treatment is unclear, however current evidence does not suggest a clear benefit of 10 days over 5 days.

It is unclear whether remdesivir increases or decreases mortality in patients who are hospitalised with COVID-19 and who do not require oxygen. For this population, remdesivir should still be considered for use in randomised trials with appropriate ethical approval.

On 31 July, the Australian Government provided specific criteria that needed to be met in order to access remdesivir for clinical treatment. These included age ≥ 18 years (or 12 to 17 years weighing ≥ 40 kg), an oxygen saturation of SpO2 ≤ 92% on room air and requiring supplemental oxygen, and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) and/or ALT < 3 x ULN and bilirubin < 2 ULN. Patients with evidence of multiorgan failure, renal failure or those receiving mechanical ventilation for > 48 hours at time of application or extracorporeal membrane oxygenation (ECMO) are unable to receive remdesivir.

It is unclear whether older people or those requiring palliative care were included in the studies this recommendation is based on. Until further evidence in these populations is available, the Taskforce does not believe a different recommendation should apply, unless contraindicated.

Due to antagonism observed in vitro, concomitant use of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].

Evidence To Decision

**Benefits and harms**

In patients who are hospitalised with moderate COVID-19 and who require oxygen but not ventilation (non-invasive ventilation, mechanical ventilation or ECMO), remdesivir reduces the incidence of death.

Evidence from randomised trials versus standard care demonstrates that remdesivir has an acceptable safety profile and may reduce the incidence of serious adverse events. Based on the results of two studies that compared 10-day to 5-day courses of remdesivir, it is unclear which of these regimens provide the optimal duration of treatment—current evidence does not suggest a clear benefit for 10 days over 5 days.

**Older people living with frailty or cognitive impairment**

People aged over 65 years were included in the trials but no details were reported for frailty or cognitive impairment.

**People requiring palliative care**

In addition to the concerns in the general adult population, there is uncertainty regarding benefits and harms for people requiring palliative care as no details were reported in the trials for this population. In particular, the benefits for symptom management are uncertain.

**Certainty of the Evidence**

Certainty of the evidence is moderate for death at day 28 in patients who do not require oxygen and in patients who require oxygen but not ventilation. Certainty is also moderate for patients requiring ventilation, discharge from hospital, serious adverse events, time to recovery and time to improvement. Certainty is low for all other outcomes.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Remdesivir in patients hospitalised with COVID-19 who do not require ventilation decreases the incidence of death—its use should be considered in this population. Because of this, the Taskforce gives a conditional recommendation for remdesivir both within and outside the context of a randomised trial.

It is unclear which regimen of remdesivir (5-day or 10-day) provides the optimal duration of treatment. In Australia, criteria for accessing remdesivir from the National Medical Stockpile limits the treatment course to 5 days for eligible patients.
Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: Remdesivir
Comparator: Standard care

Summary
Evidence indicates that remdesivir reduces the incidence of death in hospitalised adults who require oxygen but not ventilation, increases the incidence of death in hospitalised adults who require ventilation, and has little or no impact on death in hospitalised adults who do not require oxygen.

What is the evidence informing this recommendation?
Evidence comes from four randomised trials that compared remdesivir with standard care in 7333 adults hospitalised with COVID-19 [39][40][43][50]. The majority of evidence is from the WHO SOLIDARITY and ACTT-1 trials, which randomised 5451 and 1062 patients with moderate to critical COVID-19 [50][39].

Publication status
The WHO SOLIDARITY trial has reported interim results as a preprint and has therefore not been peer reviewed [50]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

Study characteristics
For a comprehensive description, see the study characteristics table. There was variability in disease severity among patients included in the trials (see table).

<table>
<thead>
<tr>
<th>Disease severity</th>
<th>Number of patients</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate</td>
<td>584</td>
<td>[43]</td>
</tr>
<tr>
<td>Moderate-Critical</td>
<td>6513</td>
<td>[39][50]</td>
</tr>
<tr>
<td>Severe-Critical</td>
<td>236</td>
<td>[40]</td>
</tr>
</tbody>
</table>

What are the main results?
Compared with standard care, remdesivir probably reduces death at day 28 in patients who require oxygen but not ventilation (four fewer deaths per 1000 patients (RR 0.80, CI 95% 0.43 to 1.49; 2047 patients in 3 studies), and probably increases death at day 28 in patients who require ventilation (50 more deaths per 1000 patients (RR 1.20 CI 95% 0.98 to 1.47; 1004 patients in 4 studies)). There was no difference in mortality in hospitalised adults treated with remdesivir who did not require oxygen.

Remdesivir may decrease time to recovery by a few days (HR 1.24, 95% CI 1.08 to 1.42; 1643 patients in 2 studies) and time to improvement only slightly (HR 1.17, 95% CI 1.00 to 1.38; 810 patients in 2 studies). Clinical recovery was defined as the first day in which a patient satisfied categories 1, 2 or 3 on the eight-point WHO ordinal scale [39] or improvement from a baseline score of 2 to 5 to a score of 6 or 7 on a 7-point ordinal scale [43]. Clinical improvement was defined as an improvement of 2 or more points on a 7-point ordinal scale [43] or 6-point ordinal scale [40].

Compared with standard care, remdesivir probably reduces serious adverse events (63 fewer SAEs per 1000 patients (RR 0.75, CI 95% 0.68 to 0.89; 1865 patients in 3 studies)). There was no important difference between remdesivir and standard care regarding the number of patients requiring ventilation and number of patients discharged from hospital at day 28. We are uncertain whether remdesivir impacts respiratory failure or ARDS, clinical recovery at day 28, septic shock, adverse events and discontinuation due to adverse events.

Our confidence in the results
Certainty of the evidence for death (all patients) at day 28 is high. Certainty is moderate for death in all three subgroups (patients who do not require oxygen, patients who require oxygen but not ventilation, and patients that require ventilation), all due to serious imprecision (few events or wide confidence intervals). Certainty is also moderate for patients requiring ventilation and discharge from hospital (due to reliance on a single study), serious adverse events, time to recovery and time to improvement (due to non-blinding of patients and personnel).
Certainty of the evidence is low for respiratory failure or ARDS (due to inconsistency in direction of effect and wide confidence intervals), number of patients requiring invasive mechanical ventilation or ECMO (due to non-blinding of patients and personnel and reliance on a single study), clinical recovery, septic shock and adverse events (due to non-blinding of patients and personnel and inconsistency in direction of effect) and discontinuation due to adverse events (due to non-blinding of patients and personnel and wide confidence intervals).

Additional information
The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [all patients]</td>
<td>Relative risk 0.93 (CI 95% 0.82 - 1.06) Based on data from 7,333 patients in 4 studies. (Randomized controlled)</td>
<td>112 per 1000</td>
<td>104 per 1000</td>
<td>High</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>9 Critical</td>
<td>Difference: 8 fewer per 1000 (CI 95% 20 fewer - 7 more)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality [hospitalised, no oxygen] Within 28 days of commencing treatment</td>
<td>Relative risk 0.8 (CI 95% 0.43 - 1.49) Based on data from 2,047 patients in 3 studies. (Randomized controlled)</td>
<td>22 per 1000</td>
<td>18 per 1000</td>
<td>Moderate Due to serious imprecision</td>
</tr>
<tr>
<td>All-cause mortality [hospitalised, oxygen no ventilation] Within 28 days of commencing treatment</td>
<td>Relative risk 0.64 (CI 95% 0.34 - 1.21) Based on data from 4,271 patients in 3 studies. (Randomized controlled)</td>
<td>121 per 1000</td>
<td>77 per 1000</td>
<td>Moderate Due to serious imprecision</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 1.2 (CI 95% 0.98 - 1.47)</td>
<td>248</td>
<td>298</td>
<td>Moderate Due to serious</td>
</tr>
</tbody>
</table>

Relative to standard care.
<table>
<thead>
<tr>
<th>Clinical Outcome</th>
<th>Relative Risk</th>
<th>Based on data from</th>
<th>Difference</th>
<th>CI 95%</th>
<th>Criticality</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>[hospitalised,</td>
<td></td>
<td>1,004 patients in 4</td>
<td>50 more</td>
<td>5 fewer - 117 more</td>
<td>9 Critical</td>
<td>Slightly in hospitalised patients who require ventilation.</td>
</tr>
<tr>
<td>requiring ventilation]</td>
<td></td>
<td>studies. 6</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>(Randomized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory failure or ARDS</td>
<td>0.79</td>
<td>1,296 patients in 2</td>
<td>30 fewer</td>
<td>93 fewer - 112 more</td>
<td>9 Critical</td>
<td>We are uncertain whether remdesivir increases or decreases respiratory failure or ARDS (132 events).</td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>studies. 8</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>(Randomized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>0.57</td>
<td>766 patients in 1</td>
<td>97 fewer</td>
<td>131 fewer - 47 fewer</td>
<td>9 Critical</td>
<td>Remdesivir may decrease the need for invasive mechanical ventilation or ECMO (134 events).</td>
</tr>
<tr>
<td>or ECMO</td>
<td></td>
<td>studies. 10</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>(Randomized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients requiring ventilation</td>
<td>1.03</td>
<td>4,964 patients in 1</td>
<td>3 more</td>
<td>13 fewer - 23 more</td>
<td>6 Important</td>
<td>Remdesivir probably has no impact on number of patients requiring ventilation.</td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>studies. 12</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>(Randomized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical recovery</td>
<td>0.99</td>
<td>1,876 patients in 3</td>
<td>7 fewer</td>
<td>100 fewer - 100 more</td>
<td>6 Important</td>
<td>We are uncertain whether remdesivir improves or worsens clinical recovery at day 28.</td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>studies. 14</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>(Randomized</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Septic shock</td>
<td>1.02</td>
<td>1,296 patients in 2</td>
<td>0 fewer</td>
<td></td>
<td>16</td>
<td>We are uncertain whether remdesivir increases or decreases septic shock (13 events).</td>
</tr>
<tr>
<td>Within 28 days of commencing</td>
<td></td>
<td>studies. 16</td>
<td>per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Serious adverse events

**End of follow-up**

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Number of Patients</th>
<th>Difference</th>
<th>Type</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td>0.75</td>
<td>0.63 - 0.89</td>
<td>1,865</td>
<td>63 fewer per 1000</td>
<td>Moderate</td>
<td>Due to serious risk of bias</td>
</tr>
<tr>
<td>6 Important</td>
<td>1.04</td>
<td>0.89 - 1.21</td>
<td>1,880</td>
<td>22 more per 1000</td>
<td>Low</td>
<td>Due to serious risk of bias and serious inconsistency</td>
</tr>
<tr>
<td>6 Important</td>
<td>1.73</td>
<td>0.57 - 5.28</td>
<td>1,880</td>
<td>68 more per 1000</td>
<td>Low</td>
<td>We are uncertain whether remdesivir increases or decreases adverse events leading to discontinuation</td>
</tr>
<tr>
<td>6 Important</td>
<td>0.99</td>
<td>0.96 - 1.03</td>
<td>5,451</td>
<td>7 fewer per 1000</td>
<td>Moderate</td>
<td>Due to serious imprecision</td>
</tr>
</tbody>
</table>

**Notes:** Relative risk based on data from 3 studies (1,865 patients) for 6 Important and 6 Important for 6 Important. Relative risk based on data from 3 studies (1,880 patients) for 6 Important. Relative risk based on data from 3 studies (1,880 patients) for 6 Important. Relative risk based on data from 1 study (5,451 patients) for 6 Important. Remdesivir probably decreases serious adverse events slightly (340 events).

### Time to recovery

**Days**

<table>
<thead>
<tr>
<th>Event</th>
<th>Hazard Ratio</th>
<th>CI 95%</th>
<th>Number of Patients</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td>1.24</td>
<td>1.08 - 1.42</td>
<td>1,643</td>
<td>7 fewer</td>
</tr>
<tr>
<td>6 Important</td>
<td>1.17</td>
<td>1.01 - 1.38</td>
<td>810</td>
<td>7 fewer</td>
</tr>
</tbody>
</table>

**Notes:** Hazard ratio based on data from 2 studies (1,643 patients) for 6 Important. Hazard ratio based on data from 2 studies (810 patients) for 6 Important. Remdesivir may decrease time to recovery by a few days.

### Time to improvement

**Days**

<table>
<thead>
<tr>
<th>Event</th>
<th>Hazard Ratio</th>
<th>CI 95%</th>
<th>Number of Patients</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td>1.17</td>
<td>1.01 - 1.38</td>
<td>810</td>
<td>7 fewer</td>
</tr>
</tbody>
</table>

**Notes:** Hazard ratio based on data from 2 studies (810 patients) for 6 Important. Remdesivir may decrease time to improvement slightly.

---


---
**Imprecision:** Serious. due to few events.
**Imprecision:** Serious. Wide confidence intervals.
**Imprecision:** Serious. Wide confidence intervals.
**Imprecision:** Serious. The direction of the effect is not consistent between the included studies.  
**Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.  
**Imprecision:** Serious. Wide confidence intervals.
**Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision:** Serious. Low number of patients, Only data from one study.
**Imprecision:** Serious. Only data from one study.
**Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.  
**Inconsistency:** Serious. The confidence interval of some of the studies do not overlap with those of most included studies/ the point estimate of some of the included studies, The direction of the effect is not consistent between the included studies.
**Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.
**Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.  
**Imprecision:** Serious. Wide confidence intervals.
**Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for detection bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision:** Serious. Wide confidence intervals.
**Risk of bias:** Serious. Only data from one study.
**Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Inconsistency:** Serious. The direction of the effect is not consistent between the included studies.
27. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

### Clinical Question/ PICO

- **Population:** Remdesivir dosage for COVID-19
- **Intervention:** 5 days' treatment
- **Comparator:** Up to 10 days' treatment

### Summary

There remains uncertainty whether a 5-day course of remdesivir is more effective and safer than a 10-day course.

**What is the evidence informing this recommendation?**

Evidence comes from two randomised trials that compared 5-day to 10-day treatment with remdesivir in 781 hospitalised patients with severe COVID-19 [41][43].

**Study characteristics**

For a comprehensive description, see the [study characteristics table](#).

**What are the main results?**

There is a lower risk of death within 14 days of treatment with a 5-day versus a 10-day course of remdesivir (16 fewer deaths per 1000 patients (RR 0.73, CI 95% 0.40 to 1.33; 781 patients in 2 studies)). The evidence is more uncertain for death within 28 days of treatment (5 fewer deaths per 1000 patients (RR 0.67, CI 95% 0.11 to 3.99; 384 patients in 1 study)).

There is probably little difference between a 5-day and 10-day course of remdesivir regarding adverse events, discontinuation of treatment due to adverse events and discharge from hospital.

**Our confidence in the results**

Certainty of the evidence is moderate for the following outcomes: death within 14 days, serious adverse events, adverse events and discharge from hospital within 14 days. Certainty is low for death within 28 days, acute respiratory failure or ARDS, clinical recovery within 14 days and discharge from hospital within 28 days. This judgement is based on serious risk of bias (problems with randomisation [41], lack of blinding), serious imprecision (too few who died) and very serious imprecision (reliance on a single study with few patients and/or few events).

It is important to note that Goldman et al only presents initial results from the first 400 patients in a trial that includes nearly 5000 patients (NCT04292899) [41]. The trial completed recruitment in July 2020 and we await the results from the full cohort of patients.

**Additional information**

The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].

### Outcome Timeframe

<table>
<thead>
<tr>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 10 days’ treatment</td>
<td>5 days’ treatment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### All-cause mortality

**Within 14 days of commencing treatment**

- Relative risk: 0.73 (CI 95% 0.4 - 1.33)  
  Based on data from 781 patients in 2 studies.  
  (Randomized controlled)

  **Critical**
  - Relative risk: 0.67 (CI 95% 0.11 - 3.99)  
    Based on data from 384 patients in 1 study.  
    (Randomized controlled)

  **Low**
  - Relative risk: 1.2 (CI 95% 1.02 - 1.41)  
    Based on data from 397 patients in 1 study.  
    (Randomized controlled)

### Acute respiratory failure or ARDS

**Within 30 days of commencing treatment**

- Relative risk: 0.47 (CI 95% 0.24 - 0.94)  
  Based on data from 397 patients in 1 study.  
  (Randomized controlled)

### Septic shock

**Within 30 days of commencing treatment**

- Relative risk: 0.39 (CI 95% 0.08 - 2.01)  
  Based on data from 397 patients in 1 study.  
  (Randomized controlled)

### Clinical recovery

**Within 14 days of commencing treatment**

- Relative risk: 1.2 (CI 95% 1.02 - 1.41)  
  Based on data from 397 patients in 1 study.  
  (Randomized controlled)

### Serious adverse events

**End of follow up**

- Relative risk: 0.64 (CI 95% 0.47 - 0.87)  
  Based on data from 781 patients in 2 studies.  
  (Randomized controlled)

### End of follow up

- Relative risk: 0.64 (CI 95% 0.47 - 0.87)  
  Based on data from 781 patients in 2 studies.  
  (Randomized controlled)
<table>
<thead>
<tr>
<th><strong>Adverse events</strong></th>
<th><strong>Baseline/comparator:</strong> Control arm of reference used for intervention.</th>
<th><strong>Imprecision:</strong> Serious due to few events.</th>
</tr>
</thead>
<tbody>
<tr>
<td>End of follow up</td>
<td>Relative risk 0.93 (CI 95% 0.84 - 1.03) Based on data from 781 patients in 2 studies. 13 (Randomized controlled)</td>
<td>Moderate Due to serious risk of bias 14 Remdesivir 5-day treatment probably has little or no difference on adverse events (503 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td>662 per 1000 Difference: 46 fewer per 1000 (CI 95% 106 fewer - 20 more)</td>
<td>Remdesivir 5-day treatment may have little or no difference on discontinuation due to adverse events (35 events).</td>
</tr>
<tr>
<td>Discontinuation due to adverse events During treatment</td>
<td>Relative risk 0.59 (CI 95% 0.3 - 1.15) Based on data from 781 patients in 2 studies. 15 (Randomized controlled)</td>
<td>Low Due to serious risk of bias and imprecision 16 Remdesivir 5-day treatment probably has little or no difference on number of patients discharged from hospital at day 14 (515 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td>56 per 1000 Difference: 23 fewer per 1000 (CI 95% 39 fewer - 8 more)</td>
<td>Remdesivir 5-day treatment may have little or no difference on number of patients discharged from hospital at day 14 (515 events).</td>
</tr>
<tr>
<td>Discharged from hospital Within 14 days of commencing treatment</td>
<td>Relative risk 1.06 (CI 95% 0.93 - 1.2) Based on data from 781 patients in 2 studies. 17 (Randomized controlled)</td>
<td>Moderate Due to serious risk of bias 18 Remdesivir 5-day treatment probably has little or no difference on number of patients discharged from hospital at day 14 (515 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td>638 per 1000 Difference: 38 more per 1000 (CI 95% 45 fewer - 128 more)</td>
<td>Remdesivir 5-day treatment may have little or no difference on number of patients discharged from hospital at day 14 (515 events).</td>
</tr>
<tr>
<td>Discharged from hospital Within 28 days of commencing treatment</td>
<td>Relative risk 0.99 (CI 95% 0.92 - 1.06) Based on data from 384 patients in 1 studies. 19 (Randomized controlled)</td>
<td>Low Due to very serious imprecision 20 Remdesivir 5-day treatment may have little or no difference on number of patients discharged from hospital at day 28 (344 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td>902 per 1000 Difference: 9 fewer per 1000 (CI 95% 72 fewer - 54 more)</td>
<td>Remdesivir 5-day treatment may have little or no difference on number of patients discharged from hospital at day 28 (344 events).</td>
</tr>
</tbody>
</table>

2. **Imprecision:** Serious, due to few events.
4. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
6. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
8. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. Only data from one study.
12. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.


14. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


16. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision: Serious.** due to few events.


18. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


20. **Imprecision: Very Serious.** Low number of patients, Only data from one study.

---

**Not recommended**

Do not start remdesivir in adults hospitalised with COVID-19 who require ventilation.

*Remdesivir should be continued with the appropriate dose and duration, if it was started prior to requiring ventilation.*

*Within this population, ventilation includes invasive or non-invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO).*  
*Use of remdesivir may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include remdesivir.*

---

**Evidence To Decision**

**Benefits and harms**

In patients who are hospitalised with COVID-19 and who require ventilation, risk of death may be higher in patients using remdesivir compared with standard care.

**Older people living with frailty or cognitive impairment**

People aged over 65 years were included in the trials but no details were reported for frailty or cognitive impairment.

**People requiring palliative care**

In addition to the concerns in the general adult population, there is uncertainty regarding benefits and harms for people requiring palliative care as no details were reported in the trials for this population. In particular, the benefits for symptom management are uncertain.

---

**Certainty of the Evidence**

Certainty of the evidence is moderate for death at day 28 in hospitalised adults who require ventilation. Certainty is also
Rationale
Remdesivir in adults hospitalised with COVID-19 who require ventilation probably increases the incidence of death—its use should be avoided in this population.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Remdesivir</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

Summary
Evidence indicates that remdesivir reduces the incidence of death in hospitalised adults who require oxygen but not ventilation, increases the incidence of death in hospitalised adults who require ventilation, and has little or no impact on death in hospitalised adults who do not require oxygen.

What is the evidence informing this recommendation?
Evidence comes from four randomised trials that compared remdesivir with standard care in 7333 adults hospitalised with COVID-19 [39][40][43][50]. The majority of evidence is from the WHO SOLIDARITY and ACTT-1 trials, which randomised 5451 and 1062 patients with moderate to critical COVID-19 [50][39].

Publication status
The WHO SOLIDARITY trial has reported interim results as a preprint and has therefore not been peer reviewed [50]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.
What are the main results?

Compared with standard care, remdesivir probably reduces death at day 28 in patients who require oxygen but not ventilation (four fewer deaths per 1000 patients (RR 0.80, CI 95% 0.43 to 1.49; 2047 patients in 3 studies)), and probably increases death at day 28 in patients who require ventilation (50 more deaths per 1000 patients (RR 1.20 CI 95% 0.98 to 1.47; 1004 patients in 4 studies)). There was no difference in mortality in hospitalised adults treated with remdesivir who did not require oxygen.

Remdesivir may decrease time to recovery by a few days (HR 1.24, 95% CI 1.08 to 1.42; 1643 patients in 2 studies) and time to improvement only slightly (HR 1.17, 95% CI 1.00 to 1.38; 810 patients in 2 studies). Clinical recovery was defined as the first day in which a patient satisfied categories 1, 2 or 3 on the eight-point WHO ordinal scale [39] or improvement from a baseline score of 2 to 5 to a score of 6 or 7 on a 7-point ordinal scale [43]. Clinical improvement was defined as an improvement of 2 or more points on a 7-point ordinal scale [43] or 6-point ordinal scale [40].

Compared with standard care, remdesivir probably reduces serious adverse events (63 fewer SAEs per 1000 patients (RR 0.75, CI 95% 0.68 to 0.89; 1865 patients in 3 studies)). There was no important difference between remdesivir and standard care regarding the number of patients requiring ventilation and number of patients discharged from hospital at day 28. We are uncertain whether remdesivir impacts respiratory failure or ARDS, clinical recovery at day 28, septic shock, adverse events and discontinuation due to adverse events.

Our confidence in the results

Certainty of the evidence for death (all patients) at day 28 is high. Certainty is moderate for death in all three subgroups (patients who do not require oxygen, patients who require oxygen but not ventilation, and patients that require ventilation), all due to serious imprecision (few events or wide confidence intervals). Certainty is also moderate for patients requiring ventilation and discharge from hospital (due to reliance on a single study), serious adverse events, time to recovery and time to improvement (due to non-blinding of patients and personnel).

Certainty of the evidence is low for respiratory failure or ARDS (due to inconsistency in direction of effect and wide confidence intervals), number of patients requiring invasive mechanical ventilation or ECMO (due to non-blinding of patients and personnel and reliance on a single study), clinical recovery, septic shock and adverse events (due to non-blinding of patients and personnel and inconsistency in direction of effect) and discontinuation due to adverse events (due to non-blinding of patients and personnel and wide confidence intervals).

Additional information

The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].
<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Risk</th>
<th>95% CI</th>
<th>Difference</th>
<th>95% CI of Difference</th>
<th>95% CI of Difference</th>
<th>Purity</th>
<th>Criticality</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality [hospitalised, no oxygen]</td>
<td>0.8</td>
<td>(0.43 - 1.49)</td>
<td>4 fewer</td>
<td>(13 fewer - 11 more)</td>
<td></td>
<td>Moderate</td>
<td>Due to serious imprecision</td>
</tr>
<tr>
<td>All-cause mortality [hospitalised, oxygen no ventilation]</td>
<td>0.64</td>
<td>(0.34 - 1.21)</td>
<td>44 fewer</td>
<td>(80 fewer - 25 more)</td>
<td></td>
<td>Moderate</td>
<td>Due to serious imprecision</td>
</tr>
<tr>
<td>All-cause mortality [hospitalised, requiring ventilation]</td>
<td>1.2</td>
<td>(0.98 - 1.47)</td>
<td>50 more</td>
<td>(5 fewer - 117 more)</td>
<td></td>
<td>Moderate</td>
<td>Due to serious imprecision</td>
</tr>
<tr>
<td>Respiratory failure or ARDS</td>
<td>0.79</td>
<td>(0.35 - 1.78)</td>
<td>30 fewer</td>
<td>(93 fewer - 112 more)</td>
<td></td>
<td>Low</td>
<td>Due to serious inconsistency and serious imprecision</td>
</tr>
</tbody>
</table>

**Within 28 days of commencing treatment**

Based on data from 7,333 patients in 4 studies. 1 (Randomized controlled)

**Difference:** 8 fewer per 1000

( CI 95% 20 fewer - 7 more )

**Moderate**

Due to serious imprecision

Remdesivir probably has little impact on death in hospitalised patients who do not require oxygen (39 events).

**All-cause mortality [hospitalised, no oxygen]**

Within 28 days of commencing treatment

Relative risk 0.8

( CI 95% 0.43 - 1.49 )

Based on data from 2,047 patients in 3 studies. 2 (Randomized controlled)

**Difference:** 4 fewer per 1000

( CI 95% 13 fewer - 11 more )

**Moderate**

Due to serious imprecision

Remdesivir probably decreases death slightly in hospitalised patients who require oxygen but not ventilation.

**All-cause mortality [hospitalised, oxygen no ventilation]**

Within 28 days of commencing treatment

Relative risk 0.64

( CI 95% 0.34 - 1.21 )

Based on data from 4,271 patients in 3 studies. 4 (Randomized controlled)

**Difference:** 44 fewer per 1000

( CI 95% 80 fewer - 25 more )

**Moderate**

Due to serious imprecision

Remdesivir probably decreases death slightly in hospitalised patients who require ventilation.

**All-cause mortality [hospitalised, requiring ventilation]**

Within 28 days of commencing treatment

Relative risk 1.2

( CI 95% 0.98 - 1.47 )

Based on data from 1,004 patients in 4 studies. 6 (Randomized controlled)

**Difference:** 50 more per 1000

( CI 95% 5 fewer - 117 more )

**Moderate**

Due to serious imprecision

Remdesivir probably increases death slightly in hospitalised patients who require ventilation.

**Respiratory failure or ARDS**

Within 28 days of commencing treatment

Relative risk 0.79

( CI 95% 0.35 - 1.78 )

Based on data from 1,296 patients in 2 studies. 8 (Randomized controlled)

**Difference:** 30 fewer per 1000

( CI 95% 93 fewer - 112 more )

**Low**

Due to serious inconsistency and serious imprecision

We are uncertain whether remdesivir increases or decreases respiratory failure or ARDS (132 events).
<table>
<thead>
<tr>
<th>Category</th>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Baseline</th>
<th>Treatment</th>
<th>Difference</th>
<th>CI 95%</th>
<th>Risk</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive mechanical ventilation or ECMO</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>0.57</td>
<td>0.42 - 0.79</td>
<td>225</td>
<td>128</td>
<td>97 fewer</td>
<td>0.42 - 0.79</td>
<td>Low</td>
<td>Remdesivir may decrease the need for invasive mechanical ventilation or ECMO (134 events).</td>
</tr>
<tr>
<td><strong>Patients requiring ventilation</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>1.03</td>
<td>0.89 - 1.2</td>
<td>115</td>
<td>118</td>
<td>3 more</td>
<td>0.13 - 2.3</td>
<td>Moderate</td>
<td>Remdesivir probably has no impact on number of patients requiring ventilation.</td>
</tr>
<tr>
<td><strong>Clinical recovery</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>0.99</td>
<td>0.86 - 1.14</td>
<td>711</td>
<td>704</td>
<td>7 fewer</td>
<td>0.17 - 2.2</td>
<td>Low</td>
<td>We are uncertain whether remdesivir improves or worsens clinical recovery at day 28.</td>
</tr>
<tr>
<td><strong>Septic shock</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>1.02</td>
<td>0.34 - 3.01</td>
<td>10</td>
<td>10</td>
<td>0 fewer</td>
<td>0.7 - 2.0</td>
<td>Low</td>
<td>We are uncertain whether remdesivir increases or decreases septic shock (13 events).</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>End of follow-up</td>
<td>0.75</td>
<td>0.63 - 0.89</td>
<td>253</td>
<td>190</td>
<td>63 fewer</td>
<td>0.94 - 2.8</td>
<td>Moderate</td>
<td>Remdesivir probably decreases serious adverse events slightly (340 events).</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>End of follow-up</td>
<td>1.04</td>
<td>0.89 - 1.21</td>
<td>548</td>
<td>570</td>
<td>22 more</td>
<td>0.60 - 1.15</td>
<td>Low</td>
<td>We are uncertain whether remdesivir increases or decreases adverse events.</td>
</tr>
<tr>
<td>Discontinuation due to adverse events During treatment</td>
<td>Relative risk 1.73 (CI 95% 0.57 - 5.28) Based on data from 1,880 patients in 3 studies.</td>
<td>93 per 1000</td>
<td>161 per 1000</td>
<td>Low Due to serious risk of bias and serious imprecision. We are uncertain whether remdesivir increases or decreases adverse events leading to discontinuation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital Within 28 days of commencing treatment</td>
<td>Relative risk 0.99 (CI 95% 0.96 - 1.03) Based on data from 5,451 patients in 1 study.</td>
<td>720 per 1000</td>
<td>713 per 1000</td>
<td>Moderate Due to serious imprecision. Remdesivir probably makes little or no difference on discharge from hospital.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to recovery Days</td>
<td>Hazard Ratio 1.24 (CI 95% 1.08 - 1.42) Based on data from 1,643 patients in 2 studies.</td>
<td>Moderate Due to serious risk of bias. Remdesivir may decrease time to recovery by a few days.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to improvement Days</td>
<td>Hazard Ratio 1.17 (CI 95% 1 - 1.38) Based on data from 810 patients in 2 studies.</td>
<td>Moderate Due to serious risk of bias. Remdesivir may decrease time to improvement slightly.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. **Imprecision:** Serious. due to few events.
5. **Imprecision:** Serious. Wide confidence intervals.
7. **Imprecision:** Serious. Wide confidence intervals.
9. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Imprecision:** Serious. Wide confidence intervals.
11. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. Low number of patients. Only data from one study.
used for intervention.

13. Imprecision: Serious. Only data from one study.
15. Risk of bias: Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inconsistency: Serious. The confidence interval of some of the studies do not overlap with those of most included studies/ the point estimate of some of the included studies., The direction of the effect is not consistent between the included studies.
17. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
Inconsistency: Serious. The direction of the effect is not consistent between the included studies.
19. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
21. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
Inconsistency: Serious. The direction of the effect is not consistent between the included studies.
23. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
Imprecision: Serious. Wide confidence intervals.
25. Imprecision: Serious. Only data from one study.
26. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
27. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
6.2.2 - Remdesivir for pregnant or breastfeeding women

**Conditional recommendation against**

Use of remdesivir for pregnant or breastfeeding women with COVID-19 outside of a trial setting should not be considered routinely.

*As pregnant and breastfeeding women are often excluded from clinical trials, use of remdesivir in this population would be outside a clinical trial setting. Pregnant and breastfeeding women receiving remdesivir should nonetheless be enrolled in national COVID-19 registries. Currently, there is no direct evidence of the effects of remdesivir in pregnant and breastfeeding women.*

*Due to antagonism observed in vitro, concomitant use of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].*

*The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMo2007764). These studies are currently under review by the Pregnancy and Perinatal Care panel and an updated recommendation will be included in a future version of the guideline.*

**Evidence To Decision**

**Benefits and harms**

There remains uncertainty around the benefits and harms of remdesivir for pregnant or breastfeeding women with COVID-19. Evidence from trials that compared 10-day to 5-day courses of remdesivir is too uncertain to inform decisions regarding length of treatment at this point.

**Certainty of the Evidence**

Certainty of the evidence for death at day 14 is low due to some concerns about inconsistency and serious indirectness. Certainty for most remaining outcomes is very low due to serious risk of bias, serious indirectness and either serious imprecision or serious inconsistency in the direction of effect between studies. The exception is serious adverse events, which is considered to be of low certainty.

**Preference and values**

We have no systematically collected information regarding the preferences and values of pregnant or breastfeeding women at this point. Since there is uncertainty regarding the benefit to harm ratio for women and their babies, the panel believes some women might prefer to wait while others might be more willing to opt for treatment.

**Resources**

We have no systematically collected evidence regarding cost-benefit. At this point, remdesivir remains an experimental therapy so the potential costs for this therapy outside a research setting are unclear.

**Equity**

There is a risk of creating inequity as pregnant or breastfeeding women are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent. Inequity may be further exacerbated in individuals who are eligible for treatment based on compassionate grounds due to factors that may limit access (such as geographic area).
Rationale
There is currently no direct evidence about the impact of remdesivir on outcomes relevant to pregnant and breastfeeding women with COVID-19 and insufficient data on safety. The effect of remdesivir on mortality is uncertain, but it may decrease time to recovery in non-pregnant adults.

The severity of disease is an important factor when considering the use of remdesivir. For pregnant women with severe or critical COVID-19, the harm to benefit ratio may differ compared to pregnant women with mild or moderate illness. The populations in the four studies to date include patients from moderate, severe and critical illness categories outlined in these guidelines [39][41][40].

The studies had insufficient power to perform adequate subgroup analyses. Beigel et al, however, reported small numerical differences between study arms in the outcomes of patients with critical COVID-19, but no statistically significant difference in the primary outcome (time to recovery) by baseline disease severity [39]. Two studies compared 5-day to 10-day treatment, but since there is no established benefit for either approach yet, it remains uncertain whether these results can inform the length of treatment at this point [41][43].

Acceptability
We have no systematically collected evidence regarding acceptability by pregnant or breastfeeding women.

Feasibility
On 10 July, the Therapeutic Goods Administration granted provisional approval to use remdesivir in hospitalised adults with severe COVID-19 symptoms (requiring oxygen or high level support to breathe).

Implementability may be limited by the current arrangements for accessing remdesivir, in terms of the total number of doses available and more general criteria (such as geographic area).

Clinical Question/ PICO
Population: Special populations with COVID-19 [adapted from general adult population]
Intervention: Remdesivir
Comparator: Standard care

Summary
There remains uncertainty whether remdesivir is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from three randomised trials that compared remdesivir to standard care in 1883 hospitalised adults with COVID-19 [39][40][43]. One trial was of patients with moderate to critical illness (1063 patients) [39], one of severe to critical illness (236 patients) [40] and one of moderate illness (584 patients) [43]. In the first two trials, randomisation was stratified by disease severity, in particular whether respiratory support was required.

The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMoa2007764). These studies are currently under review and an updated recommendation will be included in a future version of the guideline.

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
Remdesivir probably reduces death at day 14 compared to standard care (30 fewer deaths per 1000 patients (RR
0.63, CI 95% 0.44 to 0.91; 1874 patients in 3 studies)) but may not affect death at day 28 (1 fewer death per 1000 patients (RR 0.97, CI 95% 0.52 to 1.79; 820 patients in 2 studies)). We are awaiting publication of 28-day mortality data from the ACTT-1 Study Group [39] to determine if the mortality benefit observed at 14 days extends to this later time point.

Remdesivir may decrease time to recovery by a few days (HR 1.24, 95% CI 1.08 to 1.42; 1643 patients in 2 studies) and time to improvement only slightly (HR 1.17, 95% CI 1.00 to 1.38; 810 patients in 2 studies). Clinical recovery was defined as the first day in which a patient satisfied categories 1, 2 or 3 on the eight-point WHO ordinal scale [39] or improvement from a baseline score of 2 to 5 to a score of 6 or 7 on a 7-point ordinal scale [43]. Clinical improvement was defined as an improvement of 2 or more points on a 7-point ordinal scale [43] or 6-point ordinal scale [40].

There is little difference between remdesivir and standard care for the outcomes of respiratory failure / acute respiratory distress syndrome, septic shock, adverse events and clinical recovery. Compared with standard care, remdesivir probably reduces serious adverse events (58 fewer SAEs per 1000 patients (RR 0.74, CI 95% 0.62 to 0.90; 1880 patients in 3 studies)).

Our confidence in the results
Certainty of the evidence for death (day 14) is low due to some inconsistency and indirectness, low for time to recovery, time to improvement and serious adverse events due to serious risk of bias (lack of personnel blinding) and indirectness. For all other outcomes—death (day 28), respiratory failure or ARDS, adverse events, discontinuation due to adverse events, septic shock and clinical recovery—certainty is very low due to serious risk of bias (lack of personnel blinding), serious imprecision (wide confidence intervals), serious indirectness (exclusion or absence of children, adolescents and pregnant women) and/or serious inconsistency in the direction of effect between studies.

Additional information
The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Within 14 days of commencing treatment</td>
<td>Relative risk 0.63 (CI 95% 0.44 - 0.91)</td>
<td>Standard care&lt;br&gt;81 per 1000&lt;br&gt;Difference: 30 fewer per 1000 (CI 95% 45 fewer - 7 fewer)&lt;br&gt;Remdesivir&lt;br&gt;51 per 1000&lt;br&gt;Low&lt;br&gt;Remdesivir may decrease death (day 14 day).</td>
<td>9 Critical</td>
</tr>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.97 (CI 95% 0.52 - 1.79)</td>
<td>Standard care&lt;br&gt;50 per 1000&lt;br&gt;Difference: 1 fewer per 1000 (CI 95% 24 fewer - 39 more)&lt;br&gt;Remdesivir&lt;br&gt;49 per 1000&lt;br&gt;Very Low&lt;br&gt;Remdesivir may have little impact on death (day 28).</td>
<td>9 Critical</td>
</tr>
<tr>
<td>Outcome</td>
<td>Relative risk</td>
<td>CI 95%</td>
<td>Number of Patients</td>
<td>Type</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>--------------------</td>
<td>------</td>
</tr>
<tr>
<td><strong>Respiratory failure or ARDS</strong></td>
<td>0.84</td>
<td>0.47 - 1.53</td>
<td>1,296 patients in 2 studies.</td>
<td>Critical</td>
</tr>
<tr>
<td><strong>Septic shock</strong></td>
<td>1.02</td>
<td>0.34 - 3.01</td>
<td>1,296 patients in 2 studies.</td>
<td>Important</td>
</tr>
<tr>
<td><strong>Clinical recovery (Day 28)</strong></td>
<td>1</td>
<td>0.85 - 1.18</td>
<td>1,873 patients in 3 studies.</td>
<td>Important</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>0.74</td>
<td>0.62 - 0.9</td>
<td>1,880 patients in 3 studies.</td>
<td>Important</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>1.04</td>
<td>0.89 - 1.22</td>
<td>1,880 patients in 3 studies.</td>
<td>Important</td>
</tr>
<tr>
<td><strong>Discontinuation due to adverse events</strong></td>
<td>1.7</td>
<td>0.72 - 3.99</td>
<td>1,880 patients in 3 studies.</td>
<td>Important</td>
</tr>
</tbody>
</table>

**Difference:** 58 fewer per 1000

(Confidence Interval: 85 fewer - 22 fewer)

2. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: No serious. Publication bias: No serious.


4. Inconsistency: Serious. Effects not consistent with day 14 data (from a different trials). Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Few events, Wide confidence intervals. Publication bias: No serious.


6. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Wide confidence intervals.


8. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Wide confidence intervals.


10. Risk of bias: Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inconsistency: Very Serious. The confidence interval of some of the studies do not overlap with those of most included studies/ the point estimate of some of the included studies. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied.


12. Risk of bias: Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Indirectness: Serious. Differences between the population of interest and those studied.


14. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. Indirectness: Serious.

<table>
<thead>
<tr>
<th>Time to recovery (Days)</th>
<th>Hazard Ratio 1.24 (CI 95% 1.08 - 1.42) Based on data from 1,643 patients in 2 studies. (Randomized controlled)</th>
<th>Low Due to serious risk of bias and indirectness</th>
<th>Remdesivir may decrease time to recovery by a few days.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to improvement (Days)</th>
<th>Hazard Ratio 1.17 (CI 95% 1 - 1.38) Based on data from 810 patients in 2 studies. (Randomized controlled)</th>
<th>Low Due to serious risk of bias and indirectness</th>
<th>Remdesivir may decrease time to improvement slightly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce
Serious. Differences between the population of interest and those studied. Imprecision: Serious. The direction of the effect is not consistent between the included studies.


16. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. Inconsistency: Serious. The direction of the effect is not consistent between the included studies. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. Wide confidence intervals.

17. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. Indirectness: Serious. Differences between the population of interest and those studied.

18. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. Indirectness: Serious. Differences between the population of interest and those studied.

Clinical Question/ PICO

Population: Special populations with COVID-19 [adapted from general adult population]
Intervention: 5 days’ treatment
Comparator: Up to 10 days’ treatment

Summary
There remains uncertainty whether a 5-day course of remdesivir is more effective and safer than a 10-day course.

What is the evidence informing this recommendation?
Evidence comes from two randomised trials that compared 5-day to 10-day treatment with remdesivir in 781 hospitalised patients with severe COVID-19 [41][43].

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
There is a lower risk of death within 14 days of treatment with a 5-day versus a 10-day course of remdesivir (16 fewer deaths per 1000 patients (RR 0.73, CI 95% 0.40 to 1.33; 781 patients in 2 studies)). The evidence is more uncertain for death within 28 days of treatment (5 fewer deaths per 1000 patients (RR 0.67, CI 95% 0.11 to 3.99; 384 patients in 1 study)).

There is probably little difference between a 5-day and 10-day course of remdesivir regarding adverse events, discontinuation of treatment due to adverse events and discharge from hospital.

Our confidence in the results
Certainty of the evidence is low for the following outcomes: death within 14 days, serious adverse events, adverse events and discharge from hospital within 14 days. Certainty is very low for death within 28 days, acute respiratory failure or ARDS, clinical recovery within 14 days, septic shock and discharge from hospital within 28 days. This judgement is based on serious risk of bias (problems with randomisation [41], lack of blinding), serious imprecision (too few who died), serious indirectness (exclusion or absence of children, adolescents and pregnant women) and very serious imprecision (reliance on a single study with few patients and/or few events).

It is important to note that Goldman et al only presents initial results from the first 400 patients in a trial that includes nearly 5000 patients (NCT04292899) [41]. The trial completed recruitment in July 2020 and we await the results from the full cohort of patients.
**Additional information**
The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong> Within 14 days of commencing treatment</td>
<td>Relative risk 0.73 (CI 95% 0.4 - 1.33) Based on data from 781 patients in 2 studies. 1 (Randomized controlled)</td>
<td></td>
<td></td>
<td>Remdesivir 5-day treatment probably has little impact on death (40 events).</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td>59 per 1000</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>43 per 1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Difference: 16 fewer (CI 95% 35 fewer - 19 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All-cause mortality</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 0.67 (CI 95% 0.11 - 3.99) Based on data from 384 patients in 1 studies. 2 (Randomized controlled)</td>
<td></td>
<td></td>
<td>We are uncertain whether remdesivir 5-day treatment increases or decreases death at 28 days (5 events).</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td></td>
<td>Very Low</td>
<td></td>
</tr>
<tr>
<td><strong>Acute respiratory failure or ARDS</strong> Within 30 days of commencing treatment</td>
<td>Relative risk 0.47 (CI 95% 0.24 - 0.94) Based on data from 397 patients in 1 studies. 3 (Randomized controlled)</td>
<td></td>
<td></td>
<td>We are uncertain whether remdesivir 5-day treatment decreases acute respiratory failure or ARDS (34 events).</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td></td>
<td>Very Low</td>
<td></td>
</tr>
<tr>
<td><strong>Septic shock</strong> Within 30 days of commencing treatment</td>
<td>Relative risk 0.39 (CI 95% 0.08 - 2.01) Based on data from 397 patients in 1 studies. 7 (Randomized controlled)</td>
<td></td>
<td></td>
<td>We are uncertain whether remdesivir 5-day treatment increases or decreases septic shock (7 events).</td>
</tr>
<tr>
<td></td>
<td>6 Important</td>
<td></td>
<td>Very Low</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical recovery</strong> Within 14 days</td>
<td>Relative risk 1.2 (CI 95% 1.02 - 1.41) Based on data from 397 patients in 1</td>
<td></td>
<td></td>
<td>We are uncertain whether remdesivir 5-day treatment improves clinical</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>CI (95%)</td>
<td>Difference</td>
<td>Patients treated</td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------</td>
<td>-------------------</td>
<td>------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Discharged from hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 14 days of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.06</td>
<td>0.93 - 1.2</td>
<td>38 more</td>
<td>638 per 1000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>676 per 1000</td>
</tr>
<tr>
<td>Discharged from hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 28 days of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.99</td>
<td>0.92 - 1.06</td>
<td>38 more</td>
<td>638 per 1000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>676 per 1000</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>0.64</td>
<td>0.47 - 0.87</td>
<td>72 fewer</td>
<td>200 per 1000</td>
</tr>
<tr>
<td>End of follow-up</td>
<td></td>
<td></td>
<td></td>
<td>128 per 1000</td>
</tr>
<tr>
<td>Adverse events</td>
<td>0.93</td>
<td>0.84 - 1.03</td>
<td>46 fewer</td>
<td>662 per 1000</td>
</tr>
<tr>
<td>End of follow up</td>
<td></td>
<td></td>
<td></td>
<td>616 per 1000</td>
</tr>
<tr>
<td>Discontinuation due to adverse events</td>
<td>0.59</td>
<td>0.3 - 1.15</td>
<td>52 more</td>
<td>624 per 1000</td>
</tr>
<tr>
<td>During treatment</td>
<td></td>
<td></td>
<td></td>
<td>676 per 1000</td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. due to few events.
4. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.


6. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


8. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.


12. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


16. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. due to few events.


18. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


20. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
6.2.3 - Remdesivir for children or adolescents

Conditional recommendation against

Use of remdesivir for children or adolescents with COVID-19 outside of a trial setting should not be considered routinely.

If treatment is considered—in exceptional circumstances—it should be in consultation with a clinical reference group, such as the ANZPID COVID-19 Clinical Reference Group. Informed consent from parents/caregivers should also be obtained. Currently, there is no direct evidence for the use of remdesivir in children or adolescents. Information about the patients and the intervention (dosages, duration) in the trials used for this recommendation can be found in the Practical info tab.

Due to antagonism observed in vitro, concomitant use of remdesivir with chloroquine or hydroxychloroquine is not recommended [42].

The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMoa2007764). These studies are currently under review by the Paediatric and Adolescent Care panel and an updated recommendation will be included in a future version of the guideline.

Practical Info

Use of remdesivir in children or adolescents with COVID-19 should be considered in consultation with an appropriate clinical reference group. The Australasian Society for Infectious Diseases (ASID) paediatric special interest group (ANZPID) has formed a clinical reference group to advise paediatric infection specialists on therapy for children with COVID-19. The ANZPID COVID-19 Clinical Reference Group can be urgently convened to discuss individual patient management and provide a recommendation to the treating team on the use of a disease-modifying treatment when needed. Informed consent from parents/caregivers should also be obtained.

Evidence To Decision

Benefits and harms

The three trials of remdesivir versus standard care provide preliminary evidence that remdesivir as a 10-day treatment has an acceptable safety profile. Evidence from two trials that compared 10-day to 5-day courses of remdesivir is too uncertain to inform decisions regarding length of treatment at this point. The trials are all based on adult patients. There remains uncertainty around the benefits and harms of remdesivir for children and adolescents with COVID-19.

Certainty of the Evidence

Certainty of the evidence for death at day 14 is low due to some concerns about inconsistency and serious indirectness. Certainty for most remaining outcomes is very low due to serious risk of bias, serious indirectness and either serious imprecision or serious inconsistency in the direction of effect between studies. The exception is serious adverse events, which is considered to be of low certainty.

Preference and values

We have no systematically collected information regarding the preferences and values of patients, parents, carers, families and guardians. The panel believes that since there is uncertainty regarding the benefit to harm ratio some patients (and their parents/caregivers/guardians) may prefer to wait while others might be more willing to opt for treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. At this point, remdesivir remains an experimental therapy so the potential costs for this therapy outside a research setting are unclear.
### Rationale

The effect of remdesivir on mortality is uncertain but it may decrease the time to recovery and the risk of serious adverse events in adults. Currently, there is no direct evidence for the use of remdesivir in children or adolescents. Because of this the Taskforce gives a conditional recommendation against the use of remdesivir outside the context of a randomised trial for children and adolescents.

The adult populations in the four studies published to date approximate to the moderate, severe and critical illness categories outlined in this guideline. The studies had insufficient power to perform adequate subgroup analyses. Beigel et al, however, reported small numerical differences between study arms in the outcomes of patients with critical COVID-19, but no statistically significant difference in the primary outcome (time to recovery) by baseline disease severity [39]. Two studies compared 5-day to 10-day treatment, but since there is no established benefit for either approach yet, it remains uncertain whether these results can inform the length of treatment at this point [41][43].

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th><strong>Population:</strong></th>
<th>Special populations with COVID-19 [adapted from general adult population]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention:</strong></td>
<td>Remdesivir</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
<td>Standard care</td>
</tr>
</tbody>
</table>

### Summary

There remains uncertainty whether remdesivir is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from three randomised trials that compared remdesivir to standard care in 1883 hospitalised adults with COVID-19 [39][40][43]. One trial was of patients with moderate to critical illness (1063 patients) [39], one of severe to critical illness (236 patients) [40] and one of moderate illness (584 patients) [43]. In the first two trials, randomisation was stratified by disease severity, in particular whether respiratory support was required.

The Taskforce notes the publication of the interim results of the WHO SOLIDARITY trial in medRxiv on 15 October (doi: 10.1101/2020.10.15.20209817) and the final report of the ACTT-1 trial in NEJM on 8 October (doi: 10.1056/NEJMoa2007764). These studies are currently under review and an updated recommendation will be included in a
future version of the guideline.

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
Remdesivir probably reduces death at day 14 compared to standard care (30 fewer deaths per 1000 patients (RR 0.63, CI 95% 0.44 to 0.91; 1874 patients in 3 studies)) but may not affect death at day 28 (1 fewer death per 1000 patients (RR 0.97, CI 95% 0.52 to 1.79; 820 patients in 2 studies)). We are awaiting publication of 28-day mortality data from the ACTT-1 Study Group [39] to determine if the mortality benefit observed at 14 days extends to this later time point.

Remdesivir may decrease time to recovery by a few days (HR 1.24, 95% CI 1.08 to 1.42; 1643 patients in 2 studies) and time to improvement only slightly (HR 1.17, 95% CI 1.00 to 1.38; 810 patients in 2 studies). Clinical recovery was defined as the first day in which a patient satisfied categories 1, 2 or 3 on the eight-point WHO ordinal scale [39] or improvement from a baseline score of 2 to 5 to a score of 6 or 7 on a 7-point ordinal scale [43]. Clinical improvement was defined as an improvement of 2 or more points on a 7-point ordinal scale [43] or 6-point ordinal scale [40].

There is little difference between remdesivir and standard care for the outcomes of respiratory failure / acute respiratory distress syndrome, septic shock, adverse events and clinical recovery. Compared with standard care, remdesivir probably reduces serious adverse events (58 fewer SAEs per 1000 patients (RR 0.74, CI 95% 0.62 to 0.90; 1880 patients in 3 studies)).

Our confidence in the results
Certainty of the evidence for death (day 14) is low due to some inconsistency and indirectness, low for time to recovery, time to improvement and serious adverse events due to serious risk of bias (lack of personnel blinding) and indirectness. For all other outcomes—death (day 28), respiratory failure or ARDS, adverse events, discontinuation due to adverse events, septic shock and clinical recovery—certainty is very low due to serious risk of bias (lack of personnel blinding), serious imprecision (wide confidence intervals), serious indirectness (exclusion or absence of children, adolescents and pregnant women) and/or serious inconsistency in the direction of effect between studies.

Additional information
The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].
### All-cause mortality

**Within 28 days of commencing treatment**

- **Relative risk**: 0.97 (CI 95% 0.52 - 1.79)
- Based on data from 820 patients in 2 studies. ³ (Randomized controlled)

**Critical**

<table>
<thead>
<tr>
<th>Difference</th>
<th>Per 1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>49</td>
</tr>
</tbody>
</table>

**Very Low**

Some concerns about inconsistency, serious imprecision and indirectness ⁴

Remdesivir may have little impact on death (day 28).

### Respiratory failure or ARDS

**During treatment (28 days)**

- **Relative risk**: 0.84 (CI 95% 0.47 - 1.53)
- Based on data from 1,296 patients in 2 studies. ⁵ (Randomized controlled)

**Critical**

<table>
<thead>
<tr>
<th>Difference</th>
<th>Per 1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>49</td>
</tr>
</tbody>
</table>

**Very Low**

Due to serious risk of bias, inconsistency, imprecision and indirectness ⁶

We are uncertain whether remdesivir increases or decreases respiratory failure or ARDS (132 events).

### Septic shock

**During treatment (28 days)**

- **Relative risk**: 1.02 (CI 95% 0.34 - 3.01)
- Based on data from 1,296 patients in 2 studies. ⁷ (Randomized controlled)

**Important**

We are uncertain whether remdesivir increases or decreases septic shock (13 events).

### Clinical recovery (Day 28)

**During treatment (28 days)**

- **Relative risk**: 1 (CI 95% 0.85 - 1.18)
- Based on data from 1,873 patients in 3 studies. ⁹ (Randomized controlled)

**Important**

We are uncertain whether remdesivir improves or worsens clinical recovery at day 28.

### Serious adverse events

**Number of patients experiencing one or more serious adverse events**

- **Relative risk**: 0.74 (CI 95% 0.62 - 0.9)
- Based on data from 1,880 patients in 3 studies. ¹¹ (Randomized controlled)

**Important**

Remdesivir may decrease serious adverse events slightly (340 events).

### Adverse events

**Number of patients experiencing one or more adverse events**

- **Relative risk**: 1.04 (CI 95% 0.89 - 1.22)
- Based on data from 1,880 patients in 3 studies. ¹³ (Randomized controlled)

**Important**

We are uncertain whether remdesivir increases or decreases adverse events.
2. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** No serious. **Publication bias:** No serious.
4. **Inconsistency:** Serious. Effects not consistent with day 14 data (from a different trials). **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Few events, Wide confidence intervals. **Publication bias:** No serious.
6. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.
8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.
10. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** Very Serious. The confidence interval of some of the studies do not overlap with those of most included studies/ the point estimate of some of the included studies., The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study Design</th>
<th>Effect Measures</th>
<th>Risk of Bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Publication bias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discontinuation due to adverse events</strong></td>
<td><strong>Baseline/comparator:</strong> Control arm of reference used for intervention.</td>
<td>Relative risk 1.7 (CI 95% 0.72 - 3.99) Based on data from 1,880 patients in 3 studies. (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias, inconsistency, imprecision and indirectness</td>
<td>We are uncertain whether remdesivir increases or decreases adverse events leading to discontinuation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Time to recovery (Days)</strong></td>
<td><strong>Baseline/comparator:</strong> Control arm of reference used for intervention.</td>
<td>Hazard Ratio 1.24 (CI 95% 1.08 - 1.42) Based on data from 1,643 patients in 2 studies. (Randomized controlled)</td>
<td>Low Due to serious risk of bias and indirectness</td>
<td>Remdesivir may decrease time to recovery by a few days.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Time to improvement (Days)</strong></td>
<td><strong>Baseline/comparator:</strong> Control arm of reference used for intervention.</td>
<td>Hazard Ratio 1.17 (CI 95% 1 - 1.38) Based on data from 810 patients in 2 studies. (Randomized controlled)</td>
<td>Low Due to serious risk of bias and indirectness</td>
<td>Remdesivir may decrease time to improvement slightly.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical Question/ PICO

Population: Special populations with COVID-19 [adapted from general adult population]  
Intervention: 5 days’ treatment  
Comparator: Up to 10 days’ treatment

Summary
There remains uncertainty whether a 5-day course of remdesivir is more effective and safer than a 10-day course.

What is the evidence informing this recommendation?
Evidence comes from two randomised trials that compared 5-day to 10-day treatment with remdesivir in 781 hospitalised patients with severe COVID-19 [41][43].

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
There is a lower risk of death within 14 days of treatment with a 5-day versus a 10-day course of remdesivir (16 fewer deaths per 1000 patients (RR 0.73, CI 95% 0.40 to 1.33; 781 patients in 2 studies)). The evidence is more uncertain for death within 28 days of treatment (5 fewer deaths per 1000 patients (RR 0.67, CI 95% 0.11 to 3.99; 384 patients in 1 study)).

There is probably little difference between a 5-day and 10-day course of remdesivir regarding adverse events, discontinuation of treatment due to adverse events and discharge from hospital.
Our confidence in the results

Certainty of the evidence is low for the following outcomes: death within 14 days, serious adverse events, adverse events and discharge from hospital within 14 days. Certainty is very low for death within 28 days, acute respiratory failure or ARDS, clinical recovery within 14 days, septic shock and discharge from hospital within 28 days. This judgement is based on serious risk of bias (problems with randomisation [41], lack of blinding), serious imprecision (too few who died), serious indirectness (exclusion or absence of children, adolescents and pregnant women) and very serious imprecision (reliance on a single study with few patients and/or few events).

It is important to note that Goldman et al only presents initial results from the first 400 patients in a trial that includes nearly 5000 patients (NCT04292899) [41]. The trial completed recruitment in July 2020 and we await the results from the full cohort of patients.

Additional information

The safety profile for remdesivir is incompletely characterised in humans. Preliminary results from manufacturer-led trials indicate that patients may experience side effects, including transient elevations in alanine aminotransferase and aspartate transaminase, headache, nausea, phlebitis, constipation, ecchymosis, pain in extremity and possible hypotension [42].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Within 14 days of commencing</td>
<td>Relative risk 0.73 (CI 95% 0.4 - 1.33) Based on data from 781 patients in 2 studies. † (Randomized controlled)</td>
<td>59 per 1000</td>
<td>Low Due to serious imprecision and indirectness ²</td>
<td>Remdesivir 5-day treatment probably has little impact on death (40 events).</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Within 28 days of commencing</td>
<td>Relative risk 0.67 (CI 95% 0.51 - 0.99) Based on data from 384 patients in 1 studies. ‡ (Randomized controlled)</td>
<td>43 per 1000</td>
<td>Very Low Due to very serious imprecision and serious indirectness ³</td>
<td>We are uncertain whether remdesivir 5-day treatment increases or decreases death at 28 days (5 events).</td>
</tr>
<tr>
<td>Acute respiratory failure or ARDS</td>
<td>Within 30 days of commencing treatment</td>
<td>Relative risk 0.47 (CI 95% 0.24 - 0.94) Based on data from 397 patients in 1 studies. § (Randomized controlled)</td>
<td>24 per 1000</td>
<td>Very Low Due to very serious imprecision and serious indirectness ⁴</td>
<td>We are uncertain whether remdesivir 5-day treatment decreases acute respiratory failure or ARDS (34 events).</td>
</tr>
<tr>
<td>Septic shock</td>
<td></td>
<td>Relative risk 0.39</td>
<td></td>
<td>Very Low</td>
<td>We are uncertain</td>
</tr>
</tbody>
</table>
### Within 30 days of commencing treatment

**Important**

Due to very serious imprecision and serious indirectness

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Based on data from</th>
<th>Implication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Clinical recovery</td>
<td>1.2</td>
<td>1.02 - 1.41</td>
<td>397 patients in 1 studies.</td>
<td>Due to serious risk of bias, imprecision and indirectness</td>
</tr>
<tr>
<td>2. Serious adverse events</td>
<td>0.64</td>
<td>0.47 - 0.87</td>
<td>781 patients in 2 studies.</td>
<td>Due to serious risk of bias and indirectness</td>
</tr>
<tr>
<td>3. Adverse events</td>
<td>0.93</td>
<td>0.84 - 1.03</td>
<td>781 patients in 2 studies.</td>
<td>Due to serious risk of bias and indirectness</td>
</tr>
<tr>
<td>4. Discontinuation due to adverse events</td>
<td>0.59</td>
<td>0.3 - 1.15</td>
<td>781 patients in 2 studies.</td>
<td>We are uncertain whether remdesivir 5-day treatment has any impact on number of patients discharged from hospital at day 14 (515 events)</td>
</tr>
<tr>
<td>5. Discharged from hospital</td>
<td>1.06</td>
<td>0.93 - 1.2</td>
<td>781 patients in 2 studies.</td>
<td>Remdesivir 5-day treatment may have little impact on number of patients discharged from hospital at day 14 (515 events)</td>
</tr>
<tr>
<td>6. Discharged from hospital</td>
<td>0.99</td>
<td>0.92 - 1.06</td>
<td>384 patients in 1 studies.</td>
<td>Remdesivir 5-day treatment may have little impact on number of patients discharged from hospital at day 14 (515 events)</td>
</tr>
</tbody>
</table>

**Clinical recovery**

Within 14 days of commencing treatment

**Important**

Relative risk 1.2

Based on data from 397 patients in 1 studies. **(Randomized controlled)**

Due to very serious imprecision and serious indirectness

**Very Low**

Due to serious risk of bias, imprecision and indirectness

**Low**

Remdesivir 5-day treatment may decrease serious adverse events slightly (129 events).

**Low**

Remdesivir 5-day treatment may have little impact on adverse events (503 events).

**Very Low**

We are uncertain whether remdesivir 5-day treatment improves clinical recovery (235 events).

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. due to few events.


4. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.


6. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


8. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Only data from one study.


12. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


16. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. due to few events.


18. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied.


20. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious.
Low number of patients, Only data from one study.

6.3 - Hydroxychloroquine

Not recommended

Do not use hydroxychloroquine for the treatment of COVID-19.

This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care.

Use of hydroxychloroquine may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include hydroxychloroquine.

Evidence To Decision

Benefits and harms

In addition to uncertainty around benefits for patients with COVID-19, there are well-known harms with potentially severe adverse events. Although most of the information on side effects and harms is derived from long-term use, potential acute harms include prolonged QT interval and lowered convulsive threshold. Long-term harms include retinopathy and chronic cardiac myopathy, among several others.

Certainty of the Evidence

General adult population
Certainty of the evidence is high for death, number of patients requiring mechanical ventilation and number of patients discharged from hospital at day 28. Certainty is moderate for number of patients requiring ventilation (due to reliance on a single study), adverse events and serious adverse events (due to lack of blinding of patients and personnel). Certainty is low for hospitalisation (due to lack of blinding and low number of events) and for virological clearance and duration of hospital stay (due to low number of patients and reliance on a single/two small studies).

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
Certainty of the evidence is low for death, requirement for mechanical ventilation/ECMO, discharge from hospital and adverse events (due to serious imprecision or risk of bias and indirectness). Certainty is very low for serious adverse events, virological clearance and hospitalisation (due to serious inconsistency, indirectness and imprecision).

Preference and values

The panel believes that patients would not choose hydroxychloroquine because of the well-known harms (with potentially severe adverse events) and uncertainty regarding benefit.

The NC19CET Consumer Panel believes that as there is substantial evidence demonstrating well-known harms of hydroxychloroquine, informed patients would not choose this treatment.
Rationale
Based on the available evidence, hydroxychloroquine is potentially harmful and no more effective than standard care in treating patients with COVID-19. We therefore recommend that hydroxychloroquine should not be used.

Resources
As hydroxychloroquine is not recommended there are no resource considerations.

Equity
As hydroxychloroquine is not recommended there are no equity considerations.

Acceptability
As hydroxychloroquine is not recommended there are no acceptability considerations.

Feasibility
As hydroxychloroquine is not recommended there are no feasibility considerations.

Clinical Question/ PICO
Population: Patients with COVID-19  
Intervention: Hydroxychloroquine  
Comparator: Standard care

Summary
Evidence indicates that hydroxychloroquine is potentially harmful and no more effective than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from 13 randomised trials that compared hydroxychloroquine with standard care in nearly 8300 patients [50][55][56][59][64][66][67][73][75][76][78][79]. The majority of evidence is from the RECOVERY trial, which randomised 4716 patients hospitalised with COVID-19 [79].

We have found a pre-print of one new study comparing hydroxychloroquine with placebo (Dubee et al. medRxiv doi: 10.1101/2020.10.19.20214940). This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Publication status
The WHO SOLIDARITY trial, which randomised over 1800 patients, has reported interim results as a preprint [50]. Three other studies, which contribute 125 patients to the results, are also published as preprints and have therefore not been peer reviewed [56][64][68]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
Mean or median age across the trials ranged from 39 to 66 years, and the proportion of women ranged from 20 to 72%. In the two largest trials (accounting for nearly 80% of the data) women comprised approximately 40% of included patients. There was significant variability in disease severity among patients included in the trials (see table).

<table>
<thead>
<tr>
<th>Disease severity</th>
<th>Number of patients</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>776</td>
<td>[66][67]</td>
</tr>
</tbody>
</table>
What are the main results?
Hydroxychloroquine has little or no impact on the two critical outcomes of death and the need for mechanical ventilation. For every 1000 patients given hydroxychloroquine, 15 more are likely to die compared with those receiving standard care (RR 1.08, CI 95% 0.99 to 1.19; 8041 patients in 9 studies) and 8 more are likely to require mechanical ventilation (RR 1.10, CI 95% 0.90 to 1.35; 4870 patients in 5 studies). Hydroxychloroquine also has little or no impact on the number of patients requiring any form of ventilation (i.e. non-invasive ventilation, invasive mechanical ventilation and ECMO) or the number of patients discharged from hospital at day 28.

Hydroxychloroquine probably increases the risk of adverse events, with 262 more patients per 1000 experiencing one or more adverse events with hydroxychloroquine compared with standard care (RR 2.27, CI 95% 1.26 to 4.12; 1508 patients in 8 studies). Since serious adverse events were rare, hydroxychloroquine may make little or no difference compared with standard care (38 events; 1403 patients in 7 studies; 5 fewer per 1000 with hydroxychloroquine (RR 0.82, CI 95% 0.44 to 1.51)).

For all other outcomes—virological clearance, hospitalisation and discharge from hospital—we are uncertain if hydroxychloroquine makes a difference compared to standard care.

Our confidence in the results
Certainty of evidence is high for death, number of patients requiring mechanical ventilation and number of patients discharged from hospital at day 28. Certainty is moderate for number of patients requiring any form of ventilation (due to reliance on a single study), adverse events and serious adverse events (due to lack of blinding of patients and personnel). Certainty is low for hospitalisation (due to lack of blinding and low number of events) and for virological clearance and duration of hospital stay (due to low number of patients and reliance on a single/two small studies).

For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information
According to the Therapeutic Goods Administration, known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiomyopathy [60]. There are several known and potential interactions with other drugs [60]. Overdose of hydroxychloroquine may have potentially fatal complications. In pregnancy, it is only recommended when benefits outweigh harms [60].

Pregnant and breastfeeding women
Hydroxychloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases. Studies of hydroxychloroquine for these indications have shown a favourable safety profile, with no increase in fetal malformations [69][70]. There is no evidence to suggest that stillbirth, preterm birth, low birth weight or early childhood disability are more common following treatment with hydroxychloroquine [69][70][71]. While this evidence is reassuring, further research is needed.

Children and adolescents
Paediatricians have considerable experience with hydroxychloroquine in children and adolescents for other indications. To date, no specific information on the benefits or harms of hydroxychloroquine use has been collected in this population.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Risk (CI)</th>
<th>End of follow-up</th>
<th>Critical Risk</th>
<th>Randomized controlled</th>
<th>Difference (per 1000)</th>
<th>Clinical Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>1.08 (0.99 - 1.19)</td>
<td>9</td>
<td>Critical</td>
<td>Based on data from 8,041 patients in 9 studies.</td>
<td>15 more (CI 95% 2 fewer - 35 more)</td>
<td>High (does not decrease death)</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or ECMO</td>
<td>1.1 (0.9 - 1.35)</td>
<td>9</td>
<td>Critical</td>
<td>Based on data from 4,870 patients in 5 studies.</td>
<td>8 more (CI 95% 8 fewer - 27 more)</td>
<td>High (has no impact on the need for invasive mechanical ventilation or ECMO)</td>
</tr>
<tr>
<td>Patients requiring ventilation within 28 days of commencing treatment</td>
<td>1.09 (0.79 - 1.49)</td>
<td>6</td>
<td>Important</td>
<td>Based on data from 1,686 patients in 1 studies.</td>
<td>7 more (CI 95% 17 fewer - 39 more)</td>
<td>Moderate (probably has little impact on number of patients requiring ventilation (141 events))</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>0.82 (0.44 - 1.51)</td>
<td>6</td>
<td>Important</td>
<td>Based on data from 1,403 patients in 7 studies.</td>
<td>5 fewer (CI 95% 16 fewer - 15 more)</td>
<td>Moderate (probably has little impact on serious adverse events)</td>
</tr>
<tr>
<td>Adverse events</td>
<td>2.27 (1.26 - 4.12)</td>
<td>6</td>
<td>Important</td>
<td>Based on data from 1,508 patients in 8 studies.</td>
<td>262 more (CI 95% 54 more - 643 more)</td>
<td>Moderate (probably increases adverse events)</td>
</tr>
<tr>
<td>Hospitalisation</td>
<td>0.53 (0.26 - 1.07)</td>
<td>6</td>
<td>Important</td>
<td>Based on data from 716 patients in 2 studies.</td>
<td>29 fewer (CI 95% 45 fewer - 4 more)</td>
<td>Low (are we uncertain whether hydroxychloroquine decreases or increases hospitalisation (33 events))</td>
</tr>
<tr>
<td>Discharge from hospital within 28 days of commencing treatment</td>
<td>0.97 (0.95 - 1)</td>
<td>6</td>
<td>Important</td>
<td>Based on data from 6,569 patients in 2 studies.</td>
<td>687 fewer (CI 95% 34 fewer - 0 fewer)</td>
<td>High (has little impact on discharge from hospital)</td>
</tr>
</tbody>
</table>


3. Includes non-invasive ventilation, invasive ventilation, mechanical ventilation, ECMO


5. **Imprecision:** Serious. Only data from one study.


7. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


9. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


11. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. due to few events.


14. **Imprecision:** Very Serious. Low number of patients, due to two studies.


16. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
6.4 - Interferon β-1a

Not recommended

Do not use interferon β-1a for the treatment of COVID-19.

This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care.

Use of interferon β-1a may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include interferon β-1a.

Evidence To Decision

Benefits and harms

General adult population
Interferon β-1a does not impact on the incidence of death or number of patients requiring ventilation. Although included trials did not report on adverse or serious adverse events, there are well-known side effects and harms associated with interferon β-1a including thrombotic microangiopathy, hepatic injury, nephrotic syndrome and depression with suicidal ideation.

Children and adolescents, people requiring palliative care and older people living with frailty or cognitive impairment
There are additional concerns regarding harms as interferon β-1a has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

Pregnant and breastfeeding women
Evidence suggests that interferon β-1a in pregnant women is not associated with an increase in early pregnancy loss, stillbirths or congenital anomalies.

Certainty of the evidence

General adult population
Certainty of the evidence is high for mortality, patients requiring ventilation and discharge from hospital. For the remaining outcomes (septic shock and duration of hospital stay), certainty is very low due to non-blinding of patients and personnel, reliance on a single study, low patient and event numbers and wide confidence intervals.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values

General adult population
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in
Based on the available evidence, interferon β-1a is no more effective than standard care in treating patients with COVID-19. We therefore recommend that interferon β-1a should not be used.

Clinical Question/ PICO

- **Population:** Patients with COVID-19
- **Intervention:** Interferon β-1a
- **Comparator:** Standard care
**Summary**

Evidence indicates that interferon β-1a is no more effective than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from two randomised trials that compared interferon β-1a with standard care. The vast majority of data come from the WHO SOLIDARITY trial that included 4100 adults hospitalised with moderate to critical COVID-19 [50]. The second, smaller trial randomised 81 adults hospitalised with severe COVID-19 [85].

**Publication status**

The SOLIDARITY trial is only available as preprint (posted to medRxiv on 15 October 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

**Study characteristics**

In the SOLIDARITY trial, 35% of patients were under 50 years of age, 46% were aged between 50-69, and 19% were 70 years or older; 37% were women. In the smaller study, mean age was 56-60 years across the two arms and 46% were women. In both studies pregnant women were ineligible.

In the SOLIDARITY trial, patients received three doses of interferon β-1a (44 µg subcutaneously) over six days, while patients on high-flow oxygen, ventilators or ECMO were given 10 µg intravenously once daily for six days.

**What are the main results?**

There were no differences in incidence of death, requirement of ventilation and discharge from hospital between interferon β-1a and standard care at day 28. We are uncertain whether treatment with interferon β-1a has an impact on the number of people experiencing septic shock and duration of hospital stay.

**Our confidence in the results**

Certainty of the evidence is high for mortality, patients requiring ventilation and discharge from hospital. For incidence of septic shock and duration of hospital stay, certainty is very low due to non-blinding of patients and personnel, reliance on a single study, low patient and event numbers and wide confidence intervals.

For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

**Additional information**

The Therapeutic Goods Administration highlights several potential side effects associated with the use of interferon β-1a. Including thrombotic microangiopathy, hepatic injury, nephrotic syndrome and depression with suicidal ideation. Interferon β-1a is also associated with immune reactions that can produce flu-like symptoms [82][83].

**Children and adolescents**

Paediatricians have limited experience with interferon β-1a in children and adolescents for other indications. To date, no specific information on its benefits or harms has been collected for treating COVID-19 in this population.

**Pregnant and breastfeeding women**

Interferon β-1a is used in pregnancy for the treatment of multiple sclerosis. Evidence has shown no correlation between the use of Interferon β-1a and increases in early pregnancy loss, stillbirths or congenital anomalies [84].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 1.07  (CI 95% 0.91 - 1.27) Based on data from</td>
<td></td>
<td></td>
<td>Interferon β-1a does not decrease death.</td>
</tr>
<tr>
<td>Within 28 days</td>
<td></td>
<td>112 per 1000</td>
<td>120 per 1000</td>
<td></td>
</tr>
</tbody>
</table>
### Patients requiring ventilation

Within 28 days of commencing treatment

- **Patients requiring ventilation**
  - **Baseline/comparator:** Control arm of reference used for intervention.
  - **Risk of bias:** Serious.
    - Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
    - Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
  - **Imprecision:** Very Serious.
    - Low number of patients, Only data from one study.

#### Results

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of Patients</th>
<th>Difference</th>
<th>CI 95%</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon β-1a</td>
<td>116 per 1000</td>
<td>115 per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**High**

Interferon β-1a has no impact on number of patients requiring ventilation.

### Septic shock

Within 28 days of commencing treatment

- **Septic shock**
  - **Baseline/comparator:** Control arm of reference used for intervention.
  - **Risk of bias:** Very Low.
    - Due to serious risk of bias and very serious imprecision.
  - **Imprecision:** Very Low.
    - Due to serious risk of bias and very serious imprecision.

#### Results

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of Patients</th>
<th>Difference</th>
<th>CI 95%</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon β-1a</td>
<td>778 per 1000</td>
<td>739 per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**High**

Interferon β-1a has no impact on number of patients discharged from hospital.

### Discharge from hospital

Within 28 days of commencing treatment

- **Discharge from hospital**
  - **Baseline/comparator:** Control arm of reference used for intervention.
  - **Risk of bias:** Very Low.
    - Due to serious risk of bias and very serious imprecision.
  - **Imprecision:** Very Low.
    - Due to serious risk of bias and very serious imprecision.

#### Results

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of Patients</th>
<th>Difference</th>
<th>CI 95%</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon β-1a</td>
<td>12.3 (Mean)</td>
<td>14.8 (Mean)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**High**

Interferon β-1a has no impact on number of patients discharged from hospital.

### Duration of hospital stay

Mean days to discharge

- **Duration of hospital stay**
  - **Baseline/comparator:** Control arm of reference used for intervention.
  - **Risk of bias:** Very Low.
    - Due to serious risk of bias and very serious imprecision.
  - **Imprecision:** Very Low.
    - Due to serious risk of bias and very serious imprecision.

#### Results

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Difference</th>
<th>CI 95%</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon β-1a</td>
<td>MD 2.55 higher</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Very Low**

We are uncertain whether interferon β-1a increases or decreases duration of hospital stay.

---

4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
6.5 - Lopinavir-ritonavir

Not recommended


This recommendation applies to adults, children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care.

Use of lopinavir-ritonavir may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include lopinavir-ritonavir.

Evidence To Decision

Benefits and harms

General adult population
Evidence indicates no difference in incidence of death, requirement of mechanical ventilation or duration of hospital stay between lopinavir-ritonavir and standard care. Uncertainty remains regarding the incidence of serious adverse events and adverse events, however there are well-known side effects and harms associated with lopinavir-ritonavir.

Although most information on side effects is derived from long-term use, potential acute harms include: gastrointestinal symptoms, hyperglycaemia, pancreatitis, lipid elevations, hepatic impairment, QT interval prolongation and PR interval prolongation. Chronic harms include: increased risk of bleeding in patients with haemophilia, fat redistribution and immune reconstitution syndrome, among others. Lopinavir-ritonavir interacts with CYP3A and may result in increased plasma concentrations of the other drugs.

Harms associated with short-term use have been reported in three trials [57][58][91]. These include transient elevation of alanine aminotransferase and gastrointestinal symptoms, such as diarrhoea.

Children and adolescents
Paediatricians have considerable experience with the use of lopinavir-ritonavir in children and adolescents for other indications.

Pregnant and breastfeeding women
Lopinavir-ritonavir is recommended for pregnant and breastfeeding women living with HIV as part of highly active antiretroviral therapy. Studies of women receiving lopinavir-ritonavir for this indication have shown a favourable safety profile.

People requiring palliative care and older people living with frailty or cognitive impairment
The benefits of lopinavir-ritonavir for symptom management for this population are uncertain.

Certainty of the Evidence

General adult population
Certainty of the evidence is high for mortality, mechanical ventilation or ECMO and discharge from hospital at day 28.
Certainty is moderate for patients requiring ventilation (reliance on a single study) and low for respiratory failure (inconsistency in direction of effect and wide confidence intervals), clinical improvement at day 14 (lack of blinding of patients/personnel and wide confidence intervals) and time to discharge from hospital (lack of blinding of patients/personnel and reliance on a single study). Certainty is very low for adverse and serious adverse events.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, uncertainty of the evidence is further downgraded because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values

General adult population

We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of lopinavir-ritonavir during pregnancy and breastfeeding are unknown in the context of COVID-19.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the potential impact on reduced access to these treatments by patients currently using them for other indications.

Equity

General adult population

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population

Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of
Rationale

Based on the available evidence, lopinavir-ritonavir is no more effective than standard care in treating patients with COVID-19. We therefore recommend that lopinavir-ritonavir should not be used.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Clinical Question/ PICO

- **Population:** Patients with COVID-19
- **Intervention:** Lopinavir-ritonavir
- **Comparator:** Standard care

Summary

Evidence indicates that lopinavir-ritonavir is no more effective than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from five randomised trials that compared lopinavir-ritonavir with standard care in 8121 patients with COVID-19 [50][57][58][91][99]. The vast majority of data come from the RECOVERY and WHO SOLIDARITY trials, which included 5040 patients [99] and 2771 patients [50] with moderate to critical illness. The SOLIDARITY trial was stopped early for reasons of futility. The remaining three trials included 199 patients with severe illness [58], 60 patients with moderate or severe illness [91] and 51 patients with mild or moderate illness [57].

Study characteristics

In the RECOVERY trial, mean age was 66 years and 40% were women. In the SOLIDARITY trial, 37% of patients were under 50 years of age, 43% were aged between 50-69, and 20% were 70 years or older; 40% were women. For the three smaller trials, mean or median age ranged from 41 to 58 years and the proportion of women ranged from 38 to 59%. In the RECOVERY trial, six women were pregnant at randomisation—of the remaining studies, three excluded pregnant and breastfeeding women, and for one their eligibility was unclear [91].

In the RECOVERY and SOLIDARITY trials, patients received lopinavir 400 mg plus ritonavir 100 mg orally twice daily for either 10 days or 14 days, respectively.

What are the main results?

There were no differences in incidence of death, requirement of mechanical ventilation or ECMO, discharge from hospital or time to discharge from hospital between lopinavir-ritonavir and standard care. Lopinavir-ritonavir may decrease the incidence of respiratory failure or ARDS. For all other outcomes, we are uncertain if lopinavir-ritonavir makes a difference.

Our confidence in the results

Certainty of the evidence is high for mortality, invasive mechanical ventilation or ECMO and discharge from hospital at day 28. Certainty is moderate for patients requiring ventilation (reliance on a single study) and low for respiratory failure (inconsistency in direction of effect and wide confidence intervals), clinical improvement at day 14 (lack of blinding of patients/personnel and wide confidence intervals) and time to discharge from hospital (lack of blinding of patients/personnel and reliance on a single study). Certainty is very low for adverse and serious adverse events.
For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information
According to the Therapeutic Goods Administration, there are well-known side effects and harms associated with lopinavir-ritonavir. Although most of the information on side effects and harms is derived from long-term use, potential acute harms include gastrointestinal symptoms, hyperglycaemia, pancreatitis, lipid elevations, hepatic impairment, QT interval prolongation and PR interval prolongation. Chronic harms include increased risk of bleeding in patients with haemophilia, fat redistribution and immune reconstitution syndrome, among others. Lopinavir-ritonavir interacts with CYP3A and may result in increased plasma concentrations of the other drugs [89].

Children and adolescents
Paediatricians have considerable experience with lopinavir-ritonavir in children and adolescents for other indications. To date, no specific information on its benefits or harms for children and adolescents has been collected for treating COVID-19 in this population.

Pregnant and breastfeeding women
Lopinavir-ritonavir is recommended for treating pregnant or breastfeeding women living with HIV, as part of highly active antiretroviral therapy. Studies of women receiving lopinavir-ritonavir for this indication have shown a favourable safety profile, with no increase in stillbirth, preterm birth, low birth weight or birth defects [92][93][94][96][97].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Standard care</td>
<td>Lopinavir-ritonavir</td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>End of treatment</td>
<td>Relative risk 1.02 (CI 95% 0.92 - 1.12) Based on data from 8,061 patients in 4 studies. 1 (Randomized controlled)</td>
<td>191 per 1000</td>
<td>195 per 1000</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td></td>
<td>Difference: 4 more per 1000 ( CI 95% 15 fewer - 23 more )</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation or ECMO</td>
<td>End of treatment</td>
<td>Relative risk 1.15 (CI 95% 0.95 - 1.38) Based on data from 5,074 patients in 3 studies. 2 (Randomized controlled)</td>
<td>84 per 1000</td>
<td>97 per 1000</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td></td>
<td>Difference: 13 more per 1000 ( CI 95% 4 fewer - 32 more )</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-invasive or invasive ventilation</td>
<td>Within 28 days after commencing treatment</td>
<td>Relative risk 1.02 (CI 95% 0.8 - 1.29) Based on data from 2,545 patients in 1 studies. 3 (Randomized controlled)</td>
<td>95 per 1000</td>
<td>97 per 1000</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

1 (Randomized controlled)
<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Pooled n</th>
<th>Randomized Controlled</th>
<th>Level of Evidence</th>
<th>Reason for Low Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory failure or ARDS</strong></td>
<td>0.59</td>
<td>0.34 - 1.03</td>
<td>95%</td>
<td>248 patients in 2 studies</td>
<td>Low</td>
<td>Due to serious risk of bias, serious inconsistency and serious imprecision</td>
<td>Lopinavir-ritonavir may decrease respiratory failure or ARDS (44 events).</td>
</tr>
<tr>
<td><strong>End of treatment</strong></td>
<td>233</td>
<td>137</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>0.63</td>
<td>0.39 - 1.02</td>
<td>95%</td>
<td>222 patients in 2 studies</td>
<td>Very Low</td>
<td>We are uncertain whether lopinavir-ritonavir increases or decreases serious adverse events (52 events).</td>
<td></td>
</tr>
<tr>
<td><strong>End of treatment</strong></td>
<td>377</td>
<td>475</td>
<td></td>
<td></td>
<td>Very Low</td>
<td>We are uncertain whether lopinavir-ritonavir increases or decreases adverse events.</td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>1.39</td>
<td>0.48 - 4.05</td>
<td>95%</td>
<td>287 patients in 3 studies</td>
<td>Very Low</td>
<td>Low due to serious risk of bias, serious inconsistency and serious imprecision</td>
<td>Lopinavir-ritonavir may have little impact on clinical improvement.</td>
</tr>
<tr>
<td><strong>Clinical improvement</strong></td>
<td>1.26</td>
<td>0.96 - 1.64</td>
<td>95%</td>
<td>241 patients in 2 studies</td>
<td>Low</td>
<td>Due to serious risk of bias and serious imprecision</td>
<td>Lopinavir-ritonavir may have little impact on clinical improvement.</td>
</tr>
<tr>
<td><strong>Day 14 after treatment</strong></td>
<td>377</td>
<td>475</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td>1.00</td>
<td>0.98 - 1.03</td>
<td>95%</td>
<td>7,811 patients in 2 studies</td>
<td>High</td>
<td>Lopinavir-ritonavir has no impact on discharge from hospital at 28 days.</td>
<td></td>
</tr>
<tr>
<td><strong>28 Days after commencing treatment</strong></td>
<td>747</td>
<td>747</td>
<td></td>
<td>6,040 patients in 1 study</td>
<td>Low</td>
<td>Due to serious risk of bias and only one study</td>
<td>Lopinavir-ritonavir may have little impact on time to discharge from hospital.</td>
</tr>
<tr>
<td><strong>Time to discharge from hospital</strong></td>
<td>Lower better</td>
<td>Based on data from: 5,040 patients in 1 study</td>
<td>(Median) 11</td>
<td>(Median) 11</td>
<td>Low</td>
<td>Due to serious risk of bias and only one study</td>
<td>Lopinavir-ritonavir may have little impact on time to discharge from hospital.</td>
</tr>
</tbody>
</table>

**Notes:**
2. Systematic review [100] with included studies: Li 2020, RECOVERY, Cao 2020. **Baseline/comparator:** Control arm of reference used for intervention.
6.6 - Disease-modifying treatments not recommended outside of clinical trials

Many therapies are being evaluated to determine their effectiveness and safety in treating people with COVID-19. Since the start of the pandemic, 2000 randomised trials have been registered (see COVID-NMA Initiative). We continually monitor new research for randomised trials that evaluate any disease-modifying treatments for COVID-19. As each new trial is published, our panels assess and make recommendations on whether the treatment should be used in the clinical care of patients.

While we have sufficient evidence to make recommendations in support of using or not using some treatments, such as dexamethasone, remdesivir, hydroxychloroquine and lopinavir-ritonavir, for most treatments the evidence is uncertain because there are too few trials or the overall patient numbers are low. In this section of the guideline, we list all those treatments that are only recommended for use in research, i.e. in randomised trials with appropriate ethical approval.

As soon as sufficient evidence emerges that changes the recommendation from 'research only', the treatment is moved to the 'Disease-modifying treatments' section above.
6.6.1 - Aprepitant

Not recommended

Do not use aprepitant for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Aprepitant should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use aprepitant to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

Evidence To Decision

Benefits and harms

General adult population
In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with aprepitant, including fatigue, muscle weakness, headache or dizziness, gastrointestinal symptoms and rash.

Certainty of the Evidence

General adult population
Certainty of the evidence is very low for both outcomes. This judgement is based on very serious risk of bias (patients and personnel not blinded, deviation from intended intervention [20 mg dexamethasone provided to both groups compared to 6 mg as stated in the ClinicalTrials.gov entry] and selective outcome reporting), serious indirectness (due to insufficient timeframe), and very serious imprecision (results based on only one study with low patient numbers and few events).

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trial.

Preference and values

General adult population
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by
Rationale
General adult population
There is currently limited evidence about the impact of aprepitant on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that aprepitant should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Equity
General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability
General adult population, children and adolescents, pregnant and breastfeeding women
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility
Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale
General adult population
There is currently limited evidence about the impact of aprepitant on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that aprepitant should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of aprepitant to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Aprepitant</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>
Summary
There remains significant uncertainty whether aprepitant is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared aprepitant with standard care in 18 adults hospitalised with laboratory-confirmed COVID-19 [101].

Publication status
The study is only available as a preprint paper (posted to medRxiv on 4 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

Study characteristics
Median age was 61 years in the aprepitant group and 48 years in the control group; the proportion of women was 20% and 63% respectively. Both groups received 20 mg of dexamethasone daily, and standard care included treatment with azithromycin, remdesivir and tocilizumab. Pregnant and breastfeeding women were ineligible.

What are the main results?
Preliminary results were presented for death and discharge from hospital within five days of starting treatment. For both outcomes, there were too few events (two deaths and two discharged from hospital) to determine whether aprepitant makes a difference. No data were reported on adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence is very low for both outcomes. This judgement is based on very serious risk of bias (patients and personnel not blinded, deviation from intended intervention and selective outcome reporting), serious indirectness (insufficient timeframe), and very serious imprecision (results based on only one study with low patient numbers and few events).

Additional information
According to the Therapeutic Goods Administration, known acute harms for aprepitant include fatigue, muscle weakness, headache or dizziness, gastrointestinal symptoms, chills, hot flushes, hiccups and rash [102]. There are several known and potential interactions with other drugs, including hormonal contraceptives [102].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
</table>
| **All-cause mortality**
Within 5 days of commencing treatment
9 Critical | Relative risk 0.8 (CI 95% 0.06 - 10.89)
Based on data from 18 patients in 1 studies. ¹
(Randomized controlled) | Very Low
Due to very serious risk of bias, very serious imprecision and serious indirectness ² | There were too few who died to determine whether aprepitant makes a difference (2 events). |
| **Invasive mechanical ventilation**
Within 5 days of commencing treatment | No studies were found that looked at patients requiring invasive mechanical ventilation. |

2. **Risk of bias:** Very Serious. Incomplete data and/or large loss to follow up, Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.


4. **Risk of bias:** Very Serious. Selective outcome reporting, Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. The outcome time frame in studies were insufficient. **Imprecision:** Very Serious. Only data from one study, Low number of patients, due to few events.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Special populations with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Aprepitant</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

---
Summary
There remains significant uncertainty whether aprepitant is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared aprepitant with standard care alone in 18 adults hospitalised with laboratory confirmed COVID-19 [101].

Publication status
The study is only available as a preprint paper (posted to medRxiv on 4 August 2020) and has therefore not been peer-reviewed. In addition to our daily evidence surveillance processes, we also follow up with the corresponding author every two months to request an update on the study’s publication status.

Study characteristics
Median age was 61 in the aprepitant group and 48 in the control group; the proportion of women was 20% and 63% respectively. Both groups received 20 mg dexamethasone daily, and standard care included treatment with azithromycin, remdesivir and tocilizumab. Pregnant and breastfeeding women were ineligible.

What are the main results?
Preliminary results were presented for death and discharge from hospital within five days of starting treatment. For both outcomes, there were too few events (two deaths and two discharged from hospital) to determine whether aprepitant makes a difference. No data were reported on adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence is very low for both outcomes. This judgement is based on very serious risk of bias (patients and personnel not blinded, deviation from intended intervention and selective outcome reporting), serious indirectness (insufficient timeframe and limited inclusion of these populations), and very serious imprecision (results based on only one study with low patient numbers and few events).

Additional information
According to the Therapeutic Goods Administration, known acute harms for aprepitant include fatigue, muscle weakness, headache or dizziness, gastrointestinal symptoms, chills, hot flushes, hiccups, rash [102]. There are several known and potential interactions with other drugs including hormonal contraceptives [102].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates Standard care Aprepitant</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 0.8 (CI 95% 0.06 - 10.89)</td>
<td>Based on data from 18 patients in 1 studies. 1 (Randomized controlled)</td>
<td>Very Low Due to very serious risk of bias, very serious imprecision and serious indirectness 2</td>
<td>There were too few who died to determine whether aprepitant makes a difference 2 events.</td>
</tr>
<tr>
<td>Within 5 days of commencing treatment</td>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td></td>
<td></td>
<td></td>
<td>No studies were found that looked at patients requiring invasive mechanical ventilation.</td>
</tr>
<tr>
<td>Within 5 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce 133 of 418

2. **Risk of bias:** Very Serious. Incomplete data and/or large loss to follow up, Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness: Serious.** The outcome timeframe in studies was insufficient, and there were differences between the population of interest and those studied. **Imprecision: Very Serious.** Low number of patients, Only data from one study, due to few events.


4. **Risk of bias:** Very Serious. Selective outcome reporting, Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness: Serious.** The outcome timeframe in studies was insufficient, and there were differences between the population of interest and those studied. **Imprecision: Very Serious.** Only data from one study, Low number of patients, due to few events.

### Adverse events

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Timeframe</th>
<th>Evidence</th>
<th>Risk of Bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Critical</strong></td>
<td>Within 5 days of commencing treatment</td>
<td>No studies were found that looked at adverse events.</td>
<td>Very Serious</td>
<td>Serious</td>
<td>Very Serious</td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>Within 5 days of commencing treatment</td>
<td>No studies were found that looked at serious adverse events.</td>
<td>Very Serious</td>
<td>Serious</td>
<td>Very Serious</td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td>Within 5 days of commencing treatment</td>
<td>Relative risk 0.8 (CI 95% 0.06 - 10.89) Based on data from 18 patients in 1 studies. ³ (Randomized controlled)</td>
<td>Very Low</td>
<td>Due to very serious risk of bias, very serious imprecision and serious indirectness ⁴</td>
<td>There were too few who were discharged from hospital to determine whether aprepitant makes a difference (2 events).</td>
<td></td>
</tr>
</tbody>
</table>

³ (Randomized controlled)
6.6.2 - Azithromycin

**Not recommended**

Do not use azithromycin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Azithromycin should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use azithromycin to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**

According to the Therapeutic Goods Administration, reported adverse events are generally mild or moderate and include rash, heart palpitations, urinary tract infection, headache, fatigue and gastrointestinal symptoms such as dyspepsia and vomiting [107]

**Pregnant and breastfeeding women**

Azithromycin has only been taken by a limited number of pregnant women and women of childbearing age, and its safety profile is therefore uncertain.

**Children and adolescents**

The safety and effectiveness of azithromycin in children has not been established.

**Certainty of the Evidence**

**General adult population**

Certainty of the evidence is moderate for mortality (days 15 and 29) and serious adverse events due to imprecision (only two studies with limited patient numbers). Certainty is low for all other outcomes due to very serious imprecision (reliance on a single study with limited patient numbers). The exception is duration of hospital stay, which is low certainty due to serious inconsistency (inconsistent direction of effect) and serious imprecision (wide confidence intervals).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is downgraded further because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed
patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Acceptability**

**General adult population**

Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Rationale**

**General adult population**

There is currently limited evidence about the impact of azithromycin on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that azithromycin should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of azithromycin to treat COVID-19 in these populations should be avoided until evidence becomes available.

**Clinical Question/ PICO**

- **Population:** Patients with COVID-19
- **Intervention:** Azithromycin
Summary
We are uncertain if azithromycin is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
No trials compared azithromycin with standard care. Instead, evidence comes from two randomised trials that compared azithromycin plus hydroxychloroquine with hydroxychloroquine alone in 397 adults hospitalised with severe or critical COVID-19 [105] and 331 with moderate COVID-19 [73], and from one randomised trial that compared azithromycin plus hydroxychloroquine and lopinavir-ritonavir with hydroxychloroquine and lopinavir-ritonavir alone in 111 hospitalised adults with severe COVID-19 [106].

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
Azithromycin probably has little impact on death within 15 or 29 days of treatment compared with standard care, but probably increases the incidence of serious adverse events (25 more SAEs per 1000 patients with azithromycin compared with standard care (19 fewer to 81 more; RR 1.13 CI 95% 0.90 to 1.42; 877 patients in 2 studies)).

We are uncertain if azithromycin increases or decreases adverse events, discontinuation due to adverse events, clinical progression (as measured by admission to ICU), duration of hospital stay or discharge from hospital at day 15 or 29.

Our confidence in the results
Certainty of the evidence is moderate for death (day 15 and day 29) and serious adverse events due to imprecision (only two studies with limited patient numbers). Certainty is low for all other outcomes due to very serious imprecision (results from one study with limited patient numbers). The exception is duration of hospital stay, which is low certainty due to serious inconsistency (inconsistent direction of effect) and serious imprecision (wide confidence intervals).

Additional information
According to the Therapeutic Goods Administration, reported adverse events are generally mild or moderate and include rash, heart palpitations, urinary tract infection, dizziness, headache, fatigue and gastrointestinal symptoms such as dyspepsia and vomiting [107].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality Within 15 days of commencing treatment</td>
<td>Relative risk 1 (CI 95% 0.75 - 1.34) Based on data from 728 patients in 2 studies. 1 (Randomized controlled)</td>
<td><strong>175</strong> per 1000</td>
<td><strong>175</strong> per 1000</td>
<td>Moderate Due to serious imprecision 2 Azithromycin probably has little impact on death at day 15 (129 events).</td>
</tr>
<tr>
<td>All-cause mortality Within 29 days of commencing treatment</td>
<td>Relative risk 1.05 (CI 95% 0.83 - 1.33) Based on data from 508 patients in 2 studies. 3 (Randomized controlled)</td>
<td><strong>311</strong> per 1000</td>
<td><strong>327</strong> per 1000</td>
<td>Moderate Due to serious imprecision 3 Azithromycin probably has little impact on death at day 29 (164 events).</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>Confidence Interval</td>
<td>Difference</td>
<td>CI 95%</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>------------</td>
<td>--------</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>1.46</td>
<td>(0.73 - 2.92)</td>
<td>35</td>
<td>20 more</td>
</tr>
<tr>
<td>Adverse events</td>
<td>1.17</td>
<td>(0.91 - 1.5)</td>
<td>57</td>
<td>30 more</td>
</tr>
<tr>
<td>Clinical progression (ICU admission)</td>
<td>0.28</td>
<td>(0.06 - 1.29)</td>
<td>91</td>
<td>19 fewer</td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>0.93</td>
<td>(0.83 - 1.04)</td>
<td>57</td>
<td>32 more</td>
</tr>
</tbody>
</table>

2. **Imprecision:** Serious. due to only two studies.


4. **Imprecision:** Serious. Wide confidence intervals.


6. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.


8. **Imprecision:** Very Serious. Only data from one study, Wide confidence intervals.


10. **Imprecision:** Serious. Wide confidence intervals.


12. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.


14. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


16. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


18. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Imprecision:** Serious. Wide confidence intervals.

---

**Clinical Question/ PICO**

**Population:** Special populations with COVID-19
**Intervention:** Azithromycin  
**Comparator:** Standard care

**Summary**

We are uncertain if azithromycin is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

No trials compared azithromycin with standard care. Instead, evidence comes from two randomised trials that compared azithromycin plus hydroxychloroquine with hydroxychloroquine alone in 397 adults hospitalised with severe or critical COVID-19 [105] and 331 with moderate COVID-19 [73], and from one randomised trial that compared azithromycin plus hydroxychloroquine and lopinavir-ritonavir with hydroxychloroquine and lopinavir-ritonavir alone in 111 hospitalised adults with severe COVID-19 [106].

**Study characteristics**

For a comprehensive description, see the study characteristics table.

**What are the main results?**

Azithromycin probably has little impact on death within 15 or 29 days of treatment compared with standard care, but probably increases the incidence of serious adverse events (25 more SAEs per 1000 patients with azithromycin compared with standard care (19 fewer to 81 more; RR 1.13 CI 95% 0.90 to 1.42; 877 patients in 2 studies)).

We are uncertain if azithromycin increases or decreases adverse events, discontinuation due to adverse events, clinical progression (as measured by admission to ICU), duration of hospital stay or discharge from hospital at day 15 or 29.

**Our confidence in the results**

Certainty of the evidence is low for death (day 15 and day 29) and serious adverse events due to imprecision (only two studies with limited patient numbers) and indirectness. Certainty is very low for all other outcomes due to very serious imprecision (results from one study with limited patient numbers) and/or serious inconsistency (inconsistent direction of effect), and serious indirectness (absence of these populations from the included studies).

**Additional information**

According to the Therapeutic Goods Administration, reported adverse events are generally mild or moderate and include rash, heart palpitations, urinary tract infection, dizziness, headache, fatigue and gastrointestinal symptoms such as dyspepsia and vomiting [107].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong> Within 15 days of commencing treatment</td>
<td>Relative risk 1.05 (CI 95% 0.83 - 1.33) Based on data from 508 patients in 2 studies.</td>
<td>175 per 1000</td>
<td>Low Due to serious imprecision and indirectness</td>
<td>Azithromycin may have little impact on death at day 15 (129 events).</td>
</tr>
<tr>
<td><strong>All-cause mortality</strong> Within 29 days of commencing</td>
<td>Relative risk 1.05 (CI 95% 0.83 - 1.33) Based on data from 508 patients in 2 studies.</td>
<td>311 per 1000</td>
<td>Low Due to serious imprecision and indirectness</td>
<td>Azithromycin may have little impact on death at day 29 (164 events).</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>N of Patients</td>
<td>Study Details</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------</td>
<td>--------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Invasive mechanical ventilation Within 15 days of commencing treatment</td>
<td>1.46</td>
<td>0.73 - 2.92</td>
<td>331 patients</td>
<td>1 study.</td>
</tr>
<tr>
<td>Adverse events</td>
<td>1.17</td>
<td>0.91 - 1.5</td>
<td>438 patients</td>
<td>1 study.</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>1.13</td>
<td>0.9 - 1.42</td>
<td>877 patients</td>
<td>2 studies.</td>
</tr>
<tr>
<td>Clinical progression (ICU admission) Within 15 days of commencing treatment</td>
<td>0.28</td>
<td>0.06 - 1.29</td>
<td>111 patients</td>
<td>1 study.</td>
</tr>
<tr>
<td>Discharge from hospital Within 15 days of commencing treatment</td>
<td>0.93</td>
<td>0.83 - 1.04</td>
<td>331 patients</td>
<td>1 study.</td>
</tr>
<tr>
<td>Duration of hospital stay</td>
<td>Within 29 days of commencing treatment</td>
<td>6 Important</td>
<td>Based on data from 397 patients in 1 studies. Baseline/comparator: Control arm of reference used for intervention.</td>
<td>Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Serious. due to only two studies.</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------------------</td>
<td>-------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Difference: MD 0.41 lower</td>
<td></td>
<td>(CI 95% 2.42 lower - 1.59 higher) Very Low Due to serious inconsistency, imprecision and indirectness.</td>
<td>We are uncertain whether azithromycin has any impact on duration of hospital stay.</td>
</tr>
<tr>
<td></td>
<td>Based on data from: 442 patients in 2 studies. Randomized controlled</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. due to only two studies.
4. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.
6. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
8. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Only data from one study, Wide confidence intervals.
10. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Wide confidence intervals.
12. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
14. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
16. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
18. **Inconsistency:** Serious. The direction of the effect is not consistent between the included studies. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.
6.6.3 - Baloxavir marboxil

Not recommended

Do not use baloxavir marboxil for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Evidence To Decision**

**Benefits and harms**

**General adult population**
In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with baloxavir marboxil, including diarrhoea, bronchitis, nausea, sinusitis and headache.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There are additional concerns regarding harms as baloxavir marboxil has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

**Certainty of the Evidence**

**General adult population**
Certainty of the evidence for each outcome is very low. This judgement is based on serious risk of bias due to lack of blinding, and very serious imprecision due to the low number of patients and/or observed events and the reliance on a single study.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of baloxavir marboxil in pregnancy are unknown.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.
**Rationale**

**General adult population**
There is currently limited evidence about the impact of baloxavir marboxil on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that baloxavir marboxil should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of baloxavir marboxil to treat COVID-19 in these populations should be avoided until evidence becomes available.

---

**Resources**
We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

---

**Acceptability**

**General adult population, children and adolescents, pregnant and breastfeeding women**
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

---

**Feasibility**
Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

---

**Rationale**

**General adult population**
There is currently limited evidence about the impact of baloxavir marboxil on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that baloxavir marboxil should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of baloxavir marboxil to treat COVID-19 in these populations should be avoided until evidence becomes available.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Baloxavir marboxil</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>
Summary
There remains significant uncertainty whether baloxavir marboxil is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from one randomised trial that compared baloxavir marboxil with standard care in 20 adults hospitalised with COVID-19 [112].

Study characteristics
Mean age was 54 years in the baloxavir marboxil group and 47 years in the control group; the proportion of women was 30% in both groups. It is unclear whether pregnant or breastfeeding women were eligible. Patients concomitantly used lopinavir-ritonavir, darunavir-cobicistat and/or arbidol.

What are the main results?
For the critical outcomes of death and mechanical invasive ventilation there were too few events (one death and one requiring ventilation) to determine whether baloxavir marboxil makes a difference. We are uncertain whether baloxavir marboxil increases or decreases respiratory support or likelihood of clinical improvement after 14 days. No data were reported on adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence for each outcome is very low. This judgement is based on serious risk of bias due to lack of blinding and very serious imprecision due to low patient numbers, few observed events and reliance on a single study.

Additional information
The Therapeutic Goods Administration highlights several mild side effects associated with baloxavir marboxil, including diarrhoea, bronchitis, nausea, sinusitis and headache. In addition, post-marketing surveillance has identified cases of anaphylactic reactions, angioedema, vomiting and other gastrointestinal and skin/subcutaneous tissue disorders [111].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>During treatment (14 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Critical</td>
<td>Based on data from 20 patients in 1 studies. ¹</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory support and ARDS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>During treatment (14 days)</td>
<td></td>
<td>Odds Ratio 2.25 (CI 95% 0.38 - 13.47)</td>
<td>Based on data from 20 patients in 1 studies. ² (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias and very serious imprecision ³ We are uncertain whether baloxavir marboxil increases or decreases respiratory support and ARDS (10 events).</td>
</tr>
<tr>
<td>9 Critical</td>
<td>Based on data from 20 patients in 1 studies. ²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation or ECMO During treatment (14 days)</td>
<td>Odds Ratio 3.32 (CI 95% 0.12 - 91.6) Based on data from 20 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>During treatment (14 days)</td>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Serious adverse events**

<table>
<thead>
<tr>
<th>During treatment (14 days)</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 Critical</td>
<td></td>
</tr>
</tbody>
</table>

**Adverse events**

<table>
<thead>
<tr>
<th>During treatment (14 days)</th>
<th>7</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Clinical improvement End of treatment (14 days)</th>
<th>Odds Ratio 1.5 (CI 95% 0.26 - 8.82) Based on data from 20 patients in 1 studies.</th>
<th>Very Low Due to serious risk of bias and very serious imprecision</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data for number of patients experiencing one or more events were not reported.

Data for number of patients experiencing one or more events were not reported.

3. **Risk of bias**: **Serious. Imprecision**: **Very Serious.** Low number of patients, Only data from one study.
5. **Risk of bias**: **Serious. Imprecision**: **Very Serious.** Low number of patients, Only data from one study.
7. Systematic review [109] with included studies: [110]. **Baseline/comparator**: Control arm of reference used for intervention.
9. **Risk of bias**: **Serious. Imprecision**: **Very Serious.** Low number of patients, Only data from one study.
Clinical Question/ PICO

**Population:** Special populations with COVID-19  
**Intervention:** Baloxavir marboxil  
**Comparator:** Standard care

Summary

There remains significant uncertainty whether baloxavir marboxil is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from one randomised trial that compared baloxavir marboxil with standard care in 20 adults hospitalised with COVID-19 [112].

**Study characteristics**

Mean age was 54 years in the baloxavir marboxil group and 47 years in the control group; the proportion of women was 30% in both groups. It is unclear whether pregnant or breastfeeding women were eligible. Patients concomitantly used lopinavir-ritonavir, darunavir-cobicistat and/or arbidol.

**What are the main results?**

For the critical outcomes of death and mechanical ventilation there were too few events (one death and one requiring ventilation) to determine whether baloxavir marboxil makes a difference. We are uncertain whether baloxavir marboxil increases or decreases respiratory support or likelihood of clinical improvement after 14 days. No data were reported on adverse or serious adverse events.

**Our confidence in the results**

Certainty of the evidence for each outcome is very low. This judgement is based on serious risk of bias due to lack of blinding, serious indirectness due to limited inclusion of these populations, and very serious imprecision due to low patient numbers, few observed events and reliance on a single study.

**Additional information**

The Therapeutic Goods Administration highlights several mild side effects associated with baloxavir marboxil, including diarrhoea, bronchitis, nausea, sinusitis and headache. In addition, post-marketing surveillance has identified cases of anaphylactic reactions, angioedema, vomiting and other gastrointestinal and skin/subcutaneous tissue disorders [111].

**Children and adolescents**

There is insufficient safety data on the use of baloxavir marboxil in children or adolescents for other indications.

**Pregnant and breastfeeding women**

No studies pertained to the safety of baloxavir marboxil (for any indication) when used in pregnant or breastfeeding women.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
</table>
| **Mortality**  
During treatment (14 days) | Based on data from 20 patients in 1 studies.¹ | | | There were no deaths in the study. |

¹ Based on data from 20 patients in 1 studies.
1. Systematic review [109] with included studies: Lou 2020. **Baseline/comparator:** Control arm of reference used for

### Respiratory support and ARDS

<table>
<thead>
<tr>
<th>Event</th>
<th>Odds Ratio</th>
<th>CI 95%</th>
<th>Studies</th>
<th>Risk of Bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Risk of Baloxavir Marboxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>During treatment (14 days)</td>
<td>Odds Ratio 2.25</td>
<td>CI 95% 0.38 - 13.47</td>
<td>2</td>
<td>Very Low</td>
<td>Serious</td>
<td>Very Serious</td>
<td>Uncertain increases or decreases respiratory support and ARDS (10 events)</td>
</tr>
</tbody>
</table>

### Invasive mechanical ventilation or ECMO

<table>
<thead>
<tr>
<th>Event</th>
<th>Odds Ratio</th>
<th>CI 95%</th>
<th>Studies</th>
<th>Risk of Bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Risk of Baloxavir Marboxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>During treatment (14 days)</td>
<td>Odds Ratio 3.32</td>
<td>CI 95% 0.12 - 91.6</td>
<td>4</td>
<td>Very Low</td>
<td>Serious</td>
<td>Very Serious</td>
<td>Too few who required mechanical ventilation or ECMO (1 event) to determine whether baloxavir marboxil makes a difference</td>
</tr>
</tbody>
</table>

### Serious adverse events

<table>
<thead>
<tr>
<th>Event</th>
<th>Risk of Baloxavir Marboxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>During treatment (14 days)</td>
<td>Data for number of patients experiencing one or more events were not reported</td>
</tr>
</tbody>
</table>

### Adverse events

<table>
<thead>
<tr>
<th>Event</th>
<th>Risk of Baloxavir Marboxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>During treatment (14 days)</td>
<td>Data for number of patients experiencing one or more events were not reported</td>
</tr>
</tbody>
</table>

### Clinical improvement

<table>
<thead>
<tr>
<th>Event</th>
<th>Odds Ratio</th>
<th>CI 95%</th>
<th>Studies</th>
<th>Risk of Bias</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Risk of Baloxavir Marboxil</th>
</tr>
</thead>
<tbody>
<tr>
<td>End of treatment (14 days)</td>
<td>Odds Ratio 1.5</td>
<td>CI 95% 0.26 - 8.82</td>
<td>8</td>
<td>Very Low</td>
<td>Serious</td>
<td>Very Serious</td>
<td>Uncertain increases or decreases clinical improvement (11 events)</td>
</tr>
</tbody>
</table>
6.6.4 - Bromhexine hydrochloride

Do not use bromhexine hydrochloride for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Bromhexine hydrochloride should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use bromhexine hydrochloride for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

Evidence To Decision

**Benefits and harms**

**General adult population**
In addition to uncertainty around benefits for patients with COVID-19, there are common side effects associated with bromhexine hydrochloride including nausea, vomiting, diarrhoea, allergy and severe, low-risk skin reactions—erythema multiforme, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis.

**Pregnant and breastfeeding women**
Benefits can be assumed to outweigh possible risks for pregnant women—limited clinical experience has not resulted in adverse effects to the fetus. Bromhexine hydrochloride is safe to use in women who are breastfeeding.

**Certainty of the Evidence**

**General adult population**
Certainty of the evidence is very low for all outcomes due to very serious risk of bias (lack of blinding of patients and outcome assessors) and very serious imprecision (low patient numbers, few events and wide confidence intervals).
Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, certainty of the evidence is further considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of bromhexine hydrochloride during pregnancy and breastfeeding are unknown in the context of COVID-19.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Acceptability**

**General adult population, children and adolescents, pregnant and breastfeeding women**

We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

**People requiring palliative care and older people living with frailty or cognitive impairment**

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.
Rationale

**General adult population**
There is currently limited evidence about the impact of bromhexine hydrochloride on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that bromhexine hydrochloride should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of bromhexine hydrochloride for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Bromhexine hydrochloride</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

**Summary**
There remains significant uncertainty whether bromhexine hydrochloride is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**
Evidence comes from two randomised trials that compared bromhexine hydrochloride with placebo in 96 adults hospitalised with mild or moderate COVID-19 [114]/[115].

**Study characteristics**
In the study by Ansarin et al. mean age was 60 years and the proportion of women was 45% [115]; in Li et al. mean age was 50 years and the proportion of women was 22% [114].

Patients in Ansarin et al. received 8 mg bromhexine hydrochloride three times a day for 14 days; patients in Li et al. received 32 mg three times a day for 14 days. Pregnant and breastfeeding women were ineligible.

**What are the main results?**
There were too few who died (five deaths) or suffered adverse events to determine whether bromhexine hydrochloride makes a difference. No patients experienced serious adverse events. It is unclear whether bromhexine hydrochloride increases or decreases time to clinical improvement or viral clearance by day 28.

**Our confidence in the results**
Certainty of the evidence is very low for all outcomes due to very serious risk of bias (lack of blinding of patients and outcome assessors) and very serious imprecision (low patient numbers, few events and wide confidence intervals).

For children & adolescents and pregnant & breastfeeding women, certainty is also downgraded for serious indirectness (absence or limited inclusion of these populations in the included studies).

**Additional information**
The safety profile for bromhexine hydrochloride indicates the following adverse effects: nausea, vomiting, diarrhoea and allergy (e.g. rash, urticaria, angioedema). Bromhexine hydrochloride has been associated with a low risk of severe skin reactions including erythema multiforme, Stevens-Johnson syndrome and acute generalised exanthematous pustulosis [160].

**Pregnant and breastfeeding women**
Bromhexine hydrochloride is considered safe in pregnancy [160].
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care Bromhexine hydrochloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 0.09 (CI 95% 0.01 - 1.59) Based on data from 96 patients in 2 studies.</td>
<td>Very Low</td>
<td>Due to serious risk of bias and very serious imprecision</td>
<td>There were too few who died to determine whether bromhexine hydrochloride makes a difference (5 deaths).</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Relative risk 0.11 (CI 95% 0.01 - 0.84) Based on data from 78 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious risk of bias and very serious imprecision</td>
<td>There were too few who required invasive mechanical ventilation to determine whether bromhexine hydrochloride makes a difference (10 events).</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Based on data from 78 patients in 2 studies.</td>
<td>Very Low</td>
<td>Due to very serious risk of bias and very serious imprecision</td>
<td>No patients experienced serious adverse events.</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>Relative risk 0.38 (CI 95% 0.12 - 1.16) Based on data from 18 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious risk of bias and very serious imprecision</td>
<td>No patients discontinued treatment due to adverse events.</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinuation due to adverse events</td>
<td>Based on data from 18 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious risk of bias and very serious imprecision</td>
<td>No patients discontinued treatment due to adverse events.</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICU admission</td>
<td>Relative risk 0.18 (CI 95% 0.04 - 0.77) Based on data from 96 patients in 2 studies.</td>
<td>Very Low</td>
<td>Due to very serious risk of bias and serious imprecision</td>
<td>There were too few who required ICU admission to determine whether bromhexine hydrochloride makes a difference (13 events).</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virological</td>
<td>Relative risk 1 (CI 95% 0.79 - 1.26)</td>
<td>Very Low</td>
<td>We are uncertain whether bromhexine</td>
<td></td>
</tr>
</tbody>
</table>
2. **Risk of bias: Very Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency: No serious.** Point estimates vary widely. **Indirectness: Very Serious.** Low number of patients, only two small studies and Wide confidence intervals. **Publication bias: No serious.**
4. **Risk of bias: Very Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency: No serious.** **Indirectness: No serious.** **Imprecision: Very Serious.** Wide confidence intervals, Low number of patients. **Publication bias: No serious.**
6. **Risk of bias: Very Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness: No serious.** **Imprecision: Serious.** Low number of patients. **Publication bias: No serious.**
7. Systematic review [113] with included studies: Li 2020. **Baseline/comparator:** Control arm of reference used for intervention.
8. **Risk of bias: Very Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness: No serious.** **Imprecision: Very Serious.** Low number of patients, Wide confidence intervals. **Publication bias: No serious.**
10. **Risk of bias: Very Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness: No serious.** **Imprecision: Very Serious.** Wide confidence intervals, Low number of patients. **Publication bias: No serious.**
12. **Risk of bias: Very Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness: No serious.** **Imprecision: Serious.** Low number of patients. **Publication bias: No
6.6.5 - Calcifediol

**Not recommended**

Do not use calcifediol for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Calcifediol should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use calcifediol to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

### Evidence To Decision

#### Benefits and harms

- **General adult population**
  - There are limited harms associated with calcifediol, a vitamin D analog, at the doses specified in the included study. However, there remains significant uncertainty around benefits for patients with COVID-19.

#### Certainty of the Evidence

- **General adult population**
  - Certainty of the evidence is very low for all outcomes due to serious risk of bias and very serious imprecision.

- **Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
  - In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the study.

#### Preference and values

- **General adult population**
  - We have no systematically collected information regarding patients' preferences and values. The panel believes that
since there is uncertainty about the benefits, some patients would be willing to opt for the treatment while others may prefer to wait.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources
We have no systematically collected information regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Equity
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Acceptability
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

Feasibility
Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale
General adult population
There is currently limited evidence about the impact of calcifediol on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that calcifediol should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of calcifediol to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO
- **Population:** Patients with COVID-19
- **Intervention:** Calcifediol
- **Comparator:** Standard care
Summary
There remains significant uncertainty whether calcifediol, a vitamin D analog, is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared calcifediol with standard care in 76 adults hospitalised with COVID-19 [116].

Study characteristics
Mean age was 53 years in both the calcifediol and standard care groups; the proportion of women was 46% and 31% respectively. Standard care was a combination of hydroxychloroquine and azithromycin. Pregnant women were ineligible.

What are the main results?
For the critical outcome of death there were too few who died (two deaths) to determine whether calcifediol makes a difference. We are uncertain whether calcifediol increases or decreases the likelihood of admission to ICU or being discharged from hospital. No data were reported on adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence for all outcomes is very low due to serious risk of bias (lack of personnel blinding and selective outcome reporting) and very serious imprecision (low patient numbers and/or observed events, incomplete data and/or large loss to follow-up).

Additional information
As a vitamin D analog, there are limited harms associated with calcifediol at the doses specified in the study.
<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Critical</td>
<td>Relative risk 0.11 (CI 0.95% 0.01 - 2.13) Based on data from 76 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>There were too few who died to determine whether calcifediol makes a difference to all-cause mortality (2 events).</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical deterioration (Admission to ICU)</strong></td>
<td>Relative risk 0.04 (CI 0.95% 0.01 - 0.29) Based on data from 76 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether calcifediol increases or decreases clinical deterioration (admission to ICU) (14 events).</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td>Relative risk 1.09 (CI 0.95% 0.96 - 1.23) Based on data from 76 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether calcifediol increases or decreases discharge from hospital (63 events).</td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Serious. Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Incomplete data and/or large loss to follow up. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
4. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up, Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few patients.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow up, Selective outcome reporting. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.

**Clinical Question/ PICO**

- **Population:** Special populations with COVID-19
- **Intervention:** Calcifediol
- **Comparator:** Standard care
Summary
There remains significant uncertainty whether calcifediol, a vitamin D analog, is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared calcifediol with standard care in 76 adults hospitalised with COVID-19 [116].

Study characteristics
Mean age was 53 years in both the calcifediol and standard care groups; the proportion of women was 46% and 31% respectively. Standard care was a combination of hydroxychloroquine and azithromycin. Pregnant women were ineligible.

What are the main results?
For the critical outcome of death there were too few who died (two deaths) to determine whether calcifediol makes a difference. We are uncertain whether calcifediol increases or decreases the likelihood of admission to ICU or being discharged from hospital. No data were reported on adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence for all outcomes is very low due to serious risk of bias (lack of personnel blinding and selective outcome reporting), serious indirectness (exclusion of children, adolescents and pregnant women) and very serious imprecision (low patient numbers and/or observed events, incomplete data and/or large loss to follow-up).

Additional information
As a vitamin D analog, there are limited harms associated with calcifediol at the doses specified in the study.
<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Relative risk 0.11 (CI 95% 0.01 - 2.13) Based on data from 76 patients in 1 studies. ¹  (Randomized controlled)</td>
<td></td>
<td>Very Low  Due to serious risk of bias and indirectness, and very serious imprecision ²</td>
<td>There were too few who died to determine whether calcifediol makes a difference (2 events).</td>
</tr>
<tr>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical deterioration (Admission to ICU)</strong></td>
<td>Relative risk 0.04 (CI 95% 0.01 - 0.29) Based on data from 76 patients in 1 studies. ³ (Randomized controlled)</td>
<td></td>
<td>Very Low  Due to serious risk of bias and indirectness, and very serious imprecision ⁴</td>
<td>We are uncertain whether calcifediol increases or decreases clinical deterioration (admission to ICU) (14 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td>Relative risk 1.09 (CI 95% 0.96 - 1.23) Based on data from 76 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td></td>
<td>Very Low  Due to serious risk of bias and indirectness, and very serious imprecision ⁶</td>
<td>We are uncertain whether calcifediol increases or decreases discharge from hospital (63 events).</td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Serious. Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow-up. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
4. **Risk of bias:** Serious. Incomplete data and/or large loss to follow-up, Selective outcome reporting, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few patients.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow up, Selective outcome reporting. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
6.6.6 - Chloroquine

Do not use chloroquine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Chloroquine should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use chloroquine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

General adult population

In addition to uncertainty around benefits for patients with COVID-19, there are well-known harms with potentially severe adverse events. Although most of the information on side effects and harms associated with chloroquine is derived from long-term use, potential acute harms include prolonged QT interval and lowered convulsive threshold.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

There are additional concerns regarding harms as chloroquine has not been sufficiently tested in these populations. Chloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases in some countries. The available evidence is limited, though it is not associated with pregnancy loss, stillbirth or neonatal death [118]. For people requiring palliative care, the benefits for symptom management are uncertain.

Certainty of the evidence for each outcome is very low. This is based on serious risk of bias due to non-blinding of participants and personnel and incomplete outcome data, and very serious imprecision due to the low number of patients and/or events for some outcomes and the reliance on a single study.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, certainty of the evidence is additionally considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of chloroquine in pregnancy are unknown.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to
Rationale

General adult population
There is currently limited evidence about the impact of chloroquine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that chloroquine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of chloroquine to treat COVID-19 in these populations should be avoided until evidence becomes available.

Resources
We have no systematically collected evidence regarding cost-benefit.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

Special populations (people requiring palliative care and older people living with frailty or cognitive impairment)
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent. In addition, although chloroquine is registered on the Australian Register of Therapeutic Goods, it is not marketed in Australia and is therefore not readily available.

Rationale

General adult population
There is currently limited evidence about the impact of chloroquine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that chloroquine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of chloroquine to treat COVID-19 in these populations should be avoided until evidence becomes available.
**Clinical Question/ PICO**

- **Population:** Patients with COVID-19
- **Intervention:** Chloroquine
- **Comparator:** Standard care

**Summary**

There remains significant uncertainty whether chloroquine is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared chloroquine with standard care in 30 adults hospitalised with moderate COVID-19 [64].

**Publication status**

The study is only available as a preprint paper (posted to medRxiv on 22 June 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

**Study characteristics**

Mean age was 45 years in the chloroquine group and 51 years in the control group; the proportion of women was 61% and 42% respectively. It is unclear if pregnant or breastfeeding women were eligible.

**What are the main results?**

No patients in either arm died, progressed to severe or critical disease, or experienced a serious adverse event. We are uncertain whether chloroquine increases or decreases time to clinical recovery, time to termination of oxygen therapy or the likelihood of experiencing adverse events. The study did not report results for respiratory failure or requirement for mechanical ventilation.

**Our confidence in the results**

Certainty of the evidence for each outcome is very low. This judgement is based on serious risk of bias (patients, personnel and outcome assessors not blinded, and incomplete reporting of data) and very serious imprecision (low patient numbers, few observed events and reliance on a single study).

**Additional information**

Although listed on the Australian Register of Therapeutic Goods, chloroquine is not marketed in Australia and is not available for general use.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care</td>
<td>Chloroquine</td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Based on data from 30 patients in 1 studies, ¹ (Randomized controlled)</td>
<td></td>
<td>²</td>
<td>There were no deaths.</td>
</tr>
<tr>
<td>Progression to</td>
<td></td>
<td></td>
<td>⁴</td>
<td>No patients</td>
</tr>
<tr>
<td>Outcome</td>
<td>Definition</td>
<td>Methodology</td>
<td>Results</td>
<td>Risk of Bias</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>Severe or critical disease</td>
<td>Within 28 days after commencing treatment</td>
<td>Based on data from 30 patients in 1 studies. (Randomized controlled)</td>
<td>progressed to severe or critical disease.</td>
<td>6 Important</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Within 28 days after commencing treatment</td>
<td>Relative risk 2.67 (CI 95% 0.68 - 10.46) Based on data from 30 patients in 1 studies. (Randomized controlled)</td>
<td>Very Low</td>
<td>We are uncertain whether chloroquine increases or decreases adverse events (10 events).</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Within 28 days after commencing treatment</td>
<td>Based on data from 30 patients in 1 studies. (Randomized controlled)</td>
<td>There were no serious adverse events.</td>
<td>6 Important</td>
</tr>
<tr>
<td>Time to clinical recovery</td>
<td>Median time to clinical recovery (Days)</td>
<td>Measured by: Median time to clinical recovery; chloroquine: 5.5 days (IQR 3.25-7.5), control: 7.5 days (IQR 5.0-16.25) Lower better (Randomized controlled)</td>
<td>7.5 (Median) CI 95%</td>
<td>Very Low</td>
</tr>
<tr>
<td>Time to termination of oxygen therapy</td>
<td>Median time from randomisation to termination of oxygen therapy (Days)</td>
<td>Measured by: Median time to termination of oxygen therapy; chloroquine: 8.5 days (IQR 0-9.25); control: 8 days (IQR 3.25-14) Lower better (Randomized controlled)</td>
<td>8 (Median) CI 95%</td>
<td>Very Low</td>
</tr>
</tbody>
</table>

intervention.

2. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow up. **Imprecision: Very Serious.** Low number of patients, Only data from one study.


4. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Incomplete data and/or large loss to follow up. **Imprecision: Very Serious.** Low number of patients, Only data from one study.

5. Systematic review [61] with included studies: Chen L 2020. **Baseline/comparator:** Control arm of reference used for intervention.

6. **Risk of bias: Serious.** Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for performance bias. **Imprecision: Very Serious.** Low number of patients, Only data from one study.

7. **Risk of bias: Serious.** Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision: Very Serious.** Only data from one study, Low number of patients.

8. **Risk of bias: Serious.** Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision: Very Serious.** Low number of patients, Only data from one study.

9. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow up. **Imprecision: Very Serious.** Low number of patients, Only data from one study.

### Clinical Question/ PICO

**Population:** Special populations with COVID-19  
**Intervention:** Chloroquine  
**Comparator:** Standard care

### Summary

There remains significant uncertainty whether chloroquine is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared chloroquine with standard care in 30 adults hospitalised with moderate COVID-19 [64].

**Publication status**

The study is only available as a preprint paper (posted to medRxiv on 22 June 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

**Study characteristics**

Mean age was 45 years in the chloroquine group and 51 years in the control group; the proportion of women was 61% and 42% respectively. It is unclear if pregnant or breastfeeding women were eligible.

**What are the main results?**

No patients in either arm died, progressed to severe or critical disease, or experienced a serious adverse event. We
are uncertain whether chloroquine increases or decreases time to clinical recovery, time to termination of oxygen therapy or the likelihood of experiencing adverse events. The study did not report results for respiratory failure or requirement for mechanical ventilation.

**Our confidence in the results**

Certainty of the evidence for each outcome is very low. This judgement is based on serious risk of bias (patients, personnel and outcome assessors not blinded, and incomplete reporting of data), serious indirectness (limited inclusion of these populations) and very serious imprecision (low patient numbers, few observed events and reliance on a single study).

**Additional information**

Although listed on the Australian Register of Therapeutic Goods, chloroquine is not marketed in Australia and is not available for general use.

**Children and adolescents**

Paediatricians have considerable experience with using chloroquine in children and adolescents for other indications. To date, no specific information on benefits or harms for children and adolescents with COVID-19 has been collected.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Based on data from 30 patients in 1 studies. 1 (Randomized controlled)</td>
<td>Standard care Chloroquine</td>
<td>2</td>
<td>There were no deaths.</td>
</tr>
<tr>
<td><strong>Progression to severe or critical disease</strong></td>
<td>Based on data from 30 patients in 1 studies. 3 (Randomized controlled)</td>
<td>4</td>
<td>No patients progressed to severe or critical disease.</td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>Relative risk 2.67 (CI 95% 0.68 - 10.46) Based on data from 30 patients in 1 studies. 5 (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias, serious indirectness and very serious imprecision 6</td>
<td>We are uncertain whether chloroquine increases or decreases adverse events (10 events).</td>
<td></td>
</tr>
</tbody>
</table>
**Serious adverse events**

Within 28 days after commencing treatment

<table>
<thead>
<tr>
<th>Time to clinical recovery</th>
<th>Median time to clinical recovery; chloroquine: 5.5 days (IQR 3.25-7.5), control: 7.5 days (IQR 5.0-16.25)</th>
<th>7.5 (Median)</th>
<th>5.5 (Median)</th>
<th>CI 95%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower better (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There were no serious adverse events.

**Time to clinical recovery**

Median time from randomisation to termination of oxygen therapy (Days)

<table>
<thead>
<tr>
<th>Time to clinical recovery</th>
<th>Median time to clinical recovery; chloroquine: 8.5 days (IQR 0-9.25); control: 8 days (IQR 3.25-14)</th>
<th>8 (Median)</th>
<th>8.5 (Median)</th>
<th>CI 95%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower better (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Very Low

Due to serious risk of bias, serious indirectness and very serious imprecision

We are uncertain whether chloroquine increases or decreases time to clinical recovery.

**Time to termination of oxygen therapy**

<table>
<thead>
<tr>
<th>Time to termination of oxygen therapy</th>
<th>Median time from randomisation to termination of oxygen therapy; chloroquine: 8.5 days (IQR 0-9.25); control: 8 days (IQR 3.25-14)</th>
<th>8 (Median)</th>
<th>8.5 (Median)</th>
<th>CI 95%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower better (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Very Low

Due to serious risk of bias, serious indirectness and very serious imprecision

We are uncertain whether chloroquine increases or decreases time to termination of oxygen therapy.

2. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Incomplete data and/or large loss to follow up. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients. Only data from one study.
4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Incomplete data and/or large loss to follow up. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients. Only data from one study.
5. Systematic review [61] with included studies: Chen L 2020. **Baseline/comparator:** Control arm of reference used for intervention.
6. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients. Only data from one study.
7. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome...
assessors, resulting in potential for detection bias. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness: Serious. Imprecision: Very Serious.** Only data from one study, Low number of patients.

8. **Risk of bias: Serious.** Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness: Serious. Imprecision: Very Serious.** Low number of patients, Only data from one study.

9. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Incomplete data and/or large loss to follow up. **Indirectness: Serious. Imprecision: Very Serious.** Low number of patients, Only data from one study.

### 6.6.7 - Colchicine

**Not recommended**

Do not use colchicine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Colchicine should still be considered for other evidence-based indications in people who have COVID-19.**

**Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use colchicine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.**

### Evidence To Decision

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Important harms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td></td>
</tr>
<tr>
<td>In addition to uncertainty around benefits for patients with COVID-19, there are known side effects and harms associated with colchicine including diarrhoea. Overdose of colchicine can cause severe diarrhoea and dehydration, bone marrow suppression, metabolic acidosis and shock.</td>
<td></td>
</tr>
</tbody>
</table>

| Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment |  |
|---|  |
| There are additional concerns regarding harms as colchicine has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain. Studies of colchicine in pregnancy for some rheumatological conditions have shown no increase in major fetal anomalies or pregnancy loss [121]. |  |

### Certainty of the Evidence

**Certainty of the evidence is low for all-cause mortality, mechanical ventilation, clinical deterioration and discontinuation due to adverse events. This judgement is based on very serious imprecision due to either the reliance on a single study, low patient numbers and/or few observed events. Certainty of the evidence for adverse and serious adverse events and duration of hospital stay was additionally downgraded for risk of bias since patients, personnel and outcome assessors were not blinded, which may have affected the reporting and/or severity of these outcomes.**

### Preference and values

**Substantial variability is expected or uncertain**
Rationale

General adult population

There is currently limited evidence about the impact of colchicine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that colchicine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Resources

We have no systematically collected evidence regarding cost-benefit.

Equity

General adult population

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women

Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale

General adult population

There is currently limited evidence about the impact of colchicine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that colchicine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.
Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of colchicine to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Colchicine</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

Summary

There remains significant uncertainty whether colchicine is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from three randomised trials that compared colchicine with standard care in 240 adults hospitalised with COVID-19 [120][122][124].

Publication status

Two of the studies are only available as preprint papers (posted to medRxiv on 11 August 2020 and Research Square on 21 September 2020) and have therefore not been peer reviewed [122][124]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics

Median age ranged from 48 to 63 years in the colchicine groups and from 54 to 65 years in the control groups; the proportion of women was 49% and 52% respectively. Pregnant and breastfeeding women were ineligible.

What are the main results?

For the critical outcomes of death and mechanical ventilation, there were too few events (five deaths and seven who required ventilating) to determine whether colchicine makes a difference. We are uncertain whether colchicine increases or decreases discharge from hospital, duration of hospital stay or the likelihood of experiencing adverse events. No data were reported on serious adverse events. For the remaining outcomes, too few patients experienced clinical deterioration (eight events) or were admitted to ICU (two events) to determine whether colchicine makes a difference.

Our confidence in the results

Certainty of the evidence is low for mortality, mechanical ventilation, clinical deterioration and discontinuation due to adverse events. This judgement is based on very serious imprecision due to the reliance on a single study, low patient numbers and few events. Certainty of the evidence for adverse and serious adverse events and duration of hospital stay was additionally downgraded for risk of bias since patients, personnel and outcome assessors were not blinded, which may have affected the reporting and/or severity of these outcomes.

For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information

According to the Therapeutic Goods Administration, known acute harms for colchicine include diarrhoea and stomach cramps. Colchicine overdose can cause severe diarrhoea and dehydration, bone marrow suppression, metabolic acidosis and shock [119]. There are several known and potential interactions with other drugs [119].

Children and adolescents

Paediatricians have limited experience with colchicine in children and adolescents for other indications. To date, no specific information on its benefits or harms has been collected for treating COVID-19 in this population.
Pregnant and breastfeeding women
Colchicine should be avoided in pregnancy and during breastfeeding, and in children under 2 years of age.

Older people living with frailty or cognitive impairment
Caution should be taken when prescribing colchicine to elderly patients who may be more susceptible to cumulative toxicity.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Absolute risk 0.23 (CI 95% 0.03 - 1.97) Based on data from 140 patients in 2 studies.</td>
<td>59 per 1000</td>
<td>Low</td>
<td>There were too few who died to determine whether colchicine makes a difference (5 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Absolute risk 0.15 (CI 95% 0.02 - 1.22) Based on data from 105 patients in 1 studies.</td>
<td>120 per 1000</td>
<td>Low</td>
<td>There were too few who received invasive mechanical ventilation to determine whether colchicine makes a difference (7 events).</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Absolute risk 2.61 (CI 95% 1.67 - 4.07) Based on data from 105 patients in 1 studies.</td>
<td>6 Important</td>
<td>Very Low</td>
<td>We are uncertain whether colchicine increases or decreases adverse events (58 events).</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Based on data from 105 patients in 1 studies.</td>
<td>6 Important</td>
<td></td>
<td>There were no serious adverse events.</td>
</tr>
<tr>
<td>Discontinuation due to adverse events</td>
<td>Absolute risk 4.55 (CI 95% 0.22 - 92.62) Based on data from 140 patients in 2 studies.</td>
<td>Very Low</td>
<td>There were too few who experienced discontinuation due to adverse events to determine whether colchicine makes a</td>
<td></td>
</tr>
</tbody>
</table>

2. **Imprecision:** Very Serious. Low number of patients, due to few events.


4. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

### Important Difference (2 events)

**Clinical deterioration**
- Increase of 2 grades on 7-grade ordinal scale; 21 days after commencing treatment.
- Relative risk 0.13 (CI 95% 0.02 - 1.02)
- Based on data from 105 patients in 1 studies.
- (Randomized controlled)

**Risk of bias:** Serious.
- Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
- Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Low***
- Due to very serious imprecision
- There were too few who experienced clinical deterioration (8 events) to determine whether colchicine makes a difference.

**Clinical deterioration**
- Admission to ICU; end of treatment
- Relative risk 1.06 (CI 95% 0.07 - 15.62)
- Based on data from 35 patients in 1 studies.
- (Randomized controlled)

**Risk of bias:** Serious.
- Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
- Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Low***
- Due to very serious imprecision
- There were too few who were admitted to ICU to determine whether colchicine makes a difference (2 events).

**Discharge from hospital**
- 10 days after commencing treatment
- Relative risk 1.3 (CI 95% 0.96 - 1.78)
- Based on data from 35 patients in 1 studies.
- (Randomized controlled)

**Risk of bias:** Serious.
- Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
- Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Low***
- Due to very serious imprecision
- We are uncertain whether colchicine increases or decreases discharge from hospital (29 events).

**Duration of hospital stay**
- Days
- Lower better
- Based on data from: 100 patients in 1 studies.
- (Randomized controlled)

**Risk of bias:** Very Low
- Due to very serious risk of bias and very serious imprecision
- We are uncertain whether colchicine increases or decreases duration of hospital stay.

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>(CI)</th>
<th>Mean</th>
<th>Difference</th>
<th>(CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical deterioration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase of 2 grades on 7-grade</td>
<td>0.13</td>
<td>0.02 - 1.02</td>
<td>140</td>
<td>122 fewer</td>
<td>0.02 - 3</td>
</tr>
<tr>
<td>ordinal scale; 21 days after</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical deterioration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Admission to ICU; end of</td>
<td>1.06</td>
<td>0.07 - 15.62</td>
<td>56</td>
<td>3 more</td>
<td>0.52 - 819</td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 days after commencing</td>
<td>1.3</td>
<td>0.96 - 1.78</td>
<td>722</td>
<td>217 more</td>
<td>0.29 - 563</td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Duration of hospital stay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days</td>
<td></td>
<td></td>
<td></td>
<td>1.84 lower</td>
<td></td>
</tr>
</tbody>
</table>

1. **Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce**
9. **Imprecision:** Very Serious. Low number of patients, due to few events.
11. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
13. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
15. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
16. Primary study[124]. **Baseline/comparator:** Control arm of reference used for intervention.
17. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Selective outcome reporting. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

### 6.6.8 - Convalescent plasma

**Not recommended**

Do not use convalescent plasma for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use convalescent plasma to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.**

#### Evidence To Decision

**Benefits and harms**

**General adult population**
Although evidence suggests convalescent plasma does not result in more serious adverse events compared with standard care, it remains unclear if convalescent plasma is safe for the treatment of COVID-19.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There are additional concerns regarding harms as convalescent plasma has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain. There is insufficient evidence pertaining to the safety of convalescent plasma for pregnant or breastfeeding women (for any indication) [126].

**Certainty of the Evidence**

Very Low
**General adult population**

Certainty of the evidence is low for mortality, clinical deterioration, invasive mechanical ventilation, resolution of dyspnea, viral nucleic acid negative and duration of hospital stay due to serious imprecision (reliance on a single study and/or low patient numbers) and serious risk of bias. Certainty is very low for all other outcomes.

Certainty has been downgraded for all outcomes due to the high prevalence of baseline neutralising antibodies (NAb) in trial participants. One study excluded patients with a NAb titer of 1:640 or lower [127]. One study did not report specific NAb titers of included patients. The remaining studies detected NAb in 76% [131], 49% [130] and 80% [128] of patients at baseline.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

<table>
<thead>
<tr>
<th>Preference and values</th>
<th>Substantial variability is expected or uncertain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td>We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.</td>
</tr>
<tr>
<td><strong>Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
<td>In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of convalescent plasma in pregnancy are unknown. The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td>There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.</td>
</tr>
<tr>
<td><strong>Children and adolescents, pregnant and breastfeeding women</strong></td>
<td>Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.</td>
</tr>
<tr>
<td><strong>People requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
<td>As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
</table>
General adult population, children and adolescents, pregnant and breastfeeding women
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility
Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale

General adult population
There is currently limited evidence about the impact of convalescent plasma on patient-relevant outcomes in the treatment of COVID-19 [126]. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that convalescent plasma should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of convalescent plasma to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with COVID-19</td>
<td>Convalescent plasma</td>
<td>Control</td>
</tr>
</tbody>
</table>

Summary
There remains significant uncertainty whether convalescent plasma is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from five randomised trials that compared convalescent plasma with standard care in 631 adults with moderate COVID-19 [128][130][134] and 152 adults with severe COVID-19 [127][133].

Publication status
Two studies are only available as preprint papers (posted to medRxiv on 3 July and 1 September 2020) and have therefore not been peer reviewed [128][130]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
Compared with standard care, convalescent plasma may decrease death slightly at day 28 (57 fewer deaths per 1000 patients; 110 fewer to 57 more (RR 0.64; CI 95% 0.30 to 1.36; 695 patients in 4 studies)).
For all other outcomes—requirement for mechanical ventilation, clinical deterioration, serious adverse events, clinical improvement (day 15 or day 28), hospital discharge, resolution of dyspnea, viral nucleic acid negative, duration of hospital stay and time to clinical improvement—we are uncertain if convalescent plasma makes a difference compared with standard care.

**Our confidence in the results**

Certainty of the evidence is low for mortality, clinical deterioration, invasive mechanical ventilation, resolution of dyspnea, viral nucleic acid negative and duration of hospital stay due to serious imprecision (reliance on a single study and/or low patient numbers) and serious risk of bias. Certainty is very low for all other outcomes.

Certainty has been downgraded for all outcomes due to the high prevalence of baseline neutralising antibodies (NAb) in trial participants. One study excluded patients with a NAb titer of 1:640 or lower [127]. One study did not report specific NAb titers of included patients [133]. The remaining studies detected NAb in 76% [134], 49% [130] and 80% [128] of patients at baseline.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.64 (CI 95% 0.3 - 1.36) Based on data from 695 patients in 4 studies.</td>
<td>157 per 1000 Convalescent plasma</td>
<td>Low</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.88 (CI 95% 0.48 - 1.61) Based on data from 464 patients in 1 studies.</td>
<td>87 per 1000 Convalescent plasma</td>
<td>Low</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.97 (CI 95% 0.36 - 2.63) Based on data from 81 patients in 1 studies.</td>
<td>74 per 1000 Convalescent plasma</td>
<td>Very Low</td>
</tr>
</tbody>
</table>
| Clinical deterioration (progression to severe/critical) | | Relative risk 0.71 (CI 95% 0.18 - 2.78) Based on data from 545 patients in 2 studies. | 53 per 1000 Convalescent plasma | Low | **Due to serious risk of bias and imprecision**⁹ Convalescent plasma may have little impact on clinical deterioration (progression to severe/
<table>
<thead>
<tr>
<th>Event</th>
<th>Timeframe</th>
<th>Relative Risk (CI 95%)</th>
<th>patients</th>
<th>studies</th>
<th>Study Design</th>
<th>Evidence Quality</th>
<th>Risk of Bias and Imprecision</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical improvement</td>
<td>Within 28 days of commencing treatment</td>
<td>1.2 (0.8 - 1.81)</td>
<td>103</td>
<td>1</td>
<td>(Randomized controlled)</td>
<td>Low</td>
<td>Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether convalescent plasma improves or worsens clinical improvement (49 events).</td>
</tr>
<tr>
<td>Hospital discharge</td>
<td>Within 28 days of commencing treatment</td>
<td>1.18 (0.89 - 1.55)</td>
<td>182</td>
<td>2</td>
<td>(Randomized controlled)</td>
<td>Low</td>
<td>Due to serious risk of bias and imprecision</td>
<td>Convalescent plasma may increase slightly hospital discharge within 28 days (113 events).</td>
</tr>
<tr>
<td>Resolution of dyspnea</td>
<td>Within 7 days of commencing treatment</td>
<td>1.15 (0.97 - 1.35)</td>
<td>464</td>
<td>1</td>
<td>(Randomized controlled)</td>
<td>Low</td>
<td>Due to serious risk of bias and imprecision</td>
<td>Convalescent plasma may increase slightly resolution of dyspnea (259 events).</td>
</tr>
<tr>
<td>Viral nucleic acid negative</td>
<td>72 hours after commencing treatment</td>
<td>2.33 (1.54 - 3.52)</td>
<td>87</td>
<td>1</td>
<td>(Randomized controlled)</td>
<td>Low</td>
<td>Due to serious risk of bias and very serious imprecision</td>
<td>Convalescent plasma may increase number of patients who are viral nucleic acid negative at 72 hours.</td>
</tr>
</tbody>
</table>
### Duration of Hospital Stay

<table>
<thead>
<tr>
<th>Days</th>
<th>Important</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Important</td>
</tr>
</tbody>
</table>

Duration of hospital stay based on data from 464 patients in 1 study.  
**13 (Median)**  
**14 (Median)**  
CI 95%

### Time to Clinical Improvement

<table>
<thead>
<tr>
<th>Days</th>
<th>Important</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Important</td>
</tr>
</tbody>
</table>

Time to clinical improvement based on data from 49 patients in 1 study.  
**8.45 (Mean)**  
**4.52 (Mean)**  
Difference: **MD 3.93 lower**  
( CI 95% 5.12 lower - 2.74 lower )  
**Very Low**  
Due to serious risk of bias and very serious imprecision

We are uncertain whether convalescent plasma decreases time to clinical improvement.

### Summary

   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to high level of neutralising antibodies at baseline in both treatment and control groups.  
   **Imprecision:** Serious. Wide confidence intervals.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high prevalence of convalescent plasma in standard care patients.  
   **Imprecision:** Serious. Only data from one study.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
   **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.  
4. Measured by the number of patients who progressed from moderate to either severe or critical illness.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Serious. Due to low event numbers.  
6. Measured by a ≥ 1 point improvement on the 8-point WHO disease severity scale  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Very Serious. Low number of patients, Only data from one study.  
8. Measured by reduction of 2 points on a 6-point disease severity scale  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Very Serious. Low number of patients, Only data from one study.  
10. as measured by a ≥ 1 point improvement on the 8-point WHO disease severity scale.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Very Serious. Low number of patients.  
12. as measured by reduction of 2 points on a 6-point disease severity scale.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Very Serious. Low number of patients.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Serious. Low number of patients.  
   **Baseline/comparator:** Control arm of reference used for intervention.  
   **Risk of bias:** Serious. Due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.  
   **Imprecision:** Serious. Only data from one study.
Clinical Question/ PICO

Population: Special populations with COVID-19
Intervention: Convalescent plasma
Comparator: Control

Summary
There remains significant uncertainty whether convalescent plasma is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from five randomised trials that compared convalescent plasma with standard care in 631 adults with moderate COVID-19 [128][130][134] and 152 adults with severe COVID-19 [127][133].

Publication status
Two studies are only available as preprint papers (posted to medRxiv on 3 July and 1 September 2020) and have therefore not been peer reviewed [128][130]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
For a comprehensive description, see the study characteristics table.

What are the main results?
Compared with standard care, convalescent plasma may decrease death slight at day 28 (57 fewer deaths per 1000 patients; 110 fewer to 57 more (RR 0.64; CI 95% 0.30 to 1.36; 695 patients in 4 studies)).

For all other outcomes—requirement for mechanical ventilation, clinical deterioration, serious adverse events, clinical improvement (day 15 or day 28), hospital discharge, resolution of dyspnea, viral nucleic acid negative, duration of hospital stay and time to clinical improvement—we are uncertain if convalescent plasma makes a difference compared with standard care.

Our confidence in the results
Certainty of the evidence is very low for all outcomes due to serious imprecision (reliance on a single study and/or low patient numbers), serious risk of bias and serious indirectness (absence of these populations from the included studies).
Certainty has been downgraded for all outcomes due to the high prevalence of baseline neutralising antibodies (NAb) in trial participants. One study excluded patients with a NAb titer of 1:640 or lower [127]. One study did not report specific NAb titers of included patients [133]. The remaining studies detected NAb in 76% [134], 49% [130] and 80% [128] of patients at baseline.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.64 (CI 95% 0.3 - 1.36) Based on data from 695 patients in 4 studies. ¹ (Randomized controlled)</td>
<td>Control: Convalescent plasma:</td>
<td>Very Low Due to serious risk of bias, serious indirectness and imprecision ²</td>
<td>We are uncertain whether convalescent plasma decreases death (98 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.88 (CI 95% 0.48 - 1.61) Based on data from 464 patients in 1 studies. ³ (Randomized controlled)</td>
<td>Control: Convalescent plasma:</td>
<td>Very Low Due to serious risk of bias, serious indirectness and imprecision ⁴</td>
<td>We are uncertain whether convalescent plasma has any impact on invasive mechanical ventilation at day 28 (38 events).</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.97 (CI 95% 0.36 - 2.63) Based on data from 81 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td>Control: Convalescent plasma:</td>
<td>Very Low Due to serious risk of bias, very serious imprecision and serious indirectness ⁶</td>
<td>We are uncertain whether convalescent plasma increases or decreases serious adverse events at day 28 (13 events).</td>
</tr>
<tr>
<td>Clinical deterioration</td>
<td>(progression to severe/critical)</td>
<td>Relative risk 0.71 (CI 95% 0.18 - 2.78) Based on data from 545 patients in 2 studies. ⁸ (Randomized controlled)</td>
<td>Control: Convalescent plasma:</td>
<td>Very Low Due to serious risk of bias, serious indirectness and imprecision ⁹</td>
<td>We are uncertain whether convalescent plasma has any impact on clinical deterioration (progression to severe/critical) at day 28 (37 events).</td>
</tr>
<tr>
<td>Outcome</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Number of Patients</td>
<td>Study Type</td>
<td>Risk of Bias</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>--------------------</td>
<td>---------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Clinical improvement 10</td>
<td>1.00</td>
<td>0.70 - 1.43</td>
<td>86</td>
<td>Randomized controlled</td>
<td>Yes</td>
</tr>
<tr>
<td>Within 15 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical improvement 13</td>
<td>1.20</td>
<td>0.80 - 1.81</td>
<td>103</td>
<td>Randomized controlled</td>
<td>Yes</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital discharge 14</td>
<td>1.18</td>
<td>0.89 - 1.55</td>
<td>182</td>
<td>Randomized controlled</td>
<td>Yes</td>
</tr>
<tr>
<td>Within 28 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resolution of dyspnea 15</td>
<td>1.15</td>
<td>0.97 - 1.35</td>
<td>464</td>
<td>Randomized controlled</td>
<td>Yes</td>
</tr>
<tr>
<td>Within 7 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral nucleic acid negative 16</td>
<td>2.33</td>
<td>1.54 - 3.52</td>
<td>87</td>
<td>Randomized controlled</td>
<td>Yes</td>
</tr>
<tr>
<td>72 hours after commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of hospital stay 17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 (Median)</td>
<td></td>
<td>CI 95%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 (Median)</td>
<td></td>
<td>CI 95%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very Low</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>We are uncertain whether convalescent plasma improves or worsens clinical improvement at day 15 (50 events).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>We are uncertain whether convalescent plasma improves or worsens clinical improvement (49 events).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>We are uncertain if convalescent plasma increases hospital discharge within 28 days (113 events).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>We are uncertain if convalescent plasma increases resolution of dyspnea (259 events).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>We are uncertain if convalescent plasma increases the number of patients who are viral nucleic acid negative at 72 hours.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convalescent plasma may have little impact on duration of hospital stay.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

2. **Risk of bias:** Serious. Due to high level of neutralising antibodies at baseline in both treatment and control groups. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.


4. **Risk of bias:** Serious, due to the high prevalence of convalescent plasma in standard care patients. **Imprecision:** Serious. Only data from one study.


6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.

7. Measured by the number of patients who progressed from moderate to either severe or critical illness.


9. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. **Imprecision:** Serious. due to low event numbers.

10. as measured by a ≥ 1 point improvement on the 8-point WHO disease severity scale


12. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

13. as measured by reduction of 2 points on a 6-point disease severity scale


15. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


17. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. **Imprecision:** Serious. Low number of patients.


19. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. due to [reason]. **Imprecision:** Serious. Only data from one study.

20. Systematic review [125] with included studies: Li 2020. **Baseline/comparator:** Control arm of reference used for intervention.

21. **Risk of bias:** Serious. due to the high proportion of patients in the standard care arm possessing neutralising antibodies at baseline.. **Imprecision:** Very Serious. Low number of patients. Only data from one study.

22. Systematic review [125]. **Baseline/comparator:** Control arm of reference used for intervention.

23. **Risk of bias:** Serious. **Imprecision:** Serious. Only data from one study.
24. Defined as the mean time in which patients were released from ICU to infectious disease ward due to improvement in the signs and symptoms of critical infection, namely (1) relief of severe dyspnea; (2) no requirement of ventilators or oxygen therapy; (3) declining fever, if any; (4) decline of respiratory rate to <30/min; (5) increase in oxygen saturation to >93% at rest.


26. **Risk of bias:** Serious. Uncertainty regarding neutralising antibodies at baseline in treated patients and presence/concentration of antibodies in donor patients. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

### 6.6.9 - Darunavir-cobicistat

**Not recommended**

Do not use darunavir-cobicistat for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Darunavir-cobicistat should still be considered for other evidence-based indications in people who have COVID-19.**

**Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use darunavir-cobicistat to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.**

**Evidence To Decision**

#### Benefits and harms

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known short-term harms associated with darunavir-cobicistat including severe skin reactions. There are several known and potential interactions with drugs that inhibit CYP3A4 and anti-arrhythmic drugs.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

The benefits and harms associated with darunavir-cobicistat in pregnant women and young children with COVID-19 are not well established. Darunavir plus cobicistat is not recommended for the treatment of HIV in pregnant women because of inadequate safety data for cobicistat. Caution should be taken when prescribing darunavir-cobicistat to children, adolescents or elderly patients.

#### Certainty of the Evidence

**General adult population**

Certainty of the evidence for each outcome is very low due to serious risk of bias and very serious imprecision (low number of patients and/or observed events and reliance on a single study).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.
<table>
<thead>
<tr>
<th>Preference and values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
</tr>
<tr>
<td>We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.</td>
</tr>
<tr>
<td><strong>Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
</tr>
<tr>
<td>In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of darunavir-cobicistat in pregnancy are unknown.</td>
</tr>
<tr>
<td>The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
</tr>
<tr>
<td>There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.</td>
</tr>
<tr>
<td><strong>Children and adolescents, pregnant and breastfeeding women</strong></td>
</tr>
<tr>
<td>Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.</td>
</tr>
<tr>
<td><strong>People requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
</tr>
<tr>
<td>As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population, children and adolescents, pregnant and breastfeeding women</strong></td>
</tr>
<tr>
<td>We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.</td>
</tr>
<tr>
<td><strong>People requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
</tr>
<tr>
<td>Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
</tr>
<tr>
<td>There is currently limited evidence about the impact of darunavir-cobicistat on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that darunavir-cobicistat should only be used to treat COVID-19 in the context of randomised trials with</td>
</tr>
</tbody>
</table>
appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of darunavir-cobicistat to treat COVID-19 in these populations should be avoided until evidence becomes available.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir-cobicistat for COVID-19</td>
<td>Darunavir-cobicistat</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

**Summary**

There remains significant uncertainty whether darunavir-cobicistat is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared darunavir-cobicistat with standard care in 30 adults hospitalised with mild-to-moderate symptoms of laboratory-confirmed COVID-19 [138].

**Study characteristics**

Mean age was 47 years (SD 2.8) and 40% were women. Patients considered unlikely to complete the study (e.g. severely or critically ill) or deemed not suitable by the investigators were excluded. It is unlikely that pregnant or breastfeeding women were eligible.

**What are the main results?**

There were no deaths and only one patient progressed to critical illness. We are uncertain whether darunavir-cobicistat makes a difference to viral clearance (days 3, 5 or 7) or to the likelihood of patients experiencing adverse events.

**Our confidence in the results**

Certainty of the evidence for viral clearance and adverse events is very low. This judgement is based on very serious imprecision (low patient numbers, few observed events and reliance on a single study) and serious risk of bias (patients, personnel and outcome assessors not blinded).

---

**Outcome**

**Timeframe**

<table>
<thead>
<tr>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality 14 days after commencing treatment</td>
<td>Standard care</td>
<td>Darunavir-cobicistat</td>
<td>2</td>
</tr>
<tr>
<td>9 Critical</td>
<td>14 days after progression to critical illness</td>
<td>Based on data from 30 patients in 1 studies. (Randomized controlled)</td>
<td></td>
</tr>
</tbody>
</table>


Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

184 of 418
### Adverse events

**Within 14 days of commencing treatment**
- **Odds Ratio 1.31** (C 95% 0.31 - 5.48)
  - Based on data from 30 patients in 1 studies.
  - (Randomized controlled)
  - Risk of bias: Serious
  - Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
  - Inconsistency: No serious
  - Indirectness: No serious
  - Imprecision: Very Serious
  - Low number of patients, Only data from one study, due to no events.

**Publication bias:** No serious

**Very Low**
- Due to serious risk of bias and very serious imprecision

We are uncertain whether darunavir-cobicistat increases or decreases adverse events within 14 days (15 events).

### Viral clearance

**Day 7 of treatment**
- **Relative risk 0.78** (C 95% 0.39 - 1.54)
  - Based on data from 30 patients in 1 studies.
  - (Randomized controlled)
  - Risk of bias: Serious
  - Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
  - Inconsistency: No serious
  - Indirectness: No serious
  - Imprecision: Very Serious
  - Low number of patients, Only data from one study.

**Very Low**
- Due to serious risk of bias and very serious imprecision

We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 7 (16 events).

**Day 5 of treatment**
- **Odds Ratio 1.45** (C 95% 0.26 - 8.01)
  - Based on data from 30 patients in 1 studies.
  - (Randomized controlled)
  - Risk of bias: Serious
  - Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
  - Inconsistency: No serious
  - Indirectness: No serious
  - Imprecision: Very Serious
  - Low number of patients, Only data from one study.

**Very Low**
- Due to serious risk of bias and very serious imprecision

We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 5 (5 events).

**Day 3 of treatment**
- **Odds Ratio 1** (C 95% 0.17 - 5.98)
  - Based on data from 30 patients in 1 studies.
  - (Randomized controlled)
  - Risk of bias: Serious
  - Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
  - Inconsistency: No serious
  - Indirectness: No serious
  - Imprecision: Very Serious
  - Low number of patients, Only data from one study.

**Very Low**
- Due to serious risk of bias and very serious imprecision

We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 3 (6 events).

---

2. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to no events. **Publication bias:** No serious.
4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
5. Primary study[138]. **Baseline/comparator:** Control arm of reference used for intervention.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.


12. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Special populations with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Darunavir-cobicistat</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

---

**Summary**

There remains significant uncertainty whether darunavir-cobicistat is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared darunavir-cobicistat with standard care in 30 adults hospitalised with mild-to-moderate symptoms of laboratory-confirmed COVID-19 [138].

**Study characteristics**

Mean age was 47 years (SD 2.8) and 40% were women. Patients considered unlikely to complete the study (e.g. severely or critically ill) or deemed not suitable by the investigators were excluded. It is unlikely that pregnant or breastfeeding women were eligible.

**What are the main results?**

There were no deaths and only one patient progressed to critical illness. We are uncertain whether darunavir-cobicistat makes a difference to viral clearance (days 3, 5 or 7) or to the likelihood of patients experiencing adverse events.

**Our confidence in the results**

Certainty of the evidence for viral clearance and adverse events is very low. This judgement is based on very serious imprecision (low patient numbers, few observed events and reliance on a single study), serious indirectness (limited inclusion of these populations) and serious risk of bias (patients, personnel and outcome assessors not blinded).

**Children and adolescents**

Paediatricians have limited experience of darunavir-cobicistat in children and adolescents for other indications. To date, no specific information on its benefits or harms for children and adolescents has been collected for treating COVID-19 in this population.

**Pregnant and breastfeeding women**

Darunavir plus cobicistat is not recommended for the treatment of HIV in pregnant women because of inadequate safety data for cobicistat [139].
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Based on data from 30 patients in 1 studies. 1 (Randomized controlled)</td>
<td></td>
<td>2</td>
<td>There were no deaths in the study.</td>
</tr>
<tr>
<td>14 days after commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Progression to critical illness</strong></td>
<td>Based on data from 30 patients in 1 studies. 3 (Randomized controlled)</td>
<td></td>
<td>4</td>
<td>There were too few who experienced progression to critical illness to determine whether darunavir-</td>
</tr>
<tr>
<td>14 days after commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td>cobicistat makes a difference (1 event).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 14 days of commencing treatment</td>
<td>Odds Ratio 1.31 (C 95% 0.31 - 5.48) Based on data from 30 patients in 1 studies. 5 (Randomized controlled)</td>
<td></td>
<td>Very Low</td>
<td>We are uncertain whether darunavir-cobicistat increases or decreases adverse events within 14 days (15 events).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Due to serious risk of bias, serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>indirectness and very serious imprecision 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Viral clearance</strong></td>
<td>Relative risk 0.78 (C 95% 0.39 - 1.54) Based on data from 30 patients in 1 studies. 7 (Randomized controlled)</td>
<td></td>
<td>Very Low</td>
<td>We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 7 (16 events).</td>
</tr>
<tr>
<td>Day 7 of treatment</td>
<td></td>
<td></td>
<td>Due to serious risk of bias, serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>indirectness and very serious imprecision 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Viral clearance</strong></td>
<td>Odds Ratio 1.45 (C 95% 0.26 - 8.01) Based on data from 30 patients in 1 studies. 9 (Randomized controlled)</td>
<td></td>
<td>Very Low</td>
<td>We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 5 (5 events).</td>
</tr>
<tr>
<td>Day 5 of treatment</td>
<td></td>
<td></td>
<td>Due to serious risk of bias, serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>indirectness and very serious imprecision 10</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Viral clearance</strong></td>
<td>Odds Ratio 1 (C 95% 0.17 - 5.98) Based on data from 30 patients in 1 studies. 11 (Randomized controlled)</td>
<td></td>
<td>Very Low</td>
<td>We are uncertain whether darunavir-cobicistat increases or decreases viral clearance at day 3 (6 events).</td>
</tr>
<tr>
<td>Day 3 of treatment</td>
<td></td>
<td></td>
<td>Due to serious risk of bias, serious</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>indirectness and very serious imprecision 12</td>
<td></td>
</tr>
</tbody>
</table>
6.6.10 - Favipiravir

**Not recommended**

Do not use favipiravir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*Favipiravir should still be considered for other evidence-based indications in people who have COVID-19.*

*Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use favipiravir to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.*

**Evidence To Decision**

**Benefits and harms**

**General adult population**

As the safety profile for favipiravir is incompletely characterised in humans, there is uncertainty around the benefits and
harms for patients with COVID-19.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There are additional concerns regarding harms as favipiravir has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

**Certainty of the Evidence**

**General adult population**

Certainty of the evidence for all-cause mortality, respiratory failure or ARDS and negative PCR is low based on very serious imprecision due to the low number of patients and events. Certainty for remaining outcomes is very low. This judgement is based on serious risk of bias due to lack of blinding and very serious imprecision due to the low number of patients and/or observed events and the reliance on a single study.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**

We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of favipiravir in pregnancy are unknown.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of
Rationale

General adult population
There is currently limited evidence about the impact of favipiravir on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that favipiravir should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Acceptability

General adult population
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Clinical Question/ PICO

| Population: | Patients with COVID-19 |
| Intervention: | Favipiravir |
| Comparator: | Standard care |

Summary
There remains significant uncertainty whether favipiravir is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from two randomised trials that compared favipiravir with standard care in 79 adults hospitalised with COVID-19 [112][140].

Study characteristics
Mean age ranged from 52 to 58 years in the favipiravir groups and from 47 to 49 years in the control groups; the proportion of women was 43% and 47% respectively. In the first study, patients concomitantly used lopinavir-ritonavir, darunavir-obicicstat and/or arbidol. It is unclear if pregnant or breastfeeding women were eligible [110]. In the second study, pregnant and breastfeeding women were ineligible [140].
### What are the main results?

For the critical outcomes of death, respiratory failure and mechanical ventilation there were too few events (two deaths, eight experiencing respiratory failure and none requiring ventilation) to determine whether favipiravir makes a difference. We are uncertain whether favipiravir increases or decreases likelihood of clinical improvement, negative PCR and adverse events. Two patients experienced serious adverse events.

### Our confidence in the results

Certainty of the evidence for all-cause mortality, respiratory failure or ARDS and negative PCR is low based on very serious imprecision due to low patient numbers and few events. Certainty for the remaining outcomes is very low based on serious risk of bias due to lack of blinding and very serious imprecision due to low patient numbers, few events and reliance on a single study.

### Additional information

As of 18 August 2020, favipiravir (Avigan) is not approved for use in Australia. The safety profile for favipiravir is incompletely characterised in humans.

---

#### Table of results

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>End of follow-up</td>
<td>Relative risk 2.56 (CI 95% 0.13 - 50.95) Based on data from 79 patients in 2 studies.</td>
<td>Low Due to very serious imprecision</td>
<td>There were too few who died to determine whether favipiravir makes a difference (2 events).</td>
</tr>
<tr>
<td>Respiratory failure or ARDS</td>
<td>End of follow-up</td>
<td>Relative risk 1.11 (CI 95% 0.29 - 3.19) Based on data from 19 patients in 1 studies.</td>
<td>Low Due to very serious imprecision</td>
<td>There were too few who experienced respiratory failure or ARDS to determine whether favipiravir makes a difference (8 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or ECMO</td>
<td>End of follow-up</td>
<td>Based on data from 19 patients in 1 studies.</td>
<td></td>
<td>No patients required mechanical ventilation.</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>29 days after commencing treatment</td>
<td>Relative risk 2.56 (CI 95% 0.13 - 50.95) Based on data from 60 patients in 1 studies.</td>
<td>Very Low Due to very serious imprecision and serious risk of bias</td>
<td>There were too few who experienced serious adverse events to determine whether favipiravir makes a difference (2 events).</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Baseline/comparator</td>
<td>Risk of bias</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>1. Adverse events 29 days after commencing treatment</td>
<td>1.5</td>
<td>0.64 - 3.54</td>
<td>Control arm of reference used for intervention.</td>
<td>Very Low</td>
</tr>
<tr>
<td>2. Discontinuation due to adverse events End of treatment</td>
<td>1.5</td>
<td>0.17 - 13.52</td>
<td>Control arm of reference used for intervention.</td>
<td>Very Low</td>
</tr>
<tr>
<td>3. Clinical improvement End of follow up</td>
<td>1.11</td>
<td>0.47 - 2.6</td>
<td>Control arm of reference used for intervention.</td>
<td>Very Low</td>
</tr>
<tr>
<td>4. Negative PCR 10 days after commencing treatment</td>
<td>1.16</td>
<td>0.91 - 1.46</td>
<td>Control arm of reference used for intervention.</td>
<td>Very Low</td>
</tr>
<tr>
<td>5. Discharged from hospital 15 days after commencing treatment</td>
<td>0.88</td>
<td>0.68 - 1.14</td>
<td>Control arm of reference used for intervention.</td>
<td>Very Low</td>
</tr>
</tbody>
</table>

2. **Imprecision: Very Serious.** Low number of patients, Only data from one study, few events.
4. **Imprecision: Very Serious.** Low number of patients, Only data from one study, few events.
6. **Imprecision: Very Serious.** Low number of patients, Only data from one study.
8. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
Imprecision: Very Serious. Low number of patients, Only data from one study.

10. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

12. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

16. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

18. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

Clinical Question/ PICO

**Population:** Special populations with COVID-19

**Intervention:** Favipiravir

**Comparator:** Standard care

Summary
There remains significant uncertainty whether favipiravir is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**
Evidence comes from two randomised trials that compared favipiravir with standard care in 79 adults hospitalised with COVID-19 [112][140].

**Publication status**
Results of the smaller study of 19 patients are only available as a preprint paper (posted to medRxiv on 5 May 2020) and have therefore not been peer reviewed [110]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

**Study characteristics**
Mean age ranged from 52 to 58 years in the favipiravir groups and from 47 to 49 years in the control groups; the proportion of women was 43% and 47% respectively. In the first study, patients concomitantly used lopinavir-ritonavir, darunavir-cobicistat and/or arbidol. It is unclear if pregnant or breastfeeding women were eligible [110]. In the second study, pregnant and breastfeeding women were ineligible [140].
What are the main results?
For the critical outcomes of death, respiratory failure and mechanical ventilation there were too few events (two deaths, eight experiencing respiratory failure and none requiring ventilation) to determine whether favipiravir makes a difference. We are uncertain whether favipiravir increases or decreases likelihood of clinical improvement, negative PCR and adverse events. Two patients experienced serious adverse events.

Our confidence in the results
Certainty of the evidence is very low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers and few events and serious indirectness due to limited inclusion of these populations. Adverse and serious adverse events were also downgraded based on serious risk of bias due to lack of blinding.

Additional information
As of 18 August 2020, favipiravir (Avigan) is not approved for use in Australia. The safety profile for favipiravir is incompletely characterised in humans.

Children and adolescents
There is insufficient safety data on the use of favipiravir in children and adolescents for other indications.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>End of follow-up 9 Critical</td>
<td>Relative risk 2.56 (CI 95% 0.13 - 50.95) Based on data from 79 patients in 2 studies.</td>
<td>Very Low Due to very serious imprecision and serious indirectness 2</td>
<td>There were too few who died (2 events) to determine whether favipiravir makes a difference.</td>
</tr>
<tr>
<td>Respiratory failure or ARDS</td>
<td>End of follow-up 9 Critical</td>
<td>Relative risk 1.11 (CI 95% 0.39 - 3.19) Based on data from 19 patients in 1 studies.</td>
<td>Very Low Due to very serious imprecision and serious indirectness 4</td>
<td>There were too few who experienced respiratory failure or ARDS (8 events) to determine whether favipiravir makes a difference.</td>
</tr>
<tr>
<td>Invasive mechanical ventilation or ECMO</td>
<td>End of follow-up 9 Critical</td>
<td>Based on data from 19 patients in 1 studies.</td>
<td></td>
<td>No patients required mechanical ventilation.</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>29 days after commencing treatment</td>
<td>Relative risk 2.56 (CI 95% 0.13 - 50.95) Based on data from 60 patients in 1 studies.</td>
<td>Very Low Due to very serious imprecision, serious risk of adverse events 6</td>
<td>There were too few who experienced serious adverse events to determine whether favipiravir makes a difference.</td>
</tr>
</tbody>
</table>
### Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

2. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study, few events.
4. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study, few events.

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Data Details</th>
<th>Quality Assessment</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 days after commencing treatment</td>
<td>Relative risk 1.5</td>
<td>(CI 95% 0.64 - 3.54)</td>
<td>Based on data from 60 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious imprecision, serious risk of bias and serious indirectness 8 difference (2 events).</td>
</tr>
<tr>
<td>Discontinuation due to adverse events</td>
<td>Relative risk 1.5</td>
<td>(CI 95% 0.17 - 13.52)</td>
<td>Based on data from 60 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious imprecision, serious risk of bias and serious indirectness 10. We are uncertain whether favipiravir increases adverse events.</td>
</tr>
<tr>
<td><strong>Clinical improvement</strong></td>
<td>Relative risk 1.11</td>
<td>(CI 95% 0.47 - 2.6)</td>
<td>Based on data from 19 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious imprecision, serious risk of bias and serious indirectness 12. There were too few who discontinued due to adverse events to determine whether favipiravir makes a difference (4 events).</td>
</tr>
<tr>
<td><strong>Negative PCR</strong></td>
<td>Relative risk 1.16</td>
<td>(CI 95% 0.91 - 1.46)</td>
<td>Based on data from 60 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious imprecision and serious indirectness 14. We are uncertain whether favipiravir increases the number of patients with negative PCR at day 10 (43 events).</td>
</tr>
<tr>
<td><strong>Discharged from hospital</strong></td>
<td>Relative risk 0.88</td>
<td>(CI 95% 0.68 - 1.14)</td>
<td>Based on data from 60 patients in 1 studies.</td>
<td>Very Low</td>
<td>Due to very serious imprecision, serious risk of bias and serious indirectness 18. We are uncertain whether favipiravir decreases discharged from hospital at day 15 (47 events).</td>
</tr>
</tbody>
</table>

---

2. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study, few events.
4. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study, few events.

6. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


12. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


16. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.


18. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
### 6.6.11 - Hydroxychloroquine plus azithromycin

**Not recommended**

Do not use hydroxychloroquine plus azithromycin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*Hydroxychloroquine plus azithromycin should still be considered for other evidence-based indications in people who have COVID-19.*

**Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine plus azithromycin for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.**

---

**Evidence To Decision**

<table>
<thead>
<tr>
<th>Benefits and harms</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are concerns regarding the safety of hydroxychloroquine plus azithromycin. Hydroxychloroquine has several known and potential interactions with other drugs. See the summary for details of the adverse events of hydroxychloroquine or azithromycin, administered individually.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certainty of the Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
</tr>
<tr>
<td>Certainty of the evidence is low for all outcomes. This judgement is based on very serious imprecision (wide confidence intervals, reliance on a single study and few events—for death and serious adverse events).</td>
</tr>
</tbody>
</table>

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment** |

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

<table>
<thead>
<tr>
<th>Preference and values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
</tr>
<tr>
<td>We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.</td>
</tr>
</tbody>
</table>

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment** |

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of hydroxychloroquine plus azithromycin during pregnancy and breastfeeding are unknown in the context of COVID-19.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

<table>
<thead>
<tr>
<th>Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by...</td>
</tr>
</tbody>
</table>
There is currently limited evidence about the impact of hydroxychloroquine plus azithromycin on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. Therefore, the recommendation protects these more vulnerable populations.

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Hydroxychloroquine plus Azithromycin</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>
Summary
There remains significant uncertainty whether hydroxychloroquine plus azithromycin is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from one three-armed randomised trial that compared hydroxychloroquine plus azithromycin with azithromycin alone and standard care. The comparison of hydroxychloroquine plus azithromycin with standard care included 444 hospitalised adults with moderate illness (345 with laboratory-confirmed COVID-19) [73].

Study characteristics
Mean age was 50 years in both groups. The proportion of women was 43% in the hydroxychloroquine plus azithromycin group and 46% in the control group. Children, adolescents and pregnant women were ineligible.

What are the main results?
For death and serious adverse events, there were too few events (eight deaths and seven who experienced serious adverse events) to determine whether hydroxychloroquine plus azithromycin makes a difference. We are uncertain whether hydroxychloroquine plus azithromycin increases or decreases the likelihood of invasive mechanical ventilation or discharge from hospital, but it may increase slightly the duration of hospital stay and result in more adverse events.

Our confidence in the results
Certainty of the evidence is low or very low for all outcomes. This judgement is based on serious or very serious imprecision (wide confidence intervals, reliance on a single study and/or few observed events) and/or serious risk of bias (lack of blinding).

Additional information
According to the Therapeutic Goods Administration, known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiomyopathy. There are several known and potential interactions with other drugs. Overdose of hydroxychloroquine may have potentially fatal complications. In pregnancy, it is only recommended when benefits outweigh harms [60].

For azithromycin, reported adverse events are generally mild or moderate and include rash, heart palpitations, urinary tract infection, dizziness, headache, fatigue and gastrointestinal symptoms such as dyspepsia and vomiting [107].

In addition to the known harms associated with hydroxychloroquine and azithromycin, there are concerns regarding the safety of combination treatment using these two therapeutics.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Within 15 days of commencing treatment</td>
<td>Relative risk 0.6 (CI 95% 0.15 - 2.49) Based on data from 345 patients in 1 studies [1] (Randomized controlled)</td>
<td>Standard care: 29 per 1000 (CI 95% 25 fewer - 43 more)</td>
<td>Low Due to very serious imprecision [2]</td>
<td>There were too few who died to determine whether hydroxychloroquine plus azithromycin makes a difference (8 events).</td>
</tr>
<tr>
<td>Outcome</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Number of Events</td>
<td>Difference</td>
<td>Risk of Bias</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>---------------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 15 days of commencing treatment</td>
<td>Relative risk 1.59 (CI 95% 0.8 - 3.18) Based on data from 345 patients in 1 studies.</td>
<td>69 per 1000</td>
<td>Difference: 41 more per 1000 (CI 95% 14 fewer - 150 more)</td>
<td>Low Due to very serious imprecision</td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 15 days of commencing treatment</td>
<td>Relative risk 1.74 (CI 95% 1.27 - 2.38) Based on data from 416 patients in 1 studies.</td>
<td>226 per 1000</td>
<td>Difference: 167 more per 1000 (CI 95% 61 more - 312 more)</td>
<td>Low Due to serious risk of bias and serious imprecision</td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 15 days of commencing treatment</td>
<td>Relative risk 1.85 (CI 95% 0.36 - 9.43) Based on data from 416 patients in 1 studies.</td>
<td>9.5 (Mean)</td>
<td>Difference: MD 0.8 higher (CI 95% 0.85 lower - 2.45 higher)</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td></td>
</tr>
<tr>
<td><strong>Discharge from hospital</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 15 days of commencing treatment</td>
<td>Relative risk 0.96 (CI 95% 0.86 - 1.08) Based on data from 345 patients in 1 studies.</td>
<td>10.3 (Mean)</td>
<td></td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td></td>
</tr>
<tr>
<td><strong>Duration of hospital stay</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days</td>
<td>Based on data from: 345 patients in 1 studies.</td>
<td>9.5 (Mean)</td>
<td>Difference: MD 0.8 higher (CI 95% 0.85 lower - 2.45 higher)</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td></td>
</tr>
</tbody>
</table>

2. **Imprecision:** Very Serious, due to few events, Only data from one study.
4. **Imprecision:** Very Serious, due to few events, Only data from one study.
6. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Imprecision: Serious.** Only data from one study, Wide confidence intervals.


8. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Imprecision: Very Serious.** Due to few events. Only data from one study.


10. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Imprecision: Very Serious.** Only data from one study, Wide confidence intervals.


12. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.

**Imprecision: Very Serious.** Only data from one study, Wide confidence intervals.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Special populations with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Hydroxychloroquine plus Azithromycin</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

**Summary**

There remains significant uncertainty whether hydroxychloroquine plus azithromycin is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from one three-armed randomised trial that compared hydroxychloroquine plus azithromycin with azithromycin alone and standard care. The comparison of hydroxychloroquine plus azithromycin with standard care included 444 hospitalised adults with moderate illness (345 with laboratory-confirmed COVID-19) [73].

**Study characteristics**

Mean age was 50 years in both groups. The proportion of women was 43% in the hydroxychloroquine plus azithromycin group and 46% in the control group. Children, adolescents and pregnant women were ineligible.

**What are the main results?**

For death and serious adverse events, there were too few events (eight deaths and seven who experienced serious adverse events) to determine whether hydroxychloroquine plus azithromycin makes a difference. We are uncertain whether hydroxychloroquine plus azithromycin increases or decreases the likelihood of invasive mechanical ventilation or discharge from hospital, but it may increase slightly the duration of hospital stay and result in more adverse events.

**Our confidence in the results**

Certainty of the evidence is very low for all outcomes. This judgement is based on serious or very serious imprecision (wide confidence intervals, reliance on a single study and/or few observed events), serious risk of bias (lack of blinding) and serious indirectness (limited inclusion of these populations).
Additional information

According to the Therapeutic Goods Administration, known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiomyopathy. There are several known and potential interactions with other drugs. Overdose of hydroxychloroquine may have potentially fatal complications. In pregnancy, it is only recommended when benefits outweigh harms [60].

For azithromycin, reported adverse events are generally mild or moderate and include rash, heart palpitations, urinary tract infection, dizziness, headache, fatigue and gastrointestinal symptoms such as dyspepsia and vomiting [107].

In addition to the known harms associated with hydroxychloroquine and azithromycin, there are concerns regarding the safety of combination treatment using these two therapeutics.

Pregnant and breastfeeding women

Hydroxychloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases. Studies of hydroxychloroquine for these indications have shown a favourable safety profile, with no increase in fetal malformations [69]/[70]. There is no evidence to suggest that stillbirth, preterm birth, low birth weight or early childhood disability are more common following treatment with hydroxychloroquine [69]/[70]/[71]. While this evidence is reassuring, further research is needed.

Azithromycin is classified as a Category B1 drug (drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed).

Children and adolescents

Paediatricians have considerable experience with hydroxychloroquine in children and adolescents for other indications. To date, no specific information on the benefits or harms of hydroxychloroquine use has been collected in this population.

The safety and effectiveness of azithromycin powder for solution for infusion for the treatment of infections in children has not been established. Infantile hypertrophic pyloric stenosis (IHPS) has been reported following the use of azithromycin in neonates (treatment up to 42 days of life) [107].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 0.6 (CI 95% 0.15 - 2.49) Based on data from 345 patients in 1 studies. ¹ (Randomized controlled)</td>
<td>Relative risk 0.6</td>
<td>Very Low Due to very serious imprecision and serious indirectness ²</td>
<td>There were too few who died to determine whether hydroxychloroquine plus azithromycin makes a difference (8 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Relative risk 1.59 (CI 95% 0.8 - 3.18) Based on data from 345 patients in 1 studies. ³ (Randomized controlled)</td>
<td>Relative risk 1.59</td>
<td>Very Low Due to very serious imprecision and serious indirectness ⁴</td>
<td>We are uncertain whether hydroxychloroquine plus azithromycin increases or decreases the need for invasive mechanical ventilation</td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Due to few events, Only data from one study.


4. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Due to few events, Only data from one study.


6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Due to few events, Only data from one study.

---

The table below presents the data for critical events within 15 days of commencing treatment.

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Number of Patients</th>
<th>Study Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
<td>1.74 (1.27 - 2.38)</td>
<td>416 patients</td>
<td>Randomized controlled</td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>1.85 (0.36 - 9.43)</td>
<td>416 patients</td>
<td>Randomized controlled</td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>0.96 (0.86 - 1.08)</td>
<td>345 patients</td>
<td>Randomized controlled</td>
<td></td>
</tr>
<tr>
<td>Duration of hospital stay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Duration of Hospital Stay

<table>
<thead>
<tr>
<th></th>
<th>(Mean)</th>
<th>(Mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9.5</td>
<td>10.3</td>
</tr>
<tr>
<td>Difference</td>
<td>MD 0.8 higher</td>
<td>0.85 lower - 2.45 higher</td>
</tr>
</tbody>
</table>

---

9 Critical

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Number of Patients</th>
<th>Study Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of hospital stay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce
6.6.12 - Human umbilical cord mesenchymal stem cells

Do not use human umbilical cord mesenchymal stem cells for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Human umbilical cord mesenchymal stem cells should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use human umbilical cord mesenchymal stem cells (hUC-MSCs) to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

Benefits and harms

General adult population
There is uncertainty around benefits and harms associated with human umbilical cord mesenchymal stem cells (hUC-MSCs) in patients with COVID-19.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There are additional concerns regarding harms as hUC-MSCs have not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain. There is insufficient evidence pertaining to the safety of hUC-MSCs for pregnant or breastfeeding women (for any indication) [143].

In Australia, stem cell therapy is only approved for haematopoietic stem cell (HPC) transplantation (using stem cells from umbilical cord blood or bone marrow), which is standard practice for the treatment of disorders of the blood and
immune system, such as leukaemia [143].

Certainty of the Evidence

General adult population
Certainty of the evidence is very low for all outcomes due to very serious risk of bias (not all participants were randomly allocated, patients and personnel not blinded, deviation from intended intervention and selective outcome reporting) and very serious imprecision (low patient numbers, few events and reliance on a single study).

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is downgraded for indirectness due to limited inclusion (or absence) of these populations in the study.

Preference and values

General adult population
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of hUC-MSCs in pregnancy are unknown.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications. There is very limited capacity to produce stem cell-related products, which would limit implementation of this treatment if effective.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

Important issues, or potential issues not investigated
Rationale

**General adult population**

There is currently limited evidence about the impact of human umbilical cord mesenchymal stem cells (hUC-MSCs) on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that human umbilical cord mesenchymal stem cells should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent. Stem cell therapies outside very specific settings and diseases remain a very experimental treatment and difficult to implement as a wide-use treatment.

Clinical Question/ PICO

**Population:** Patients with COVID-19  
**Intervention:** Human umbilical cord mesenchymal stem cells (hUC-MSCs)  
**Comparator:** Standard care

Summary

There remains significant uncertainty whether therapy with human umbilical cord mesenchymal stem cells (hUC-MSCs) is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from a single randomised trial that compared hUC-MSC therapy with standard care in 41 adults hospitalised with severe COVID-19 [144].

Study characteristics

Median age was 61 years in the hUC-MSC therapy group and 58 years in the control group; the proportion of women was 33% and 45% respectively. Standard care comprised supplemental oxygen (non-invasive or invasive ventilation), antiviral agents (abidor/oseltamivir), antibiotic agents and glucocorticoid therapy.

What are the main results?

For the critical outcomes of death and mechanical ventilation within 28 days of commencing treatment, there were too few events (three deaths and four requiring invasive mechanical ventilation) to determine whether hUC-MSC therapy makes a difference. We are uncertain whether hUC-MSC therapy increases or decreases the likelihood of requiring supplemental oxygen or being discharged from hospital. There were no adverse or serious adverse events in patients receiving hUC-MSC therapy.
Our confidence in the results
Certainty of the evidence is very low for all outcomes due to very serious risk of bias (not all participants were randomly allocated, patients and personnel not blinded, deviation from intended intervention and selective outcome reporting) and very serious imprecision (low patient numbers, few events and reliance on a single study).

Additional information
Stem cell therapies outside of specific settings and diseases are very experimental and highly regulated in Australia [143].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Within 14 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.02 - 5.94) Based on data from 41 patients in 1 studies. (<a href="#">Randomized controlled</a>)</td>
<td></td>
<td>Very Low</td>
<td>There were too few events to determine whether hUC-MSC therapy increases or decreases death at day 14 (3 events).</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.02 - 5.94) Based on data from 41 patients in 1 studies. (<a href="#">Randomized controlled</a>)</td>
<td></td>
<td>Very Low</td>
<td>There were too few events to determine whether hUC-MSC therapy increases or decreases death at day 28 (3 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.26 (CI 95% 0.01 - 4.43) Based on data from 41 patients in 1 studies. (<a href="#">Randomized controlled</a>)</td>
<td></td>
<td>Very Low</td>
<td>There were too few events to determine whether hUC-MSC therapy increases or decreases the need for invasive mechanical ventilation at day 28 (4 events).</td>
</tr>
<tr>
<td>Requiring supplemental oxygen</td>
<td>Within 14 days of commencing treatment</td>
<td>Relative risk 2.42 (CI 95% 0.16 - 35.56) Based on data from 41 patients in 1 studies. (<a href="#">Randomized controlled</a>)</td>
<td></td>
<td>Very Low</td>
<td>There were too few events to determine whether hUC-MSC therapy increases or decreases the need for supplemental oxygen at day 14 (2 events).</td>
</tr>
<tr>
<td>Discharged from hospital Within 14 days of commencing treatment</td>
<td>Relative risk 2.42 (CI 95% 0.85 - 6.85) Based on data from 41 patients in 1 studies.</td>
<td>Very Low Due to very serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether hUC-MSC therapy increases or decreases number discharged from hospital at day 14 (10 patients discharged).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events Within 28 days of commencing treatment</td>
<td>Based on data from 41 patients in 1 studies.</td>
<td>There were no adverse events.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Very Serious. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.
4. **Risk of bias:** Very Serious. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.
6. **Risk of bias:** Very Serious. Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias, Inadequate concealment of allocation during randomization process, resulting in potential for selection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/ lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.
8. **Risk of bias:** Very Serious. Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias, Inadequate concealment of allocation during randomization process, resulting in potential for selection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/ lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.
10. **Risk of bias:** Very Serious. Inadequate sequence generation/ generation of comparable groups, resulting in potential for selection bias, Inadequate concealment of allocation during randomization process, resulting in potential for selection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/ lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study. **Publication bias:** No serious.
11. Systematic review [145]. **Baseline/comparator:** Control arm of reference used for intervention.
12. **Risk of bias:** Very Serious. Incomplete data and/or large loss to follow up, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate concealment of allocation during randomization process, resulting in
potential for selection bias, inadequate sequence generation/generation of comparable groups, resulting in potential for selection bias. **Indirectness: Serious.** Direct comparisons not available. **Imprecision: Serious.** Due to [reason]. **Publication bias: No serious.**

---

**Clinical Question/ PICO**

**Population:** Special populations with COVID-19  
**Intervention:** Human umbilical cord mesenchymal stem cells (hUC-MSCs)  
**Comparator:** Standard care

**Summary**

There remains significant uncertainty whether therapy with human umbilical cord mesenchymal stem cells (hUC-MSCs) is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared hUC-MSC therapy with standard care in 41 adults hospitalised with severe COVID-19 [144].

**Study characteristics**

Median age was 61 years in the hUC-MSC therapy group and 58 years in the control group; the proportion of women was 33% and 45% respectively. Standard care comprised supplemental oxygen (non-invasive or invasive ventilation), antiviral agents (abidors/oseltamivir), antibiotic agents and glucocorticoid therapy.

**What are the main results?**

For the critical outcomes of death and mechanical ventilation within 28 days of commencing treatment, there were too few events (three deaths and four requiring ventilation) to determine whether hUC-MSC therapy makes a difference. We are uncertain whether hUC-MSC therapy increases or decreases the likelihood of requiring supplemental oxygen or being discharged from hospital. There were no adverse or serious adverse events in patients receiving hUC-MSC therapy.

**Our confidence in the results**

Certainty of the evidence is very low for all outcomes due to very serious risk of bias (not all participants were randomly allocated, patients and personnel not blinded, deviation from intended intervention and selective outcome reporting), serious indirectness (no reported inclusion of children or pregnant women) and very serious imprecision (low patient numbers, few events and reliance on a single study).

**Additional information**

Stem cell therapies outside of specific settings and diseases are very experimental and highly regulated in Australia [143].

---

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
</table>
| All-cause mortality  
Within 14 days of commencing treatment | Relative risk 0.33  
(CI 95% 0.02 - 5.94)  
Based on data from 41 patients in 1 studies.  
(Randomized controlled) | Standard care  
hUC-MSCs | Very Low  
Due to very serious risk of bias, serious indirectness and very serious | There were too few events to determine whether hUC-MSC therapy increases or decreases death at day 14 (3 events). |

---

209 of 418
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Result</th>
<th>Confidence Interval</th>
<th>Events</th>
<th>Study Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 0.33</td>
<td>(CI 95% 0.02 - 5.94)</td>
<td>3 events</td>
<td>1 studies</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>Relative risk 0.26</td>
<td>(CI 95% 0.01 - 4.43)</td>
<td>4 events</td>
<td>1 studies</td>
</tr>
<tr>
<td>Requiring supplemental oxygen</td>
<td>Relative risk 2.42</td>
<td>(CI 95% 0.16 - 35.56)</td>
<td>2 events</td>
<td>1 studies</td>
</tr>
<tr>
<td>Discharged from hospital</td>
<td>Relative risk 2.42</td>
<td>(CI 95% 0.85 - 6.85)</td>
<td>10 patients</td>
<td>1 studies</td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Very Serious. **Inconsistency:** No serious. **Indirectness:** Serious. Differences between the population of...
6.6.13 - Immunoglobulin plus methylprednisolone

We have found a new study comparing intravenous immunoglobulin gamma with placebo. This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Not recommended

Do not use immunoglobulin plus methylprednisolone for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Immunoglobulin plus methylprednisolone should still be considered for other evidence-based indications in people who have COVID-19.**

This recommendation does not apply to the use of immunoglobulin plus methylprednisolone in children and adolescents when managing PIMS-TS, Kawasaki disease or toxic shock syndrome related to COVID-19 (see section for specific guidance). The Taskforce is currently developing recommendations for the management of these conditions in children and adolescents with COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use combination immunoglobulin plus methylprednisolone to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

### Benefits and harms

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with immunoglobulin including flu-like symptoms, dermatologic side effects, arrhythmia, hypotension and transfusion-related acute lung injury.

**Children and adolescents, pregnant and breastfeeding women**

Intravenous immunoglobulin and methylprednisolone are used in these populations for other medical conditions.

**People requiring palliative care and older people living with frailty or cognitive impairment**

There are additional concerns regarding harms as intravenous immunoglobulin and methylprednisolone has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

### Certainty of the Evidence

**General adult population**

Certainty of the evidence is very low for all outcomes based on very serious imprecision due to the low number of trial participants, low number of events and reliance on a single study.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

### Preference and values

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of immunoglobulin in pregnancy are unknown.
The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation may protect these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Acceptability**

**General adult population, children and adolescents, pregnant and breastfeeding women**

Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

**People requiring palliative care and older people living with frailty or cognitive impairment**

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Rationale**

**General adult population**

There is currently limited evidence about the impact of immunoglobulin plus methylprednisolone on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that immunoglobulin plus methylprednisolone should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of immunoglobulin plus methylprednisolone to treat COVID-19 in these populations should be avoided until evidence becomes available.
Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: Immunoglobulin plus methylprednisolone
Comparator: Standard care

Summary
There remains significant uncertainty whether immunoglobulin is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared combination immunoglobulin plus methylprednisolone with standard care in 34 patients with moderate or severe COVID-19 [148].

We have found one new study comparing immunoglobulin with placebo (Gharebahgi et al. BMC Infect Dis doi: 10.1186/s12879-020-05507-4). This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Publication status
The study is only available as a preprint paper (posted to medRxiv on 25 July 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

Study characteristics
Mean age was 54 years in both groups and 39% were women. It is unclear if pregnant or breastfeeding women were eligible.

What are the main results?
For the critical outcomes of death and invasive mechanical ventilation, there were too few events (four deaths and eight requiring ventilation) to determine whether combination immunoglobulin plus methylprednisolone makes a difference. No patient experienced an adverse event.

Our confidence in the results
Certainty of the evidence is very low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers, few events and reliance on a single study.

Additional information
Adverse effects associated with immunoglobulin include flu-like symptoms, dermatologic side effects, arrhythmia, hypotension and transfusion-related acute lung injury [147].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality 30 days after commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.04 - 2.89) Based on data from 34 patients in 1 studies. 1 (Randomized controlled)</td>
<td></td>
<td></td>
<td>There were too few who died to determine whether combination immunoglobulin plus methylprednisolone makes a difference (4 events).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Standard care</td>
<td>Immunoglobulin plus methylprednisolone</td>
<td>(Quality of evidence)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Very Low Due to very serious imprecision 2</td>
</tr>
</tbody>
</table>

2. **Imprecision:** Very Serious. Low number of patients, Only data from one study, few events.


4. **Imprecision:** Very Serious. Low number of patients, Only data from one study, low events.


6. Systematic review [146]. **Baseline/comparator:** Control arm of reference used for intervention.

### Clinical Question/ PICO

**Population:** Special populations with COVID-19  
**Intervention:** Immunoglobulin plus methylprednisolone  
**Comparator:** Standard care

### Summary

There remains significant uncertainty whether immunoglobulin is more effective and safer than standard care in treating patients with COVID-19.
What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared combination immunoglobulin plus methylprednisolone with standard care in 34 patients with moderate or severe COVID-19 [148].

We have found one new study comparing immunoglobulin with placebo (Gharebahgi et al. BMC Infect Dis doi: 10.1186/s12879-020-05507-4). This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Publication status
The study is only available as a preprint paper (posted to medRxiv on 25 July 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
Mean age was 54 years in both groups and 39% were women. It is unclear if pregnant or breastfeeding women were eligible.

What are the main results?
For the critical outcomes of death and mechanical ventilation there were too few events (four deaths and eight requiring ventilation) to determine whether combination immunoglobulin plus methylprednisolone makes a difference. No patient experienced an adverse event.

Our confidence in the results
Certainty of the evidence is very low for all outcomes. This judgement is based on serious indirectness and very serious imprecision due to low patient numbers, few events and reliance on a single study.

Additional information
Adverse effects associated with immunoglobulin include flu-like symptoms, dermatologic side effects, arrhythmia, hypotension and transfusion-related acute lung injury [147].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>30 days after commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.04 - 2.89) Based on data from 34 patients in 1 studies.¹ (Randomized controlled)</td>
<td>¹</td>
<td>Very Low: Due to very serious imprecision and serious indirectness</td>
<td>There were too few who died to determine whether combination immunoglobulin plus methylprednisolone makes a difference (4 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>30 days after commencing treatment</td>
<td>Relative risk 0.29 (CI 95% 0.07 - 1.18) Based on data from 34 patients in 1 studies.² (Randomized controlled)</td>
<td>²</td>
<td>Very Low: Due to very serious imprecision and serious indirectness</td>
<td>There were too few who experienced invasive mechanical ventilation to determine whether combination immunoglobulin plus methylprednisolone makes a difference (9 events).</td>
</tr>
</tbody>
</table>
Adverse events

Within 30 days of commencing treatment

- Based on data from 34 patients in 1 studies, 5

6 Important

Serious adverse events

Within 30 days of commencing treatment

- 6 Important

2. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study, low events.
4. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study, few events.
6. Systematic review [146]. **Baseline/comparator:** Control arm of reference used for intervention.

**6.6.14 - Interferon β-1b**

**Not recommended**

Do not use interferon β-1b for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Interferon β-1b should still be considered for other evidence-based indications in people who have COVID-19.**

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use interferon β-1b to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with interferon β-1b, including thrombotic microangiopathy, hepatic injury, nephrotic syndrome and depression with suicidal ideation.
Children and adolescents, people requiring palliative care and older people living with frailty or cognitive impairment
There are additional concerns regarding harms as interferon β-1b has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

Pregnant and breastfeeding women
Evidence suggests that interferon β-1b in pregnant women is not associated with an increase in early pregnancy loss, stillbirths or congenital anomalies.

Certainty of the Evidence
Certainty of the evidence is low for discharge from hospital (days 14 and 28) and clinical deterioration (admission to ICU) due to very serious imprecision (low patient numbers and reliance on a single study). Certainty for the remaining outcomes is additionally downgraded due to few observed events.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values
General adult population
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources
We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Equity
General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.
Rationale

General adult population
There is currently limited evidence about the impact of interferon β-1b on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that interferon β-1b should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of interferon β-1b to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Interferon β-1b</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

Summary
There remains significant uncertainty whether interferon β-1b is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared interferon β-1b with standard care in 66 adults hospitalised with severe laboratory-confirmed COVID-19 [149].

Publication status
The study is only available as a preprint paper (posted to medRxiv on 1 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
Median age was 60 years in the interferon β-1b group and 61 years in the standard care group; the proportion of women was 39% and 42% respectively. A slightly higher proportion of patients had ischemic heart disease (39% vs 21%) and diabetes (36% vs 27%) in the standard care group compared to the interferon β-1b group.

What are the main results?
For the critical outcomes, there were too few events (eight deaths and eight who experienced respiratory failure) to determine whether interferon β-1b makes a difference. We are uncertain whether interferon β-1b reduces septic shock, clinical deterioration, discharge from hospital or time to discharge from hospital. Data for adverse and serious events were not reported.

**Our confidence in the results**
Certainty of the evidence is low for discharge from hospital (days 14 and 28) and clinical deterioration (admission to ICU) due to very serious imprecision (low patient numbers and reliance on a single study). Certainty for the remaining outcomes is additionally downgraded due to few observed events.

**Additional information**
According to the Therapeutic Goods Administration, there are well-known side effects and harms associated with interferon β-1b, including thrombotic microangiopathy, hepatic injury, nephrotic syndrome and depression with suicidal ideation [152].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality Within 14 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.04 - 3.04) Based on data from 66 patients in 1 studies. ¹ (Randomized controlled)</td>
<td>Relative risk 0.33 (CI 95% 0.04 - 3.04) Based on data from 66 patients in 1 studies. ¹ (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision ²</td>
<td>There were too few events to determine whether interferon β-1b increases or decreases all-cause mortality at 14 days (4 events).</td>
</tr>
<tr>
<td>All-cause mortality Within 28 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.07 - 1.53) Based on data from 66 patients in 1 studies. ³ (Randomized controlled)</td>
<td>Relative risk 0.33 (CI 95% 0.07 - 1.53) Based on data from 66 patients in 1 studies. ³ (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision ⁴</td>
<td>There were too few events to determine whether interferon β-1b increases or decreases all-cause mortality at 28 days (8 events).</td>
</tr>
<tr>
<td>Respiratory failure or ARDS Within 28 days after commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.07 - 1.53) Based on data from 66 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td>Relative risk 0.33 (CI 95% 0.07 - 1.53) Based on data from 66 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision ⁶</td>
<td>There were too few events to determine whether interferon β-1b increases or decreases respiratory failure or ARDS (8 events).</td>
</tr>
<tr>
<td>Septic shock Within 28 days of commencing</td>
<td>Relative risk 0.25 (CI 95% 0.03 - 2.12) Based on data from 66</td>
<td>Relative risk 0.25 (CI 95% 0.03 - 2.12) Based on data from 66</td>
<td>Very Low Due to very serious</td>
<td>There were too few events to determine whether interferon β-1b increases or decreases septic shock (8 events).</td>
</tr>
<tr>
<td>Treatment</td>
<td>Important</td>
<td>(Randomized controlled)</td>
<td>Imprecision</td>
<td>Decreases septic shock (5 events).</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------</td>
<td>-------------------------</td>
<td>-------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Important</td>
<td>9</td>
<td>Data for adverse events were not reported.</td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Important</td>
<td>10</td>
<td>Data for serious adverse events were not reported.</td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>Within 14 days of commencing treatment</td>
<td>Relative risk 1.44 (CI 95% 1.01 - 2.07)</td>
<td>Very Low</td>
<td>We are uncertain if interferon β-1b increases discharge from hospital within 14 days (44 events).</td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 1.15 (CI 95% 0.96 - 1.38)</td>
<td>Very Low</td>
<td>We are uncertain if interferon β-1b makes any difference to discharge from hospital within 28 days (58 events).</td>
</tr>
<tr>
<td>Clinical deterioration (admission to ICU)</td>
<td>Within 28 days of commencing treatment</td>
<td>Relative risk 0.64 (CI 95% 0.4 - 1.01)</td>
<td>Very Low</td>
<td>We are uncertain if interferon β-1b decreases clinical deterioration (based on admission to ICU; 36 events).</td>
</tr>
<tr>
<td>Time to discharge from hospital</td>
<td>Days</td>
<td>Based on data from: 66 patients in 1 studies.</td>
<td>Very Low</td>
<td>We are uncertain whether interferon β-1b increases or decreases time to discharge from hospital.</td>
</tr>
</tbody>
</table>

| 6 Important | 13 (Median) | 11 (Median) | CI 95% |
There remains significant uncertainty whether interferon β-1b is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared interferon β-1b with standard care in 66 adults hospitalised with severe laboratory-confirmed COVID-19 [149].
Publication status
The study is only available as a preprint paper (posted to medRxiv on 1 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
Median age was 60 years in the interferon β-1b group and 61 years in the standard care group; the proportion of women was 39% and 42% respectively. A slightly higher proportion of patients had ischemic heart disease (39% vs 21%) and diabetes (36% vs 27%) in the standard care group compared to the interferon β-1b group. Pregnant or breastfeeding women were ineligible.

What are the main results?
For the critical outcomes, there were too few events (eight deaths and eight who experienced respiratory failure) to determine whether interferon β-1b makes a difference. We are uncertain whether interferon β-1b reduces septic shock, clinical deterioration, discharge from hospital or time to discharge from hospital. Data for adverse and serious events were not reported.

Our confidence in the results
Certainty of the evidence is very low for all outcomes. This judgement is based on serious risk of bias (lack of blinding), very serious imprecision (low patient numbers, few observed events and reliance on a single study) and serious indirectness (limited inclusion of these populations). Mortality, respiratory failure or ARDS and septic shock were not downgraded for risk of bias as these outcomes are unlikely to be affected by lack of blinding.

Additional information
According to the Therapeutic Goods Administration, there are well-known side effects and harms associated with interferon β-1b, including thrombotic microangiopathy, hepatic injury, nephrotic syndrome and depression with suicidal ideation [152].

Children and adolescents
Efficacy and safety of interferon β-1b has not been investigated in children and adolescents for other indications. To date, no specific information on its benefits or harms has been collected for treating COVID-19 in this population.

Pregnant and breastfeeding women
Interferon β-1b is used in pregnancy for the treatment of multiple sclerosis. Evidence has shown no correlation between the use of Interferon β-1b and increases in early pregnancy loss, stillbirths or congenital anomalies [84].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care</td>
<td>Interferon β-1b</td>
<td></td>
</tr>
<tr>
<td>All-cause mortality Within 14 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.04 - 3.04) Based on data from 66 patients in 1 studies. (^1) (Randomized controlled)</td>
<td></td>
<td>Very Low Due to very serious imprecision and serious indirectness (^2)</td>
<td>We are uncertain whether interferon β-1b increases or decreases all-cause mortality at 14 days (4 events).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality Within 28 days of commencing</td>
<td>Relative risk 0.33 (CI 95% 0.07 - 1.53) Based on data from 66 patients in 1 studies. (^3)</td>
<td></td>
<td>Very Low Due to very serious imprecision and</td>
<td>We are uncertain whether interferon β-1b increases or decreases all-cause</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Study Details</td>
<td>Certainty</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Respiratory failure or ARDS</strong></td>
<td><strong>Relative risk 0.33</strong></td>
<td><strong>(C) 0.07 - 1.53</strong></td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>Very Low</td>
</tr>
<tr>
<td><strong>Septic shock</strong></td>
<td><strong>Relative risk 0.25</strong></td>
<td><strong>(C) 0.03 - 2.12</strong></td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>Very Low</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td>Important</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
<td></td>
<td></td>
<td>Important</td>
</tr>
<tr>
<td><strong>Discharge from hospital within 14 days of commencing treatment</strong></td>
<td><strong>Relative risk 1.44</strong></td>
<td><strong>(C) 1.01 - 2.07</strong></td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>Very Low</td>
</tr>
<tr>
<td><strong>Discharge from hospital within 28 days of commencing treatment</strong></td>
<td><strong>Relative risk 1.15</strong></td>
<td><strong>(C) 0.96 - 1.38</strong></td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>Very Low</td>
</tr>
<tr>
<td>Clinical deterioration (admission to ICU)</td>
<td>Relative risk 0.64 (CI 95%: 0.4 - 1.01) Based on data from 66 patients in 1 study.</td>
<td>Very Low Due to very serious imprecision, serious risk of bias and serious indirectness We are uncertain whether interferon β-1b has any impact on clinical deterioration (based on admission to ICU: 36 events).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to discharge from hospital</td>
<td>Based on data from: 66 patients in 1 study.</td>
<td>Very Low Due to very serious imprecision, serious risk of bias and serious indirectness We are uncertain whether interferon β-1b increases or decreases time to discharge from hospital.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
4. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
6. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
8. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study, due to few events.
9. Systematic review [151]. **Baseline/comparator:** Control arm of reference used for intervention.
10. Systematic review [151]. **Baseline/comparator:** Control arm of reference used for intervention.
12. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
16. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for
performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

17. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

### 6.6.15 - Interferon gamma

**Not recommended**

Do not use interferon gamma for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Interferon gamma should still be considered for other evidence-based indications in people who have COVID-19.**

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use interferon gamma to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with interferon gamma including gastrointestinal disorders (such as diarrhoea, vomiting, nausea and abdominal pain), rash, fever and headache, and depression.

**Certainty of the Evidence**

**General adult population**

Certainty of the evidence is very low for all outcomes due to serious imprecision (low patient numbers and the reliance on a single study) and risk of bias (missing outcome data for negative PCR and adverse events, and lack of blinding for discharge from hospital).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.
The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Acceptability**

**General adult population, children and adolescents, pregnant and breastfeeding women**

Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

**People requiring palliative care and older people living with frailty or cognitive impairment**

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Rationale**

**General adult population**

There is currently limited evidence about the impact of interferon gamma on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that interferon gamma should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of interferon gamma to treat COVID-19 in these populations should be avoided until evidence becomes available.
Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: Interferon gamma
Comparator: Standard care

Summary
There remains significant uncertainty whether interferon gamma is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared interferon gamma with standard care in 63 adults hospitalised with mild or moderate COVID-19 [154].

Publication status
The study is only available as a preprint paper (posted to medRxiv on 1 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

Study characteristics
Median age was 42 years in the interferon gamma group and 31 years in the control group; the proportion of women was 53% and 39% respectively. Pregnant and breastfeeding women were ineligible.

What are the main results?
No patients died or experienced serious adverse events. We are uncertain whether interferon gamma increases or decreases the likelihood of negative PCR at days 3 and 5, discharge from hospital or adverse events.

Our confidence in the results
Certainty of the evidence is very low for all outcomes due to serious imprecision (low patient numbers and reliance on a single study) and serious risk of bias (missing outcome data for negative PCR and adverse events, and lack of blinding for discharge from hospital).

Additional information
According to the Therapeutic Goods Administration, common adverse effects related to interferon gamma include gastrointestinal disorders (such as diarrhoea, vomiting, nausea and abdominal pain), rash, depression, fever and headache [155].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong>&lt;br&gt;21 days after commencing treatment</td>
<td>Based on data from 63 patients in 1 studies.</td>
<td>Standard care</td>
<td>Interferon gamma</td>
<td>Very Low Due to serious risk of bias and we are uncertain whether interferon gamma increases or decreases the likelihood of negative PCR.</td>
</tr>
<tr>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong>&lt;br&gt;21 days after</td>
<td>Relative risk 1.21 (CI 95% 0.56 - 2.61)&lt;br&gt;Based on data from 57 patients in 1 study</td>
<td></td>
<td>No patients died in the study.</td>
<td></td>
</tr>
</tbody>
</table>

228 of 418
<table>
<thead>
<tr>
<th>Event</th>
<th>Event Time</th>
<th>Relative Risk</th>
<th>Confidence Interval</th>
<th>Number of Patients</th>
<th>Risk of Bias</th>
<th>Imprecision</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative PCR (Day 3)</td>
<td>3 days after commencing treatment</td>
<td>Relative risk 1.84 (CI 95% 1.04 - 3.25)</td>
<td>Based on data from 59 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether interferon gamma increases the number of patients with negative PCR at day 3 (29 events).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative PCR (Day 5)</td>
<td>5 days after commencing treatment</td>
<td>Relative risk 1.3 (CI 95% 1.04 - 1.68)</td>
<td>Based on data from 47 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether interferon gamma increases the number of patients with negative PCR at day 5 (40 events).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>14 days after commencing treatment</td>
<td>Relative risk 1.1 (CI 95% 0.97 - 1.24)</td>
<td>Based on data from 63 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias and very serious imprecision</td>
<td>We are uncertain whether interferon gamma increases discharge from hospital (60 events).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up. **Imprecision:** Very Serious. Low number of patients. Only data from one study.
6. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up. **Imprecision:** Very Serious. Low number of
patients, Only data from one study.
8. **Risk of bias:** Serious. Incomplete data and/or large loss to follow up. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population</th>
<th>Special populations with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

**Summary**
There remains significant uncertainty whether interferon gamma is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**
Evidence comes from a single randomised trial that compared interferon gamma with standard care in 63 adults hospitalised with mild or moderate COVID-19 [154].

**Publication status**
The study is only available as a preprint paper (posted to medRxiv on 1 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

**Study characteristics**
Median age was 42 years in the interferon gamma group and 31 years in the control group; the proportion of women was 53% and 39% respectively. Pregnant and breastfeeding women were ineligible.

**What are the main results?**
No patients died or experienced serious adverse events. We are uncertain whether interferon gamma increases or decreases the likelihood of negative PCR at days 3 and 5, discharge from hospital or adverse events.

**Our confidence in the results**
Certainty of the evidence is very low for all outcomes due to serious imprecision (low patient numbers and reliance on a single study), serious risk of bias (missing outcome data for negative PCR and adverse events, and lack of blinding for discharge from hospital) and serious indirectness (absence of these populations from the included studies).

**Additional information**
According to the Therapeutic Goods Administration, common adverse effects related to interferon gamma include gastrointestinal disorders (such as diarrhoea, vomiting, nausea and abdominal pain), rash, depression, fever and headache [155].
<table>
<thead>
<tr>
<th>Event</th>
<th>Time after treatment</th>
<th>Standard care</th>
<th>Interferon gamma</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>21 days after commencing treatment</td>
<td>Based on data from 63 patients in 1 studies.</td>
<td></td>
<td>No patients died in the study.</td>
</tr>
<tr>
<td>Adverse events</td>
<td>21 days after commencing treatment</td>
<td>Relative risk 1.21 (CI 95% 0.56 - 2.61) Based on data from 57 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias, very serious imprecision and serious indirectness</td>
<td>We are uncertain whether interferon gamma increases or decreases adverse events (18 events).</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>21 days after commencing treatment</td>
<td>Based on data from 63 patients in 1 studies.</td>
<td></td>
<td>No patients had serious adverse events.</td>
</tr>
<tr>
<td>Negative PCR (Day 3)</td>
<td>3 days after commencing treatment</td>
<td>Relative risk 1.84 (CI 95% 1.04 - 3.25) Based on data from 59 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias, very serious imprecision and serious indirectness</td>
<td>We are uncertain whether interferon gamma increases the number of patients with negative PCR at day 3 (29 events).</td>
</tr>
<tr>
<td>Negative PCR (Day 5)</td>
<td>5 days after commencing treatment</td>
<td>Relative risk 1.3 (CI 95% 1 - 1.68) Based on data from 47 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias, very serious imprecision and serious indirectness</td>
<td>We are uncertain whether interferon gamma increases the number of patients with negative PCR at day 5 (40 events).</td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td>14 days after commencing treatment</td>
<td>Relative risk 1.1 (CI 95% 0.97 - 1.24) Based on data from 63 patients in 1 studies.</td>
<td>Very Low Due to serious risk of bias, very serious imprecision and serious indirectness</td>
<td>We are uncertain whether interferon gamma increases discharge from hospital (60 events).</td>
</tr>
</tbody>
</table>
6.6.16 - Interferon kappa plus trefoil factor 2 (IFN-κ plus TFF2)

**Not recommended**

Do not use IFN-κ plus TFF2 for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

IFN-κ plus TFF2 should still be considered for other evidence-based indications in people who have COVID-19.

*Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use IFN-κ plus TFF2 to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.*

Evidence To Decision

**Benefits and harms**

**General adult population**

Data for deaths, adverse events or serious adverse events were not reported in the study. There remains uncertainty regarding the benefits of IFN-κ plus TFF2 in patients with COVID-19, as well as uncertainty regarding the safety profile of this combination therapy.
Certainty of the evidence is very low for all reported outcomes due to serious risk of bias (lack of blinding of patients and personnel) and very serious imprecision (reliance on a single study with low patient numbers and wide confidence intervals).

### Preference and values

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of IFN-κ plus TFF2 during pregnancy and breastfeeding are unknown in the context of COVID-19.

### Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

### Equity

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

### Acceptability

**General adult population, children and adolescents, pregnant and breastfeeding women**

We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

**People requiring palliative care and older people living with frailty or cognitive impairment**

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

### Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

### Rationale

**General adult population**
There is currently limited evidence about the impact of IFN-κ plus TFF2 on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that IFN-κ plus TFF2 should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of IFN-κ plus TFF2 for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

---

**Clinical Question/ PICO**

- **Population:** Patients with COVID-19
- **Intervention:** IFN-κ plus TFF2
- **Comparator:** Standard care

---

**Summary**

There remains significant uncertainty whether therapy with interferon kappa plus trefoil factor 2 (IFN-κ plus TFF2) is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from one randomised trial that compared IFN-κ plus TFF2 with standard care in 80 adults hospitalised with moderate laboratory-confirmed COVID-19 [157].

**Study characteristics**

Mean age was 35 years in both groups. The proportion of women in the IFN-κ plus TFF2 group was 35% and in the standard care group 37%. IFN-κ (2 mg) and TFF2 (5 mg) were dissolved in 5 ml of water and administered via aerosol inhalation once every 24 hours for six days. Standard care included hydroxychloroquine, antibiotics, vasopressors, antifever medicine, vitamin C, immune enhancers and/or traditional Chinese medicine. Paediatric patients and pregnant or breastfeeding women were ineligible.

**What are the main results?**

There were no deaths or serious adverse events in either group. Compared with standard care, we are uncertain if IFN-κ plus TFF2 leads to clinical improvement based on chest CT scans, or increases or decreases time to discharge from hospital or time to negative PCR.

**Our confidence in the results**

Certainty of the evidence is very low for all reported outcomes due to serious risk of bias (lack of blinding of patients and personnel) and very serious imprecision (reliance on a single study with low patient numbers and wide confidence intervals).

**Additional information**

As of 5 October 2020, IFN-κ plus TFF2 is not listed on the Australian Register of Therapeutic Goods and is not available for use in Australia.

---

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality Within 12 days of commencing</td>
<td>Based on data from 80 patients in 1 studies.</td>
<td></td>
<td></td>
<td>No patients died.</td>
</tr>
</tbody>
</table>


3. Based on chest CT imaging; reduction in the size and density of lesions.


5. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

6. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

7. **Imprecision:** Very Serious. Wide confidence intervals, Low number of patients, Only data from one study.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>9 Critical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
</tr>
<tr>
<td>Within 12 days of commencing treatment</td>
<td>Based on data from 80 patients in 1 studies. ²</td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical improvement</strong>³</td>
<td>Relative risk 1.21 (CI 95% 0.96 - 1.51) Based on data from 80 patients in 1 studies. ⁴ (Randomized controlled)</td>
</tr>
<tr>
<td>Within 12 days of commencing treatment</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
</tr>
<tr>
<td><strong>Time to discharge from hospital</strong> Days</td>
<td>Lower better Based on data from: 80 patients in 1 studies. (Randomized controlled)</td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
</tr>
<tr>
<td><strong>Time to negative PCR</strong> Days</td>
<td>Lower better Based on data from: 80 patients in 1 studies.</td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: MD 4.55 lower CI 95%</td>
<td>Very Low Due to serious risk of bias and very serious imprecision ⁵</td>
</tr>
<tr>
<td></td>
<td>We are uncertain whether IFN-κ plus TFF2 increases or decreases clinical improvement based on chest CT scan (64 events).</td>
</tr>
<tr>
<td></td>
<td>7.4 (Mean) 3.8 (Mean)</td>
</tr>
<tr>
<td>Difference: MD 3.6 lower CI 95%</td>
<td>Very Low Due to very serious imprecision ⁶</td>
</tr>
<tr>
<td></td>
<td>We are uncertain whether IFN-κ plus TFF2 increases or decreases time to discharge from hospital.</td>
</tr>
<tr>
<td></td>
<td>³</td>
</tr>
</tbody>
</table>
6.6.17 - Ivermectin

**Not recommended**

Do not use ivermectin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*Ivermectin should still be considered for other evidence-based indications in people who have COVID-19.*

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use ivermectin to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

---

**Evidence To Decision**

**Benefits and harms**

**General adult population**
In addition to uncertainty around benefits for patients with COVID-19, there are common side effects and harms associated with ivermectin, including diarrhoea, nausea and dizziness [159].

**Children and adolescents**
Ivermectin should not be used in children under five years of age as safety in this age group has not been established. The safety profile of ivermectin in children 5 to 12 years of age is similar to that observed in adults [159].

**Pregnant and breastfeeding women**
Limited information suggests that ivermectin is not associated with an increased risk of congenital abnormalities. Ivermectin may be used in women who are breastfeeding [160].

**Certainty of the Evidence**

**General adult population**
Certainty of the evidence is very low for all outcomes due to very serious imprecision (reliance on a single study with low patient numbers and wide confidence intervals) and serious to very serious risk of bias.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, certainty of the evidence is further considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of ivermectin during pregnancy and breastfeeding are unknown in the context of COVID-19.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the
cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

**Equity**

**General adult population**
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Acceptability**

**General adult population, children and adolescents, pregnant and breastfeeding women**
We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Rationale**

**General adult population**
There is currently limited evidence about the impact of ivermectin on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that ivermectin should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women**
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

**Clinical Question/ PICO**

- **Population:** Patients with COVID-19
- **Intervention:** Ivermectin
- **Comparator:** Standard care
Summary
There remains significant uncertainty whether ivermectin is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from one randomised trial that compared ivermectin with standard care in 62 adults with mild (81%) or moderate (19%) COVID-19 [158].

We have found a pre-print of one new study comparing ivermectin plus doxycycline with standard care (Hashim et al. medRxiv doi: 10.1101/2020.10.26.20219345). This study is currently under review and an updated recommendation will be included in a future version of the guideline.

Study characteristics
Mean age was 39 years and the proportion of women was 29%. Patients in the intervention group received a single dose of ivermectin (200 μg/kg), in addition to standard care. Standard care for symptomatic treatment included antipyretics, cough suppressants and capsule doxycycline. Patients taking other antibiotics or hydroxychloroquine were excluded from the study. Pregnant and breastfeeding women were ineligible.

What are the main results?
The study did not report the number of patients who experienced adverse or serious adverse events. It is unclear whether ivermectin increases or decreases viral clearance at day 10 (37 events) or time to clinical recovery from either onset of illness or randomisation.

Our confidence in the results
Certainty of the evidence is very low for viral clearance at day 10 (due to serious risk of bias and very serious imprecision) and both time to clinical recovery outcomes (due to very serious risk of bias and serious imprecision).

For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information
Common side effects and harms associated with ivermectin are diarrhoea, nausea and dizziness [159].

Pregnant and breastfeeding women
Limited information suggests that ivermectin is not associated with an increased risk of congenital abnormalities. Ivermectin may be used in women who are breastfeeding [160].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Day 28</td>
<td><em>Based on data from 62 patients in 1 studies.</em></td>
<td></td>
<td></td>
<td>Data for number of patients who died were not reported.</td>
</tr>
<tr>
<td></td>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>End of follow-up</td>
<td><em>Based on data from 62 patients in 1 studies.</em></td>
<td></td>
<td></td>
<td>Data for number of patients experiencing one or more events were not reported.</td>
</tr>
</tbody>
</table>
1. Systematic review [195]. **Baseline/comparator**: Control arm of reference used for intervention.
2. Systematic review [195]. **Baseline/comparator**: Control arm of reference used for intervention.

5. **Risk of bias**: **Serious**. Inadequate sequence generation (odd-even method) resulting in potential for selection bias; concealment of allocation during randomization process not reported, resulting in potential for selection bias; no protocol, analysis plan or trial registration record available. **Inconsistency**: **No serious**. **Indirectness**: **No serious**.
   **Imprecision**: **Very Serious**. Wide confidence intervals. Low number of patients, Only data from one study.
6. Measured as time to clinical recovery from onset of illness to complete resolution of symptoms.
7. **Risk of bias**: **Very Serious**. **Imprecision**: **Very Serious**. Low number of patients, Only data from one study. Wide confidence intervals.
8. **Risk of bias**: **Very Serious**. **Imprecision**: **Very Serious**. Low number of patients, Only data from one study.
6.6.18 - N-acetylcysteine

**Not recommended**

Do not use N-acetylcysteine for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*N-acetylcysteine should still be considered for other evidence-based indications in people who have COVID-19.*

**Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use N-acetylcysteine to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.**

**Evidence To Decision**

**Benefits and harms**

**General adult population**
In addition to uncertainty around benefits for patients with COVID-19, there are common side effects and harms associated with N-acetylcysteine, including nausea, vomiting and other gastrointestinal symptoms [163].

**Pregnant and breastfeeding women**
Benefits can be assumed to outweigh possible risks for pregnant women; limited clinical experience has not resulted in adverse effects to the fetus. N-acetylcysteine is safe to use in women who are breastfeeding [160].

**Certainty of the Evidence**

**General adult population**
Certainty of the evidence is low for mechanical ventilation, ICU admission and hospital length of stay. This judgement is based on very serious imprecision due to reliance on a single study, low patient numbers and few events. Certainty of the evidence is additionally very low for death due to serious risk of bias (incomplete data).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, certainty of the evidence is further considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

**Preference and values**

**General adult population**
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of N-acetylcysteine during pregnancy and breastfeeding are unknown in the context of COVID-19.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.
Rationale

General adult population
There is currently limited evidence about the impact of N-acetylcysteine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that N-acetylcysteine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women
We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale

General adult population
There is currently limited evidence about the impact of N-acetylcysteine on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that N-acetylcysteine should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of N-acetylcysteine for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: N-acetylcysteine
Comparator: Placebo

Summary
There remains significant uncertainty whether N-acetylcysteine is more effective and safer than standard care in treating patients with COVID-19.
What is the evidence informing this recommendation?
Evidence comes from one randomised trial that compared N-acetylcysteine with placebo in 135 adults with suspected (5%) or confirmed (95%) severe COVID-19 [162].

Study characteristics
Median age was 59 years in the N-acetylcysteine group and 58 years in the control group; the proportion of women was 33% and 46% respectively. N-acetylcysteine was administered intravenously for each patient in two doses (totalling 1000 ml over 20 hours). Standard care included oxygen supplementation, non-invasive and invasive ventilation, and antibiotics (ceftriaxone 2 g/day and azithromycin 500 mg/day). Pregnant women were ineligible.

What are the main results?
There were too few events to determine whether N-acetylcysteine makes a difference to death. N-acetylcysteine may decrease the need for admission to ICU but increase the need for invasive mechanical ventilation. N-acetylcysteine may have little or no impact on ICU admission or hospital length of stay.

Our confidence in the results
Certainty of the evidence is low for mechanical ventilation and ICU admission, hospital length of stay and ICU length of stay. This judgement is based on very serious imprecision due to reliance on a single study, low patient numbers and few events. Certainty of the evidence is additionally very low for mortality due to serious risk of bias (incomplete data).

For children & adolescents and pregnant & breastfeeding women, certainty is further downgraded due to serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information
Common side effects associated with N-acetylcysteine are nausea, vomiting and other gastrointestinal symptoms [163].

Pregnant and breastfeeding women
Benefits can be assumed to outweigh possible risks for pregnant women; limited clinical experience has not resulted in adverse effects to the fetus. N-acetylcysteine is safe to use in women who are breastfeeding [160].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>End of follow-up 9 Critical</td>
<td>Relative risk 1.01 (CI 95% 0.43 - 2.4) Based on data from 135 patients in 1 studies, 1 (Randomized controlled)</td>
<td>Relative risk 1.01 Placebo 1.01 N-acetylcysteine</td>
<td>Very Low Due to serious risk of bias and very serious imprecision 2</td>
<td>There were too few events to determine whether N-acetylcysteine made a difference regarding death (18 events).</td>
</tr>
<tr>
<td>Invasive mechanical ventilation 3</td>
<td>End of follow-up 9 Critical</td>
<td>Relative risk 1.16 (CI 95% 0.62 - 2.18) Based on data from 135 patients in 1 studies, 4 (Randomized controlled)</td>
<td>206 per 1000 Placebo 239 per 1000 N-acetylcysteine</td>
<td>Low Due to very serious imprecision 5</td>
<td>N-acetylcysteine may make little or no difference to the need for invasive mechanical ventilation (30 events).</td>
</tr>
</tbody>
</table>

Outcome: All-cause mortality
Timeframe: End of follow-up 9 Critical
Study results and measurements: Relative risk 1.01 (CI 95% 0.43 - 2.4) Based on data from 135 patients in 1 studies, 1 (Randomized controlled)
Absolute effect estimates: Relative risk 1.01 Placebo 1.01 N-acetylcysteine
Certainty of the Evidence (Quality of evidence): Very Low Due to serious risk of bias and very serious imprecision 2
Plain text summary: There were too few events to determine whether N-acetylcysteine made a difference regarding death (18 events).

Outcome: Invasive mechanical ventilation
Timeframe: End of follow-up 9 Critical
Study results and measurements: Relative risk 1.16 (CI 95% 0.62 - 2.18) Based on data from 135 patients in 1 studies, 4 (Randomized controlled)
Absolute effect estimates: 206 per 1000 Placebo 239 per 1000 N-acetylcysteine
Certainty of the Evidence (Quality of evidence): Low Due to very serious imprecision 5
Plain text summary: N-acetylcysteine may make little or no difference to the need for invasive mechanical ventilation (30 events).

2. **Risk of bias**: Serious. Incomplete data (6 patients still in ICU at end of follow-up excluded from mortality analysis) and/or reporting error (denominator different between narrative and table result). Pre-print only. Wait for peer-reviewed publication. **Inconsistency**: No serious. **Indirectness**: No serious. **Imprecision**: Very Serious. Low number of patients, Only data from one study, Few events, Wide confidence intervals. **Publication bias**: No serious.

3. Need for endotracheal intubation/invasive mechanical ventilation


5. **Inconsistency**: No serious. **Indirectness**: No serious. **Imprecision**: Very Serious. Wide confidence intervals, Low number of patients, Only data from one study. **Publication bias**: No serious.


7. **Inconsistency**: No serious. **Indirectness**: No serious. **Imprecision**: Very Serious. Wide confidence intervals, Low number of patients, Only data from one study. **Publication bias**: No serious.


9. **Inconsistency**: No serious. **Indirectness**: No serious. **Imprecision**: Very Serious. Only data from one study, Low number of patients. **Publication bias**: No serious.


11. **Inconsistency**: No serious. **Indirectness**: No serious. **Imprecision**: Very Serious. Low number of patients, Only data from one study, Wide confidence intervals. **Publication bias**: No serious.

### ICU admission

**End of follow-up**

- **Relative risk**: 0.92 (CI 95% 0.63 - 1.33)
- Based on data from 135 patients in 1 studies. 6 (Randomized controlled)
- **Difference**: 38 fewer per 1000 (CI 95% 174 fewer - 155 more)
- **Low due to very serious imprecision**
- N-acetylcysteine may make little or no difference to ICU admission (61 events).

### Hospital length of stay

**Days**

- Lower better Based on data from: 135 patients in 1 studies. 8 (Randomized controlled)
- **Low due to very serious imprecision**
- N-acetylcysteine may have little or no impact on hospital length of stay.

### ICU length of stay

**Days**

- Lower better Based on data from: 135 patients in 1 studies. 10 (Randomized controlled)
- **Low due to very serious imprecision**
- N-acetylcysteine may have little or no impact on ICU length of stay.
6.6.19 - Recombinant human granulocyte colony-stimulating factor (rhG-CSF)

**Not recommended**

Do not use rhG-CSF for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Recombinant human granulocyte colony-stimulating factor should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use rhG-CSF to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

### Benefits and harms

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with rhG-CSF, including thrombocytopaenia (common), pulmonary haemorrhage, haemoptysis, aortitis and glomerulonephritis. There have also been occasional reports of adult respiratory distress syndrome in patients receiving rhG-CSF.

**Children and adolescents**

Paediatricians have considerable experience with the use of rhG-CSF in children and adolescents for other indications.

**Pregnant and breastfeeding women**

Transplacental passage of rhG-CSF has been demonstrated, and it is not known if rhG-CSF is excreted in human milk. rhG-CSF is therefore not recommended for pregnant and breastfeeding women unless the potential benefit outweighs the potential risk to the fetus or newborn/infant.

**People requiring palliative care and older people living with frailty or cognitive impairment**

The benefits of rhG-CSF for this population are uncertain.

### Certainty of the Evidence

**General adult population**

Certainty of the evidence is low for death and mechanical ventilation due to very serious imprecision (low patient numbers, few events and reliance on a single study); low for duration of hospital stay due serious risk of bias (lack of blinding) and serious imprecision (low patient numbers and reliance on a single study); and very low for adverse and serious adverse events due to serious risk of bias and very serious imprecision (low patient numbers and reliance on a single study).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

### Preference and values

**General adult population**

We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

Substantial variability is expected or uncertain.
Rationale

General adult population
There is currently limited evidence about the impact of rhG-CSF on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that rhG-CSF should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of rhG-CSF to treat COVID-19 in these populations should be avoided.

Resources
We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered, but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility
Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.
Clinical Question/ PICO

**Population:** Patients with COVID-19  
**Intervention:** rhG-CSF  
**Comparator:** Standard care

Summary

There remains significant uncertainty whether therapy with recombinant human granulocyte colony-stimulating factor (rhG-CSF) is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from one randomised trial that compared three days of subcutaneous rhG-CSF therapy (5 μg/kg) with standard care in 200 hospitalised lymphopaenic adults with no comorbidities and moderate to severe COVID-19 [164].

**Study characteristics**

Median age was 45 years in the rhG-CSF group and 46 years in the control group; the proportion of women was 42% and 46% respectively. Standard care comprised supplemental oxygen, non-invasive ventilation, or intravenous antibiotics when indicated. Participants were required to have a peripheral blood leukocyte count ≤ 1500 per μL and peripheral blood lymphocyte ≤ 800 per μL for inclusion. Pregnant and breastfeeding women were ineligible.

**What are the main results?**

For the critical outcomes of death and mechanical ventilation within 21 days of starting treatment, there were too few events (12 deaths and 16 who required ventilation) to determine whether rhG-CSF therapy makes a difference. It is unclear whether rhG-CSF therapy increases or decreases adverse or serious adverse events. rhG-CSF therapy may have little or no impact on the duration of hospital stay.

**Our confidence in the results**

Certainty of the evidence is low for death and mechanical ventilation due to very serious imprecision (low patient numbers, few events and reliance on a single study); low for duration of hospital stay due serious risk of bias (lack of blinding) and serious imprecision (low patient numbers and reliance on a single study); and very low for adverse and serious adverse events due to serious risk of bias and very serious imprecision (low patient numbers and reliance on a single study).

**Additional information**

There are well-known side effects and harms associated with rhG-CSF therapy, including thrombocytopenia (common), pulmonary haemorrhage, haemoptysis, aortitis and glomerulonephritis. There have also been occasional reports of adult respiratory distress syndrome in patients receiving rhG-CSF therapy [165].

---

### Outcome

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Within 21 days of commencing treatment</td>
<td>Relative risk 0.2 (CI 95% 0.04 - 0.89) Based on data from 200 patients in 1 studies.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 per 1000 20 per 1000</td>
<td>Low Due to very serious imprecision (^2)</td>
<td>There were too few who died to determine whether rhG-CSF makes a difference (12 events).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Difference: 80 fewer per 1000 ( CI 95% 96 fewer - 11 fewer )</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Invasive mechanical ventilation

**Within 21 days of commencing treatment**

- **9 Critical**

### Serious adverse events

**End of treatment**

- **6 Important**

### Adverse events

**End of treatment**

- **6 Important**

### Duration of hospital stay

**Days**

- **6 Important**

#### Relative risk

- **Relative risk 0.14 (CI 95% 0.03 - 0.61)**
  - Based on data from 200 patients in 1 studies.  
  - (Randomized controlled)

#### Relative risk

- **Relative risk 0.72 (CI 95% 0.49 - 1.05)**
  - Based on data from 200 patients in 1 studies.  
  - (Randomized controlled)

#### Relative risk

- **Relative risk 2.02 (CI 95% 1.62 - 2.5)**
  - Based on data from 200 patients in 1 studies.  
  - (Randomized controlled)

#### Based on data from:

- **200 patients in 1 studies.**
  - (Randomized controlled)

#### Based on data from:

- **200 patients in 1 studies.**
  - (Randomized controlled)

#### Based on data from:

- **200 patients in 1 studies.**
  - (Randomized controlled)

### Key Results

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Number of Events</th>
<th>Risk of Bias</th>
<th>Imprecision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive mechanical ventilation</td>
<td>0.14</td>
<td>0.03 - 0.61</td>
<td>120 fewer</td>
<td>Low</td>
<td>Very Serious</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>0.72</td>
<td>0.49 - 1.05</td>
<td></td>
<td>Very Low</td>
<td>Very Serious</td>
</tr>
<tr>
<td>Adverse events</td>
<td>2.02</td>
<td>1.62 - 2.5</td>
<td></td>
<td>Very Low</td>
<td>Very Serious</td>
</tr>
<tr>
<td>Duration of hospital stay</td>
<td></td>
<td></td>
<td>1 fewer</td>
<td>Low</td>
<td>Very Low</td>
</tr>
</tbody>
</table>

#### Notes

2. **Risk of bias:** No serious. Inadequate/lack of blinding of participants, personnel, and outcome assessors. Indicent: No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Only data from one study, Low number of patients, Few events. Publication bias: No serious.
4. **Risk of bias:** No serious. Inadequate/lack of blinding of participants, personnel and outcome assessors. Indicent: No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Only data from one study, Low number of patients, only data from one study, Few events. Publication bias: No serious.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. Indicent: No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Low number of patients, Wide confidence intervals, Only data from one study. Publication bias: No serious.
8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for
performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency: No serious. Indirectness: No serious. Imprecision: Very Serious.** Wide confidence intervals, Low number of patients, Only data from one study. **Publication bias: No serious.**


10. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency: No serious. Indirectness: No serious. Imprecision: Serious.** Only data from one study, Low number of patients. **Publication bias: No serious.**

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Special populations with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>rhG-CSF</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

**Summary**

There remains significant uncertainty whether therapy with recombinant human granulocyte colony-stimulating factor (rhG-CSF) is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from one randomised trial that compared three days of subcutaneous rhG-CSF therapy (5 μg/kg) with standard care in 200 hospitalised lymphopaenic adults with no comorbidities and moderate to severe COVID-19 [164].

**Study characteristics**

Median age was 45 years in the rhG-CSF group and 46 years in the control group; the proportion of women was 42% and 46% respectively. Standard care comprised supplemental oxygen, non-invasive ventilation, or intravenous antibiotics when indicated. Participants were required to have a peripheral blood leukocyte count ≤ 1500 per μL and peripheral blood lymphocyte ≤ 800 per μL for inclusion. Pregnant and breastfeeding women were ineligible.

**What are the main results?**

For the critical outcomes of death and invasive mechanical ventilation within 21 days of starting treatment, there were too few events (12 deaths and 16 who required ventilation) to determine whether rhG-CSF therapy makes a difference. It is unclear whether rhG-CSF therapy increases or decreases adverse or serious adverse events. rhG-CSF therapy may have little or no impact on the duration of hospital stay.

**Our confidence in the results**

Certainty of the evidence is very low for all outcomes. This judgement is based on serious risk of bias (lack of blinding), very serious imprecision (low patient numbers, few observed events and reliance on a single study) and serious indirectness (limited inclusion of these populations).

**Additional information**

There are well-known side effects and harms associated with rhG-CSF therapy, including thrombocytopaenia (common), pulmonary haemorrhage, haemoptysis, aortitis and glomerulonephritis. There have also been occasional reports of adult respiratory distress syndrome in patients receiving rhG-CSF therapy [165].

**Children and adolescents**

Paediatricians have considerable experience with the use of rhG-CSF in children and adolescents for other indications.

**Pregnant and breastfeeding women**
Transplacental passage of rhG-CSF has been demonstrated, and it is not known if rhG-CSF is excreted in human milk. rhG-CSF is therefore not recommended for pregnant and breastfeeding women unless the potential benefit outweighs the potential risk to the fetus or newborn/infant [165].
<table>
<thead>
<tr>
<th>Outcome/Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong>&lt;br&gt;Within 21 days of commencing treatment</td>
<td>Relative risk 0.2 (CI 95% 0.04 - 0.89) Based on data from 200 patients in 1 studies.&lt;sup&gt;1&lt;/sup&gt; (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision and serious indirectness&lt;sup&gt;2&lt;/sup&gt;</td>
<td>There were too few who died to determine whether rhG-CSF makes a difference (12 events).</td>
<td></td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong>&lt;br&gt;Within 21 days of commencing treatment</td>
<td>Relative risk 0.14 (CI 95% 0.03 - 0.61) Based on data from 200 patients in 1 studies.&lt;sup&gt;3&lt;/sup&gt; (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision and serious indirectness&lt;sup&gt;4&lt;/sup&gt;</td>
<td>There were too few who required invasive mechanical ventilation to determine whether rhG-CSF makes a difference (16 events).</td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong>&lt;br&gt;End of treatment</td>
<td>Relative risk 0.72 (CI 95% 0.49 - 1.05) Based on data from 200 patients in 1 studies.&lt;sup&gt;5&lt;/sup&gt; (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision, serious risk of bias and serious indirectness&lt;sup&gt;6&lt;/sup&gt;</td>
<td>We are uncertain whether rhG-CSF increases or decreases serious adverse events</td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong>&lt;br&gt;End of treatment</td>
<td>Relative risk 2.02 (CI 95% 1.62 - 2.5) Based on data from 200 patients in 1 studies.&lt;sup&gt;7&lt;/sup&gt; (Randomized controlled)</td>
<td>Very Low Due to very serious imprecision, serious risk of bias and serious indirectness&lt;sup&gt;8&lt;/sup&gt;</td>
<td>We are uncertain whether rhG-CSF increases adverse events.</td>
<td></td>
</tr>
<tr>
<td><strong>Duration of hospital stay</strong>&lt;br&gt;Days</td>
<td>Based on data from: 200 patients in 1 studies.&lt;sup&gt;9&lt;/sup&gt; (Randomized controlled)</td>
<td>Difference: <strong>1 fewer</strong></td>
<td>We are uncertain whether rhG-CSF increases or decreases duration of hospital stay.</td>
<td></td>
</tr>
</tbody>
</table>

2. Risk of bias: No serious. Inadequate/lack of blinding of participants, personnel, and outcome assessors. Inconsistency: No serious. Indirectness: Serious. Differences between the population of interest and those studied. Imprecision: Very Serious. Only data from one study, Low number of patients, Few events. Publication bias: No serious.

4. **Risk of bias:** **No serious.** Inadequate/lack of blinding of participants, personnel and outcome assessors. **Inconsistency:** **No serious.** Indirectness: **Serious.** Differences between the population of interest and those studied. **Imprecision:** **Very Serious.** Low number of patients, only data from one study, few events. **Publication bias:** **No serious.**


6. **Risk of bias:** **Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** **No serious.** Indirectness: **Serious.** Differences between the population of interest and those studied. **Imprecision:** **Very Serious.** Low number of patients, Wide confidence intervals, Only data from one study. **Publication bias:** **No serious.**


8. **Risk of bias:** **Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** **No serious.** Indirectness: **Serious.** Differences between the population of interest and those studied. **Imprecision:** **Very Serious.** Wide confidence intervals, Low number of patients, Only data from one study. **Publication bias:** **No serious.**


10. **Risk of bias:** **Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** **No serious.** Indirectness: **Serious.** Differences between the population of interest and those studied. **Imprecision:** **Serious.** Only data from one study, Low number of patients. **Publication bias:** **No serious.**

### 6.6.20 - Ruxolitinib

**Not recommended**

Do not use ruxolitinib for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*Ruxolitinib should still be considered for other evidence-based indications in people who have COVID-19.*

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use ruxolitinib to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**

In addition to uncertainty around the benefits for patients with COVID-19, there are well-known side effects and harms of ruxolitinib. Although most of the information on side effects and harms is derived from long-term use, potential harms include thrombocytopenia and other haematological adverse reactions, and increased incidence of bacterial and other infections.
Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

There are additional concerns regarding harms as ruxolitinib has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain. No studies pertained to the safety of ruxolitinib (for any indication) for pregnant or breastfeeding women.

### Certainty of the Evidence

**General adult population**

Certainty of the evidence is low for mortality and very low for all other outcomes due to serious risk of bias (lack of blinding of outcome assessors) and very serious imprecision (low number of patients and observed events).

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

### Preference and values

**General adult population**

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the potential effects of ruxolitinib in pregnancy are unknown.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

### Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

### Equity

**General adult population**

There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

**Children and adolescents, pregnant and breastfeeding women**

Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

**People requiring palliative care and older people living with frailty or cognitive impairment**

As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.
Rationale

General adult population

There is currently limited evidence about the impact of ruxolitinib on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that ruxolitinib should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of ruxolitinib to treat COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Ruxolitinib</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

Summary

We are uncertain if ruxolitinib is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from a single randomised trial that compared ruxolitinib with placebo (vitamin C) in 41 adults hospitalised with severe COVID-19 [168].

Study characteristics

Median age was 63 years in the ruxolitinib group and 64 years in the control group; the proportion of women was 40% and 43% respectively. Pregnant and breastfeeding women were ineligible.

What are the main results?

For the critical outcomes, there were too few events (three deaths, nine who required invasive mechanical ventilation and two who experienced septic shock) to determine whether ruxolitinib makes a difference. We are uncertain whether ruxolitinib increases or decreases the likelihood of clinical improvement, time to discharge from hospital or adverse events. Four patients in the control group experienced serious adverse events.

Our confidence in the results

Certainty of the evidence is low for mortality and very low for all other outcomes. This judgement is based on serious risk of bias (unblinded outcome assessors) and very serious imprecision (low patient numbers, few observed
events and reliance on a single study). Mortality was not downgraded for risk of bias as this outcome is unlikely to be affected by lack of blinding.

**Additional information**
The Therapeutic Goods Administration highlights several potential side effects associated with ruxolitinib, including thrombocytopenia and other haematological adverse reactions, and increased incidence of bacterial and other infections. Cases of progressive multifocal leukoencephalopathy and non-melanoma skin cancer have also been reported in patients treated with ruxolitinib [167].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality (Day 28)</strong></td>
<td>Odds Ratio 0.13 (CI 95% 0.01 - 2.67) Based on data from 41 patients in 1 studies.</td>
<td><strong>143</strong> per 1000 <em>Difference: 122 fewer</em> per 1000 (CI 95% 141 fewer - 165 more)</td>
<td>Low</td>
<td>There were too few who died to determine whether ruxolitinib makes a difference (3 events).</td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong></td>
<td>Odds Ratio 0.22 (CI 95% 0.04 - 1.24) Based on data from 41 patients in 1 studies.</td>
<td><strong>21</strong> per 1000</td>
<td>Very Low</td>
<td>There were too few who required invasive mechanical ventilation to determine whether ruxolitinib makes a difference (9 events).</td>
</tr>
<tr>
<td><strong>Septic shock</strong></td>
<td>Odds Ratio 0.19 (CI 95% 0.01 - 4.22) Based on data from 41 patients in 1 studies.</td>
<td><strong>21</strong> per 1000</td>
<td>Very Low</td>
<td>There were too few who experienced septic shock to determine whether ruxolitinib makes a difference (2 events).</td>
</tr>
<tr>
<td><strong>Clinical improvement</strong></td>
<td>Odds Ratio 2 (CI 95% 0.58 - 6.94) Based on data from 41 patients in 1 studies.</td>
<td><strong>21</strong> per 1000</td>
<td>Very Low</td>
<td>We are uncertain whether ruxolitinib improves or worsens clinical improvement (21 events).</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>Odds Ratio 1.35 (CI 95% 0.36 - 5.04) Based on data from 41</td>
<td><strong>21</strong> per 1000</td>
<td>Very Low</td>
<td>We are uncertain whether ruxolitinib increases or decreases</td>
</tr>
<tr>
<td>Clinical outcome</td>
<td>Study details</td>
<td>Risk of bias</td>
<td>Imprecision</td>
<td>Conclusion</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>Odds Ratio 0.09 (CI 95% 0 - 1.89) Based on data from 41 patients in 1 studies.</td>
<td>Serious</td>
<td>Very Serious</td>
<td>Due to serious risk of bias and very serious imprecision</td>
</tr>
<tr>
<td><strong>Clinical deterioration</strong></td>
<td>Odds Ratio 0.09 (CI 95% 0 - 1.89) Based on data from 41 patients in 1 studies.</td>
<td>Serious</td>
<td>Very Serious</td>
<td>Due to serious risk of bias and very serious imprecision</td>
</tr>
<tr>
<td><strong>Time to improvement</strong></td>
<td>Lower better (Median)</td>
<td>Very Low (Median)</td>
<td>Very Low</td>
<td>Due to serious risk of bias and very serious imprecision</td>
</tr>
<tr>
<td><strong>Time to discharge</strong></td>
<td>Lower better (Median)</td>
<td>Very Low (Median)</td>
<td>Very Low</td>
<td>Due to serious risk of bias and very serious imprecision</td>
</tr>
</tbody>
</table>

2. **Imprecision**: Very Serious. Low number of patients, Only data from one study.
4. **Risk of bias**: Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision**: Very Serious. Low number of patients, Only data from one study.
6. **Risk of bias**: Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision**: Very Serious. Low number of patients, Only data from one study.
intervention.
8. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.
10. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.
12. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.
14. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.
15. Systematic review with included studies: [168]. **Baseline/comparator:** Control arm of reference used for intervention.
16. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.
17. Systematic review with included studies: [168]. **Baseline/comparator:** Control arm of reference used for intervention.
18. **Risk of bias: Serious.** Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.  
**Imprecision: Very Serious.** Low number of patients. Only data from one study.

### Clinical Question/ PICO

**Population:** Special populations with COVID-19  
**Intervention:** Ruxolitinib  
**Comparator:** Placebo

### Summary

We are uncertain if ruxolitinib is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**  
Evidence comes from a single randomised trial that compared ruxolitinib with placebo (vitamin C) in 41 adults hospitalised with severe COVID-19 [168].

**Study characteristics**  
Median age was 63 years in the ruxolitinib group and 64 years in the control group; the proportion of women was 40% and 43% respectively. Pregnant and breastfeeding women were ineligible.

**What are the main results?**  
For the critical outcomes, there were too few events (three deaths, nine who required invasive mechanical ventilation and two who experienced septic shock) to determine whether ruxolitinib makes a difference. We are uncertain whether ruxolitinib increases or decreases the likelihood of clinical improvement, time to discharge from hospital or adverse events. Four patients in the control group experienced serious adverse events.

**Our confidence in the results**  
Certainty of the evidence is very low for all outcomes. This judgement is based on serious risk of bias (unblinded...
outcome assessors), serious indirectness (limited inclusion or absence of these populations) and very serious imprecision (low patient numbers, few observed events and reliance on a single study). Mortality was not downgraded for risk of bias as this outcome is unlikely to be affected by lack of blinding.

Additional information
The Therapeutic Goods Administration highlights several potential side effects associated with ruxolitinib, including thrombocytopenia and other haematological adverse reactions, and increased incidence of bacterial and other infections. Cases of progressive multifocal leukoencephalopathy and non-melanoma skin cancer have also been reported in patients treated with ruxolitinib [167].

Children and adolescents
There is insufficient safety data on the use of ruxolitinib in children and adolescents for other indications.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality (Day 28)</strong> Within 28 days of commencing treatment</td>
<td>Odds Ratio 0.13 (CI 95% 0.01 - 2.67) Based on data from 41 patients in 1 studies.</td>
<td><strong>Odds Ratio 0.13</strong> (CI 95% 0.01 - 2.67)</td>
<td>Very Low Due to serious indirectness and very serious imprecision</td>
<td>There were too few who died to determine whether ruxolitinib makes a difference (3 events).</td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong> Within 28 days of commencing treatment</td>
<td>Odds Ratio 0.22 (CI 95% 0.04 - 1.24) Based on data from 41 patients in 1 studies.</td>
<td><strong>Odds Ratio 0.22</strong> (CI 95% 0.04 - 1.24)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision</td>
<td>There were too few who required invasive mechanical ventilation to determine whether ruxolitinib makes a difference (9 events).</td>
</tr>
<tr>
<td><strong>Septic shock</strong> Within 28 days of commencing treatment</td>
<td>Odds Ratio 0.19 (CI 95% 0.01 - 4.22) Based on data from 41 patients in 1 studies.</td>
<td><strong>Odds Ratio 0.19</strong> (CI 95% 0.01 - 4.22)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision</td>
<td>There were too few who experienced septic shock to determine whether ruxolitinib makes a difference (2 events).</td>
</tr>
<tr>
<td><strong>Clinical improvement</strong> At day 14 of treatment</td>
<td>Odds Ratio 2 (CI 95% 0.58 - 6.94) Based on data from 41 patients in 1 studies.</td>
<td><strong>Odds Ratio 2</strong> (CI 95% 0.58 - 6.94)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision</td>
<td>We are uncertain whether ruxolitinib improves or worsens clinical improvement (21 events).</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Odds Ratio 1.35 (CI 95% 0.36 - 5.04) Based on data from 41 patients in 1 studies. [9] (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision [10]</td>
<td>We are uncertain whether ruxolitinib increases or decreases adverse events (13 events).</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>Odds Ratio 0.09 (CI 95% 0 - 1.89) Based on data from 41 patients in 1 studies. [11] (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision [12]</td>
<td>There were too few who experienced serious adverse events to determine whether ruxolitinib makes a difference (4 events).</td>
<td></td>
</tr>
<tr>
<td>Clinical deterioration</td>
<td>Odds Ratio 0.09 (CI 95% 0 - 1.89) Based on data from 41 patients in 1 studies. [13] (Randomized controlled)</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision [14]</td>
<td>We are uncertain whether ruxolitinib improves or worsens clinical deterioration (4 events).</td>
<td></td>
</tr>
<tr>
<td>Time to improvement Median days to improvement</td>
<td>Lower better [15] (Randomized controlled)</td>
<td>15 (Median) CI 95%</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision [16]</td>
<td>We are uncertain whether ruxolitinib decreases time to improvement.</td>
</tr>
<tr>
<td>Time to discharge Median days to discharge</td>
<td>Lower better [17] (Randomized controlled)</td>
<td>16 (Median) CI 95%</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious imprecision [18]</td>
<td>We are uncertain whether ruxolitinib increases or decreases time to discharge.</td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
4. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.
6.6.21 - Sofosbuvir-daclatasvir

**Not recommended**

Do not use sofosbuvir-daclatasvir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Sofosbuvir-daclatasvir should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use sofosbuvir plus daclatasvir to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**

In addition to uncertainty around benefits for patients with COVID-19, there are well-known side effects and harms associated with sofosbuvir, including fatigue, insomnia, anaemia and irritability, and with daclatasvir, including fatigue, diarrhoea, nausea and headache.

**Certainty of the Evidence**

**Low**
Rationale

General adult population
There is currently limited evidence about the impact of sofosbuvir-daclatasvir on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that sofosbuvir-daclatasvir should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of combination sofosbuvir-daclatasvir to treat COVID-19 in these populations should be avoided until evidence becomes available.

Preference and values

General adult population
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Certainty of the evidence is low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers and reliance on a single study (clinical recovery and time to clinical recovery) and few events (all-cause mortality and patients requiring mechanical ventilation).

Substantial variability is expected or uncertain

Preference and values

General adult population
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Important issues, or potential issues not investigated

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Important issues, or potential issues not investigated

Acceptability

General adult population
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

Important issues, or potential issues not investigated

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Important issues, or potential issues not investigated

Rationale

General adult population
There is currently limited evidence about the impact of sofosbuvir-daclatasvir on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that sofosbuvir-daclatasvir should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of combination sofosbuvir-daclatasvir to treat COVID-19 in these populations should be avoided until evidence becomes available.
Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: Sofosbuvir + daclatasvir
Comparator: Standard care

Summary
There remains significant uncertainty whether combination sofosbuvir + daclatasvir is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from a single randomised trial that compared combination sofosbuvir + daclatasvir with standard care in 66 adults hospitalised with moderate or severe COVID-19 [169].

Study characteristics
Median age was 58 years in the sofosbuvir + daclatasvir group and 62 in the control group; the proportion of women was 39% and 58% respectively. A similar proportion of patients received concomitant corticosteroid and antibiotic treatment, however, more patients received lopinavir-ritonavir in the control group (64%) compared to the sofosbuvir + daclatasvir group (33%). Pregnant and breastfeeding women were ineligible.

What are the main results?
For the critical outcomes of death and invasive mechanical ventilation, there were too few events (eight deaths and 10 who required ventilation) to determine whether combination sofosbuvir + daclatasvir makes a difference. It is unclear whether combination sofosbuvir + daclatasvir improves the rate of clinical recovery at day 14, although preliminary evidence suggests it may decrease time to clinical recovery. No data were reported for adverse or serious adverse events.

Our confidence in the results
Certainty of the evidence is low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers and reliance on a single study (clinical recovery) and few events (all-cause mortality and invasive mechanical ventilation).

Additional information
According to the Therapeutic Goods Administration, known acute harms for sofosbuvir include fatigue, insomnia, anaemia and irritability [170], and known acute harms for daclatasvir include fatigue, diarrhoea, nausea and headache. There are several known and potential interactions with other drugs [171].

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Relative risk 0.6 (CI 95% 0.16 - 2.31) Based on data from 66 patients in 1 studies. (Randomized controlled)</td>
<td>152 per 1000 91 per 1000</td>
<td>Low DUE TO VERY SERIOUS IMPRECISION 2</td>
<td>There were too few who died to determine whether sofosbuvir + daclatasvir makes a difference (8 events).</td>
</tr>
<tr>
<td>Within 14 days after commencing treatment</td>
<td>Difference: 61 fewer per 1000 (CI 95% 128 fewer - 199 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive mechanical</td>
<td>Relative risk 0.43 (CI 95% 0.12 - 1.52)</td>
<td>212 91</td>
<td>Low</td>
<td>There were too few who required invasive</td>
</tr>
<tr>
<td>Event</td>
<td>Time Frame</td>
<td>Baseline/Comparator</td>
<td>Outcome</td>
<td>Imprecision</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Mechanical ventilation</strong></td>
<td>Within 14 days</td>
<td>Control arm</td>
<td>per 1000 per 1000</td>
<td>121 fewer per 1000 (CI 95% 187 fewer - 110 more)</td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>Within 14 days</td>
<td>Control arm</td>
<td>per 1000</td>
<td>667 fewer per 1000 (CI 95% 0 fewer - 487 more)</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>Within 14 days</td>
<td>Control arm</td>
<td>per 1000</td>
<td>880 fewer per 1000</td>
</tr>
<tr>
<td><strong>Clinical recovery</strong></td>
<td>Within 14 days</td>
<td>Control arm</td>
<td>per 1000</td>
<td>11 (Median) CI 95%</td>
</tr>
<tr>
<td><strong>Time to clinical recovery</strong></td>
<td>Days</td>
<td>Control arm</td>
<td>CI 95%</td>
<td>6 (Median)</td>
</tr>
</tbody>
</table>

2. **Imprecision: Very Serious**. Low number of patients, Only data from one study, due to few events.
4. **Imprecision: Very Serious**. Low number of patients, Only data from one study, due to few events.
5. Systematic review [172]. **Baseline/comparator**: Control arm of reference used for intervention.
Clinical Question/ PICO

Population: Special populations with COVID-19
Intervention: Sofosbuvir + daclatasvir
Comparator: Standard care

Summary

There remains significant uncertainty whether combination sofosbuvir + daclatasvir is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from a single randomised trial that compared combination sofosbuvir + daclatasvir with standard care in 66 adults hospitalised with moderate or severe COVID-19 [169].

Study characteristics

Median age was 58 years in the sofosbuvir + daclatasvir group and 62 in the control group; the proportion of women was 39% and 58% respectively. Pregnant and breastfeeding women were ineligible. A similar proportion of patients received concomitant corticosteroid and antibiotic treatment, however, more patients received lopinavir-ritonavir in the control group (64%) compared to the sofosbuvir + daclatasvir group (33%).

What are the main results?

For the critical outcomes of death and invasive mechanical ventilation, there were too few events (eight deaths and 10 who required ventilation) to determine whether combination sofosbuvir + daclatasvir makes a difference. It is unclear whether combination sofosbuvir + daclatasvir improves the rate of clinical recovery at day 14, although preliminary evidence suggests it may decrease time to clinical recovery. No data were reported for adverse or serious adverse events.

Our confidence in the results

Certainty of the evidence is very low for all outcomes. This judgement is based on very serious imprecision (low patient numbers, few events and reliance on a single study) and serious indirectness (limited inclusion of these populations).

Additional information

According to the Therapeutic Goods Administration, known acute harms for sofosbuvir include fatigue, insomnia, anaemia and irritability [170], and known acute harms for daclatasvir include fatigue, diarrhoea, nausea and headache. There are several known and potential interactions with other drugs [171].
<table>
<thead>
<tr>
<th>All-cause mortality</th>
<th>Relative risk 0.6 (CI 95% 0.16 - 2.31)</th>
<th>Very Low</th>
<th>Due to very serious imprecision and serious indirectness</th>
<th>There were too few who died to determine whether sofosbuvir + daclatasvir makes a difference (8 events).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 14 days after commencing treatment</td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invasive mechanical ventilation</th>
<th>Relative risk 0.43 (CI 95% 0.12 - 1.52)</th>
<th>Very Low</th>
<th>Due to very serious imprecision and serious indirectness</th>
<th>There were too few who required invasive mechanical ventilation to determine whether sofosbuvir + daclatasvir makes a difference (10 events).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 14 days after commencing treatment</td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adverse events</th>
<th></th>
<th></th>
<th>No studies were found that looked at adverse events.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 14 days after commencing treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serious adverse events</th>
<th></th>
<th></th>
<th>No studies were found that looked at serious adverse events.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 14 days after commencing treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical recovery</th>
<th>Relative risk 1.32 (CI 95% 1 - 1.73)</th>
<th>Very Low</th>
<th>Due to very serious imprecision and serious indirectness</th>
<th>We are uncertain whether sofosbuvir + daclatasvir increases clinical recovery at day 14 (51 events).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within 14 days after commencing treatment</td>
<td>Based on data from 66 patients in 1 studies.</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to clinical recovery</th>
<th>Based on data from:</th>
<th>Very Low</th>
<th>Due to very serious</th>
<th>We are uncertain whether sofosbuvir + daclatasvir decreases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Randomized controlled; 2. Very Low; 3. Very Low; 4. Very Low; 5. 6 Important; 6. 6 Important; 7. 6 Important; 8. 8 Important; 9. Very Low; 10. Very Low; 11. (Median)
6.6.22 - Telmisartan

<table>
<thead>
<tr>
<th>6 Important</th>
<th>66 patients in 1 studies, 10 (Randomized controlled)</th>
<th>CI 95%</th>
<th>imprecision and serious indirectness</th>
<th>time to clinical recovery</th>
</tr>
</thead>
</table>

2. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study, due to few events.
4. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.
5. Systematic review [172]. **Baseline/comparator**: Control arm of reference used for intervention.
7. Defined as normalisation of fever (/= 94% without supplementary oxygen therapy sustained for at least 24 hours.
9. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.
10. Systematic review [172]. **Baseline/comparator**: Control arm of reference used for intervention.
11. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.

**Not recommended**

Do not use telmisartan for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

**Telmisartan should still be considered for other evidence-based indications in people who have COVID-19.**

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use telmisartan to treat COVID-19 in these populations unless they are eligible to be enrolled in trials.

**Evidence To Decision**

**Benefits and harms**

**General adult population**
Although there are no significant harms associated with telmisartan, there is uncertainty around the benefits and harms for patients with COVID-19.

**Certainty of the Evidence**

**General adult population**
Certainty of the evidence is low for all outcomes due to serious imprecision (low patient numbers and the reliance on a
Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

<table>
<thead>
<tr>
<th>Preference and values</th>
<th>Substantial variability is expected or uncertain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td></td>
</tr>
<tr>
<td>We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.</td>
<td></td>
</tr>
<tr>
<td>The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td></td>
</tr>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population</strong></td>
<td></td>
</tr>
<tr>
<td>There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.</td>
<td></td>
</tr>
<tr>
<td><strong>Children and adolescents, pregnant and breastfeeding women</strong></td>
<td></td>
</tr>
<tr>
<td>Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.</td>
<td></td>
</tr>
<tr>
<td><strong>People requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
<td></td>
</tr>
<tr>
<td>As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General adult population, children and adolescents, pregnant and breastfeeding women</strong></td>
<td></td>
</tr>
<tr>
<td>Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.</td>
<td></td>
</tr>
<tr>
<td><strong>People requiring palliative care and older people living with frailty or cognitive impairment</strong></td>
<td></td>
</tr>
<tr>
<td>Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.</td>
<td></td>
</tr>
</tbody>
</table>
Rationale

**General adult population**
There is currently limited evidence about the impact of telmisartan on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that telmisartan should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of telmisartan for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Telmisartan</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

Summary

There remains significant uncertainty whether telmisartan is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**
Evidence comes from a single randomised trial that compared telmisartan with standard care in 78 adults hospitalised with confirmed COVID-19 [173].

**Publication status**
The study is only available as a preprint paper (posted to medRxiv on 11 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

**Study characteristics**
Median age was 60 years in the telmisartan group and 64 years in the control group; the proportion of women was 33% and 45% respectively. Pregnant and breastfeeding women were ineligible.

**What are the main results?**
For the outcomes of death, invasive mechanical ventilation and admission to intensive care, there were too few events (six deaths, four who required invasive ventilation and nine who were admitted to ICU) to determine whether telmisartan makes a difference. Telmisartan may increase the likelihood of patients being discharged from hospital and may reduce the time to discharge. No adverse events related to telmisartan were reported.

**Our confidence in the results**
Certainty of the evidence is low for all outcomes due to very serious imprecision (low patient numbers and reliance on a single study).

**Additional information**
According to the Therapeutic Goods Administration, common adverse effects related to telmisartan use include pain, fatigue, headache and upper respiratory tract infections. However, the incidence of these adverse effects was equivalent in patients receiving placebo [174].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care</td>
<td>Telmisartan</td>
<td></td>
</tr>
</tbody>
</table>
### All-cause mortality

**15 days after commencing treatment**

- **Relative risk**: 0.95 (CI 95% 0.14 - 6.41)
- **Number of patients**: 78
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>0.95</td>
<td>0.14 - 6.41</td>
<td>3 fewer (CI 95% 46 fewer - 287 more)</td>
</tr>
</tbody>
</table>

**Critical**

- Low due to very serious imprecision

- There were too few who had died by day 15 to determine whether telmisartan makes a difference (4 events).

### All-cause mortality

**30 days after commencing treatment**

- **Relative risk**: 0.48 (CI 95% 0.09 - 2.44)
- **Number of patients**: 78
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>0.48</td>
<td>0.09 - 2.44</td>
<td>55 fewer (CI 95% 96 fewer - 151 more)</td>
</tr>
</tbody>
</table>

**Critical**

- Low due to very serious imprecision

- There were too few who had died by day 30 to determine whether telmisartan makes a difference (6 events).

### Invasive mechanical ventilation

**15 days after commencing treatment**

- **Relative risk**: 0.32 (CI 95% 0.03 - 2.91)
- **Number of patients**: 78
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive mechanical ventilation</td>
<td>0.32</td>
<td>0.03 - 2.91</td>
<td>54 fewer (CI 95% 77 fewer - 151 more)</td>
</tr>
</tbody>
</table>

**Critical**

- Low due to very serious imprecision

- There were too few who required invasive mechanical ventilation at day 15 to determine whether telmisartan makes a difference (4 events).

### Invasive mechanical ventilation

**30 days after commencing treatment**

- **Relative risk**: 0.32 (CI 95% 0.03 - 2.91)
- **Number of patients**: 78
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive mechanical ventilation</td>
<td>0.32</td>
<td>0.03 - 2.91</td>
<td>54 fewer (CI 95% 77 fewer - 151 more)</td>
</tr>
</tbody>
</table>

**Critical**

- Low due to very serious imprecision

- There were too few who required invasive mechanical ventilation at day 30 to determine whether telmisartan makes a difference (4 events).

### ICU admission

**30 days after commencing treatment**

- **Relative risk**: 0.76 (CI 95% 0.22 - 2.62)
- **Number of patients**: 78
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICU admission</td>
<td>0.76</td>
<td>0.22 - 2.62</td>
<td>32 fewer (CI 95% 103 fewer - 214 more)</td>
</tr>
</tbody>
</table>

**Important**

- Low due to very serious imprecision

- There were too few who were admitted to intensive care to determine whether telmisartan makes a difference (9 events).

### Discharge from hospital

**15 days after commencing treatment**

- **Relative risk**: 1.43 (CI 95% 1.01 - 2.02)
- **Number of patients**: 68
- **Study type**: Randomized controlled

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Difference (per 1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge from hospital</td>
<td>1.43</td>
<td>1.01 - 2.02</td>
<td>242 more (CI 95% 6 more - 574 more)</td>
</tr>
</tbody>
</table>

**Important**

- Low due to very serious imprecision

- Telmisartan may increase discharge from hospital (47 events).
2. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
4. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
6. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
8. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
10. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
12. **Imprecision:** Very Serious. Low number of patients, Only data from one study.
13. Systematic review [175]. **Baseline/comparator:** Control arm of reference used for intervention.
14. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

---

**Clinical Question/ PICO**

- **Population:** Special populations with COVID-19
- **Intervention:** Telmisartan
- **Comparator:** Standard care

---

**Summary**

There remains significant uncertainty whether telmisartan is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**

Evidence comes from a single randomised trial that compared telmisartan with standard care in 78 adults hospitalised with confirmed COVID-19 [173].

**Publication status**

The study is only available as a preprint paper (posted to medRxiv on 11 August 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

**Study characteristics**
Median age was 60 years in the telmisartan group and 64 years in the control group; the proportion of women was 33% and 45% respectively. Pregnant and breastfeeding women were ineligible.

**What are the main results?**

For the outcomes of death, invasive mechanical ventilation and admission to intensive care, there were too few events (six deaths, four who required invasive ventilation and nine who were admitted to ICU) to determine whether telmisartan makes a difference. Telmisartan may increase the likelihood of patients being discharged from hospital and may reduce the time to discharge. No adverse events related to telmisartan were reported.

**Our confidence in the results**

Certainty of the evidence is very low for all outcomes due to very serious imprecision (low patient numbers and reliance on a single study) and serious indirectness (limited inclusion of these populations).

**Additional information**

According to the Therapeutic Goods Administration, common adverse effects related to telmisartan use include pain, fatigue, headache and upper respiratory tract infections. However, the incidence of these adverse effects was equivalent in patients receiving placebo [174].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong> 15 days after commencing treatment</td>
<td>Relative risk 0.95 (CI 95% 0.14 - 6.41) Based on data from 78 patients in 1 studies. ¹ (Randomized controlled)</td>
<td><strong>53</strong> per 1000 50 per 1000</td>
<td>Very Low Due to very serious imprecision and serious indirectness</td>
<td>There were too few who had died by day 15 to determine whether telmisartan makes a difference (4 events).</td>
</tr>
<tr>
<td><strong>All-cause mortality</strong> 30 days after commencing treatment</td>
<td>Relative risk 0.48 (CI 95% 0.09 - 2.44) Based on data from 78 patients in 1 studies. ³ (Randomized controlled)</td>
<td>79 per 1000 25 per 1000</td>
<td>Very Low Due to very serious imprecision and serious indirectness</td>
<td>There were too few who had died by day 30 to determine whether telmisartan makes a difference (6 events).</td>
</tr>
<tr>
<td><strong>Mechanical ventilation</strong> 15 days after commencing treatment</td>
<td>Relative risk 0.32 (CI 95% 0.03 - 2.91) Based on data from 78 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td><strong>54</strong> fewer per 1000 (CI 95% 46 fewer - 287 more)</td>
<td>Very Low Due to very serious imprecision and serious indirectness</td>
<td>There were too few who required mechanical ventilation at day 15 to determine whether telmisartan makes a difference (4 events).</td>
</tr>
<tr>
<td><strong>Mechanical ventilation</strong> 30 days after</td>
<td>Relative risk 0.32 (CI 95% 0.03 - 2.91) Based on data from 78</td>
<td>54 fewer per 1000 (CI 95% 77 fewer - 151 more)</td>
<td>Very Low Due to very serious</td>
<td>There were too few who required mechanical ventilation at day 30 to determine whether telmisartan makes a difference (6 events).</td>
</tr>
</tbody>
</table>

² 10% uncertainty range. ³ 10% uncertainty range. ⁵ 10% uncertainty range.

2. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.


4. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.


6. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.


8. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.


10. **Indirectness**: Serious. Differences between the population of interest and those studied. **Imprecision**: Very Serious. Low number of patients, Only data from one study.


---

### ICU admission 30 days after commencing treatment

- **Relative risk**: 0.76 (C.I. 95% 0.22 - 2.62)
- Based on data from 78 patients in 1 studies.
- **Imprecision and serious indirectness**:
- at day 30 to determine whether telmisartan makes a difference (4 events).

### Discharge from hospital 15 days after commencing treatment

- **Relative risk**: 1.43 (C.I. 95% 1.01 - 2.02)
- Based on data from 68 patients in 1 studies.
- **Imprecision and serious indirectness**:
- We are uncertain whether telmisartan may increase discharge from hospital (47 events).

### Time to discharge from hospital Days

- Based on data from: 78 patients in 1 studies.
- **Imprecision and serious indirectness**: We are uncertain whether telmisartan decreases time to discharge from hospital.

### Important

- Relative risk: 0.76 (CI 95% 0.22 - 2.62)
- Based on data from 78 patients in 1 studies.
- Relative risk: 1.43 (CI 95% 1.01 - 2.02)
- Based on data from 68 patients in 1 studies.
- Relative risk: 1.43 (CI 95% 1.01 - 2.02)
- Based on data from 68 patients in 1 studies.
6.6.23 - Tocilizumab

Not recommended

Do not use tocilizumab for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Tocilizumab should still be considered for other evidence-based indications in people who have COVID-19.

This recommendation does not apply to the use of tocilizumab in children and adolescents when managing paediatric inflammatory multisystem syndrome (PIMS-TS), Kawasaki disease or toxic shock syndrome related to COVID-19. The Taskforce is currently developing recommendations for the management of these conditions in children and adolescents with COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use tocilizumab for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

Evidence To Decision

Benefits and harms

General adult population
In addition to uncertainty around benefits for patients with COVID-19, there are common side effects and harms associated with tocilizumab use, including headache, dizziness, infections and injection site reactions [181].

Children and adolescents
The safety profile in children and adolescents with COVID-19 has not been established.

Pregnant and breastfeeding women
According to the Therapeutic Goods Administration, tocilizumab should not be used during pregnancy unless clearly necessary. It is unknown whether tocilizumab is excreted in human breast milk, and its efficacy and safety in lactating women has not been established.

Certainty of the Evidence

General adult population
Certainty of the evidence is moderate for mortality, patients requiring mechanical ventilation or admission to ICU, and adverse and serious adverse events. Each of these outcomes was downgraded for serious imprecision due to wide confidence intervals. Certainty for all remaining outcomes is low due to very serious imprecision (reliance on a single study).

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.
Rationale

General adult population
There is currently limited evidence about the impact of tocilizumab on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that tocilizumab should only be used to treat COVID-19 in the context of randomised trials with appropriate

Preference and values

General adult population
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of tocilizumab during pregnancy and breastfeeding are unknown in the context of COVID-19.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women
We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale

General adult population
There is currently limited evidence about the impact of tocilizumab on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that tocilizumab should only be used to treat COVID-19 in the context of randomised trials with appropriate
ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of tocilizumab for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Tocilizumab</td>
</tr>
<tr>
<td>Comparator</td>
<td>Standard care</td>
</tr>
</tbody>
</table>

Summary

There remains significant uncertainty whether tocilizumab is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?

Evidence comes from four randomised trials that compared tocilizumab with either placebo [179][186] or standard care [180][185] in 875 adults hospitalised with moderate to severe COVID-19.

We have found two new studies comparing tocilizumab with placebo (Salama et al. medRxiv doi: 10.1101/2020.10.21.20210203) and tocilizumab with standard care (Salvarani et al. JAMA Intern Med doi: jamantermed.2020.6615). These studies are currently under review and an updated recommendation will be included in a future version of the guideline.

Publication status

The study by Rosas et al is only available as a preprint paper (posted to medRxiv on 12 September 2020) and has therefore not been peer reviewed [179]. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study’s publication status.

Study characteristics

Mean or median age ranged from 60 to 64 years and women comprised 30 to 50% of patients across the studies. Pregnant and breastfeeding women were ineligible. Studies included patients with moderate COVID-19 (242 patients) [186], moderate to critical COVID-19 (438 patients) [179] and moderate to severe COVID-19 (195 patients) [180][185].

What are the main results?

Tocilizumab probably has little impact on death, adverse events or serious adverse events. Tocilizumab probably decreases slightly the number of patients who require invasive mechanical ventilation (60 fewer per 1000 patients; RR 0.75 CI 95% 0.54 to 1.04; 515 patients in 2 studies) and may decrease the number of patients who require admission to ICU (137 fewer per 1000 patients; RR 0.65 CI 95% 0.48 to 0.87; 397 patients in 2 studies). The effect of tocilizumab on other outcomes is uncertain.

Our confidence in the results

Certainty of the evidence is moderate for mortality, patients requiring invasive mechanical ventilation or admission to ICU, and adverse or serious adverse events. Each of these outcomes was downgraded for serious imprecision due to wide confidence intervals. Certainty for all remaining outcomes is low due to very serious imprecision (reliance on a single study).

For children & adolescents and pregnant & breastfeeding women, certainty is also downgraded for serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information

According to the Therapeutic Goods Administration, common adverse effects related to tocilizumab are generally mild and include headache, dizziness, infections and injection site reactions [181].
Children and adolescents
According to the Therapeutic Goods Administration, the safety and efficacy of intravenous tocilizumab in children under 18 years of age with conditions other than polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) or cytokine release syndrome (CRS) have not been established. The use of tocilizumab in children under two years of age has not been studied.

Pregnant and breastfeeding women
According to the Therapeutic Goods Administration, tocilizumab should not be used during pregnancy unless clearly necessary. There are no adequate data from the use of tocilizumab in pregnant women. The potential risk for humans is unknown. Women of childbearing potential should be advised to use adequate contraception during and for several months after therapy with tocilizumab. It is unknown whether tocilizumab is excreted in human breast milk, and its efficacy and safety in lactating women has not been established.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 1.03 (CI 95% 0.72 - 1.48) Based on data from 810 patients in 3 studies.</td>
<td>134 per 1000</td>
<td>Moderate Due to serious imprecision</td>
<td>Tocilizumab probably has little impact on death (113 events).</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td>138 per 1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Difference: 4 more per 1000 (CI 95% 38 fewer - 64 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong> End of follow-up</td>
<td>Relative risk 0.75 (CI 95% 0.54 - 1.04) Based on data from 515 patients in 2 studies.</td>
<td>240 per 1000</td>
<td>Moderate Due to serious imprecision</td>
<td>Tocilizumab probably decreases slightly the requirement for invasive mechanical ventilation.</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td>180 per 1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Difference: 60 fewer per 1000 (CI 95% 110 fewer - 10 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All-cause mortality or invasive mechanical ventilation (composite)</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 0.86 (CI 95% 0.41 - 1.78) Based on data from 242 patients in 1 studies.</td>
<td>123 per 1000</td>
<td>Low Due to very serious imprecision</td>
<td>We are uncertain whether tocilizumab increases or decreases the composite outcome of all-cause mortality or invasive mechanical ventilation (27 events).</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td>106 per 1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Difference: 17 fewer per 1000 (CI 95% 73 fewer - 96 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory failure or ARDS</strong> Within 14 days</td>
<td>Relative risk 0.5 (CI 95% 0.25 - 1.03) Based on data from 130 patients in 1 study.</td>
<td>284 per 1000</td>
<td>Low Due to very serious imprecision</td>
<td>We are uncertain whether tocilizumab increases or decreases respiratory failure or</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td>142 per 1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Critical studies.

#### ARDS (28 events).

**SERIOUS adverse events**

<table>
<thead>
<tr>
<th>Event</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
<th>Relative Risk</th>
<th>Based on data</th>
<th>Difference:</th>
<th>CI 95%</th>
<th>Important</th>
</tr>
</thead>
<tbody>
<tr>
<td>of commencing treatment</td>
<td>9 Critical</td>
<td>studies. 9</td>
<td>142 fewer</td>
<td>9 more</td>
<td>Moderate</td>
<td>322 per 1000</td>
<td>283 per 1000</td>
<td>39 fewer</td>
<td>23 more</td>
<td>Moderate</td>
<td>529 per 1000</td>
<td>524 per 1000</td>
<td>5 fewer</td>
<td>53 more</td>
<td>Moderate</td>
<td>49 per 1000</td>
<td>24 per 1000</td>
<td>25 fewer</td>
<td>18 more</td>
<td>Moderate</td>
<td>390 per 1000</td>
<td>253 per 1000</td>
<td>137 fewer</td>
<td>51 more</td>
<td>Moderate</td>
<td>804 per 1000</td>
<td>852 per 1000</td>
<td>48 more</td>
<td>129 more</td>
<td>Moderate</td>
</tr>
<tr>
<td>End of follow-up</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of follow-up</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Septic shock</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 21 days of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>commencing treatment</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Admission to ICU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of follow-up</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge from ICU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 14 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of commencing treatment</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical recovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of follow-up</td>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ARDS: Acute Respiratory Distress Syndrome. ICU: Intensive Care Unit.

**Tocilizumab probably has little impact on serious adverse events.**
<table>
<thead>
<tr>
<th>Clinical improvement</th>
<th>Relative risk 1.03 (C.I 0.94 - 1.12) Based on data from 242 patients in 1 studies.</th>
<th>889 per 1000</th>
<th>916 per 1000</th>
<th>Low Due to very serious imprecision</th>
<th>We are uncertain whether tocilizumab increases or decreases clinical improvement.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical progression</td>
<td>Relative risk 1.11 (C.I 0.63 - 1.97) Based on data from 242 patients in 1 studies.</td>
<td>173 per 1000</td>
<td>192 per 1000</td>
<td>Low Due to very serious imprecision</td>
<td>We are uncertain whether tocilizumab increases or decreases clinical progression</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to deterioration</td>
<td>Hazard Ratio 1.11 (C.I 0.59 - 2.1) Based on data from 45 patients in 1 studies.</td>
<td></td>
<td></td>
<td>Low Due to very serious imprecision</td>
<td>We are uncertain whether tocilizumab increases or decreases time to discharge.</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to improvement</td>
<td>Based on data from: 219 patients in 1 studies.</td>
<td>5 (Median)</td>
<td>6 (Median)</td>
<td>Low Due to very serious imprecision</td>
<td>We are uncertain whether tocilizumab increases or decreases time to improvement.</td>
</tr>
<tr>
<td></td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Imprecision:** Serious. Wide confidence intervals.
4. **Imprecision:** Serious. Wide confidence intervals.
6. **Imprecision:** Very Serious. Low number of patients, Only data from one study, Wide confidence intervals.
8. **Imprecision:** Very Serious. Wide confidence intervals, Low number of patients, Only data from one study.

10. **Imprecision:** Serious. Wide confidence intervals.


12. **Imprecision:** Serious. Wide confidence intervals.


14. **Imprecision:** Very Serious. Wide confidence intervals, Only data from one study, due to few events.


16. **Imprecision:** Very Serious. Wide confidence intervals.


18. **Imprecision:** Very Serious. Wide confidence intervals, due to two underpowered studies.


20. **Imprecision:** Very Serious. Wide confidence intervals, Low number of patients, Only data from one study.


22. **Imprecision:** Very Serious. Wide confidence intervals, Only data from one study, Low number of patients.


24. **Imprecision:** Very Serious. Wide confidence intervals, Low number of patients, Only data from one study.

25. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

26. Systematic review [184]. **Baseline/comparator:** Control arm of reference used for intervention.

27. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

28. Systematic review [184]. **Baseline/comparator:** Control arm of reference used for intervention.

29. **Imprecision:** Very Serious. Low number of patients, Only data from one study.

---

**6.6.24 - Triazavirin**

**Not recommended**

Do not use triazavirin for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

*Triazavirin should still be considered for other evidence-based indications in people who have COVID-19.*

*Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use triazavirin for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.*

**Evidence To Decision**

**Benefits and harms**

**General adult population**

As the safety profile for triazavirin is incompletely characterised in humans, there is uncertainty around the benefits and
 harms for patients with COVID-19.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There are additional concerns regarding harms as triazavirin has not been sufficiently tested in these populations. For people requiring palliative care, the benefits for symptom management are uncertain.

Certainty of the Evidence

General adult population
Certainty of the evidence is very low for all outcomes due to very serious imprecision (reliance on a single study with low patient numbers and wide confidence intervals) and very serious risk of bias.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is further considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values

General adult population
We have no systematically collected information regarding patients’ preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care. Further, for pregnant and breastfeeding women, the effects of triazavirin during pregnancy and breastfeeding are unknown in the context of COVID-19.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women
We have no systematically collected evidence regarding acceptability. Substantial variability is expected as some patients would accept the treatment and others not.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

---

**Feasibility**

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

---

**Rationale**

**General adult population**
There is currently limited evidence about the impact of triazavirin on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that triazavirin should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of triazavirin for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

---

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Triazavirin</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

---

**Summary**

There remains significant uncertainty whether triazavirin is more effective and safer than standard care in treating patients with COVID-19.

**What is the evidence informing this recommendation?**
Evidence comes from one randomised trial that compared triazavirin with placebo in 52 adults hospitalised with mild, severe or critical COVID-19 [189].

**Study characteristics**
Mean age was 58 years and the proportion of women was 50%. Patients received 250 mg triazavirin three times a day (mild patients) or four times a day (severe or critical patients) for seven days. Pregnant and breastfeeding women were ineligible.

**What are the main results?**
There were too few who died (one death) or suffered adverse or serious adverse events to determine whether triazavirin makes a difference. It is unclear whether triazarivin increases or decreases viral clearance at day 28 or time to clinical improvement.

**Our confidence in the results**
Certainty of the evidence is very low for all outcomes due to very serious risk of bias (trial stopped early, selective outcome reporting) and very serious imprecision (reliance on a single study with low patient numbers and few
For children & adolescents and pregnant & breastfeeding women, certainty is also downgraded for serious indirectness (absence or limited inclusion of these populations in the included studies).

**Additional information**
As the safety profile for triazavirin is incompletely characterised in humans, there is uncertainty around the benefits and harms for patients with COVID-19.

**Pregnant and breastfeeding women**
There are additional concerns regarding harms, as triazavirin has not been sufficiently tested in this population.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All-cause mortality</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 0.33 (CI 95% 0.01 - 7.82) Based on data from 52 patients in 1 studies. ¹ (Randomized controlled)</td>
<td>Placebo</td>
<td>Triazavirin</td>
<td>Very Low Due to very serious risk of bias and very serious imprecision. ² There were too few who died to determine whether triazavirin makes a difference (1 death).</td>
</tr>
<tr>
<td><strong>Invasive mechanical ventilation</strong> Within 28 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td>Data for patients requiring mechanical ventilation were not reported.</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 0.8 (CI 95% 0.24 - 2.65) Based on data from 52 patients in 1 studies. ³ (Randomized controlled)</td>
<td></td>
<td></td>
<td>Very Low Due to very serious risk of bias and very serious imprecision. ⁴ There were too few who experienced one or more serious adverse events to determine whether triazavirin makes a difference (9 events).</td>
</tr>
<tr>
<td><strong>Adverse events</strong> Within 28 days of commencing treatment</td>
<td>Relative risk 0.6 (CI 95% 0.26 - 1.41) Based on data from 52 patients in 1 studies. ⁵ (Randomized controlled)</td>
<td></td>
<td></td>
<td>Very Low Due to very serious risk of bias and very serious imprecision. ⁶ There were too few who experienced one or more adverse events to determine whether triazavirin made a difference (6 events).</td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, stopped without reaching pre-defined stopping criteria., Selective outcome reporting., Selective outcome reporting, due to [reason]. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Selective outcome reporting. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, due to [reason].

   **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Only data from one study, Low number of patients, Wide confidence intervals. 

   **Publication bias:** No serious.


4. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, stopped without reaching pre-defined stopping criteria., Selective outcome reporting., Selective outcome reporting, due to [reason]. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Only data from one study, Low number of patients, Wide confidence intervals.. 

   **Publication bias:** No serious.


6. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, stopped without reaching pre-defined stopping criteria., Selective outcome reporting., Selective outcome reporting, due to [reason]. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Very Serious. Wide confidence intervals, Low number of patients, Only data from one study. 

   **Publication bias:** No serious.


8. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, stopped without reaching pre-defined stopping criteria., Selective outcome reporting., Selective outcome reporting, due to [reason]. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. **Inconsistency:** No serious. **Indirectness:** No serious. **Imprecision:** Serious. Wide confidence intervals, Low number of patients. Only data from one study. 

   **Publication bias:** No serious.

9. Systematic review with included studies: [189]. **Baseline/comparator:** Control arm of reference used for intervention.

10. **Risk of bias:** Very Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, stopped without reaching pre-defined stopping criteria., Selective outcome reporting., Selective outcome reporting, due to [reason].

### Virological clearance (Negative PCR)

<table>
<thead>
<tr>
<th>Within 28 days of commencing treatment</th>
<th>Relative risk 1.14 (CI 95% 0.92 - 1.42) Based on data from 52 patients in 1 studies.</th>
<th>Very Low</th>
<th>Due to very serious risk of bias and very serious imprecision.</th>
<th>We are uncertain whether triazavirin increases virological clearance.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td>(Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Time to improvement

<table>
<thead>
<tr>
<th>Within 28 days of commencing treatment</th>
<th>Lower better 9 (Randomized controlled)</th>
<th>12 Days (Median)</th>
<th>7 Days (Median)</th>
<th>CI 95%</th>
<th>Very Low</th>
<th>Due to very serious risk of bias and very serious imprecision.</th>
<th>We are uncertain whether triazavirin decreases time to improvement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
to [reason], Trials stopping earlier than scheduled, resulting in potential for overestimating benefits. Inconsistency: No serious. Indirectness: No serious. Imprecision: Serious. Wide confidence intervals, Low number of patients, Only data from one study. Publication bias: No serious.

6.6.25 - Umifenovir

Do not use umifenovir for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval.

Umifenovir should still be considered for other evidence-based indications in people who have COVID-19.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use umifenovir for the treatment of COVID-19 in these populations unless they are eligible to be enrolled in trials.

Evidence To Decision

Benefits and harms

General adult population
As the safety profile for umifenovir is incompletely characterised in humans, there is uncertainty around the benefits and harms for patients with COVID-19.

Certainty of the Evidence

Certainty of the evidence is low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers and reliance on a single study (clinical improvement and negative PCR) and few events (adverse events and clinical progression).

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, certainty of the evidence is considered very low because of indirectness due to limited inclusion (or absence) of these populations in the trials.

Preference and values

General adult population
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to opt for the treatment.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

The NC19CET Consumer Panel believes that as there is uncertainty regarding the benefits of this treatment, informed patients may prefer to wait until the available evidence is clearer, while other informed patients may choose to participate in clinical trials of this treatment.
Rationale

General adult population
There is currently limited evidence about the impact of umifenovir on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that umifenovir should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of umifenovir for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

Equity

General adult population
There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
As older people living with frailty or cognitive impairment are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). In people requiring palliative care, trials should consider symptom management and quality of life outcomes. Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population
Although we have no systematically collected evidence regarding acceptability, treatment is probably acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale

General adult population
There is currently limited evidence about the impact of umifenovir on patient-relevant outcomes in the treatment of COVID-19. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that umifenovir should only be used to treat COVID-19 in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of umifenovir for the treatment of COVID-19 in these populations should be avoided until evidence becomes available.

Clinical Question/ PICO

Population: Patients with COVID-19
Intervention: Umifenovir
Comparator: Standard care
Summary
There remains significant uncertainty whether umifenovir is more effective and safer than standard care in treating patients with COVID-19.

What is the evidence informing this recommendation?
Evidence comes from three randomised trials that compared umifenovir with standard care in 135 adults hospitalised with mild or moderate COVID-19 [57][191][193].

Study characteristics
In Li et al mean age was 51 years in the umifenovir group (54% women) and 44 years in the standard care group (59% women). In Yethindra et al mean age was 36 years (40% women)—patients over 60 years were excluded. In Ghaderkhani et al median age was 47 years in the umifenovir group (68% women) and 42 years in the standard care group (52% women). In all three studies, pregnant and breastfeeding women were ineligible.

What are the main results?
No patients died or experienced a serious adverse event in any of the three studies. There were too few patients experiencing an adverse event or clinical deterioration to determine whether umifenovir makes a difference to these outcomes. It is unclear whether umifenovir increases the rate of negative PCR at day 14, however umifenovir may be less effective than standard care alone in facilitating clinical improvement based on chest CT scans at day 14.

Our confidence in the results
Certainty of the evidence is low for all outcomes. This judgement is based on very serious imprecision due to low patient numbers and reliance on a single study (clinical improvement and negative PCR) and few events (adverse events and clinical progression).

For children & adolescents and pregnant & breastfeeding women, certainty is also downgraded for serious indirectness (absence or limited inclusion of these populations in the included studies).

Additional information
As of 21 September 2020, umifenovir (Arbidol) is not listed in the Australian Register of Therapeutic Goods and is not approved for use in Australia. The safety profile for umifenovir is incompletely characterised in humans.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality Within 21 days of commencing treatment</td>
<td>Based on data from 52 patients in 1 studies.</td>
<td></td>
<td>No patients died.</td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>Relative risk 4.18 (CI 95% 0.51 - 34.19)</td>
<td></td>
<td>Low Due to very serious imprecision</td>
<td>There were too few who experienced one or more adverse events to determine whether umifenovir makes a difference (6 events).</td>
</tr>
<tr>
<td>Event</td>
<td>Relative Risk</td>
<td>CI 95%</td>
<td>Difference in Relative Risk</td>
<td>Imprecision</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>----------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 21 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk 0.73</td>
<td>CI 95% 0.13 - 3.96</td>
<td>17 fewer per 1000</td>
<td>Low</td>
</tr>
<tr>
<td>Clinical deterioration (mild/mod to sev/crit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 21 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk 0.75</td>
<td>CI 95% 0.57 - 0.98</td>
<td>232 fewer per 1000</td>
<td>Low</td>
</tr>
<tr>
<td>Clinical improvement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on chest CT scan 14 days after</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk 1.2</td>
<td>CI 95% 0.9 - 1.59</td>
<td>153 more per 1000</td>
<td>Low</td>
</tr>
<tr>
<td>Negative PCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 14 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk 1</td>
<td>CI 95% 0.88 - 1.13</td>
<td>0 fewer per 1000</td>
<td>Low</td>
</tr>
<tr>
<td>Discharge from hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within 21 days of commencing treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk 1</td>
<td>CI 95% 0.88 - 1.13</td>
<td>0 fewer per 1000</td>
<td>Low</td>
</tr>
</tbody>
</table>

3. **Imprecision:** Very Serious. Low number of patients, due to few events.
4. Systematic review [192] with included studies: Li 2020, Yethindra 2020. Baseline/comparator: Control arm of...
6.6.26 - Other disease-modifying treatments

**Consensus recommendation**

For people with COVID-19, do not use other disease-modifying treatments outside of randomised trials with appropriate ethical approval.

*Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use other disease-modifying treatments in these populations unless they are eligible to be enrolled in trials.*

**Evidence To Decision**

**Benefits and harms**

**General adult population**

Currently, there is no direct evidence to inform the potential benefits or harms of other disease-modifying treatments in patients with COVID-19.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There may be additional concerns regarding harms for these populations. For people requiring palliative care, the benefits for symptom management may be uncertain.

**Certainty of the Evidence**

We have no COVID-19 specific randomised trials for other potential disease-modifying treatments.

**Preference and values**

**General adult population**

Substantial variability is expected or uncertain
There is currently limited evidence about the impact of other disease-modifying treatments on patient-relevant outcomes in COVID-19. The panel has significant concerns about the potential harms of unproven treatments.

In line with the ANZICS, ASID, AHPPC and IDSA recommendations [17][19][53][54], we therefore recommend that other disease-modifying treatments not be used in the general adult population, children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment.

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the impact on potentially reducing access to these treatments by patients currently using them for other indications.

Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Implementability is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.
disease-modifying treatments should only be administered in the context of randomised trials with appropriate ethical approval.

**Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment**

There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, use of other disease-modifying treatments in these populations should be avoided until evidence becomes available.

### 6.7 - Disease-modifying treatments under review

We are continually monitoring new research for randomised trials that evaluate any disease-modifying treatments for COVID-19. As each new trial is published, our panels assess and make recommendations on whether the treatment should be used in the clinical care of patients. This section provides details of studies that are currently under review by our panels. Recommendations on whether these treatments should be used in the clinical care of patients will be included in a future update of the guideline.

#### 6.7.1 - Immunoglobulin

We have found one new study comparing immunoglobulin with placebo (Gharebaghi et al. BMC Infect Dis doi: 10.1186/s12879-020-05507-4). This study is currently under review and a recommendation will be included in a future version of the guideline.
7 - Chemoprophylaxis

The primary panel for the recommendations in this section is the Disease-Modifying Treatment and Chemoprophylaxis Panel. Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

7.1 - Hydroxychloroquine for pre-exposure prophylaxis

Evidence To Decision

**Not recommended**
For healthcare workers with no active COVID-19, do not use hydroxychloroquine for pre-exposure prophylaxis outside of randomised trials with appropriate ethical approval.

Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine for pre-exposure prophylaxis in these populations unless they are eligible to be enrolled in trials.

Benefits and harms

**General adult population**
In addition to uncertainty around the benefits for people at high risk of being exposed to individuals with COVID-19, there are well-known harms, with potentially severe adverse events. Although most of the information on side effects and harms is derived from long-term use, potential acute harms include prolonged QT interval and lowered convulsive threshold. Long-term harms include retinopathy and chronic cardiac myopathy, among several others.

There are several known and potential interactions with other drugs. Although overdose of hydroxychloroquine may have potentially fatal complications, this is unlikely when taken at prophylactic doses.

**Children and adolescents**
Paediatricians have considerable experience with hydroxychloroquine in children and adolescents for other indications.

**Pregnant and breastfeeding women**
Hydroxychloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases. Studies of hydroxychloroquine for these indications have shown a favourable safety profile, though further research is needed.

**People requiring palliative care and older people living with frailty or cognitive impairment**
There may be additional concerns regarding harms in these populations.

Certainty of the Evidence

**General adult population**
Certainty of the evidence is low for laboratory-confirmed diagnosis, moderate for adverse events and confirmed or probable infection (due to included studies terminating early), low for serious adverse events and symptoms compatible with COVID-19 (due to studies being terminated early and few events), and very low for discontinuation due to adverse events.

**Children and adolescents, pregnant women, people requiring palliative care and older people living with frailty or cognitive impairment**
Certainty of the evidence was downgraded further for all outcomes due to indirectness, as these special populations were not included in the trials.
Rationale

General adult population
There is currently limited evidence about the impact of hydroxychloroquine for pre-exposure prophylaxis on the prevention of COVID-19 in healthcare workers. The panel has significant concerns regarding the potential harms of unproven treatments. We therefore recommend that hydroxychloroquine for pre-exposure prophylaxis should only be used to prevent COVID-19 infection in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence, there is substantial variability in preferences and values, and the benefit to harm ratio is uncertain. This recommendation protects these more vulnerable populations.

Preference and values

General adult population
We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to take risks.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the potential impact on reduced access to these treatments by patients currently using them for other indications.

Equity

General adult population
We have no systematically collected direct evidence regarding impact on equity. There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
Since these populations are particularly at risk from COVID-19, we encourage trials that include these populations (with appropriate baseline measurement of frailty and cognitive impairment). Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability

General adult population, children and adolescents, pregnant and breastfeeding women
Although we have no systematically collected evidence regarding acceptability, hydroxychloroquine is likely to be acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility

Implementability of the recommendation is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

291 of 418
evidence in the general adult population, use of once-weekly hydroxychloroquine for pre-exposure prophylaxis for the prevention of COVID-19 infection in these populations should be avoided until evidence becomes available.

**Clinical Question/ PICO**

- **Population:** Healthcare workers (with no active or prior COVID-19)
- **Intervention:** Pre-exposure hydroxychloroquine
- **Comparator:** Placebo

**Summary**

Pre-exposure prophylactic hydroxychloroquine may be no more effective at preventing COVID-19 infection in high-risk healthcare workers than placebo and may result in more adverse events.

**What is the evidence informing this recommendation?**

Evidence comes from three randomised trials that compared hydroxychloroquine as pre-exposure prophylaxis with placebo in 1884 high-risk healthcare workers with no active or prior COVID-19 [202][203][204].

**Publication status**

One study is only available as a preprint (Grau-Pujol posted to Research Square on 21 September 2020) and has therefore not been peer reviewed. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request an update on the study's publication status.

**Study characteristics**

Two studies reported comparatively low doses of hydroxychloroquine: in Rajasingham et al. participants were given a loading dose of 400 mg (two 200 mg tablets) of hydroxychloroquine twice separated by 6-8 hours, followed by 400 mg (two 200 mg tablets) either once or twice-weekly for 12 weeks [204]. Participants in Grau-Pujol et al. were given 400 mg hydroxychloroquine daily for four days, followed by 400 mg once weekly for one month [202]. In the study by Abella et al. participants received 600 mg of hydroxychloroquine daily for eight weeks [203].

Median age ranged from 31 to 42 years in the hydroxychloroquine arms and from 34 to 40 years in the placebo arms. The proportion of women ranged from 53% to 83% in the hydroxychloroquine arms and 49% to 73% in the placebo arms. One study explicitly excluded pregnant women [202], one study did not specify whether pregnant or breastfeeding women were eligible [203], and no pregnant women enrolled in the third study, although 30 women reported breastfeeding at baseline [204].

**What are the main results?**

Pre-exposure prophylactic hydroxychloroquine probably increases incidence of adverse events (108 more events per 1000 healthcare workers (RR 1.45 CI 95% 1.14 to 1.84; 1801 participants in 3 studies)). Pre-exposure prophylactic hydroxychloroquine may make little or no difference to the number of people who contract laboratory-confirmed COVID-19, experience symptoms compatible with COVID-19, develop confirmed or probable infection, experience serious adverse events or who discontinue treatment due to adverse events.

**Our confidence in the results**

Certainty of the evidence is low for laboratory-confirmed diagnosis, moderate for adverse events and confirmed or probable infection (due to included studies terminating early), low for serious adverse events and symptoms compatible with COVID-19 (due to studies being terminated early and few events), and very low for discontinuation due to adverse events.

**Additional information**

According to the Therapeutic Goods Administration, known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiac myopathy [52]. There are several known and potential interactions with other drugs [52]. Although overdose of hydroxychloroquine may have potentially fatal complications, this is unlikely when taken at prophylactic doses. In pregnancy, it is only recommended when benefits outweigh harms [52].
<table>
<thead>
<tr>
<th>Timeframe</th>
<th>measurements</th>
<th>Placebo</th>
<th>Pre-exp HCQ</th>
<th>the Evidence (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Laboratory-confirmed diagnosis</strong></td>
<td>Relative risk 0.87 (CI 95% 0.4 - 1.88) Based on data from 1,877 patients in 3 studies. ³ (Randomized controlled)</td>
<td>16</td>
<td>14</td>
<td>Low Due to serious risk of bias and serious imprecision ² Hydroxychloroquine pre-exposure prophylaxis may have little impact on laboratory-confirmed diagnosis in healthcare workers (26 events).</td>
</tr>
<tr>
<td>End of treatment</td>
<td></td>
<td>per 1000</td>
<td>per 1000</td>
<td></td>
</tr>
<tr>
<td>9 Critical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>Based on data from 1,608 patients in 2 studies. ³</td>
<td></td>
<td></td>
<td>There were no deaths.</td>
</tr>
<tr>
<td>End of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td>Relative risk 0.78 (CI 95% 0.31 - 2.01) Based on data from 1,752 patients in 2 studies. ⁴ (Randomized controlled)</td>
<td>11</td>
<td>9</td>
<td>Low Due to serious risk of bias and serious imprecision ⁵ Hydroxychloroquine pre-exposure prophylaxis may have little impact on serious adverse events in healthcare workers (18 events).</td>
</tr>
<tr>
<td>End of treatment</td>
<td></td>
<td>per 1000</td>
<td>per 1000</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events</strong></td>
<td>Relative risk 1.45 (CI 95% 1.14 - 1.84) Based on data from 1,801 patients in 3 studies. ⁶ (Randomized controlled)</td>
<td>241</td>
<td>349</td>
<td>Moderate Due to serious risk of bias ⁷ Hydroxychloroquine pre-exposure prophylaxis probably increases adverse events in healthcare workers.</td>
</tr>
<tr>
<td>End of treatment</td>
<td></td>
<td>per 1000</td>
<td>per 1000</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symptoms compatible with COVID-19</strong></td>
<td>Relative risk 0.75 (CI 95% 0.5 - 1.11) Based on data from 1,483 patients in 1 studies. ⁸ (Randomized controlled)</td>
<td>77</td>
<td>58</td>
<td>Low Due to serious risk of bias and serious imprecision ⁹ Hydroxychloroquine pre-exposure prophylaxis may have little impact on development of symptoms compatible with COVID-19 in healthcare workers (95 events).</td>
</tr>
<tr>
<td>12 weeks</td>
<td></td>
<td>per 1000</td>
<td>per 1000</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Confirmed or probable infection</strong></td>
<td>Relative risk 0.87 (CI 95% 0.6 - 1.27) Based on data from 1,483 patients in 1 studies. ¹⁰ (Randomized controlled)</td>
<td>79</td>
<td>69</td>
<td>Moderate Due to serious risk of bias ¹¹ Hydroxychloroquine pre-exposure prophylaxis probably has little or no impact on confirmed or probable infection (107 events).</td>
</tr>
<tr>
<td>12 weeks</td>
<td></td>
<td>per 1000</td>
<td>per 1000</td>
<td></td>
</tr>
<tr>
<td>6 Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discontinuation due to adverse</strong></td>
<td>Relative risk 0.95 (CI 95% 0.2 - 4.54)</td>
<td></td>
<td></td>
<td>Very Low Due to serious risk of bias ¹² There were too few events (6 events) to</td>
</tr>
<tr>
<td>End of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. due to few events.


5. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Imprecision:** Serious. due to few events.


7. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for detection bias. **Imprecision:** Serious. due to few events.


9. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of outcome assessors, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. Only data from one study.


11. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


13. **Risk of bias:** Serious. Trials stopping earlier than scheduled, resulting in potential for overestimating benefits, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Very Serious. Only data from one study, due to few events, Low number of patients.
7.2 - Hydroxychloroquine for post-exposure prophylaxis

**Evidence To Decision**

For people exposed to individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, do not use hydroxychloroquine for post-exposure prophylaxis outside of randomised trials with appropriate ethical approval. Trials are needed in special populations, including children and adolescents, pregnant and breastfeeding women, older people living with frailty and those receiving palliative care. Until further evidence is available, do not use hydroxychloroquine for post-exposure prophylaxis in these populations unless they are eligible to be enrolled in trials.

### Benefits and harms

#### General adult population

In addition to uncertainty around the benefits for people exposed to individuals with COVID-19, there are well-known harms, with potentially severe adverse events. Although most of the information on side effects and harms is derived from long-term use, potential acute harms include prolonged QT interval and lowered convulsive threshold. Long-term harms include retinopathy and chronic cardiac myopathy, among several others.

There are several known and potential interactions with other drugs. Although overdose of hydroxychloroquine may have potentially fatal complications, this is unlikely when taken at prophylactic doses.

#### Children and adolescents

Paediatricians have considerable experience with hydroxychloroquine in children and adolescents for other indications.

#### Pregnant and breastfeeding women

Hydroxychloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases. Studies of hydroxychloroquine for these indications have shown a favourable safety profile, though further research is needed.

#### People requiring palliative care and older people living with frailty or cognitive impairment

There may be additional concerns regarding harms in these populations.

### Certainty of the Evidence

#### General adult population

Certainty of the evidence for the primary outcome of laboratory-confirmed diagnosis is moderate. Certainty is high for adverse events and low for all other outcomes, due either to serious risk of bias and serious imprecision (symptoms compatible with COVID-19, confirmed or probable infection and discontinuation due to adverse events) or very serious imprecision (all-cause mortality and serious adverse events).

#### Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment

Certainty of the evidence was downgraded further for all outcomes due to indirectness, as it is unclear whether these special populations were included in the trials.

### Preference and values

The NC19CET Consumer Panel believes that as there is evidence of harm with using hydroxychloroquine, informed patients would not choose this treatment.

#### General adult population

We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more
There is currently limited evidence about the impact of prophylactic hydroxychloroquine on the prevention of infection in people exposed to COVID-19. The guideline panel has significant concerns about the potential harms of unproven treatments, including the possibility of adverse effects. We, therefore, recommend that hydroxychloroquine chemoprophylaxis should only be administered in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
In addition to the concerns in the general adult population, variability may be expected in preferences and values for these populations given the potentially different goals of care.

Resources
We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the potential impact on reduced access to these treatments by patients currently using them for other indications.

Equity
General adult population
We have no systematically collected direct evidence regarding impact on equity. There is a risk of creating inequity as some populations are currently not eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Children and adolescents, pregnant and breastfeeding women
Because the benefit to harm ratio is uncertain, this recommendation protects these more vulnerable populations.

People requiring palliative care and older people living with frailty or cognitive impairment
These populations are particularly at risk from COVID-19, we encourage trials that include this population (with appropriate baseline measurement of frailty and cognitive impairment). Given the absence of trials and uncertain benefit to harm ratio, this recommendation protects these more vulnerable populations.

Acceptability
General adult population, children and adolescents, pregnant and breastfeeding women
Although we have no systematically collected evidence regarding acceptability, hydroxychloroquine is likely to be acceptable to both patients and clinicians.

People requiring palliative care and older people living with frailty or cognitive impairment
Because the benefit to harm ratio is uncertain, acceptability may vary due to individual decision-making around goals of care.

Feasibility
Implementability of the recommendation is limited by the fact that not all populations are eligible to be enrolled in trials and some will live in geographic areas where opportunities for enrolment are limited or non-existent.

Rationale
General adult population
There is currently limited evidence about the impact of prophylactic hydroxychloroquine on the prevention of infection in people exposed to COVID-19. The guideline panel has significant concerns about the potential harms of unproven treatments, including the possibility of adverse effects. We, therefore, recommend that hydroxychloroquine chemoprophylaxis should only be administered in the context of randomised trials with appropriate ethical approval.

Children and adolescents, pregnant and breastfeeding women, people requiring palliative care and older people living with frailty or cognitive impairment
There is an urgent need for trials that include these populations to inform clinical management of COVID-19. Given the limited evidence in the general adult population, the use of hydroxychloroquine as post-exposure prophylaxis in these populations should be avoided until evidence becomes available.
Clinical Question/ PICO

**Population:** People exposed to COVID-19  
**Intervention:** Hydroxychloroquine post-exposure prophylaxis  
**Comparator:** Placebo  

**Summary**

Based on the available evidence, post-exposure prophylactic hydroxychloroquine is probably no more effective at preventing COVID-19 infection than placebo, and results in more adverse events.

Evidence informing this recommendation comes from two randomised trials that compared post-exposure prophylaxis using hydroxychloroquine to placebo in 3135 asymptomatic people [205][207]. All study participants were exposed to a person with a confirmed COVID-19 infection and were asymptomatic when treatment started.

In the first trial of 821 people, median age was 40 years (IQR 33 to 50), with women accounting for 52% of trial participants [205]. In the second trial of 2314 people, mean age was 49 years (SD 19), with women accounting for 73% of participants [207].

Certainty of the evidence is moderate for laboratory-confirmed diagnosis and adverse events (due to imprecision). Certainty is low for all other outcomes either due to serious inconsistency and serious risk of bias (symptoms compatible with COVID-19, confirmed or probable infection and discontinuation due to adverse events) or very serious imprecision (all-cause mortality and serious adverse events).

According to the Therapeutic Goods Administration known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiac myopathy [60]. There are several known and potential interactions with other drugs [60]. Although overdose of hydroxychloroquine may have potentially fatal complications, this is unlikely when taken at prophylactic doses. In pregnancy, it is only recommended when benefits outweigh harms [60].

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
</table>
| **Laboratory-confirmed diagnosis**<br>14 days after commencing treatment | Relative risk 0.96 (CI 95% 0.71 - 1.3) Based on data from 3,135 patients in 2 studies.¹ (Randomized controlled) | Placebo: 52 per 1000  
Hydroxychloroquine post-exposure prophylaxis: 50 per 1000  
Difference: 2 fewer per 1000 (CI 95% 15 fewer - 16 more) | Moderate  
Disorder related to COVID-19 | Hydroxychloroquine post-exposure prophylaxis probably has no effect on the number of laboratory-confirmed diagnoses. |
| **Symptoms compatible with COVID-19**<br>14 days after commencing treatment | Relative risk 0.98 (CI 95% 0.82 - 1.18) Based on data from 3,135 patients in 2 studies. ² (Randomized controlled) | Placebo: 128 per 1000  
Hydroxychloroquine post-exposure prophylaxis: 125 per 1000  
Difference: 3 fewer per 1000 (CI 95% 23 fewer - 23 more) | Low  
Disorder related to COVID-19 | Hydroxychloroquine post-exposure prophylaxis may have no effect on the number of symptoms compatible with COVID-19. |
|                          | Relative risk 0.83 (CI 95% 0.58 - 1.18) Based on data from 821 patients in 1 studies. | 143 per 1000 | 119 per 1000 | 24 fewer per 1000 (CI 95% 60 fewer - 26 more) | Low Due to serious risk of bias and imprecision  
| Confirmed or probable infection 14 days after commencing treatment |                          |                |                |                             | Hydroxychloroquine post-exposure prophylaxis may have no effect on the number of patients with confirmed or probable infection. |
|                          | Relative risk 0.68 (CI 95% 0.22 - 2.07) Based on data from 3,318 patients in 2 studies. | 5 per 1000 | 3 per 1000 | 2 fewer per 1000 (CI 95% 4 fewer - 5 more) | Low Due to very serious imprecision  
| All-cause mortality End of treatment |                          |                |                |                             | We are uncertain whether hydroxychloroquine post-exposure prophylaxis improves or worsens all-cause mortality (13 events). |
|                          | Relative risk 0.89 (CI 95% 0.44 - 1.81) Based on data from 2,497 patients in 1 studies. | 13 per 1000 | 12 per 1000 | 1 fewer per 1000 (CI 95% 7 fewer - 11 more) | Low Due to very serious imprecision  
| Serious adverse events End of treatment |                          |                |                |                             | We are uncertain whether hydroxychloroquine post-exposure prophylaxis increases or decreases serious adverse events (31 events). |
|                          | Relative risk 4.76 (CI 95% 1.19 - 19.1) Based on data from 3,197 patients in 2 studies. | 82 per 1000 | 390 per 1000 | 308 more per 1000 (CI 95% 16 more - 1,484 more) | Moderate Due to serious risk of bias  
| Adverse events End of treatment |                          |                |                |                             | Hydroxychloroquine post-exposure prophylaxis probably increases the number of adverse events. |
|                          | Relative risk 4.1 (CI 95% 0.52 - 32.23) Based on data from 3,346 patients in 2 studies. | 5 per 1000 | 20 per 1000 | 15 more per 1000 (CI 95% 2 fewer - 156 more) | Very Low Due to serious risk of bias and very serious imprecision  
| Discontinuation due to adverse events End of treatment |                          |                |                |                             | We are uncertain whether hydroxychloroquine post-exposure prophylaxis increases discontinuation due to adverse events (33 events). |

2. **Imprecision:** Serious. Wide confidence intervals.
4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision:** Serious. Wide confidence intervals.
6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.
bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision: Serious.** Wide confidence intervals.


8. **Imprecision: Very Serious.** Only 13 events.


10. **Imprecision: Very Serious.** Only 31 events.


12. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias.


14. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Imprecision: Very Serious.** Only 33 events.

---

**Clinical Question/ PICO**

- **Population:** Special populations
- **Intervention:** Hydroxychloroquine post-exposure prophylaxis
- **Comparator:** Placebo

---

**Summary**

Based on the available evidence, post-exposure prophylactic hydroxychloroquine is probably no more effective at preventing COVID-19 infection than placebo, and results in more adverse events.

Evidence informing this recommendation comes from two randomised trials that compared post-exposure prophylaxis using hydroxychloroquine to placebo in 3135 asymptomatic adult people [205][207]. All study participants were exposed to a person with a confirmed COVID-19 infection and were asymptomatic when treatment started.

In the first trial of 821 people, median age was 40 years (IQR 33 to 50), with women accounting for 52% of trial participants [205]. In the second trial of 2314 people, mean age was 49 years (SD 19), with women accounting for 73% of participants [207].

Certainty of the evidence is low for laboratory-confirmed diagnosis and adverse events (due to imprecision and indirectness). Certainty is very low for all other outcomes due to risk of bias, imprecision and indirectness.

According to the Therapeutic Goods Administration known acute harms for hydroxychloroquine include prolonged QT interval and lowered convulsive threshold. Long-term harms of relevance include retinopathy and chronic cardiac myopathy [60]. There are several known and potential interactions with other drugs [60]. Although overdose of hydroxychloroquine may have potentially fatal complications, this is unlikely when taken at prophylactic doses. In pregnancy, it is only recommended when benefits outweigh harms [60].

**Pregnant and breastfeeding women**

Hydroxychloroquine is used in pregnant and breastfeeding women for the treatment of malaria and autoimmune diseases. Studies of hydroxychloroquine for these indications have shown a favourable safety profile, with no increase in fetal malformations [69][70]. There is no evidence to suggest that stillbirth, preterm birth, low birth weight or early childhood disability are more common following treatment with hydroxychloroquine [69][70][71]. While this evidence is
reassuring, further research is needed.

**Children and adolescents**

Paediatricians have considerable experience with hydroxychloroquine in children and adolescents for other indications. To date, no specific information on its benefits or harms for children and adolescents has been collected on the use of hydroxychloroquine as post-exposure prophylaxis in this population.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Laboratory-confirmed diagnosis</strong></td>
<td>14 days after commencing treatment&lt;br&gt;Relative risk 0.96 (CI 95% 0.71 - 1.3) Based on data from 3,135 patients in 2 studies.¹ (Randomized controlled)</td>
<td>52 per 1000 &lt;br&gt;50 per 1000</td>
<td><strong>Low</strong>&lt;br&gt;Due to serious imprecision and indirectness²</td>
<td>Hydroxychloroquine post-exposure prophylaxis may have no effect on the number of laboratory-confirmed diagnoses.</td>
</tr>
<tr>
<td><strong>Symptoms compatible with COVID-19</strong></td>
<td>14 days after commencing treatment&lt;br&gt;Relative risk 0.98 (CI 95% 0.82 - 1.18) Based on data from 3,135 patients in 2 studies.³ (Randomized controlled)</td>
<td>128 per 1000 &lt;br&gt;125 per 1000</td>
<td><strong>Very Low</strong>&lt;br&gt;Due to serious risk of bias, imprecision and indirectness⁴</td>
<td>Hydroxychloroquine post-exposure prophylaxis may have no effect on the number of symptoms compatible with COVID-19.</td>
</tr>
<tr>
<td><strong>Confirmed or probable infection</strong></td>
<td>14 days after commencing treatment&lt;br&gt;Relative risk 0.83 (CI 95% 0.58 - 1.18) Based on data from 821 patients in 1 studies.⁵ (Randomized controlled)</td>
<td>143 per 1000 &lt;br&gt;119 per 1000</td>
<td><strong>Very Low</strong>&lt;br&gt;Due to serious risk of bias, imprecision and indirectness⁶</td>
<td>Hydroxychloroquine post-exposure prophylaxis may have no effect on the number of patients with confirmed or probable infection.</td>
</tr>
<tr>
<td><strong>All-cause mortality</strong></td>
<td>End of treatment&lt;br&gt;Relative risk 0.68 (CI 95% 0.22 - 2.07) Based on data from 3,318 patients in 2 studies.⁷ (Randomized controlled)</td>
<td>5 per 1000 &lt;br&gt;3 per 1000</td>
<td><strong>Very Low</strong>&lt;br&gt;Due to very serious imprecision and serious indirectness⁸</td>
<td>We are uncertain whether hydroxychloroquine post-exposure prophylaxis improves or worsens all-cause mortality (13 events).</td>
</tr>
</tbody>
</table>

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.


4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.


6. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Wide confidence intervals.


8. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Only 13 events.


10. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Very Serious. Only 31 events.


12. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. Differences between the population of interest and those studied.

14. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Indirectness:** Serious. **Imprecision:** Very Serious. Only 33 events.
8 - Respiratory support in adults

Current evidence suggests that about 19% of patients with COVID-19 experience hypoxic respiratory failure, 14% of whom will develop severe disease requiring oxygen therapy and 5% requiring mechanical ventilation within an ICU setting [208]. The majority of early guidelines generally base recommendations on indirect evidence from studies involving SARS, MERS and influenza, although it is presently unclear if patients with COVID-19 would benefit from alternative strategies to optimise the effective administration of respiratory support.

Panels responsible for the recommendations in this section:

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Primary Panel</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFNO and NIV</td>
<td>Hospital and Acute Care Panel</td>
</tr>
<tr>
<td>Respiratory management of the deteriorating patient, video-laryngoscopy, neuromuscular blockers, PEEP, prone positioning, recruitment manoeuvres and ECMO</td>
<td>Critical Care Panel</td>
</tr>
</tbody>
</table>

Guiding principles of care

For patients with COVID-19 for whom respiratory support (HFNO/NIV) is being considered, decisions should balance likelihood of patient benefit against the risk of infection for healthcare workers. For patients with COVID-19 receiving respiratory support (HFNO/NIV) or requiring intubation, use single rooms or negative pressure rooms wherever possible and ensure contact, droplet and airborne precautions are in place. Closed circuit NIV should be used.

The relative risk of infection to healthcare workers associated with specific oxygen therapies remains uncertain and may vary from site to site.

8.1 - High-flow nasal oxygen therapy

Info Box

High-flow nasal oxygen (HFNO) therapy is a form of respiratory support where oxygen is delivered, often in conjunction with compressed air and humidification. It delivers high flow oxygen via large diameter nasal cannula that is humidified and heated. Flow rates can be given up to 60 L/min with an oxygen/air blender supplying oxygen at 21-100%.

High-flow humidified oxygen should be considered when unable to maintain SaO2 ≥ 92% despite conventional oxygen delivery at > 6 L/min or an FiO2 = 0.4.
Conditional recommendation

Consider using HFNO therapy for patients with hypoxaemia associated with COVID-19, ensuring it is used with caution and strict attention is paid to staff safety including the use of appropriate personal protective equipment (PPE). If HFNO is being used, ideally this should be in a negative pressure room. If none is available, other alternatives are single rooms, or shared ward spaces with cohorting of confirmed COVID-19 patients only.

*Use the lowest flow necessary to maintain oxygen saturation ≥ 92%.*

### Evidence To Decision

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Small net benefit, or little difference between alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFNO can improve oxygenation in patients with hypoxaemia but may be associated with a high failure rate and delayed intubation. Evidence from non-COVID patients with acute hypoxaemic respiratory failure shows uncertainty for mortality and intubation. HFNO is a known aerosol-generating procedure, with possible increased risk of aerosolisation—harms associated with potential risk of transmission to healthcare workers need to be considered and the procedure used with caution and strict attention paid to staff safety [17].</td>
<td></td>
</tr>
</tbody>
</table>

### Certainty of the Evidence

**Very Low**

No studies were identified in COVID-19 patients that address the interventions, comparators and outcomes of interest. A systematic review of non-COVID-19 patients of low to very low certainty evidence is included.

### Preference and values

**Substantial variability is expected or uncertain**

We have no systematically collected information regarding patients’ preferences and values at this point.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation and this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

### Resources

**Important issues, or potential issues not investigated**

We have no systematically collected evidence regarding cost-benefit. However, there are likely to be resource issues associated with different settings. There are limited negative pressure rooms available in private and some public hospitals, although some hospitals have transformed rooms into negative pressure rooms. There are additional resource considerations for hospital spaces where caution needs to be applied and strict attention paid to staff safety.

### Equity

**Important issues, or potential issues not investigated**

There may be equity issues due to the availability of negative pressure rooms and hospital spaces that are able to perform HFNO safely.

### Acceptability

**Important issues, or potential issues not investigated**

We have no systematically collected information regarding acceptability. We are uncertain if HFNO is likely to be acceptable to both patients and healthcare providers.

### Feasibility

**Important issues, or potential issues not investigated**

There may be feasibility issues due to the availability of negative pressure rooms and hospital spaces that are able to...
Rationale
HFNO can improve oxygenation in patients with hypoxaemia but it may be associated with a high failure rate and delayed intubation. HFNO is associated with an increased risk of aerosolisation and is only recommended in hospital spaces that limit transmission risk and where caution and strict attention is paid to staff safety.

Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>High-flow nasal oxygen therapy</td>
</tr>
<tr>
<td>Comparator</td>
<td>Conventional oxygen therapy</td>
</tr>
</tbody>
</table>

Summary
Evidence informing this recommendation comes from two rapid systematic reviews commissioned by the WHO to summarise the evidence for the efficacy, safety (review 1), and risk of aerosol generation and infection transmission (review 2) during high-flow nasal cannula (HFNC) use among patients with acute hypoxaemic respiratory failure due to COVID-19 [215].

Review 1: Effectiveness

<table>
<thead>
<tr>
<th>Study design</th>
<th>Randomised trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>High-flow nasal cannula (HFNC)</td>
</tr>
<tr>
<td>Comparison</td>
<td>Conventional oxygen therapy</td>
</tr>
<tr>
<td>Synthesis method</td>
<td>Meta-analysis</td>
</tr>
</tbody>
</table>

Results
Included 12 RCTs (n = 2217 patients). Decreased risk of requiring intubation and escalation of oxygen therapy (defined as crossover to HFNC in the control group or initiation of non-invasive or invasive ventilation in either group) in favour of HFNC over conventional oxygen therapy. There was no significant difference in mortality, intensive care unit length of stay, hospital length of stay, patient-reported dyspnea and patient-reported comfort. Treatment-reported complications were not pooled due to variability in reporting but were generally minimal across studies and comparable between interventions.

Review 2: Risk of dispersal

<table>
<thead>
<tr>
<th>Study design</th>
<th>Simulation studies and one prospective crossover study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Healthy adult volunteers (two simulation studies), model human patient simulators (two simulation studies), and critically ill patients who received supplemental oxygen therapy (one crossover study). No studies available in patients with COVID-19, which was considered a limitation in applicability (indirect evidence).</td>
</tr>
<tr>
<td>Intervention</td>
<td>High-flow nasal oxygen (HFNO)</td>
</tr>
<tr>
<td>Comparison</td>
<td>None (three simulation studies); CPAP (one simulation study); conventional therapy with face mask (one crossover study)</td>
</tr>
<tr>
<td>Synthesis method</td>
<td>None, individual study results only</td>
</tr>
</tbody>
</table>

Results
Five studies were included, of which three were simulation studies and none were randomised trials. No studies included patients with COVID-19. In summary, the findings were very uncertain and no conclusions could be drawn. One simulation study found HFNO
Increased cough-generated droplet dispersion compared to no HFNO. A prospective cohort study found HFNO did not disperse gram-negative bacteria in air samples or set plates at 0.4 m and 1.5 m compared to a facemask. Another simulation study without a control group detected water and yeast colony formation at 0.3 m. Of two studies reporting aerosol dispersion, one found HFNO does not increase the risk of aerosol dispersion, while the second found higher flow rates resulted in increased regions of high aerosol density compared with continuous positive airway pressure (CPAP).

For both reviews, certainty of the evidence is deemed to be low to very low due to indirectness (not based on COVID-19 patients), risk of bias and lack of precision in some outcomes.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>Absolute effect estimates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conventional therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Critical</td>
<td>Relative risk 0.94 (CI 95% 0.67 - 1.31)</td>
<td>272 per 1000</td>
<td></td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Based on data from 1,407 patients in 4 studies.</td>
<td></td>
<td></td>
<td>HFNO may have little or no difference on mortality.</td>
</tr>
<tr>
<td></td>
<td>Follow up 7 to 90 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive ventilation</td>
<td>Relative risk 0.85 (CI 95% 0.74 - 0.99)</td>
<td>286 per 1000</td>
<td></td>
<td>Very Low</td>
</tr>
<tr>
<td>9 Critical</td>
<td>Based on data from 1,687 patients in 8 studies.</td>
<td></td>
<td></td>
<td>We are uncertain whether HFNO increases or decreases invasive ventilation.</td>
</tr>
<tr>
<td></td>
<td>Follow up 2 to 28 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Escalation of therapy (HFNC, NIV or intubation)</td>
<td>Relative risk 0.71 (CI 95% 0.51 - 0.98)</td>
<td>320 per 1000</td>
<td></td>
<td>Very Low</td>
</tr>
<tr>
<td>9 Critical</td>
<td>Based on data from 1,703 patients in 8 studies.</td>
<td></td>
<td></td>
<td>We are uncertain whether HFNO increases or decreases escalation of therapy (HFNC, NIV or intubation).</td>
</tr>
<tr>
<td></td>
<td>Follow up 2 to 28 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICU length of stay (Days)</td>
<td>Based on data from 972 patients in 2 studies.</td>
<td>Difference: MD 1.38 fewer (CI 95% 0.9 fewer - 3.66 fewer)</td>
<td></td>
<td>Very Low</td>
</tr>
<tr>
<td>9 Critical</td>
<td>Based on data from:</td>
<td></td>
<td></td>
<td>We are uncertain whether HFNO increases or decreases ICU length of stay.</td>
</tr>
<tr>
<td></td>
<td>1,247 patients in 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital length of stay (Days)</td>
<td>Based on data from:</td>
<td>Difference: MD 0.67 more (CI 95% 1.41 fewer - 0.08 more)</td>
<td></td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>1,247 patients in 4</td>
<td></td>
<td></td>
<td>HFNO may have little or no difference on hospital length of stay.</td>
</tr>
</tbody>
</table>
1. Systematic review with included studies: [213]. **Baseline/comparator:** Control arm of reference used for intervention.

2. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious.

3. Systematic review with included studies: [213]. **Baseline/comparator:** Control arm of reference used for intervention.

4. **Risk of bias:** Serious. **Indirectness:** Serious. **Imprecision:** Serious.

5. Systematic review with included studies: [213]. **Baseline/comparator:** Control arm of reference used for intervention.

6. **Risk of bias:** Serious. **Indirectness:** Serious. **Imprecision:** Serious.

7. Inconsistency: Serious. **Indirectness:** Serious. **Imprecision:** Serious.

8. **Indirectness:** Serious. **Imprecision:** Serious.

9. **Risk of bias:** Serious. **Indirectness:** Serious. **Imprecision:** Serious.

10. **Risk of bias:** Serious. **Inconsistency:** Serious. **Indirectness:** Serious. **Imprecision:** Serious.

11. **Risk of bias:** Serious. Substantial risk of bias in all five studies. **Inconsistency:** No serious. **Indirectness:** Serious. No studies included patients with COVID-19. **Imprecision:** No serious. **Publication bias:** No serious.

---

### Patient-reported dyspnea

**Variable score:** 9 Critical

Based on data from 894 patients in 7 studies.

**Difference:** SMD 0.66 lower
( CI 95% 1.68 lower - 0.35 higher )

**Risk of bias:** Serious
**Indirectness:** Serious
**Imprecision:** Serious

**Inconsistency:** Serious

We are uncertain whether HFNO improves or worsens patient reported dyspnea.

### Patient-reported comfort

**Variable score:** 9 Critical

Based on data from 1,233 patients in 7 studies.

**Difference:** SMD 0.12 lower
( CI 95% 0.61 lower - 0.37 higher )

**Risk of bias:** Serious
**Indirectness:** Serious
**Imprecision:** Serious

**Inconsistency:** Serious

We are uncertain whether HFNO improves or worsens patient reported comfort.

### Dispersal of droplets and aerosols

**Variable score:** 9 Critical

One simulation study found HFNO increased cough-generated droplet dispersion compared to no HFNO. A prospective cohort study found HFNO did not disperse gram-negative bacteria in air samples or set plates at 0.4 m and 1.5 m compared to a facemask. Another simulation study without a control group detected water and yeast colony formation at 0.3 m. Of two studies reporting aerosol dispersion, one found HFNO does not increase the risk of aerosol dispersion, while the second found higher flow rates resulted in increased regions of high aerosol density compared with continuous positive airway pressure (CPAP).

**Risk of bias:** Serious
**Indirectness:** Serious
**Imprecision:** Serious

**Inconsistency:** Serious

We are uncertain whether HFNO increases or decreases dispersal of droplets and aerosols.
Do not use HFNO therapy for patients with hypoxaemia associated with COVID-19 in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval.

Evidence To Decision

Benefits and harms

Since HFNO is a known aerosol-generating procedure there are important harms associated with the potential risk of transmission to healthcare workers and others in this setting.

Certainty of the Evidence

No studies were identified in COVID-19 patients that address the interventions, comparators and outcomes of interest. A systematic review of non-COVID-19 patients of low to very low certainty evidence is included.

Preference and values

We have no systematically collected information regarding patients' preferences and values at this point.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation and this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

Resources

We have no systematically collected evidence regarding cost-benefit. We have not recommended HFNO in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval. However, if HFNO is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact resourcing and other considerations.

Equity

We have not recommended HFNO in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval. However, if HFNO is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact equity.

Acceptability

We have no systematically collected information regarding acceptability. We are uncertain if HFNO is likely to be acceptable to both patients and healthcare providers.

Feasibility

We have not recommended HFNO in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval. However, if HFNO is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact feasibility.

Rationale

HFNO is associated with an increased risk of aerosolisation and is only recommended in hospital spaces that limit transmission risk and where caution and strict attention is paid to staff safety. It is therefore not appropriate for use in shared
wards, emergency department cubicles or during inter-hospital patient transfer/retrieval due to the increased risk of transmission in these settings.

Clinical Question/ PICO

Population: Patients with COVID-19  
Intervention: High-flow nasal oxygen therapy  
Comparator: Conventional oxygen therapy

Summary

See the Summary in the HFNO recommendation for negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients.

8.2 - Non-invasive ventilation

Info Box

Non-invasive ventilation (NIV), also known as non-invasive positive pressure ventilation (NIPPV) or bilevel positive pressure support (BiPAP), is a form of respiratory support. Bilevel positive pressure is delivered throughout the respiratory cycle by a firm-fitting nasal-face mask. The patient breathes spontaneously and triggers the device to cycle.

A higher level of pressure is provided during the inspiratory phase to enhance ventilation, while a lower level of continuous positive pressure is delivered during the expiratory phase (also known as positive end-expiratory pressure or PEEP). Supplemental oxygen can also be delivered through the device.

Conditional recommendation

Consider using NIV therapy for patients with hypoxaemia associated with COVID-19, ensuring it is used with caution and strict attention is paid to staff safety including the use of appropriate personal protective equipment (PPE). If NIV is being used, ideally this should be in a negative pressure room. If none is available, other alternatives are single rooms, or shared ward spaces with cohorting of confirmed COVID-19 patients only.

Practical Info

Some patients receiving NIV may have a low tolerance to the pressures/mask due to anxiety or delirium. If NIV is not tolerated after a trial then early consideration should be given to its cessation.

The net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Evidence To Decision

Benefits and harms 

NIV can improve oxygenation in patients with hypoxaemia but may be associated with a high failure rate and delayed intubation. Evidence from non-COVID patients with acute hypoxaemic respiratory failure shows uncertainty for all-cause
mortality and endotracheal intubation. NIV is a known aerosol-generating procedure, with possible increased risk of aerosolisation with poor mask fit [17]. Since there is a potential risk of transmission to healthcare workers, the procedure should be used with caution and follow strict attention to staff safety.

### Certainty of the Evidence

No studies were identified in COVID-19 patients that address the interventions, comparators and outcomes of interest. A network meta-analysis of NIV in non-COVID-19 patients of low to very low certainty evidence is included.

### Preference and values

We have no systematically collected information regarding patients’ preferences and values.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation and this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

### Resources

We have no systematically collected evidence regarding cost-benefit. However, there are likely to be resource issues associated with different settings. There are limited negative pressure rooms in private and some public hospitals, although some hospitals have transformed rooms into negative pressure rooms. There are additional resource considerations for hospital spaces where caution needs to be applied and strict attention paid to staff safety.

### Equity

There may be equity issues due to the availability of negative pressure rooms and hospital spaces that are able to perform NIV safely.

### Acceptability

We have no systematically collected information regarding acceptability. We are uncertain if NIV is likely to be acceptable to both patients and healthcare providers.

### Feasibility

There may be feasibility issues due to the availability of negative pressure rooms and hospital spaces that are able to perform NIV safely.

### Rationale

NIV can improve oxygenation in patients with hypoxaemia but may be associated with a high failure rate and delayed intubation. NIV is associated with an increased risk of aerosolisation and is only recommended in hospital spaces that limit transmission risk and where caution and strict attention is paid to staff safety.

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with hypoxaemia associated with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Non-invasive ventilation (helmet or face mask)</td>
</tr>
<tr>
<td>Comparator:</td>
<td>High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT)</td>
</tr>
</tbody>
</table>
Summary
No evidence has been identified in patients with COVID-19. Evidence informing this recommendation comes from a network meta-analysis of 25 randomised trials (3804 participants) in patients with acute hypoxaemic respiratory failure [218]. Mean age ranged from 30 to 75 years, mean PaO2:Fio2 ratio was predominantly below 200 (14 trials), and more than half of the trials (14 trials) allowed inclusion of immunocompromised patients. Community-acquired pneumonia was the most common cause of acute hypoxaemic respiratory failure in 16 trials.

The results reported helmet NIV as among the most effective but we are uncertain if helmet NIV compared to supplemental oxygen therapy, HFNO and face mask NIV increases or decreases all-cause mortality up to 90 days and endotracheal intubation up to 30 days. This is followed by face mask NIV compared to supplemental oxygen therapy which probably decreases all-cause mortality and endotracheal intubation and HFNO compared to supplemental oxygen therapy for endotracheal intubation. We are uncertain if face mask NIV compared to HFNO is different for all-cause mortality and endotracheal intubation. We are uncertain if HFNO compared to supplemental oxygen therapy is different for all-cause mortality and endotracheal intubation.

The certainty of the evidence in the table below is as reported by Ferreyro [218]. In the context of this recommendation, the certainty of the evidence should be downgraded further due to indirectness as none of the patients had COVID-19.

Summary of treatments

<table>
<thead>
<tr>
<th>All-cause mortality</th>
<th>Endotracheal intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Among the most effective or safest</strong></td>
<td>****</td>
</tr>
<tr>
<td>Helmet NIV v SOT 0.40 (0.24–0.63)</td>
<td>Helmet NIV v SOT 0.26 (0.14–0.46)</td>
</tr>
<tr>
<td>Helmet NIV v HFNO 0.46 (0.26–0.80)</td>
<td>Helmet NIV v HFNO 0.35 (0.18–0.66)</td>
</tr>
<tr>
<td>Face mask NIV v HFNO 0.48 (0.29–0.76)</td>
<td>Face mask NIV v HFNO 0.35 (0.19–0.61)</td>
</tr>
<tr>
<td><strong>High-Mod certainty</strong></td>
<td><strong>Most effective</strong></td>
</tr>
<tr>
<td><strong>Among the effective</strong></td>
<td>****</td>
</tr>
<tr>
<td>Face mask NIV v SOT 0.83 (0.68 – 0.99)</td>
<td>Face mask NIV v SOT 0.76 (0.62–0.90)</td>
</tr>
<tr>
<td>HFNO v SOT 0.76 (0.55–0.99)</td>
<td><strong>High-mod certainty</strong></td>
</tr>
<tr>
<td><strong>High-mod certainty</strong></td>
<td><strong>Effective</strong></td>
</tr>
<tr>
<td><strong>Not convincingly different</strong></td>
<td>****</td>
</tr>
<tr>
<td>Face mask NIV v HFNO 0.95 (0.69 – 1.37)</td>
<td>Face mask NIV v HFNO 1.01 (0.74–1.38)</td>
</tr>
<tr>
<td>HFNO v SOT 0.87 (0.62 – 1.15)</td>
<td><strong>Low-to-low certainty</strong></td>
</tr>
<tr>
<td><strong>Low-to-low certainty</strong></td>
<td><strong>Harmful</strong></td>
</tr>
<tr>
<td><strong>Among the harmful</strong></td>
<td>****</td>
</tr>
<tr>
<td><strong>Low-to-low certainty</strong></td>
<td><strong>No difference</strong></td>
</tr>
<tr>
<td><strong>Low-to-low certainty</strong></td>
<td><strong>Potentially harmful</strong></td>
</tr>
</tbody>
</table>

| Trials (participants) | 22 (3,633) | 26 (4,067) |

Note: Estimates are network risk ratios and 95% credible intervals
Evidence To Decision

**Benefits and harms**

Since NIV is a known aerosol-generating procedure, with possible increased risk of aerosolisation with poor mask fit [17], there are important harms associated with the potential risk of transmission to healthcare workers and others in this setting.

**Certainty of the Evidence**

No studies were identified in COVID-19 patients that address the interventions, comparators and outcomes of interest. A network meta-analysis of NIV in non-COVID-19 patients of low to very low certainty is included.

**Preference and values**

We have no systematically collected information regarding patients’ preferences and values.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation and this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

**Resources**

We have no systematically collected evidence regarding cost-benefit. We do not recommend use of NIV in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval. If NIV is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact resourcing and other considerations.

**Equity**

We do not recommend use of NIV in shared wards or emergency department cubicles. If NIV is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact equity.

**Acceptability**

We have no systematically collected information regarding acceptability. We are uncertain if NIV is likely to be acceptable to both patients and healthcare providers.
**Feasibility**

We do not recommend use of NIV in shared wards or emergency department cubicles. If NIV is clinically indicated and there is no access to negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients only, this has the potential to impact feasibility.

**Rationale**

NIV is associated with an increased risk of aerosolisation and is only recommended in hospital spaces that limit transmission risk and where caution and strict attention is paid to staff safety. It is therefore not appropriate for use in shared wards, emergency department cubicles or during inter-hospital patient transfer/retrieval due to the increased risk of transmission in these settings.

**Adaptation**

The recommendation is adapted from published recommendations by ANZICS [17]. Wording has been adapted for clarity and applicability to the Australian context.

---

**Clinical Question/ PICO**

| Population: | Patients with hypoxaemia associated with COVID-19 |
| Intervention: | Non-invasive ventilation (helmet or face mask) |
| Comparator: | High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT) |

**Summary**

See the Summary in the NIV recommendation for consideration using in negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timeframe</td>
<td>Based on data from 3,804 patients in 25 studies.</td>
<td>See summary for findings on all-cause mortality and endotracheal intubation.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conditional recommendation**

In patients with COVID-19 for whom NIV is appropriate for an alternate clinical presentation (e.g. concomitant chronic obstructive pulmonary disease (COPD) with type 2 respiratory failure and hypercapnia, acute pulmonary oedema), ensure airborne and other infection control precautions are optimised.

**Evidence To Decision**

**Benefits and harms**

Small net benefit, or little difference between alternatives

NIV may be associated with a high failure rate and delayed intubation. Evidence from non-COVID patients with acute
Rationale

NIV is associated with an increased risk of aerosolisation and is only recommended in hospital spaces that reduce the risk of transmission and where caution and strict attention is paid to staff safety.

Adaptation

The recommendation is adapted from published recommendations by ANZICS [17]. Wording has been adapted for clarity and applicability to the Australian context.
Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients with hypoxaemia associated with COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Non-invasive ventilation (helmet or face mask)</td>
</tr>
<tr>
<td>Comparator:</td>
<td>High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT)</td>
</tr>
</tbody>
</table>

Summary

See the Summary in the NIV recommendation for consider using in negative pressure rooms, single rooms or shared ward spaces with cohorting of confirmed COVID-19 patients.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>See summary</td>
<td>Based on data from 3,804 patients in 25 studies.</td>
<td>Helmet or face mask NIV</td>
<td>See summary for findings on all-cause mortality and endotracheal intubation.</td>
<td></td>
</tr>
</tbody>
</table>

8.3 - Respiratory management of the deteriorating patient

Consensus recommendation

Do not delay endotracheal intubation and mechanical ventilation in patients with COVID-19 who are deteriorating despite optimised, less invasive respiratory therapies.

Patients can deteriorate rapidly 5 to 10 days after onset of symptoms.

The net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

Evidence To Decision

Benefits and harms

Benefits and harms should be considered on a case-by-case basis as the net clinical benefit is likely to vary for each patient. Frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms. Benefits can include a decrease in self-inflicted lung injury and rapid decline. Harms relevant to transmission should also be considered, as there may be different risks of transmission associated with different settings, for example ICU compared to the emergency department.

Certainty of the Evidence

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce
No studies were identified in COVID-19 patients that address the interventions, comparators and outcomes of interest.

**Preference and values**

There is no systematically collected information regarding patients' preferences and values at this point. In some patients, comfort, sedation and intubation may lead to symptom management improvement. However, in other patients intubation may not be feasible or considered suitable. Some patients may decline intubation if offered.

**People requiring palliative care and older people living with frailty or cognitive impairment**

Consider the preferences and values of the patient and whether they have an advanced care directive or plan. Decisions around proceeding to more invasive forms of ventilation should be discussed with the patient or their medical treatment decision-maker.

The Consumer Panel believes that in line with available evidence, some informed patients/carers would wish to have more invasive treatment initiated if this is consistent with their goals of care. The Panel recognises that some informed patients/carers may choose not to proceed with this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.

**Resources**

We have no systematically collected evidence regarding cost-benefit. However, there are likely to be resource issues associated with different settings.

**Equity**

There are likely no important equity issues.

**Acceptability**

Although we have no systematically collected evidence regarding acceptability, we expect some patients may decline intubation if offered.

**Feasibility**

More invasive ventilation options may be very limited in patients with frailty or underlying health issues, and in other circumstances where clinical judgement deems patients may be unlikely to benefit from intubation. In some situations and settings (where deterioration occurs outside the hospital), intensification of treatment may be further limited by access to suitably experienced clinicians.

**Adaptation**

The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.
### 8.4 - Videolaryngoscopy

**Conditional recommendation**

In adults with COVID-19 undergoing endotracheal intubation, consider using videolaryngoscopy over direct laryngoscopy if available and the operator is trained in its use.

### Evidence To Decision

#### Benefits and harms

**Small net benefit, or little difference between alternatives**

Time to intubation varies depending on the experience of the operator and the setting. Another important consideration is the potential risk of contamination to the operator due to the infectious nature of COVID-19. In a simulation study using a manikin, the distance between the operator and patient’s mouth increased when using video compared to direct laryngoscopy, thus potentially benefitting operators in the case of COVID-19.

#### Certainty of the Evidence

**Very Low**

For the two critical outcomes—distance between patient and operator, and time to successful intubation—certainty of the evidence is very low due to serious risk of bias, inconsistency, indirectness and imprecision.

#### Preference and values

**No substantial variability expected**

We have no systematically collected information regarding patients' preferences and values. Although there is uncertainty regarding the time to successful intubation, we are reasonably confident that patients would find videolaryngoscopy an acceptable intervention compared to direct laryngoscopy.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation for this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

#### Resources

**Important issues, or potential issues not investigated**

We have no systematically collected evidence regarding cost-benefit. The main costs associated with videolaryngoscopy are attributed to the initial equipment outlay, maintenance and operator training. The panel clarified in the recommendation that videolaryngoscopy should only be considered if available and operators are trained in its use.

#### Equity

**Important issues, or potential issues not investigated**

There is a risk of creating inequity as people who live in rural and remote areas may have limited access to videolaryngoscopy and experienced operators. Due to costs and maintenance, there will be variation in the type of clinical settings likely to have access to the appropriate equipment—larger, specialised centres in urban areas are more likely to provide access than those in smaller more remote centres.

The panel noted that rural and remote hospitals do not routinely have access to videolaryngoscopy. The outcome of time to successful intubation is dependent on operator expertise and would likely take longer in non-specialist centres. However, the panel felt that most people intubating would be trained in videolaryngoscopy, although experience would vary. The panel clarified in the recommendation that videolaryngoscopy should only be considered if available and operators are trained in its use.

#### Acceptability

**No important issues with the recommended alternative**

Videolaryngoscopy is generally a well-accepted intervention, and there are no important issues regarding acceptability.
### Feasibility

Feasibility is affected by the initial equipment costs, maintenance and operator training. The panel clarified in the recommendation that videolaryngoscopy should only be considered if available and operators are trained in its use.

### Rationale

Videolaryngoscopy allows for increased distance between operator and patient.

### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population:</th>
<th>Patients requiring emergency intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Direct laryngoscopy</td>
</tr>
</tbody>
</table>

### Summary

Evidence informing this recommendation comes from a systematic review of video versus direct laryngoscopy for the emergency intubation of adults in the inpatient setting [223]. A simulation study is also included that evaluated the distance between a dummy’s mouth and physician’s face during intubation [228].

### Effectiveness and adverse events

<table>
<thead>
<tr>
<th>Study design</th>
<th>Randomised trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Critically ill patients requiring emergency intubation in emergency departments or intensive care units. No studies available in patients with COVID-19.</td>
</tr>
<tr>
<td>Intervention</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparator</td>
<td>Direct laryngoscopy</td>
</tr>
<tr>
<td>Synthesis method</td>
<td>Meta-analysis</td>
</tr>
</tbody>
</table>

**Results**

We included six of the eight randomised trials (1023 patients) in the Rombey review [221][222][224][225][226][227]. (Two were excluded because patients were intubated before hospital admission.) We included an additional randomised trial of 163 patients that was published after the Rombey review [220]. This study did not change the overall results for the outcomes, but did improve the precision of the estimate for inadvertent oesophageal intubation. There was no difference between video and direct laryngoscopy with respect to successful intubation at first attempt or time to successful intubation. In the four randomised trials that reported inadvertent oesophageal intubation, the use of videolaryngoscopy was associated with fewer of these adverse events, however the number was small (27 events).

### Operator distance (Hall 2020)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Crossover study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>25 doctors of mixed experience performing tracheal intubation on a high-fidelity manikin.</td>
</tr>
<tr>
<td>Intervention</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparator</td>
<td>Direct laryngoscopy</td>
</tr>
<tr>
<td>Results</td>
<td>Videolaryngoscopy may extend the mouth-to-mouth distance from laryngoscopist to patient comp</td>
</tr>
</tbody>
</table>

Certainty of the evidence is low to very low due to indirectness (not based on COVID-19 patients or exclusively patients with ARDS), risk of bias, lack of precision in some outcomes and small number of adverse events.
### Timeframe Measurements

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>measurements</th>
<th>Direct laryngoscopy</th>
<th>Videolaryngoscopy</th>
<th>the Evidence (Quality of evidence)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-pass intubation</td>
<td>Relative risk 1.05 (CI 95% 0.94 - 1.17) 716 per 1000</td>
<td>716 per 1000</td>
<td>Very Low Due to serious risk of bias, inconsistency and indirectness 2 We are uncertain whether videolaryngoscopy increases or decreases first-pass intubation success.</td>
<td></td>
</tr>
<tr>
<td>success</td>
<td>(CI 95% 0.94 - 1.17) 716 per 1000</td>
<td>Difference: 36 more per 1000 (CI 95% 43 fewer - 122 more)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oesophageal intubation</td>
<td>Relative risk 0.4 (CI 95% 0.17 - 0.93) 50 per 1000</td>
<td>20 per 1000</td>
<td>Low Due to serious risk of bias and indirectness 4 Videolaryngoscopy may decrease oesophageal intubation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CI 95% 0.17 - 0.93) 50 per 1000</td>
<td>Difference: 30 fewer per 1000 (CI 95% 41 fewer - 3 fewer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operator distance in cm</td>
<td>Measured by: distance analysed from videorecording</td>
<td>16.4 centimetres (Mean)</td>
<td>Very Low Due to serious risk of bias, indirectness and imprecision 7 Videolaryngoscopy may increase the operator distance.</td>
<td></td>
</tr>
<tr>
<td>8 Critical</td>
<td>High better 35.6 centimetres (Mean)</td>
<td>Difference: MD 19.2 higher (CI 95% 13.28 lower - 25.12 higher)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to successful</td>
<td>Based on data from: 25 patients in 1 studies. 6 (Randomized controlled)</td>
<td>35.6 centimetres (Mean)</td>
<td>Very Low Due to serious risk of bias, indirectness and imprecision, and very serious inconsistency 9 We are uncertain whether videolaryngoscopy increases or decreases time to successful intubation.</td>
<td></td>
</tr>
<tr>
<td>intubation</td>
<td>988 patients in 6 studies. 8</td>
<td>Difference: MD 19.2 higher (CI 95% 13.28 lower - 25.12 higher)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Risk of bias: Serious. Personnel blinding was not possible for this outcome, resulting in potential for performance bias. Outcome assessor blinding was also not possible, resulting in potential for detection bias. Inconsistency: Serious. There was clinical heterogeneity across the included studies in relation to setting (ED vs ICU), operator experience and devices used. Subgroup analyses in Rombey et al 2018 reported that effect sizes were not decisively altered by sensitivity or subgroup analyses. Indirectness: Serious. The included studies were in non COVID-19 populations, with mixed presentations of respiratory and other critically ill patients. Differences between the population of interest and those studied. Imprecision: No serious. Publication bias: No serious. Rombey 2018 visually evaluated the funnel plot for publication bias, with distribution for this outcome relatively symmetrical.
4. Risk of bias: Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, and inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. Inconsistency: No serious. Indirectness: Serious. The included studies were in non COVID-19 populations, with mixed presentations of respiratory and other critically ill patients. Imprecision: No serious. Publication bias: No serious. Rombey 2018 visually evaluated the funnel plot for publication bias, with distribution for this outcome relatively symmetrical.
5. The ‘mouth-to-mouth’ distance between operator and manikin as measured by video analysis.
6. **Primary study** [228]. **Baseline/comparator**: Control arm of reference used for intervention [228].

7. **Risk of bias**: **Serious**. Blinding of personnel not possible, resulting in potential for performance bias, unclear sequence generation/ generation of comparable groups, resulting in potential for selection bias, unclear concealment of allocation during randomization process, resulting in potential for selection bias. **Inconsistency**: **No serious**. **Indirectness**: **Serious**. Use of manikins not patients. **Imprecision**: **Serious**. Only data from one study. **Publication bias**: **No serious**.

8. **Systematic review** [223].

9. **Risk of bias**: **Serious**. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, Inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency**: **Very Serious**. Point estimates vary widely. **Indirectness**: **Serious**. The included studies were in non COVID-19 populations, with mixed presentations of respiratory and other critically ill patients. **Imprecision**: **Serious**. Wide confidence intervals. **Publication bias**: **No serious**. Rombye et al 2018 visually evaluated the funnel plot for publication bias, with distribution for this outcome relatively symmetrical.

### 8.5 - Neuromuscular blockers

**Info Box**

Neuromuscular blocking agents (NMBAs) are a pharmaceutical intervention that may facilitate protective lung ventilation in patients who are mechanically ventilated with moderate to severe acute respiratory distress syndrome (ARDS). NMBAs may reduce patient-ventilator dyssynchrony and facilitate improved oxygenation by various mechanisms, including reducing the inspiratory muscle effort and the work of breathing, and reducing ventilator-induced lung injury.

**Clinical Question/ PICO**

- **Population**: Mechanically ventilated adults with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation or persistently high plateau pressures
- **Intervention**: Continuous infusion of NMBAs
- **Comparator**: No continuous infusion of NMBAs

**Summary**

Evidence informing this recommendation comes from five randomised trials involving 1461 adults with acute respiratory distress syndrome. Currently, there is no evidence in patients with COVID-19. The five trials compared continuous infusions of neuromuscular blocking agents with cisatracurium for up to 48 hours to no continuous infusions of NMBAs [230][231][232][233][234].

For all critical outcomes, it is uncertain whether infusion of neuromuscular blockers makes a difference. The ROSE trial, which had a different sedation strategy to the other trials and implemented a higher PEEP strategy, is the largest (1006 participants) and most recent trial, and may be the most reflective of current practice [231]. There were no differences for the mortality outcomes, but the trial found a small increase in muscle weakness at 28 days in the neuromuscular blocker group.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of Evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>No N MBA</td>
<td>N MBA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relative risk</td>
<td>Evidence)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>28-day mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>0.78</td>
<td>Very Low Due to serious inconsistency, indirectness and imprecision (CI 95% 0.58 - 1.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CI 95% 0.58 - 1.06)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from 1,461 patients in 5 studies. ¹ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>372 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>290 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 82 fewer per 1000</td>
<td>(CI 95% 156 fewer - 22 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>90-day mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical</td>
<td>0.81</td>
<td>Very Low Due to serious inconsistency, indirectness and imprecision (CI 95% 0.62 - 1.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CI 95% 0.62 - 1.06)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from 1,461 patients in 5 studies. ³ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>441 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>357 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 84 fewer per 1000</td>
<td>(CI 95% 168 fewer - 26 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ICU mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td>0.72</td>
<td>Very Low Due to serious inconsistency, indirectness and imprecision (CI 95% 0.57 - 0.91)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CI 95% 0.57 - 0.91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from 455 patients in 4 studies. ⁵ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>438 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>315 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 123 fewer per 1000</td>
<td>(CI 95% 188 fewer - 39 fewer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ICU weakness at day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical</td>
<td>1.23</td>
<td>Very Low Due to serious risk of bias and imprecision and very serious indirectness (CI 95% 0.81 - 1.88)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CI 95% 0.81 - 1.88)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from 356 patients in 4 studies. ⁷ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>230 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>283 per 1000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 53 more per 1000</td>
<td>(CI 95% 44 fewer - 202 more)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Barotrauma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td>0.55</td>
<td>Very Low Due to serious risk of bias, indirectness and indirectness (CI 95% 0.35 - 0.85)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CI 95% 0.35 - 0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from 1,426 patients in 4 studies. ⁹ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>74</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>41</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 33 fewer per 1000</td>
<td>(CI 95% 48 fewer - 11 fewer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mechanical ventilation duration Days</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measured by: Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from: 92 patients in 2 studies. ¹¹ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 (Median)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 (Median)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 2 higher</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ventilator-free days at day 28</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Important</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measured by: Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on data from: 1,462 patients in 5 studies. ¹³ (Randomized controlled)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.6 (Median)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.9 (Median)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Difference: 0.3 higher</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. **Inconsistency:** Serious. The magnitude of statistical heterogeneity was high, with I^2:2-50 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. Only one study (largest study) used a high PEEP strategy. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials. **Publication bias:** No serious.


4. **Inconsistency:** Serious. The magnitude of statistical heterogeneity was high, with I^2:2-56 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials. **Publication bias:** No serious.


6. **Inconsistency:** No serious. **Indirectness:** Very Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. The largest trial, with the most applicable strategy reflecting current clinical practice, did not report on this outcome. **Imprecision:** Serious. The largest trial did not report on this outcome. **Publication bias:** No serious.


8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency:** No serious. **Indirectness:** Very Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. The largest trial, with the most applicable strategy reflecting current clinical practice, only included a very small subset of patients for this outcome. **Imprecision:** Serious. Low number of patients. **Publication bias:** No serious.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in COVID-19 patients. **Imprecision:** No serious. **Publication bias:** No serious.


12. **Risk of bias:** Serious. **Inconsistency:** No serious. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. **Imprecision:** Very Serious. Low number of patients. Wide confidence intervals. **Publication bias:** No serious.


14. **Risk of bias:** Serious. **Inconsistency:** No serious. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a...
Evidence To Decision

Benefits and harms
There is no substantial net benefit to using neuromuscular blockers. Prolonged use of NMBAs could have negative effects on intubated patients, such as muscle weakness and difficulty weaning from mechanical ventilation.

Certainty of the Evidence
Outcomes identified as most critical were 90-day mortality and muscle weakness at 28 days. No studies were identified that included patients with COVID-19. Certainty of the evidence for all outcomes is very low, mostly due to serious inconsistency, indirectness and imprecision. There were substantial methodological inconsistencies between the trials.

Preference and values
We have no systematically collected information regarding patients' preferences and values. Since there is uncertainty regarding the critical outcome of muscle weakness, some patients might consider NMBAs unacceptable. The inability to move or communicate while being treated with neuromuscular blockers is likely to be an additional consideration for patients.

The Consumer Panel believes that in line with available evidence, most informed patients would agree with the recommendation for this treatment for COVID-19. The Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

Resources
We have no systematically collected evidence regarding cost-benefit. There are potential resource considerations due to supply issues for some neuromuscular blockers (e.g. cisatracurium).

Equity
There is a risk of creating inequity as some populations may have limited access to neuromuscular blockers, particularly if...
Routine use of continuous infusions of neuromuscular blockers could have negative effects on intubated patients, such as muscle weakness and difficulty weaning from mechanical ventilation. There is a shortage.

**Acceptability**

Neuromuscular blockers may be less acceptable because of possible harms—patients and clinicians may consider the benefits are not worth the risk. In addition to the risk of muscle weakness, patients and their families may deem it unacceptable to be paralysed and non-responsive.

**Feasibility**

Feasibility may be affected by potential supply issues for some neuromuscular blockers (e.g. cisatracurium).

### Rationale

Routine use of continuous infusions of neuromuscular blockers could have negative effects on intubated patients, such as muscle weakness and difficulty weaning from mechanical ventilation.

### Clinical Question/ PICO

**Population:** Mechanically ventilated adults with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation or persistently high plateau pressures  
**Intervention:** Continuous infusion of NMBA  
**Comparator:** No continuous infusion of NMBA

### Summary

Evidence informing this recommendation comes from five randomised trials involving 1461 adults with acute respiratory distress syndrome. Currently, there is no evidence in patients with COVID-19. The five trials compared continuous infusions of neuromuscular blocking agents with cisatracurium for up to 48 hours to no continuous infusions of NMBAs [230][231][232][233][234].

For all critical outcomes, it is uncertain whether infusion of neuromuscular blockers makes a difference. The ROSE trial, which had a different sedation strategy to the other trials and implemented a higher PEEP strategy, is the largest (1006 participants) and most recent trial, and may be the most reflective of current practice [231]. There were no differences for the mortality outcomes, but the trial found a small increase in muscle weakness at 28 days in the neuromuscular blocker group.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
</table>
| 28-day mortality  | Relative risk 0.78 (CI 95% 0.58 - 1.06) Based on data from 1,461 patients in 5 studies. ¹ (Randomized controlled) | 372 per 1000  
290 per 1000  
Difference: 82 fewer per 1000 ( CI 95% 156 fewer - 22 more ) | Very Low  
Due to serious inconsistency, indirectness and imprecision ² | We are uncertain whether neuromuscular blockers improve or worsen 28-day mortality (513 events). |

³ Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce
<table>
<thead>
<tr>
<th>Variable</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>Data Source</th>
<th>Study Count</th>
<th>Risk of Bias</th>
<th>Risk of Indirectness</th>
<th>Risk of Imprecision</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>90-day mortality</td>
<td>0.81</td>
<td>0.62 - 1.06</td>
<td>(Randomized controlled)</td>
<td>5</td>
<td>Very Low</td>
<td>Due to serious inconsistency, indirectness and imprecision</td>
<td>We are uncertain whether neuromuscular blockers improve or worsen 90-day mortality (612 events).</td>
<td></td>
</tr>
<tr>
<td>ICU mortality</td>
<td>0.72</td>
<td>0.57 - 0.91</td>
<td>(Randomized controlled)</td>
<td>4</td>
<td>Very Low</td>
<td>Due to serious inconsistency and very serious indirectness</td>
<td>We are uncertain whether neuromuscular blockers increase or decrease ICU mortality (171 events).</td>
<td></td>
</tr>
<tr>
<td>ICU weakness at day 28</td>
<td>1.23</td>
<td>0.81 - 1.88</td>
<td>(Randomized controlled)</td>
<td>4</td>
<td>Very Low</td>
<td>Due to serious risk of bias and imprecision, and very serious indirectness</td>
<td>We are uncertain whether neuromuscular blockers increase or decrease ICU weakness at day 28 (91 events).</td>
<td></td>
</tr>
<tr>
<td>Barotrauma</td>
<td>0.55</td>
<td>0.35 - 0.85</td>
<td>(Randomized controlled)</td>
<td>4</td>
<td>Very Low</td>
<td>Due to serious risk of bias, indirectness and indirectness</td>
<td>We are uncertain whether neuromuscular blockers improve or worsen barotrauma (81 events).</td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation duration</td>
<td></td>
<td></td>
<td>Based on data from: 92 patients in 2 studies.</td>
<td>2</td>
<td>Very Low</td>
<td>Due to serious risk of bias, inconsistency and indirectness, and very serious imprecision</td>
<td>We are uncertain whether neuromuscular blockers increase or decrease mechanical ventilation duration.</td>
<td></td>
</tr>
<tr>
<td>Ventilator-free days at day 28</td>
<td></td>
<td></td>
<td>Based on data from: 1,462 patients in 5 studies.</td>
<td>5</td>
<td>Very Low</td>
<td>Due to serious risk of bias, indirectness and indirectness</td>
<td>We are uncertain whether neuromuscular blockers improve or worsen ventilator-free days at day 28.</td>
<td></td>
</tr>
<tr>
<td>MRC score at day 28</td>
<td></td>
<td></td>
<td>Measured by: Medical Research Council (MRC) scale</td>
<td>2</td>
<td>Very Low</td>
<td>Due to serious risk of bias and indirectness, and very serious inconsistency</td>
<td>We are uncertain whether neuromuscular blockers improve or worsen MRC score at day 28.</td>
<td></td>
</tr>
</tbody>
</table>

Baseline/comparator: Control arm of reference used for intervention.

2. **Inconsistency:** Serious. The magnitude of statistical heterogeneity was high, with I^2: 2.50 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials.. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. Only one study (largest study) used a high PEEP strategy.. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials.. **Publication bias:** No serious.


Baseline/comparator: Control arm of reference used for intervention.

4. **Inconsistency:** Serious. The magnitude of statistical heterogeneity was high, with I^2: 2.56 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials.. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials.. **Publication bias:** No serious.


6. **Inconsistency:** No serious. **Indirectness:** Very Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19. The largest trial, with the most applicable strategy reflecting current clinical practice, did not report on on this outcome.. **Imprecision:** Serious. The largest trial did not report on this outcome.. **Publication bias:** No serious.


8. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency:** No serious. **Indirectness:** Very Serious. Differences between the population of interest and those studied: no studies in COVID-19 patients. The largest trial, with the most applicable strategy reflecting current clinical practice, only included a very small subset of patients for this outcome.. **Imprecision:** Serious. Low number of patients.. **Publication bias:** No serious.


10. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency:** No serious. **Indirectness:** Very Serious. Differences between the population of interest and those studied: no studies in COVID-19 patients.. **Imprecision:** No serious. **Publication bias:** No serious.


12. **Risk of bias:** Serious. **Inconsistency:** No serious. **Indirectness:** Serious. Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Imprecision:** Very Serious. Low number of patients, Wide confidence intervals. **Publication bias:** No serious.


14. **Risk of bias:** Serious. **Inconsistency:** No serious. **Indirectness:** Serious. Differences between the population of interest and those studied. **Imprecision:** Serious. Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials.. **Publication bias:** No serious.


16. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias. **Inconsistency:** Very Serious. The magnitude of statistical heterogeneity was high, with I^2: 2.91 %. Clinical heterogeneity.. **Indirectness:** Serious. Differences between the population of interest and those studied: No studies in COVID-19 patients.. **Imprecision:** Serious. **Publication bias:** No serious.
8.6 - Positive end-expiratory pressure

Consensus recommendation

For mechanically ventilated adults with COVID-19 and moderate to severe ARDS, consider using a higher PEEP strategy (PEEP > 10 cm H2O) over a lower PEEP strategy.

Evidence To Decision

Benefits and harms

Small net benefit, or little difference between alternatives

While there is no current evidence for using a higher PEEP strategy in patients with COVID-19 and moderate to severe ARDS, a higher PEEP strategy is recommended for ventilated patients with moderate to severe ARDS of other aetiologies. A higher PEEP strategy may be associated potential harms, e.g. pneumothorax.

Certainty of the Evidence

No studies were identified in COVID-19 patients that address the question of lower versus higher PEEP strategy.

Preference and values

No substantial variability expected

We have no systematically collected information regarding patients' preferences and values at this point.

The Consumer Panel believes that in line with expert consensus and the limited available evidence, some informed patients would agree with the recommendation and consider this treatment. The Panel recognises that some informed patients may choose not to have this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.

Resources

No important issues with the recommended alternative

We have no systematically collected evidence regarding cost-benefit.

Equity

No important issues with the recommended alternative

There are likely no important equity issues.

Acceptability

Factor not considered

We are uncertain if a higher PEEP ventilation strategy would be acceptable to both patients and healthcare providers.

Feasibility

No important issues with the recommended alternative

There are likely no important feasibility issues.

Rationale

While there is no current evidence for using a higher PEEP strategy in patients with COVID-19 and moderate to severe ARDS, a higher PEEP strategy is recommended for ventilated patients with moderate to severe ARDS of other aetiologies.

Adaptation

The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208].
8.7 - Prone positioning

**Info Box**
Positioning the patient in a face-down (prone) position may help to open up (recruit) collapsed alveoli and improve oxygen levels in the blood.

8.7.1 - Prone positioning for adults

**Consensus recommendation**
For mechanically ventilated adults with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning for more than 12 hours a day.

Current reports suggest prone ventilation is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

Net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

**Evidence To Decision**

**Benefits and harms**
While there is no current evidence for using prone positioning in patients with COVID-19, it is recommended for ventilated patients with moderate to severe ARDS of other aetiologies. In these patients it is known to have a survival benefit, but may increase the risk of harms from complications such as pressure injury, endotracheal tube obstruction or accidental extubation.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Net clinical benefit for each patient should be considered on a case-by-case basis. For example, older people living with frailty may be at particular risk of harm from proning. The symptom benefits of proning in palliative patients remain unclear.

**Certainty of the Evidence**
No studies were identified in COVID-19 patients that address the interventions or outcomes of interest.

**Preference and values**
We have no systematically collected information regarding patients’ preferences and values at this point.

**People requiring palliative care and older people living with frailty or cognitive impairment**
Consider the preferences and values of the patient and whether they have an advanced care directive or plan. Decisions around proceeding to more invasive forms of ventilation should be discussed with the patient or their medical treatment decision-maker.
The Consumer Panel believes that in line with expert consensus and the limited available evidence, most informed patients/carers would agree with the recommendation for this treatment. The Panel recognises that some informed patients/carers may choose not to proceed with this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Proning is associated with significant cost since additional staff are needed to move and monitor those in prone position. Healthcare workers must be effectively trained to facilitate safe practice.

**Equity**

There is the potential for inequity as some healthcare facilities may not have sufficient staff to offer prone positioning.

**Acceptability**

We have no systematically collected evidence regarding acceptability. Clear communication from health professionals regarding the possible benefits and harms of prone positioning is essential.

**Feasibility**

Prone positioning of mechanically ventilated patients is likely feasible if performed by trained personnel in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

**People requiring palliative care and older people living with frailty or cognitive impairment**

It may not be feasible to prone patients in this population as they may be at particular risk of harm from proning.

**Adaptation**

The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.
Consensus recommendation

For adults with COVID-19 and respiratory symptoms who are receiving any form of supplemental oxygen therapy and have not yet been intubated, consider prone positioning for at least 3 hours per day as tolerated. When positioning a patient in prone, ensure it is used with caution and accompanied by close monitoring of the patient. Use of prone positioning should not delay endotracheal intubation and mechanical ventilation in patients with COVID-19 who are deteriorating despite optimised less invasive respiratory therapies.

Vulnerable people who are treated outside the ICU, for example people who are older and living with frailty, cognitive impairment or unable to communicate, may particularly be at increased risk of harm from proning. Despite the potential risks of awake proning associated with frailty, there may be benefits for this group. The net clinical benefit for each individual patient should be considered on a case-by-case basis.

Currently, there is limited evidence to suggest prone positioning could be effective in improving oxygenation in patients with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events.

Evidence To Decision

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Small net benefit, or little difference between alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prone positioning is recommended in mechanically ventilated patients with moderate to severe ARDS of other aetiologies. In these patients it is known to have a survival benefit, but may increase the risk of possible harms such as pressure injury.</td>
<td></td>
</tr>
<tr>
<td>People requiring palliative care and older people living with frailty or cognitive impairment</td>
<td></td>
</tr>
<tr>
<td>Net clinical benefit for each individual patient should be considered on a case-by-case basis. For example, older people living with frailty who are treated outside the ICU and patients who are unable to communicate may be at particular risk of harm from proning.</td>
<td></td>
</tr>
</tbody>
</table>

Certainty of the Evidence

No trials were identified in COVID-19 patients that address the interventions or outcomes of interest.

Preference and values | Substantial variability is expected or uncertain |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected information regarding patients' preferences and values at this point. However, patients in one small prospective cohort study who received proning rated their comfort levels as acceptable, good or excellent.</td>
<td></td>
</tr>
<tr>
<td>The Consumer Panel believes that in line with expert consensus and the limited available evidence, most informed patients/carers would agree with the recommendation for this treatment. The Panel recognises that some informed patients/carers may choose not to proceed with this treatment based on reasons unrelated to COVID-19.</td>
<td></td>
</tr>
<tr>
<td>The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.</td>
<td></td>
</tr>
</tbody>
</table>

Resources | Important issues, or potential issues not investigated |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Proning is associated with significant cost as additional staff are needed to move and monitor those in prone position. Healthcare workers must be trained to facilitate safe practice.</td>
<td></td>
</tr>
</tbody>
</table>
Equity
Staff carrying out prone positioning need to move and monitor those who are in the prone position, which may be resource intensive. This may result in potential inequity as some healthcare facilities may not be able to offer prone positioning.

Important issues, or potential issues not investigated

Acceptability
We have no systematically collected evidence regarding acceptability of prone positioning. Clear communication from health professionals regarding the possible benefits and harms of prone positioning is essential.

Important issues, or potential issues not investigated

Feasibility
Prone positioning is likely feasible if performed by trained personnel in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events.

People requiring palliative care and older people living with frailty or cognitive impairment
It may not be feasible to prone patients in this population as older people living with frailty and patients who are unable to communicate may be at particular risk of harm from proning. Feasibility may vary depending on setting and may be less feasible when patients are treated outside the ICU.

No important issues with the recommended alternative

Rationale
Prone positioning is used in people with severe hypoxaemic respiratory failure in the context of ARDS. In ventilated people with ARDS, prone positioning improves oxygenation and clinical outcomes. Prone positioning is thought to work by improving tidal ventilation, especially to dependent parts of the lung, enhancing ventilation and perfusion matching as well as favourably distributing the pleural pressures throughout the lung thus minimising further damage.

Clinical Question/ PICO

| Population: | Patients with COVID-19 on supplementary oxygen who are not yet intubated |
| Intervention: | Prone positioning |
| Comparator: | No prone positioning |

Summary
This is a consensus based recommendation. At present, there are no randomised trials that compare proning to not proning in patients with COVID-19 who are receiving supplementary oxygen but not yet intubated (awake proning). One prospective cohort study of 56 patients with confirmed COVID-19 reported patient comfort levels [235]. All 47 patients who received proning rated their comfort levels as acceptable, good or excellent. Proning was not feasible in five patients due to discomfort during positioning.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not proning</td>
<td>Proning</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See Summary
8.7.2 - Prone positioning for pregnant and postpartum women

Consensus recommendation

For mechanically ventilated pregnant women with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning for more than 12 hours a day.

Current reports suggest prone ventilation in adult patients is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff, and that minimises the risk of adverse events, e.g. accidental extubation.

Proning of a pregnant woman should avoid abdominal compression and ensure a woman's hips and chest are supported. In the absence of specialised equipment, proning can be performed using pillows and blankets.

Proning can be challenging in late gestation and delivery of the baby may be warranted.

Evidence To Decision

Benefits and harms

The benefit of prone positioning in pregnant women with COVID-19 is unknown, but it may improve lung mechanics and gas exchange. However, it can be associated with harms such as hypoperfusion, compartment syndrome, pressure ulcers, airway swelling and peripheral arterial compression.

Certainty of the Evidence

No studies were identified in COVID-19 patients that address the interventions or outcomes of interest.

Preference and values

We have no systematically collected information regarding the preferences and values of pregnant and breastfeeding women with COVID-19 at this point.

The Consumer Panel believes that in line with expert consensus and the limited available evidence, most informed pregnant or postpartum women in this group of COVID-19 patients would agree with the recommendation and consider this treatment. The Panel recognises that some pregnant or postpartum women may choose not to have this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

Resources

We have no systematically collected evidence regarding cost-benefit. Caring for pregnant women with COVID-19 (irrespective of prone positioning) requires greater resources than for women without COVID-19. Proning is associated with significant cost since additional staff are needed to move and monitor those in prone position. Healthcare workers must be effectively trained to facilitate safe practice.

Equity

There is the potential for inequity as some healthcare facilities may not have sufficient staff to offer prone positioning.
**Acceptability**

We have no systematically collected evidence regarding acceptability. Acceptability of prone positioning is expected to vary and individual preferences should be considered. Clear communication from health professionals regarding the possible benefits and harms of prone positioning is essential.

**Feasibility**

Prone positioning may be less feasible later in pregnancy. Prone positioning of mechanically ventilated patients is likely feasible if performed by trained personnel in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

**Consensus recommendation**

For pregnant and postpartum women with COVID-19 and respiratory symptoms who are receiving any form of supplemental oxygen therapy and have not yet been intubated, consider prone positioning. When positioning a pregnant woman in prone, care should be taken to support the gravid uterus to reduce aorta-caval compression. Women who are deteriorating should be considered for early endotracheal intubation and invasive mechanical ventilation. Birth of the baby should be considered when it may enhance maternal resuscitation or be beneficial to the fetus.

Current reports suggest prone ventilation in adult patients is effective in improving hypoxia associated with COVID-19. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

Proning of a pregnant woman should avoid abdominal compression and ensure a woman’s hips and chest are supported. In the absence of specialised equipment, it can be performed using pillows and blankets.

Proning can be challenging in late gestation and delivery of the baby may be warranted.

**Evidence To Decision**

**Benefits and harms**

The benefit of prone positioning in pregnant women with COVID-19 is unknown, but it may improve lung mechanics and gas exchange. However, it can be associated with harms such as hypoperfusion, compartment syndrome, pressure ulcers, airway swelling and peripheral arterial compression.

**Certainty of the Evidence**

No studies were identified in COVID-19 patients that address the interventions or outcomes of interest.

**Preference and values**

We have no systematically collected information regarding the preferences and values of pregnant and breastfeeding women with COVID-19 at this point.

The Consumer Panel believes that in line with expert consensus and the limited available evidence, some informed pregnant or postpartum women in this group of COVID-19 patients would agree with the recommendation and consider this treatment. The Panel recognises that some pregnant or postpartum women may choose not to have this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients would agree that infection control precautions are
8.8 - Recruitment manoeuvres

Patients receiving respiratory support are at an increased risk of lung injury. Recruitment manoeuvres are used to open up ('recruit') collapsed alveoli and are a common element of an 'open lung approach' to protect the lungs during mechanical ventilation. The manoeuvres use a sustained increase in airway pressure to re-open collapsed alveoli.

Types of manoeuvres include: prolonged high continuous positive airway pressure; progressive incremental increases in positive end-expiratory pressure at a constant driving pressure (incremental PEEP, stepwise or staircase); and high driving pressures.

**Consensus recommendation**

For mechanically ventilated adults with COVID-19 and hypoxaemia despite optimising ventilation, consider using recruitment manoeuvres.

If recruitment manoeuvres are used, do not use staircase or stepwise (incremental PEEP) recruitment manoeuvres.
Evidence To Decision

**Benefits and harms**
Recruitment manoeuvres may benefit mechanically ventilated patients with COVID-19 by opening collapsed lung units during mechanical ventilation. However, they may also be associated with harms, such as increased risk of barotrauma and transient hypotension.

**Certainty of the Evidence**
No studies were identified in COVID-19 patients that compare recruitment manoeuvres to no recruitment manoeuvres or variations on recruitment manoeuvres.

**Preference and values**
We have no systematically collected information regarding patients’ preferences and values at this point.

The Consumer Panel believes that in line with expert consensus and the limited available evidence, most informed patients would agree with the recommendation for this treatment. The Panel recognises that some informed patients may choose not to proceed with this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients would agree that infection control precautions are optimised to minimise the risk of infection for others.

**Resources**
We have no systematically collected evidence regarding cost-benefit. However, patients receiving recruitment manoeuvres may require more intensive monitoring.

**Equity**
There are likely no important equity issues.

**Acceptability**
We are uncertain if recruitment manoeuvres would be acceptable to both patients and healthcare providers.

**Feasibility**
There are likely no important feasibility issues.

**Adaptation**
The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.
8.9 - Extracorporeal membrane oxygenation

Info Box

Extracorporeal membrane oxygenation (ECMO) is a form of life support that removes blood from the body via large cannulae, oxygenates and removes carbon dioxide from the blood external to the patient, and then returns the blood to the body.

Venovenous (VV) ECMO provides oxygenation support for the lungs only, while venoarterial (VA) ECMO supports the heart and lungs.

8.9.1 - ECMO for adults

Conditional recommendation

Consider early referral to an ECMO centre for patients developing refractory respiratory failure in mechanically ventilated adults with COVID-19 (despite optimising ventilation, including proning and neuromuscular blockers). Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected patients with COVID-19 and severe ARDS.

Net clinical benefit for each patient should be considered on a case-by-case basis, as factors such as frailty, advanced illness or comorbidity may lessen the benefit and increase potential harms.

Decisions around proceeding to more invasive forms of therapy should consider the preferences and values of the patient and whether they have an advanced care directive or plan, and should be discussed with the patient or their substitute / medical treatment decision-maker.

Evidence To Decision

Benefits and harms

ECMO is only used as a form of life support in patients who are severely ill—it may increase oxygenation and reduce ventilator-induced lung injuries, which may assist to increase recovery and decrease mortality. However, ECMO may be associated with risk of serious side effects, such as major bleeding, disseminated intravascular coagulation and injuries from cannulation. ECMO is only used in carefully selected patients who are at decreased risk of harms from receiving ECMO and may benefit the most from the potential survival benefits of ECMO.

People requiring palliative care and older people living with frailty or cognitive impairment

Net clinical benefit for each patient should be considered on a case-by-case basis. For example, older people living with frailty may be at particular risk of harm from more invasive forms of therapy, and the symptom benefits in palliative patients remain unclear.

Certainty of the Evidence

Two non-comparative observational studies were identified in COVID-19 patients receiving ECMO.

Preference and values

We have no systematically collected information regarding patients' preferences and values at this point. However, the serious risk of side effects may be unacceptable for some patients and their families.
People requiring palliative care and older people living with frailty or cognitive impairment
Consider the preferences and values of the patient and whether they have an advanced care directive or plan. Decisions around proceeding to more invasive forms of therapy should be discussed with the patient or their medical treatment decision-maker.

The Consumer Panel believes that in line with the limited available evidence, some informed patients/carers may prefer to wait until the available evidence is clearer, while others may agree to have more invasive treatment initiated if this is consistent with their goals of care. The Panel recognises that some patients/carers may still choose not to have this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.

Resources
We have no systematically collected evidence regarding cost-benefit. ECMO is resource-intensive and requires experienced centres, healthcare workers and infrastructure.

Equity
Due to the resource-intensive nature of ECMO there may be issues with inequity as only certain centres will have the ability to offer ECMO or ECMO retrieval. ECMO will only be considered in selected patients who are likely to have access to appropriate centres.

Acceptability
There may be important issues with acceptability. The intervention could be considered less acceptable due to its possible harms and some may not consider its benefits worth the risk.

Feasibility
Due to the resource-intensive nature of ECMO there are likely to be feasibility issues. ECMO is likely to only be feasible in a limited number of centres.

Adaptation
The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.

Clinical Question/ PICO
Population: Patients with COVID-19
Intervention: ECMO
Comparator: No ECMO

Summary
We are uncertain if extracorporeal membrane oxygenation (ECMO) is more effective than no ECMO in patients who are critically ill with COVID-19. ECMO may be associated with risk of serious side effects.

Systematic reviews of ECMO for acute respiratory failure in non-COVID-19 patients suggest there may be a benefit.
but that ECMO may also be associated with significant harms. Data comparing ECMO to no ECMO in patients with COVID-19 are still lacking.

What is the evidence informing this recommendation?
Evidence comes from two non-comparative observational studies in critically ill patients with COVID-19 receiving ECMO. One study included 1035 patients [236] and the other included 83 patients [237].

Study characteristics
The Extracorporeal Life Support Organization (ELSO) Registry included 1035 patients (median age of 49 years) from 213 hospitals in 36 countries [236]. The proportion of women was 26%, of whom 22 were pregnant. Ninety-four percent of patients received venovenous ECMO. Before initiation of ECMO, 72% of patients received neuromuscular blockers, 60% were placed in prone position and 99% were ventilated. Before ventilation, 59% of patients received non-invasive ventilation and 35% high-flow nasal oxygen therapy. Patients received pharmacological therapies for COVID-19, including chloroquine or hydroxychloroquine (52%), glucocorticoids (41%), anticytokine (28%), lopinavir–ritonavir (11%), remdesivir (8%) and intravenous immunoglobulin (3%).

In the retrospective cohort of 83 patients from five ICUs in France, median age was 49 years and the proportion of women was 27% [237]. Ninety-seven percent of patients received venovenous ECMO. Before initiation of ECMO, 96% of patients received neuromuscular blockers and 94% were placed in prone position. Patients received pharmacological therapies for COVID-19, including lopinavir-ritonavir (23%), hydroxychloroquine (19%), high-dose corticosteroids (14%), tocilizumab (10%) and remdesivir (10%).

What are the main results?
In the ELSO registry study, at 90 days following initiation of ECMO, 37% of patients had died in hospital, 30% were discharged home or to an acute rehabilitation centre, 17% were discharged to another hospital, 10% were discharged to a long-term acute care centre or unspecified location, and 6% either remained in ICU or hospital.

A subgroup analysis found that the risk of in-hospital mortality increased with age. Acute kidney injury, chronic respiratory insufficiency, an immunocompromised state, or a pre-ECMO cardiac arrest were also associated with an increased risk of in-hospital mortality. Conversely, higher PaO2:FiO2 was associated with lower mortality. Renal replacement therapy was used in 44% of patients. Complications other than renal replacement therapy were reported in 55% of patients.

The retrospective cohort of five ICUs in France reported that at 90 days 36% of patients had died, 56% were discharged from ICU, 6% were in ICU but no longer receiving ECMO and 1% were still receiving ECMO. Renal replacement therapy was used in 46% of patients. The most common ECMO-related complications were massive haemorrhage (42% of patients) and ECMO-circuit changes (27%). Other complications were also observed.

Our confidence in the results
Certainty of the evidence is very low due to reliance on non-comparative observational data.

Additional information
While the ELSO registry included data from many countries, it may not be generalisable to the Australian setting. Mortality rates in Australia have been lower than most other countries and Australia’s health system has been operating within its capacity, unlike in other parts of the world where resource considerations may have contributed to adverse outcomes.

Of note, patients received therapies for COVID-19 that are not currently recommended by our guideline, with 19 to 54% of patients receiving chloroquine or hydroxychloroquine and 11 to 23% receiving lopinavir-ritonavir. Our guideline recommends corticosteroids in patients requiring oxygen, which includes all patients receiving ECMO—only 14 to 41% of patients in these studies received steroids.
8.9.2 - ECMO for pregnant and postpartum women

**Consensus recommendation**

Consider referral to an ECMO centre for venovenous ECMO in mechanically ventilated pregnant women with COVID-19 and refractory respiratory failure (despite optimising ventilation, including proning). Delivery of the baby prior to ECMO to enhance maternal resuscitation should be considered on a case-by-case basis.

*Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected pregnant women with COVID-19 and severe ARDS.*

*The decision on whether to use ECMO should be taken in consultation with the woman’s family, as well as obstetric and intensive care specialists. Key considerations include gestational age, fetal viability, fetal well-being and the risks and benefits to mother and baby.*

*Early referral to an ECMO centre is preferred.*

*As pregnant and postpartum women may have haemostatic alterations, anticoagulation regimens may need to be modified appropriately.*

---

**Evidence To Decision**

**Benefits and harms**

The benefit of ECMO in pregnant women with COVID-19 is unclear. ECMO is only used as a form of life support in selected patients who are severely ill; it aims to increase oxygenation and reduce ventilator-induced lung injuries. However, it may be associated with risk of serious side effects, such as major bleeding and injuries from cannulation. The need for anticoagulation and risk of bleeding concomitant to the use of ECMO needs to be considered carefully in pregnant women, given that this therapy may not be effectively administrated without anticoagulation and it increases the risk of bleeding in pregnant women.

**Certainty of the Evidence**

No studies were identified in COVID-19 patients that compare ECMO to no ECMO.

**Preference and values**

We have no systematically collected information regarding patients’ preferences and values at this point. However, the...
ECMO is only used as a form of life support in those who are severely ill with refractory respiratory failure (despite optimising ventilation, including proning) and aims to increase oxygenation and reduce ventilator-induced lung injuries. It is recommended as a therapy for selected patients with severe ARDS of other aetiologies.

The Consumer Panel believes that in line with the limited available evidence, some informed patients/carers may prefer to wait until the available evidence is clearer, while others may agree to have more invasive treatment initiated if this is consistent with their goals of care. The Panel recognises that some patients/carers may still choose not to have this treatment based on reasons unrelated to COVID-19.

The Consumer Panel also believes that most informed patients/carers would agree that infection control precautions are optimised to minimise the risk of infection for others.

**Resources**

We have no systematically collected evidence regarding cost-benefit. ECMO is resource-intensive and requires experienced centres, healthcare workers and infrastructure.

**Equity**

Due to the resource-intensive nature of ECMO there may be issues with inequity as only certain centres will have the ability to offer ECMO and it will only be considered in selected patients who are likely to have access to these centres.

**Acceptability**

There may be important issues with acceptability. The intervention could be considered less acceptable due to its possible harms and some may not consider its benefits worth the risk.

**Feasibility**

Due to the resource-intensive nature of ECMO there are likely to be feasibility issues. ECMO is likely to only be feasible in a limited number of centres.

**Rationale**

ECMO is only used as a form of life support in those who are severely ill with refractory respiratory failure (despite optimising ventilation, including proning) and aims to increase oxygenation and reduce ventilator-induced lung injuries. It is recommended as a therapy for selected patients with severe ARDS of other aetiologies.
9 - Respiratory support in neonates, children and adolescents

The primary panel for the recommendations in this section is the Paediatric and Adolescent Care Panel. Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

9.1 - Requiring non-invasive respiratory support

9.1.1 - High-flow nasal oxygen and non-invasive ventilation

Info Box

High-flow nasal oxygen (HFNO) therapy is a form of respiratory support where warmed, humidified oxygen is delivered at high-flow rates.

Non-invasive ventilation (NIV) refers to any type of positive pressure support delivered without an endotracheal tube during spontaneous breathing. Supplemental oxygen can also be delivered through the device.

HFNO or NIV should be considered when low-flow oxygen is unable to maintain target peripheral oxygen saturation and/or to treat respiratory distress. Target peripheral oxygen saturations may vary in neonates, children and adolescents with co-morbid conditions, such as preterm birth, cyanotic congenital heart disease or chronic lung disease.

Practical Info

High-flow nasal oxygen

The concentration of oxygen can be titrated (using a blender) between 21% and 100%. Flow rates can be given up to 60 L/min in adults. In children, flow rates are typically 2 L/kg/min (maximum 50 L/min), except in neonates ≤ 4 kg where flow rates of 4 to 8 L/min are typically used.

Consensus recommendation

Consider using high-flow nasal oxygen (HFNO) or non-invasive ventilation (NIV) therapy for neonates, children and adolescents with hypoxaemia or respiratory distress associated with COVID-19 and not responding to low-flow oxygen. Use it with caution and pay strict attention to staff safety, including the use of appropriate PPE.

The preferred location for high-flow nasal oxygen is a negative pressure room or a single room with the door closed. If these locations are not immediately available then HFNO or NIV should not be withheld if indicated. However, it should be recognised that this therapy may pose an aerosol risk to staff and other patients, and appropriate precautions should be used.

In children and adolescents with COVID-19 for whom HFNO or NIV is appropriate for an alternate clinical presentation (e.g. concomitant bronchiolitis or severe asthma), ensure airborne and other infection control precautions are also optimised.

Consider early transfer in the deteriorating neonate, child or adolescent to a specialised paediatric or neonatal critical care unit.

Evidence To Decision

Benefits and harms

Evidence from non-COVID neonates with acute hypoxaemic respiratory failure shows a reduction in endotracheal intubation and chronic lung disease. NIV/HFNO may be helpful for children with severe bronchiolitis or asthma and may
reduce the need for intubation. Since NIV/HFNO is a known aerosol-generating procedure, with possible increased risk of aerosolisation with poor mask fit [17], harms associated with a potential risk of transmission to healthcare workers need to be considered and the procedure used with caution, with strict attention paid to staff safety. Benefits and harms need to be considered in the context of the relevant alternate clinical presentation.

Certainty of the Evidence

No studies were identified in neonates, children and adolescents with COVID-19 that address the interventions, comparators and outcomes of interest.

Preference and values

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians.

Resources

We have no systematically collected evidence regarding cost-benefit. NIV/HFNO requires less staffing and equipment than mechanical ventilation via an endotracheal tube. There are likely to be resource issues associated with different settings. There are limited negative pressure rooms in private and some public hospitals, although some hospitals have converted rooms into negative pressure rooms.

There are additional resource considerations for hospital spaces where caution needs to be applied and strict attention paid to staff safety. In single rooms or shared ward spaces with cohorting of neonates, children and adolescents with confirmed COVID-19, there are additional resource considerations for use of PPE and performing NIV/HFNO safely.

Equity

There may be equity issues due to the availability of negative pressure rooms and hospital spaces that are able to perform NIV/HFNO safely. NIV/HFNO can be provided in hospital settings outside an intensive care unit.

Acceptability

We have no systematically collected information regarding acceptability. NIV/HFNO is generally a well-accepted practice by neonates, children and adolescents, their families and healthcare providers in non-COVID-19 conditions.

Feasibility

There may be feasibility issues due to the availability of negative pressure rooms and hospital spaces that are able to perform NIV/HFNO safely.

9.1.2 - Prone positioning (non-invasive)

Consensus recommendation

For neonates, children and adolescents with COVID-19 and respiratory symptoms who are receiving non-invasive respiratory support, consider prone positioning if patient co-operation is possible. When positioning a patient prone, ensure it is used with caution and close monitoring of the patient.
Evidence To Decision

**Benefits and harms**

While there is no current evidence for using prone positioning in neonates, children and adolescents with COVID-19, it is recommended for ventilated, children and adolescents with moderate to severe ARDS due to non-COVID causes, and is frequently used in neonates requiring mechanical ventilation. In these patients it may have a survival benefit but may also increase the risk of harms from complications, such as pressure injury, endotracheal tube obstruction or accidental extubation. Younger children who are awake and not receiving mechanical ventilation are less likely to comply with prolonged periods of prone positioning.

**Certainty of the Evidence**

No studies were identified in neonates, children and adolescents with COVID-19 that address the interventions or outcomes of interest.

**Preference and values**

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians. Children with milder respiratory disease and not receiving sedation may not comply with prone positioning.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Prone positioning is not associated with significant cost for infants and small children who require minimal nursing care to position. In larger children and adolescents, additional staff are needed to move and monitor in prone position, which will increase costs. Healthcare workers must be trained to facilitate safe practice in larger children and adolescents.

**Equity**

There is the potential for inequity as some healthcare facilities may not have sufficient staff or training to offer prone positioning.

**Acceptability**

We have no systematically collected evidence regarding acceptability. Clear communication from health professionals regarding the possible benefits and harms of prone positioning is essential.

**Feasibility**

Prone positioning of mechanically ventilated neonates, children and adolescents is feasible if performed by trained personnel in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

**Adaptation**

The recommendation is adapted from published recommendations by the Surviving Sepsis Campaign [208]. Wording has been adapted for clarity and applicability to the Australian context.
9.1.3 - Respiratory management of the deteriorating child

<table>
<thead>
<tr>
<th>Consensus recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider endotracheal intubation and mechanical ventilation in neonates, children and adolescents with COVID-19 who are deteriorating despite optimised, non-invasive respiratory support.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence To Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benefits and harms</strong></td>
</tr>
<tr>
<td>Benefits and harms should be considered on a case-by-case basis before undertaking invasive respiratory support, especially in children with a pre-existing life-limiting illness. There are well-known benefits of invasive ventilation, including improved oxygenation and reduced mortality in ARDS due to causes other than COVID-19. Harms relevant to SARS-CoV-2 transmission should be considered as with all children with respiratory failure—there may be complications related to invasive mechanical ventilation. There may also be accentuated risks of COVID-19 transmission to other patients or staff in critical care settings.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certainty of the Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>No studies in neonates, children and adolescents with COVID-19 were identified that address the interventions, comparators and outcomes of interest.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preference and values</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. However, there are likely to be resource issues associated with different settings.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>We recognise that access to staff trained in paediatric critical care is not equitable, and is concentrated in tertiary metropolitan hospitals or retrieval services. Some children may therefore not have immediate access to a clinician with skills and experience intubating a critically ill child.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Although we have no systematically collected evidence regarding acceptability, we do not expect acceptability issues in neonates, children and adolescents.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to staff trained in paediatric critical care in rural and remote areas may impact on feasibility for intubation.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence for management of severe COVID-19 in children is limited. However, there are no data to suggest modifications to standard respiratory care are necessary.</td>
</tr>
</tbody>
</table>
### 9.2 - Requiring invasive mechanical ventilation

#### 9.2.1 - Prone positioning (mechanical ventilation)

**Consensus recommendation**

For mechanically ventilated neonates, children and adolescents with COVID-19 and hypoxaemia despite optimising ventilation, consider prone positioning if there are no contraindications.

#### Evidence To Decision

**Benefits and harms**

Substantial net benefits of the recommended alternative

While there is no current evidence for using prone positioning in neonates, children and adolescents with COVID-19, it is recommended for ventilated children and adolescents with moderate to severe ARDS due to non-COVID causes, and is frequently used in neonates requiring mechanical ventilation. In these patients it may have a survival benefit but may also increase the risk of harms from complications such as pressure injury, endotracheal tube obstruction or accidental extubation. Younger children are less likely to comply with prolonged periods of prone positioning.

**Certainty of the Evidence**

No studies were identified in neonates, children or adolescents with COVID-19 that address the interventions or outcomes of interest.

**Preference and values**

Substantial variability is expected or uncertain

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians.

**Resources**

Important issues, or potential issues not investigated

We have no systematically collected evidence regarding cost-benefit. Prone positioning is not associated with significant cost for infants and small children since they require minimal nursing care to position. In larger children and adolescents, additional staff are needed to move and monitor in prone position, which will increase costs. Healthcare workers must be trained to facilitate safe practice in larger children and adolescents.

**Equity**

Important issues, or potential issues not investigated

There is the potential for inequity as some healthcare facilities may not have sufficient staff or training to offer prone positioning.

**Acceptability**

Important issues, or potential issues not investigated

We have no systematically collected evidence regarding acceptability. Clear communication from health professionals regarding the possible benefits and harms of prone positioning is essential.

**Feasibility**

No important issues with the recommended alternative

Prone positioning of mechanically ventilated children and adolescents is feasible if performed by trained personnel in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.
Rationale

Current reports suggest prone ventilation is effective in improving hypoxia associated with COVID-19 in adults. This should be done in the context of a hospital guideline that includes suitable personal protective equipment (PPE) for staff and which minimises the risk of adverse events, e.g. accidental extubation.

9.2.2 - Positive end-expiratory pressure (PEEP)

For mechanically ventilated neonates, children and adolescents with COVID-19 and moderate to severe ARDS with atelectasis, consider using a higher PEEP strategy over a lower PEEP strategy. The absolute PEEP values that constitute a high and low PEEP strategy will depend on age and patient size.

Evidence To Decision

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Small net benefit, or little difference between alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>While there is no current evidence for using a higher PEEP strategy in neonates, children and adolescents with COVID-19 and moderate to severe ARDS, higher PEEP levels are recommended for ventilated neonates, children and adolescents with moderate to severe ARDS of other aetiologies. A high PEEP level may be associated with potential harms, including increased work of breathing, hypotension and air leaks.</td>
<td></td>
</tr>
</tbody>
</table>

Certainty of the Evidence

No studies were identified in neonates, children or adolescents with COVID-19 that address the question of lower versus higher PEEP strategy.

Preference and values

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians.

Resources

We have no systematically collected evidence regarding cost-benefit.

Equity

There are likely no important equity issues.

Acceptability

We are uncertain if a higher PEEP ventilation strategy would be acceptable to neonates, children, adolescents and their families, and healthcare providers.

Feasibility

There are likely no important feasibility issues.
9.2.3 - Recruitment manoeuvres

Info Box

Neonates, children and adolescents receiving respiratory support are at an increased risk of lung injury. Recruitment manoeuvres are used to open up ('recruit') collapsed alveoli and are a common element of an 'open lung approach' to protect the lungs during mechanical ventilation. The manoeuvres use a sustained increase in airway pressure to re-open collapsed alveoli.

Types of manoeuvres include: prolonged high continuous positive airway pressure; progressive incremental increases in positive end-expiratory pressure at a constant driving pressure, or the use of escalating mean airway pressure during high-frequency oscillatory ventilation (incremental PEEP, stepwise or staircase); and high driving pressures.

Consensus recommendation

For mechanically ventilated neonates, children and adolescents with COVID-19 and hypoxic respiratory failure characterised by severe atelectasis unresponsive to other ventilation strategies, consider using recruitment manoeuvres.

In neonates and infants, staircase or stepwise incremental recruitment manoeuvres should only be performed using mean airway pressure in a high-frequency oscillatory ventilation mode. Staircase or stepwise (incremental PEEP) recruitment manoeuvres should not be performed during conventional ventilation.

Evidence To Decision

Benefits and harms

Recruitment manoeuvres may benefit mechanically ventilated children and adolescents with severe hypoxaemia due to COVID-19 by opening collapsed lung units and improving oxygenation and lung mechanics during mechanical ventilation. However, they may also be associated with harms, such as the increased risk of volutrauma/barotrauma and hypotension.

Certainty of the Evidence

No studies were identified in neonates, children or adolescents with COVID-19 that compare recruitment manoeuvres to no recruitment manoeuvres or variations on recruitment manoeuvres.

Preference and values

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians.

Resources

We have no systematically collected evidence regarding cost-benefit. However, neonates, children and adolescents receiving recruitment manoeuvres may require more intensive monitoring.
Due to the potential to cause transient cardiovascular instability, and the requirement for intensive monitoring, recruitment manoeuvres in neonates, children and adolescents will usually only be performed in a dedicated paediatric critical care setting by an experienced clinician familiar with the intervention.

We are uncertain if recruitment manoeuvres would be acceptable to neonates, children, adolescents and their families, and healthcare providers.

There are likely no important feasibility issues.

9.2.4 - Neuromuscular blockers

For intubated neonates, children and adolescents with COVID-19, do not routinely use continuous infusions of neuromuscular blocking agents (NMBAs).

However, if effective lung-protective ventilation cannot be achieved, consider targeted intermittent use of NMBAs. If indicated, the choice of NMBA should be guided by the age group and regional practice.

There is no substantial net benefit to using neuromuscular blockers. Prolonged use of NMBAs could have negative effects on intubated neonates, children and adolescents, such as muscle weakness, oedema and difficulty weaning from mechanical ventilation.

Outcomes identified as most critical were 90-day mortality and muscle weakness at 28 days. No studies were identified that included neonates, children or adolescents with COVID-19. Certainty of the evidence for all outcomes is very low, mostly due to serious inconsistency, indirectness and imprecision. There were substantial methodological inconsistencies between the trials involving adults with COVID-19.

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians. Since there is uncertainty regarding the critical outcome of muscle weakness, some might consider NMBAs unacceptable. The inability to move or communicate while being treated with neuromuscular blockers is likely to be an additional consideration for children and adolescents.
We have no systematically collected evidence regarding cost-benefit. There are potential resource considerations due to supply issues for some neuromuscular blockers.

**Equity**

There is a risk of creating inequity as some facilities may have limited access to neuromuscular blockers suitable for neonates, children and adolescents.

**Acceptability**

As the indication for NMBAs in severe or critical COVID-19 disease is to improve critical care delivery, generally NMBAs will be acceptable to neonates, children, adolescents and their families. The potential harms and effects of NMBAs may be less acceptable to some children, adolescents and their families, especially being paralysed and non-responsive. Clinicians should weigh the risks and benefits in decision making.

**Feasibility**

Feasibility may be affected by potential supply issues for some neuromuscular blockers.

**Rationale**

Routine use of continuous infusions of neuromuscular blockers could have negative effects on intubated neonates, children and adolescents, such as muscle weakness, oedema and difficulty weaning from mechanical ventilation.

**Clinical Question/ PICO**

| Population: | Mechanically ventilated children and adolescents with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation or persistently high plateau pressures |
| Intervention: | Continuous infusion of NMBA |
| Comparator: | No continuous infusion of NMBA |

**Summary**

Evidence informing this recommendation comes from five randomised trials involving 1461 adults with acute respiratory distress syndrome. Currently, there is no evidence in patients with COVID-19. The five trials compared continuous infusions of neuromuscular blocking agents with cisatracurium for up to 48 hours to no continuous infusions of NMBAs.[230][231][232][233][234].

For all critical outcomes, it is uncertain whether infusion of neuromuscular blockers makes a difference. The ROSE trial, which had a different sedation strategy to the other trials and implemented a higher PEEP strategy, is the largest (1006 participants) and most recent trial, and may be the most reflective of current practice [231]. There were no differences for the mortality outcomes, but the trial found a small increase in muscle weakness at 28 days in the neuromuscular blocker group.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Relative Risk (CI 95%)</th>
<th>Based on Data</th>
<th>Randomized Controlled</th>
<th>Difference</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>28-day mortality</td>
<td>0.78 (0.58 - 1.06)</td>
<td>1,461 patients in 5 studies</td>
<td>Yes</td>
<td>82 fewer per 1000 (CI 95% 156 fewer - 22 more)</td>
<td>Very Low Due to serious inconsistency, indirectness and imprecision</td>
</tr>
<tr>
<td>90-day mortality</td>
<td>0.81 (0.62 - 1.06)</td>
<td>1,461 patients in 5 studies</td>
<td>Yes</td>
<td>84 fewer per 1000 (CI 95% 168 fewer - 26 more)</td>
<td>Very Low Due to serious inconsistency, indirectness and imprecision</td>
</tr>
<tr>
<td>ICU mortality</td>
<td>0.72 (0.57 - 0.91)</td>
<td>455 patients in 4 studies</td>
<td>Yes</td>
<td>123 fewer per 1000 (CI 95% 188 fewer - 39 fewer)</td>
<td>Very Low Due to serious inconsistency and very serious indirectness</td>
</tr>
<tr>
<td>ICU weakness at day 28</td>
<td>1.23 (0.81 - 1.88)</td>
<td>356 patients in 4 studies</td>
<td>Yes</td>
<td>53 more per 1000 (CI 95% 44 fewer - 202 more)</td>
<td>Very Low Due to serious risk of bias and imprecision, and very serious indirectness</td>
</tr>
<tr>
<td>Barotrauma</td>
<td>0.55 (0.35 - 0.85)</td>
<td>1,426 patients in 4 studies</td>
<td>Yes</td>
<td>33 fewer per 1000 (CI 95% 48 fewer - 11 fewer)</td>
<td>Very Low Due to serious risk of bias, indirectness and indirectness</td>
</tr>
<tr>
<td>Mechanical ventilation days</td>
<td>Measured by: Days</td>
<td>92 patients in 2 studies</td>
<td>Yes</td>
<td>2 higher (Median)</td>
<td>Very Low Due to serious risk of bias, inconsistency and indirectness, and very serious imprecision</td>
</tr>
<tr>
<td>Ventilator-free days at day 28</td>
<td>Measured by: Days</td>
<td>1,462 patients in 5 studies</td>
<td>Yes</td>
<td>0.3 higher (Median)</td>
<td>Very Low Due to serious risk of bias, indirectness and imprecision</td>
</tr>
</tbody>
</table>

We are uncertain whether neuromuscular blockers improve or worsen 28-day mortality (513 events).

We are uncertain whether neuromuscular blockers improve or worsen 90-day mortality (612 events).

We are uncertain whether neuromuscular blockers improve or decrease ICU mortality (171 events).

We are uncertain whether neuromuscular blockers increase or decrease ICU weakness at day 28 (91 events).

We are uncertain whether neuromuscular blockers improve or worsen barotrauma (81 events).

We are uncertain whether neuromuscular blockers increase or decrease duration of mechanical ventilation.

We are uncertain whether neuromuscular blockers improve or worsen ventilator-free days at day 28.
<table>
<thead>
<tr>
<th>MRC score at day 28</th>
<th>Measured by: Medical Research Council (MRC) scale</th>
<th>49.8 muscle strength (Median)</th>
<th>45.9 muscle strength (Median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Important</td>
<td>Scale: 0-60 High better Based on data from: 1,346 patients in 2 studies. 15 (Randomized controlled) Follow up 28 days</td>
<td>Difference: MD 4.1 lower</td>
<td>Very Low Due to serious risk of bias and indirectness, and very serious inconsistency 16</td>
</tr>
</tbody>
</table>

We are uncertain whether neuromuscular blockers improve or worsen MRC score at day 28.

2. **Inconsistency: Serious.** The magnitude of statistical heterogeneity was high, with I^2:50 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials.. **Indirectness: Serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19. Only one study (largest study) used a high PEEP strategy.. **Imprecision: Serious.** Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials.. **Publication bias: No serious.**
4. **Inconsistency: Serious.** The magnitude of statistical heterogeneity was high, with I^2:56 %. Clinical heterogeneity - ROSE trial has a different sedation strategy than the other trials.. **Indirectness: Serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Imprecision: Serious.** Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials..

**Publication bias: No serious.**
6. **Inconsistency: No serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19. The largest trial, with the most applicable strategy reflecting current clinical practice, did not report on this outcome.. **Indirectness: Serious.** The largest trial did not report on this outcome.. **Imprecision: Serious.** Substantial methodological differences between the studies. ROSE trial has a different sedation strategy than the other trials..

**Publication bias: No serious.**
8. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency: No serious.** Differences between the population of interest and those studied: no studies in COVID-19 patients. The largest trial, with the most applicable strategy reflecting current clinical practice, only included a very small subset of patients for this outcome.. **Indirectness: Serious.** The largest trial did not report on this outcome.. **Imprecision: Serious.** Low number of patients.. **Publication bias: No serious.**
10. **Risk of bias: Serious.** Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias.. **Inconsistency: Serious.** Differences between the population of interest and those studied: no studies in COVID-19 patients.. **Indirectness: Serious.** Differences between the population of interest and those studied: no studies in COVID-19 patients.. **Imprecision: No serious.** **Publication bias: No serious.**
12. **Risk of bias: Serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Inconsistency: No serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Indirectness: Serious.** Low number of patients, wide confidence intervals. **Publication bias: No serious.**
14. **Risk of bias: Serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Inconsistency: No serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Indirectness: Serious.** Differences between the population of interest and those studied: no studies in patients with COVID-19.. **Imprecision: No serious.** **Publication bias: No serious.**
9.2.5 - High-frequency oscillatory ventilation (HFOV)

Info Box

High-frequency oscillatory ventilation (HFOV) is a specialised mode of respiratory support via an endotracheal tube that delivers very small tidal volumes at a rate much faster than normal breathing rates (> 2 Hz). It is used as a rescue therapy in neonates and children for severe respiratory failure when conventional mechanical ventilation is not effective. In neonates with severe respiratory failure, HFOV reduces need for ECMO. HFOV requires specialist equipment, and nursing and medical expertise.

Consensus recommendation

Do not routinely use HFOV as a first line mode of mechanical ventilation in neonates, children and adolescents with severe COVID-19. HFOV should be limited to a rescue therapy in neonates and children not responding to conventional mechanical ventilation in a specialist centre with experience with HFOV.

HFOV delivers gas at very high flow rates. This may increase the aerosol-generating potential compared to other forms of respiratory support used in intensive care. This may limit the suitability of HFOV in patients with COVID-19 unless strict attention to staff safety and infection control measures can be applied.

Evidence To Decision

Benefits and harms

While there is no current evidence for using HFOV in neonates, children or adolescents with COVID-19, it is recommended as a rescue therapy for ventilated neonates, children and adolescents with moderate to severe respiratory failure, including ARDS of other aetiologies. In these patients, it may have a survival benefit but may also increase the risk of harms from complications, such as cardiac compromise, barotrauma, endotracheal tube obstruction or accidental extubation. Infection prevention and staff safety should also be considered.

Certainty of the Evidence

No studies were identified in neonates, children or adolescents with COVID-19 that address the interventions or outcomes of interest.
Rationale
While there is no current evidence for using HFOV in neonates, children or adolescents with COVID-19 and severe respiratory failure, HFOV is used for ventilated neonates, children and adolescents with severe respiratory failure of other aetiologies, such as rescue therapy when conventional ventilation is not effective.

9.2.6 - Videolaryngoscopy

Conditional recommendation
In neonates, children and adolescents with COVID-19 undergoing endotracheal intubation, consider using videolaryngoscopy over direct laryngoscopy if available and the operator is trained in its use.

Evidence To Decision

Benefits and harms
Laryngoscopy is a specialist medical procedure. Time to intubation varies depending on the experience of the operator and the setting, irrespective of the method of laryngoscopy. In non-COVID-19 neonates and children, videolaryngoscopy may reduce intubation failure rates. Another important consideration is the potential risk of contamination to the operator due to the infectious nature of COVID-19. In a simulation study using a manikin, the distance between the operator and patient’s mouth increased when using video compared to direct laryngoscopy, thus potentially benefitting operators in the case of COVID-19.

Certainty of the Evidence
Very Low
Rationale
Videolaryngoscopy allows for increased distance between operator and patient, and may reduce the risk of aerosol exposure.
### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Neonates, children and adolescents requiring emergency intubation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparator</td>
<td>Direct laryngoscopy</td>
</tr>
</tbody>
</table>

### Summary

Evidence informing this recommendation comes from a systematic review of video versus direct laryngoscopy for the emergency intubation of adults in the inpatient setting [223]. A simulation study is also included that evaluated the distance between a dummy’s mouth and physician’s face during intubation [228].

### Effectiveness and adverse events

<table>
<thead>
<tr>
<th>Study design</th>
<th>Randomised trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Critically ill patients requiring emergency intubation in emergency departments or intensive care units. No studies available in patients with COVID-19.</td>
</tr>
<tr>
<td>Intervention</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparison</td>
<td>Direct laryngoscopy</td>
</tr>
</tbody>
</table>

**Results**

We included six of the eight randomised trials (1023 patients) in the Rombey review [221][222][224][225][226][227]. (Two were excluded because patients were intubated before hospital admission.) We included an additional randomised trial of 163 patients that was published after the Rombey review [220]. This study did not change the overall results for the outcomes, but did improve the precision of the estimate for inadvertent oesophageal intubation.

There was no difference between video and direct laryngoscopy with respect to successful intubation at first attempt or time to successful intubation. In the four randomised trials that reported inadvertent oesophageal intubation, the use of videolaryngoscopy was associated with fewer of these adverse events, however the number was small (27 events).

### Operator distance (Hall 2020)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Crossover study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>25 doctors of mixed experience performing tracheal intubation on a high-fidelity manikin.</td>
</tr>
<tr>
<td>Intervention</td>
<td>Videolaryngoscopy</td>
</tr>
<tr>
<td>Comparison</td>
<td>Direct laryngoscopy</td>
</tr>
</tbody>
</table>

**Results**

Videolaryngoscopy may extend the mouth-to-mouth distance from laryngoscopist to patient.

Certainty of the evidence is low to very low due to indirectness (not based on COVID-19 patients or exclusively patients with ARDS), risk of bias, lack of precision in some outcomes and small number of adverse events.

### Outcome

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-pass intubation success</td>
<td>Relative risk 1.05 (CI 95% 0.94 - 1.17) Based on data from 1,186 patients in 7 studies. ¹ (Randomized</td>
<td>716 per 1000 752 per 1000</td>
<td>Very Low Due to serious risk of bias, inconsistency and indirectness</td>
<td>We are uncertain whether videolaryngoscopy increases or decreases first-pass intubation</td>
</tr>
<tr>
<td>³</td>
<td>³</td>
<td>³</td>
<td>³</td>
<td>³</td>
</tr>
</tbody>
</table>

2. **Risk of bias:** Serious. Personnel blinding was not possible for this outcome, resulting in potential for performance bias. Outcome assessor blinding was also not possible, resulting in potential for detection bias. **Inconsistency:** Serious. There was clinical heterogeneity across the included studies in relation to setting (ED vs ICU), operator experience and devices used. Subgroup analyses in Rombey et al 2018 reported that effect sizes were not decisively altered by sensitivity or subgroup analyses. **Indirectness:** Serious. The included studies were in non COVID-19 populations, with mixed presentations of respiratory and other critically ill patients. Differences between the population of interest and those studied. **Imprecision:** No serious. **Publication bias:** No serious. Rombey 2018 visually evaluated the funnel plot for publication bias, with distribution for this outcome relatively symmetrical.


4. **Risk of bias:** Serious. Inadequate/lack of blinding of participants and personnel, resulting in potential for performance bias, and inadequate/lack of blinding of outcome assessors, resulting in potential for detection bias. **Inconsistency:** No serious. **Indirectness:** Serious. The included studies were in non COVID-19 populations, with mixed presentations of respiratory and other critically ill patients. **Imprecision:** No serious. **Publication bias:** No serious. Rombey 2018 visually evaluated the funnel plot for publication bias, with distribution for this outcome relatively symmetrical.

5. The ‘mouth-to-mouth’ distance between operator and manikin as measured by video analysis.

6. Primary study[228]. **Baseline/comparator:** Control arm of reference used for intervention[228].

7. **Risk of bias:** Serious. Blinding of personnel not possible, resulting in potential for performance bias, unclear sequence generation/ generation of comparable groups, resulting in potential for selection bias, unclear concealment of allocation during randomization process, resulting in potential for selection bias. **Inconsistency:** No serious. **Indirectness:** Serious. Use of manikins not patients. **Imprecision:** Serious. Only data from one study. **Publication bias:** No serious.
9.2.7 - Extracorporeal membrane oxygenation (ECMO)

**Consensus recommendation**

Consider early referral to an ECMO centre for venovenous or venoarterial ECMO in mechanically ventilated neonates, children and adolescents with COVID-19 with refractory respiratory or cardiovascular failure despite optimising other critical care interventions.

*Due to the resource-intensive nature of ECMO and the need for experienced centres, healthcare workers and infrastructure, ECMO should only be considered in selected neonates, children and adolescents with severe or critical COVID-19 and no contraindications for ECMO, such as severe, irreversible organ dysfunction.*

*The decision on whether to use ECMO should be taken in consultation with the child’s family. Key considerations include pre-existing conditions and the suitability of anticoagulation.*

*Early referral to an ECMO centre is preferred.*

**Evidence To Decision**

**Benefits and harms**

ECMO is only used as a form of life support in selected neonates, children and adolescents who are severely ill; it aims to increase oxygenation and reduce ventilator-induced lung injuries. However, it may be associated with risk of serious side effects, such as neurological injury, major bleeding, disseminated intravascular coagulation and injuries from cannulation.

**Certainty of the Evidence**

No studies were identified involving neonates, children and adolescents with COVID-19 that compare ECMO to no ECMO.

**Preference and values**

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families and guardians. However, the serious risk of side effects may be unacceptable for some children and adolescents, carers, families and guardians.
Rationale
ECMO is only used as a form of life support in those who are severely ill with refractory respiratory failure (despite optimising ventilation, including proning) and aims to increase oxygenation and reduce ventilator-induced lung injuries. It is recommended as a therapy for selected patients with severe ARDS of other aetiologies.

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. ECMO is resource-intensive and requires experienced centres, healthcare workers and infrastructure.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paediatric ECMO is only available at some tertiary centres in Australia. Some neonates, children and adolescents live in states and territories where ECMO is not available.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>There may be important issues with acceptability. ECMO could be considered less acceptable due to its possible harms and some may not consider its benefits are worth the risk.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are likely to be feasibility issues due to the resource-intensive nature of ECMO. ECMO is likely to only be feasible in a limited number of centres.</td>
<td></td>
</tr>
</tbody>
</table>
10 - Venous thromboembolism (VTE) prophylaxis

We have found one new study comparing therapeutic dose enoxaparin thromboprophylaxis with standard dose thromboprophylaxis (Lemos et al. Thromb Res doi: 10.1016/j.thromres.2020.09.026). This study is currently under review and an updated recommendation will be included in a future version of the guideline.

The primary panel for the recommendations for adults is the Hospital and Acute Care Panel. The primary panel for the recommendations for pregnant and postpartum women is the Pregnancy and Perinatal Care Panel.

Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

10.1 - VTE prophylaxis for adults

**Consensus recommendation**

Use prophylactic doses of anticoagulants, preferably low molecular weight heparin (LMWH) (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) in adults with moderate COVID-19 or other indications, unless there is a contraindication, such as risk for major bleeding. Where the estimated glomerular filtration rate (eGFR) (see below) is less than 30 mL/min/1.73m², unfractionated heparin or clearance-adjusted doses of LMWH may be used (e.g. enoxaparin 20 mg once daily or dalteparin 2500 IU once daily).

For body weights outside 50-90 kg or heights outside 150-180 cm, calculate the body surface area (BSA) and multiply the eGFR by BSA/1.73.

The Taskforce notes that in critical illness, creatinine-based estimation of kidney function can be unreliable.

**Evidence To Decision**

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Substantial net benefits of the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is uncertainty around benefits and harms for patients with COVID-19, but the benefits as well as harms associated with the use of LMW heparin and other anticoagulants are well-known in other patient groups.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certainty of the Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no available evidence regarding outcomes for the use of LMW heparin or other anticoagulants in patients with COVID-19.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preference and values</th>
<th>Substantial variability is expected or uncertain</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected information regarding patients' preferences and values. The panel believes that since there is uncertainty regarding the benefit to harm ratio some patients may prefer to wait while other patients may be more willing to take risks.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the potential impact on reduced access to these treatments by patients currently using them for other indications.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>No important issues with the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are no identified equity issues.</td>
<td></td>
</tr>
</tbody>
</table>
Rationale
The panel believes that the benefits of pharmacologic prophylaxis among medically ill patients outweigh potential harm, such as bleeding caused by this prophylaxis. The panel believes that this will also apply to patients with COVID-19 and therefore recommend pharmacologic prophylaxis.

Adaptation
The recommendation for use of DVT prophylaxis is adapted from published recommendations by the International Society on Thrombosis and Haemostasis [238], University of Miami [239] and British Haematological Society [240]. Wording has been adapted for clarity and applicability to the Australian context.

Clinical Question/ PICO

| Population: | People with moderate COVID-19 |
| Intervention: | VTE prophylaxis |
| Comparator: | Standard care |

Summary
At present there are no randomised trials that have investigated the benefits of using anticoagulants in patients with moderate COVID-19. There is variability in existing COVID-19 specific recommendations regarding the use of anticoagulants in COVID-19 patients, such that the use of anticoagulants should be considered in all patients [238][239], all immobilised or severely ill patients [240] or used based on best existing data and best current local practices [241].

Heparin is contraindicated in individuals with ulcerative conditions showing a tendency to haemorrhage (e.g. gastrointestinal ulcer, ulcerative colitis), cerebral haemorrhage, severe thrombocytopenia or other severe coagulation disorders, and individuals with an uncontrollable active bleeding state. The use of heparin can result in side effects such as haemorrhage, thrombocytopenia, skin necrosis or irritation at the injection site, and suppression of aldosterone synthesis with hyperkalaemia and/or metabolic acidosis [242][243].
Consensus recommendation

Consider using increased prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg twice daily or dalteparin 5000 IU twice daily) in adults with severe or critical COVID-19 or other indications, unless there is a contraindication, such as risk for major bleeding or platelet count $< 30 \times 10^9/L$. Where eGFR (see below) is less than 30 mL/min/1.73m², unfractionated heparin or clearance-adjusted doses of LMWH may be used (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily).

For body weights outside 50-90 kg or heights outside 150-180 cm, calculate the BSA and multiply the eGFR by BSA/1.73.

The Taskforce notes that in critical illness, creatinine-based estimation of kidney function can be unreliable.

### Evidence To Decision

#### Benefits and harms

There is uncertainty around the benefits and harms for patients with COVID-19. However, there are well-known benefits as well as harms associated with the use of LMW heparin and other anticoagulants in other patient groups.

#### Certainty of the Evidence

There is currently no evidence relating to increased prophylactic doses of anticoagulants in patients with COVID-19.

#### Preference and values

We have no systematically collected information regarding patients' preferences and values. Since there is uncertainty regarding the benefit to harm ratio, some patients may prefer to wait while other patients may be more willing to take risks.

#### Resources

We have no systematically collected evidence regarding cost-benefit. Depending on the treatment, not only should the cost and resource implications be considered but also the potential impact on reduced access to treatments by patients currently using them for other indications.

#### Equity

There are no identified equity issues.

#### Acceptability

Treatment is probably acceptable to both patients and clinicians, however, we have no systematically collected evidence regarding acceptability.

#### Feasibility

There are no identified feasibility issues.

### Rationale

Conventional prophylactic doses of anticoagulants seem less effective in preventing VTE in severe or critically ill COVID-19 patients. It is unclear whether higher doses will improve outcomes but the risk-benefit ratio seems acceptable.
Clinical Question/ PICO

**Population:** Patients with severe or critical COVID-19  
**Intervention:** Increased-dose thromboprophylaxis  
**Comparator:** Conventional treatment

**Summary**

There are no randomised trials comparing increased-dose thromboprophylaxis to conventional treatment in patients with COVID-19 but there are observational studies. Ten studies have reported on the prevalence of venous thromboembolic (VTE) events in patients with critical or severe COVID-19, ranging from 3.3% to 69% (see Table).

**Table Prevalence of VTE events (lowest to highest)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Severity of Illnes</th>
<th>VTE events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goyal 2020</td>
<td>Moderate / Critical</td>
<td>13/393 (3.3%)*</td>
</tr>
<tr>
<td>Lodigani 2020</td>
<td>Severe / Critical</td>
<td>28/362 (7.7%)</td>
</tr>
<tr>
<td>Helms 2020</td>
<td>Severe / Critical</td>
<td>28/150 (18.7%)</td>
</tr>
<tr>
<td>Middeldorp 2020</td>
<td>Severe / Critical</td>
<td>39/198 (20%)</td>
</tr>
<tr>
<td>Poissy 2020</td>
<td>Severe / Critical</td>
<td>22/107 (20.6%)</td>
</tr>
<tr>
<td>Cui 2020</td>
<td>Severe / Critical</td>
<td>20/81 (25%)</td>
</tr>
<tr>
<td>Klok 2020</td>
<td>Severe / Critical</td>
<td>175/184 (40.8%)</td>
</tr>
<tr>
<td>Zhang 2020</td>
<td>Critical</td>
<td>66/143 (46.1%)</td>
</tr>
<tr>
<td>Wichmann 2020</td>
<td>Critical</td>
<td>7/12 (58%)</td>
</tr>
<tr>
<td>Llitjos 2020</td>
<td>Severe / Critical</td>
<td>18/26 (69%)</td>
</tr>
</tbody>
</table>

*prevalence was 7.7% and 1.1% in patients receiving and not receiving mechanical ventilation, respectively.

Eight studies were assessed as moderate risk of bias due to low external validity—cohort not representative of the target population and lack of random selection/census. One was at high risk of bias [245] and one was unclear due to limited reporting of methods [Goyal 2020].

One study reported outcomes in patients with moderate to critical COVID-19 who received systemic anticoagulants versus those who did not [Paranjpe 2020]. Mortality was similar between the groups (22.5% systemic vs 22.8% control). Although more patients receiving systemic anticoagulants required mechanical ventilation (29.8% vs 8.1%), mortality was lower in this group (29.1% vs 62.7%). Major bleeding events were slightly higher in the control group (3.0% vs 1.9%).

A meta-analysis on platelet count in patients with COVID-19 included nine studies (1779 participants) [254]. Platelet count was significantly lower in patients with more severe compared to less severe COVID-19 (mean -31 x 10^9/L), with the lowest platelet counts linked to mortality (mean -48 x 10^9/L). The authors concluded that low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19.
10.2 - VTE prophylaxis for pregnant and postpartum women

**Info Box**

Pregnant women in general are at an increased risk of venous thromboembolism (VTE). Hospitalised pregnant women with an acute infective illness (such as COVID-19) are at even greater risk of VTE. However, the exact duration of increased risk of VTE in association with COVID-19 infection is not yet established.

All pregnant and postpartum women should undergo a documented assessment of risk factors for VTE on admission to hospital, if COVID-19 is diagnosed, if COVID-19 severity changes and postpartum.

The use of pharmacological prophylaxis in women should be accompanied by other measures to prevent VTE, such as anti-embolism stockings and sequential compression devices.

**Consensus recommendation**

For pregnant or postpartum women who are admitted to hospital (for any indication) and who have COVID-19, use prophylactic doses of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding or imminent birth.

Prophylactic anticoagulants should be continued for at least 14 days after discharge or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function.
- For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.

**Evidence To Decision**

**Benefits and harms**

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19. However, acute infective illnesses such as COVID-19 are known to increase the risk of VTE.

**Certainty of the Evidence**

There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19.

**Preference and values**

We have no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

**Resources**

Important issues, or potential issues not investigated
We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for those without COVID-19.

**Equity**
There are likely no important equity issues.

**Acceptability**
There is no systematically collected information regarding the acceptability of VTE prophylaxis in women with COVID-19 at this point. However, since prophylaxis with anticoagulants is commonly used in women with risk factors for VTE, it is likely to be acceptable to all stakeholders.

**Feasibility**
There are likely no important feasibility issues.

**Rationale**
Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19, however, acute infective illnesses (such as COVID-19) are known to increase the risk of VTE.

**Consensus recommendation**
For pregnant women with severe or critical COVID-19, or where there are additional risk factors for VTE, consider using increased prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg twice daily or dalteparin 5000 IU twice daily) unless there is a contraindication, such as risk for major bleeding or platelet count < 30 x 10^9/L.

Prophylactic anticoagulants should be continued for at least four weeks after discharge or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

- **Dosing is dependent on pre-pregnancy body weight and current renal function.** For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- **There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.**
- **Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.**
- **In some situations, continuation of LMWH throughout the rest of pregnancy and postpartum may be required.** Involvement of specialist obstetricians, obstetric medicine physicians, haematologists or other physicians with expertise in VTE in pregnant women would be warranted.

**Evidence To Decision**

**Benefits and harms**
Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19. However, acute infective illnesses such as COVID-19 are known to increase the risk of VTE.

**Substantial net benefits of the recommended alternative**
Rationale

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19, however, acute infective illnesses (such as COVID-19) are known to increase the risk of VTE.

Preference and values

We have no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

Resources

We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for those without COVID-19.

Equity

There are likely no important equity issues.

Acceptability

There is no systematically collected information regarding the acceptability of VTE prophylaxis in women with COVID-19 at this point. However, since prophylaxis with anticoagulants is commonly used in women with risk factors for VTE, it is likely to be acceptable to all stakeholders.

Feasibility

There are likely no important feasibility issues.

Consensus recommendation

For pregnant or postpartum women who are self-isolating at home with mild COVID-19 and where additional risk factors for VTE are present, consider using prophylactic doses of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding or imminent birth. Prophylactic anticoagulants should be continued for at least 14 days or until COVID-19-related morbidity (including immobility, dehydration and/or shortness of breath) has resolved.

For pregnant or postpartum women who are self-isolating at home with mild COVID-19 and who have no additional risk factors for VTE, routine pharmacological prophylaxis is not recommended.

- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
- Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.
### Benefits and harms

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19. However, acute infective illnesses such as COVID-19 are known to increase the risk of VTE.

### Certainty of the Evidence

There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19.

### Preference and values

We have no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

### Resources

We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for those without COVID-19.

### Equity

There are likely no important equity issues.

### Acceptability

There is no systematically collected information regarding the acceptability of VTE prophylaxis in women with COVID-19 at this point. However, since prophylaxis with anticoagulants is commonly used in women with risk factors for VTE, it is likely to be acceptable to all stakeholders.

### Feasibility

There are likely no important feasibility issues.

### Rationale

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19, however, acute infective illnesses (such as COVID-19) are known to increase the risk of VTE.
Consensus recommendation

For postpartum women who have had COVID-19 during pregnancy, consider using at least 14 days of prophylactic dosing of anticoagulants, preferably LMWH (e.g. enoxaparin 40 mg once daily or dalteparin 5000 IU once daily) unless there is a contraindication, such as risk for major bleeding. Increased duration of six weeks should be considered if severe or critical COVID-19 and/or additional risk factors for VTE are present.

- Dosing of LMWH is dependent on pre-pregnancy body weight and current renal function. For women with early pregnancy body weight outside of 50-90 kg, consider adjusted LMWH dosing.
- There is limited evidence to guide the most appropriate dose in obese patients but standard dosing may be inadequate.
- Clinicians should refer to their local or jurisdictional guidance on additional VTE risk factors.

Evidence To Decision

Benefits and harms

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19. However, acute infective illnesses such as COVID-19 are known to increase the risk of VTE.

Certainty of the Evidence

There is currently no direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19.

Preference and values

We have no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

Resources

We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for those without COVID-19.

Equity

There are likely no important equity issues.

Acceptability

There is no systematically collected information regarding the acceptability of VTE prophylaxis in women with COVID-19 at this point. However, since prophylaxis with anticoagulants is commonly used in women with risk factors for VTE, it is likely to be acceptable to all stakeholders.

Feasibility

There are likely no important feasibility issues.

Rationale

Prophylactic anticoagulants are used routinely in pregnant and postpartum women who are at risk of VTE. There is currently no
direct evidence comparing the effectiveness of VTE prophylaxis regimens in pregnant and postpartum women with COVID-19, however, acute infective illnesses (such as COVID-19) are known to increase the risk of VTE.
11 - Therapies for pre-existing conditions in patients with COVID-19

The primary panel for the recommendations in this section is the Primary and Chronic Care Panel. Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

11.1 - ACEIs/ARBs in patients with COVID-19

<table>
<thead>
<tr>
<th><strong>Recommended</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with COVID-19 who are receiving ACEIs/ARBs, there is currently no evidence to deviate from usual care and these medications should be continued unless contraindicated.</td>
</tr>
<tr>
<td><em>Stopping these medications abruptly can lead to acute heart failure or unstable blood pressure.</em></td>
</tr>
</tbody>
</table>

**Evidence To Decision**

**Benefits and harms**

Stopping ACEI/ARB medication could lead to acute heart failure or unstable blood pressure. There is currently no randomised trial evidence specific to patients with COVID-19 and the use of ACEIs/ARBs.

**Certainty of the Evidence**

While there are no randomised trials of ACEIs/ARBs in patients with COVID-19, there are observational studies that seek to determine if there is an association between ACEIs/ARBs and diagnosis of COVID-19 or mortality for patients with a diagnosis of COVID-19.

**Preference and values**

We have no systematically collected information regarding patients’ preferences and values. The panel believes that, while there is uncertainty about the benefit to harm ratio regarding the use of ACEIs/ARBs in patients with COVID-19, there are likely harms associated with stopping ACEIs/ARBs. The panel believes that most patients would prefer to continue their current medication although some may want to discuss benefits and risks of discontinuing treatment.

The NC19CET Consumer Panel has considered issues around pre-existing conditions and treatments, and believes that in line with available evidence, informed patients would wish to continue with their current prescribed treatment for their pre-existing conditions.

**Equity**

There are no identified equity issues.

**Acceptability**

Continued concomitant ACEI/ARB medication is likely to be acceptable to both patients and clinicians.

**Resources**

We have no systematically collected information regarding cost-benefit. Continued use of ACEIs/ARBs as per usual care is unlikely to have an impact on availability of these drugs.
Rationale

ACEIs/ARBs for people with hypertension, where indicated, are considered usual care. There is currently no evidence to indicate that it is necessary to deviate from usual care. Stopping these medications abruptly can lead to acute heart failure or unstable blood pressure.

Adaptation

This recommendation is adapted from published recommendations from numerous Australian and international guidelines and position statements [260][261][262][263][264][265][266][267][268][269][270][271][272][273]. Wording has been adapted for clarity and applicability to the Australian context.

Clinical Question/ PICO

**Population:** People with COVID-19 who are taking ACEIs/ARBs

**Intervention:** Continued use of concomitant ACEIs/ARBs

**Comparator:** Stopping concomitant ACEIs/ARBs

Summary

At present no randomised trials have investigated the benefits of continuing or stopping ACEIs/ARBs in patients with COVID-19. There is, however, unanimous international consensus that ACEI or ARB medications should be continued in patients with COVID-19.

Systematic reviews of observational studies provide further support for the continuation of ACEIs/ARBs in patients with COVID-19 [274][275][276][277]. These reviews conclude that continued use of ACEIs/ARBs is unlikely to be associated with an increased risk of disease severity or death in patients with COVID-19. The conclusions are based on very low certainty evidence due to serious risk of bias, imprecision and inconsistency in findings between studies.

Despite the very low certainty evidence that continued use of concomitant ACEIs/ARBs increases or decreases death or disease severity in patients with COVID-19, there is high certainty evidence of harm if ACEIs/ARBs are stopped abruptly in patients who are already receiving them. Stopping these medications could lead to acute heart failure or unstable blood pressure. For this reason the recommendation is designated as ‘Strong’ in favour of continuation.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong></td>
<td>Odds Ratio 0.86 (CI 95% 0.63 - 1.16) Based on data from 7,492 patients in 12 studies.</td>
<td>287 per 1000</td>
<td>Very Low Due to serious risk of bias, inconsistency and imprecision</td>
<td>We are uncertain whether continued use of concomitant ACEIs/ARBs increases or decreases death in patients with COVID-19.</td>
</tr>
<tr>
<td>9 Critical</td>
<td>(Observational (non-randomized))</td>
<td>262 per 1000</td>
<td>25 fewer per 1000</td>
<td>72 fewer - 28 more</td>
</tr>
<tr>
<td><strong>Risk of severe or lethal COVID-19</strong></td>
<td>Odds Ratio 1 (CI 95% 0.84 - 1.18) Based on data from 11,334 patients in 5 studies.</td>
<td>309 per 1000</td>
<td>Very Low Due to serious risk of bias, inconsistency and imprecision</td>
<td>We are uncertain whether continued use of concomitant ACEIs/ARBs increases or decreases the risk of</td>
</tr>
<tr>
<td></td>
<td>(Observational (non-randomized))</td>
<td>309 per 1000</td>
<td>0 fewer per 1000</td>
<td></td>
</tr>
</tbody>
</table>
11.2 - ACEIs in postpartum women

**Consensus recommendation**

In postpartum women with COVID-19 who have hypertension requiring treatment with ACE inhibitors, there is currently no evidence to deviate from usual care. These medications should be initiated or continued unless otherwise contraindicated.

*ACE inhibitors are contraindicated in the antenatal period due to risk of fetal and neonatal harm.*

**Evidence To Decision**

**Benefits and harms**

ACE inhibitors, such as enalapril, captopril and quinapril, are used for the management of postpartum hypertension and are considered compatible with breastfeeding [278]. Their use is contraindicated during pregnancy as they have been associated with fetal death and neonatal renal failure. There is currently no evidence to indicate that ACE inhibitors should not be used postpartum in a woman with confirmed COVID-19.

**Certainty of the Evidence**

No studies were identified that address the use of ACE inhibitors for postpartum women with COVID-19.
11.3 - Steroids for people with asthma or COPD with COVID-19

**Consensus recommendation**

Use inhaled or oral steroids for the management of people with co-existing asthma or chronic obstructive pulmonary disease (COPD) and COVID-19 as you would normally for viral exacerbation of asthma or COPD. Do not use a nebuliser.

**Evidence To Decision**

**Benefits and harms**

Stopping long-term inhaled or oral corticosteroids suddenly can lead to exacerbation of symptoms of asthma and COPD or risk of relative adrenal insufficiency. There is currently no evidence specific to patients with COVID-19 and asthma or COPD.

**Certainty of the Evidence**

There is no available evidence about outcomes for inhaled or oral corticosteroids for patients with COVID-19 and asthma or COPD.
Preference and values

We have no systematically collected information regarding patients’ preferences and values. The panel believes that, while there is uncertainty about the benefit to harm ratio regarding the use of corticosteroids for COVID-19, there are likely harms associated with an exacerbation of asthma or COPD, as well as harms associated with a sudden stopping of corticosteroids, and thus patients may prefer to take steroids as prescribed.

The NC19CET Consumer Panel has considered issues around pre-existing conditions and treatments, and believes that in line with available evidence, informed patients would wish to continue with their prescribed treatment for their pre-existing conditions.

Resources

We have no systematically collected information regarding cost-benefit. Continued use of inhaled or oral corticosteroids as per usual care is unlikely to have an impact on availability of these drugs.

Equity

There are no identified equity issues.

Acceptability

The treatment is likely to be acceptable to both patients and clinicians.

Feasibility

There are likely no important feasibility issues as the recommendation reflects usual care.

Rationale

Oral steroids and continuation of inhaled steroids reduce harms in patients experiencing exacerbations of asthma or COPD and are considered usual care. There is currently no evidence to indicate that it is necessary to deviate from usual care.

Adaptation

The recommendation is adapted from published recommendations from three clinical guidelines: Australian Asthma Handbook [279], NICE [NG168] [280] and NICE [NG 166] [281]. Wording has been adapted for clarity and applicability to the Australian context.

Clinical Question/ PICO

| Population: | People with asthma or COPD and COVID-19 |
| Intervention: | Corticosteroids |
| Comparator: | Standard care |

Summary

For patients with severe asthma, the Australian Asthma Handbook recommends that clinicians “administer or prescribe systemic (oral) corticosteroids to manage severe flare-ups or acute asthma as indicated, following recommendations based on age-group” but to be cautious using corticosteroids when acute viral infection is suspected or confirmed (e.g. avoid use for mild flare-ups) [279]. This recommendation is in concordance with NICE NG166, which recommends that
patients who develop symptoms and signs of an asthma exacerbation should follow their personalised asthma action plan and start a course of oral corticosteroids if clinically indicated [281].

For patients with asthma who are receiving inhaled steroids, the Australian Asthma Handbook also advises patients “to continue taking inhaled corticosteroids during the COVID-19 pandemic”. It reminds clinicians to “warn patients that stopping their preventer increases the risk of severe asthma flare-ups, including those triggered by viral respiratory infections”. This recommendation is in concordance with NICE NG166, which recommends that patients continue using oral or inhaled steroids and to avoid stopping oral or inhaled steroids.

For patients with COPD, NICE NG168 recommends that patients who are having an exacerbation for COPD start a course of oral corticosteroids and/or antibiotics if oral corticosteroids and/or antibiotics are clinically indicated [280]. Oral corticosteroids are not recommended for symptoms of COVID-19 alone (e.g. fever, dry cough or myalgia).

The recommendations take into consideration potential harms with starting oral corticosteroids (particularly at high doses for a prolonged period) and harms associated with withholding corticosteroids suddenly.

According to the Therapeutic Goods Administration, starting oral corticosteroids (prednisolone or dexamethasone) can lead to disturbed endocrine function, ophthalmological conditions and adrenal suppression [282][283].

Abrupt withdrawal of corticosteroids can lead to acute adrenal insufficiency or exacerbation of symptoms of asthma or COPD.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care</td>
<td>Coticosteroids</td>
<td></td>
</tr>
<tr>
<td>See summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12 - Pregnancy and perinatal care

The primary panel for the recommendations in this section is the Pregnancy and Perinatal Care Panel. Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

Info Box

For recommendations on disease modifying treatments, chemoprophylaxis, venous thromboembolism (VTE) prophylaxis and respiratory support in pregnant or breastfeeding women, and ACE inhibitors in postpartum women, please see sections above. We are continually working on updating all recommendations to reflect special populations, including pregnant and breastfeeding women.

12.1 - Antenatal corticosteroids

Consensus recommendation

The use of antenatal corticosteroids for women at risk of preterm birth is supported as part of standard care, independent of the presence of COVID-19.

There are clear benefits to using antenatal corticosteroids for women at risk of preterm birth at less than 34 weeks gestation. There is currently no evidence to suggest that antenatal corticosteroids cause additional maternal or fetal harm in the setting of COVID-19 when used for this indication. They should therefore be given where indicated.

The Taskforce has separate recommendations regarding the use of dexamethasone as a disease-modifying treatment in pregnant or breastfeeding women for COVID-19. Women with COVID-19 who are on oxygen and receiving dexamethasone do not require additional doses of corticosteroids for fetal lung maturation.

Evidence To Decision

Benefits and harms

There are substantial known benefits to using antenatal corticosteroids in preterm birth, which is supported as part of usual care. Antenatal corticosteroids reduce preterm newborn mortality and morbidities, including respiratory distress, necrotising enterocolitis and intra-ventricular haemorrhage [284]. There is currently no evidence to indicate that antenatal corticosteroids for preterm birth should not be used in a woman with confirmed COVID-19.

Certainty of the Evidence

No studies were identified that address the use of antenatal corticosteroids for women who have COVID-19 and are at risk of preterm birth.

Preference and values

There is no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

The Consumer Panel believes that most women would agree with the recommendation as the available evidence suggests no additional harm to mother or newborn.
Rationale

There are substantial known benefits for using antenatal corticosteroids for this indication. There is currently no direct evidence to suggest additional harms of using antenatal corticosteroids for preterm birth in the setting of COVID-19. Antenatal corticosteroids should continue to be used as per usual care.

12.2 - Mode of birth

Conditional recommendation

For pregnant women with COVID-19, mode of birth should remain as per usual care.

There is currently no evidence to indicate that caesarean section for women with COVID-19 reduces the risk of vertical transmission to the newborn. Mode of birth should continue as per usual care. Respiratory deterioration due to COVID-19 may prompt urgent delivery on an individual basis.

Evidence To Decision

Benefits and harms

Evidence informing this recommendation comes from a systematic review of 49 studies comprising 655 women and 666 newborns, of whom 28 newborns (4.2%) had a COVID-19 infection. No cases of newborn COVID-19 infection met the criteria for confirmed vertical transmission, and newborn infections did not differ substantively by mode of birth (vaginal birth or caesarean section).

Certainty of the Evidence

Certainty of the evidence is very low due to reliance on case reports and case series. Evidence informing this recommendation comes from a systematic review estimating the risk of the newborn becoming infected with COVID-19 by mode of birth (vaginal or caesarean) in pregnant women with confirmed or suspected COVID-19 infection.

Preference and values

No substantial variability expected
There is no systematically collected information regarding the preferences and values of pregnant women with COVID-19 at this point. Mode of birth should be individualised, based on clinical indications and taking into consideration individual preferences and values.

The Consumer Panel believes that most women would agree with the recommendation as there is no available evidence to suggest harm to mother or newborn.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Caring for pregnant women with COVID-19 (regardless of mode of birth) requires greater resources than for women without COVID-19. The routine use of caesarean section for all pregnant women with COVID-19 would have additional resource implications.

**Equity**

For pregnant women with COVID-19, access to on-site paediatric support is needed at the time of birth. This may be more challenging for those women living in rural or remote areas.

**Acceptability**

Acceptability of different modes of birth by pregnant women is expected to vary and individual preferences should be taken into consideration. Clear communication from health professionals regarding the benefits and harms of different modes of birth is essential to aid discussion around individual preferences and acceptability.

**Feasibility**

There are no identified feasibility issues as the recommendation reflects usual care.

**Rationale**

There is currently no evidence to indicate that caesarean section for pregnant women with COVID-19 reduces the risk of vertical transmission. Usual care practices regarding clinical indications for caesarean section should be used.

No cases of newborn COVID-19 infection met the criteria for confirmed vertical transmission, and newborn infections did not differ substantively by mode of birth (vaginal birth or caesarean section). Therefore, the benefits and harms of mode of birth should be considered as per usual care, taking into consideration relevant clinical indications and a woman's individual preferences. However, clinical deterioration due to worsening COVID-19 may prompt urgent delivery of the baby.

**Clinical Question/ PICO**

| Population: | Pregnant women with COVID-19 |
| Intervention: | Caesarean section |
| Comparator: | Vaginal birth |

**Summary**

Evidence informing this recommendation comes from a systematic review that estimated the risk of the newborn becoming infected with COVID-19 by mode of birth (vaginal or caesarean) [285]. The review included 49 case reports or case series comprising 666 newborns. Cases were only included where the mother either had confirmed COVID-19 (based on a positive swab) or a high clinical suspicion of COVID-19 where a swab had not been taken. The incidence of COVID-19 infection in newborns is given in the table below.
No cases of COVID-19 infection met the criteria for confirmed vertical transmission (positive PCR in umbilical cord blood, newborn blood collected within the first 12 hours of birth, or amniotic fluid collected prior to rupture of membranes). It was not possible to apply the classification developed by Shah et al [286] (confirmed, probable, possible, unlikely or not infected) due to lack of virological testing at birth or in first 12 hours of life.

Additional evidence is available from an observational cohort study in the US of newborns whose mothers had confirmed COVID-19 [294]. The Salvatore study reported on 106 newborns born to 116 mothers who were positive for COVID-19. Newborns were tested for SARS-CoV-2 by nasopharyngeal PCR at 12-24 hours (n=106), 5-7 days (n=79) and 14 days (n=72) of life.

Mode of birth was not affected by the mother’s SARS-CoV-2 status, with 59/106 (56%) born by vaginal birth and 43/106 (41%) by caesarean section. All newborns returned negative PCR test results for SARS-CoV-2 at all timepoints, indicating there was no vertical transmission.

### Table 1. Comparison of mode of birth in infected and non-infected newborns

<table>
<thead>
<tr>
<th>Mode of birth</th>
<th>Total newborns</th>
<th>Infected</th>
<th>Not infected</th>
<th>Not tested</th>
<th>Died</th>
<th>% Infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal</td>
<td>292</td>
<td>8</td>
<td>261</td>
<td>21</td>
<td>7</td>
<td>2.7% (8/292)</td>
</tr>
<tr>
<td>Caesarean</td>
<td>374</td>
<td>20</td>
<td>313</td>
<td>26</td>
<td>1</td>
<td>5.3% (20/374)</td>
</tr>
</tbody>
</table>

*the review authors contacted the first author of the paper where there were missing newborn data (4 hospitals)

1. **Risk of bias:** Very Serious. Evidence is derived from case studies and case reports. **Inconsistency:** Serious. Variations in outcome definitions, disease severity and availability of different testing modalities. **Indirectness:** No serious. **Imprecision:** Serious. Variations in outcome definitions, disease severity and availability of different testing modalities. **Publication bias:** No serious.

### 12.3 - Delayed umbilical cord clamping

**Consensus recommendation**

Delayed umbilical cord clamping is supported as part of standard care, independent of the presence of COVID-19.

*There is currently no evidence that delayed umbilical cord clamping affects the risk of vertical transmission of COVID-19.*
Evidence To Decision

Benefits and harms

There is currently no evidence to indicate that delayed umbilical cord clamping affects the risk of vertical transmission of COVID-19. Usual care practices regarding delayed cord clamping of preterm and term newborns should be used.

Certainty of the Evidence

There is currently no evidence to indicate that delayed umbilical cord clamping increases the risk of SARS-CoV-19 transmission from mother to newborn. However, delayed umbilical cord clamping has several health benefits for term and preterm infants [287][288].

Preference and values

There is currently no direct evidence on the transmission risk of delayed cord clamping between mothers with COVID-19 and their newborns.

The Consumer Panel believes that most women would agree with the recommendation as there is no available evidence to suggest harm to mother or newborn.

Resources

We have no systematically collected evidence regarding cost-benefit. Caring for women or newborns with COVID-19 requires greater resources than for those without COVID-19.

Equity

There are likely no important equity issues.

Acceptability

Delayed umbilical cord clamping is routinely performed during the provision of neonatal care and is therefore likely to be acceptable to all stakeholders.

Feasibility

There are likely no important feasibility issues as the recommendation reflects usual care.

Rationale

There is currently no evidence to indicate that delayed umbilical cord clamping affects the risk of vertical transmission of COVID-19. Usual care practices regarding delayed cord clamping of preterm and term newborns should be used.
12.4 - Skin-to-skin contact

**Consensus recommendation**

Early skin-to-skin contact after birth and during the postnatal period is supported, irrespective of the presence of COVID-19. However, parents with COVID-19 should use infection prevention and control measures (mask and hand hygiene).

*Early skin-to-skin contact refers to placing the naked baby prone on the parent’s bare chest immediately after birth.*

Skin-to-skin contact should be encouraged and continue as per usual practice in other postnatal and neonatal settings, such as neonatal ICU and postnatal wards, providing infection prevention and control measures are maintained.

**Evidence To Decision**

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Substantial net benefits of the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are substantial known benefits for skin-to-skin contact between mother and newborn, including significantly reduced newborn mortality and morbidity and improved newborn and parental attachment [289][290]. There is currently no evidence to indicate that a woman with a known COVID-19 infection should not practice skin-to-skin with her newborn to prevent transmission of COVID-19, provided they use infection prevention and control measures (mask and hand hygiene).</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certainty of the Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is currently no direct evidence on the transmission risk of skin-to-skin contact between mothers with COVID-19 and their newborns.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preference and values</th>
<th>No substantial variability expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no systematically collected information regarding the preferences and values of women with COVID-19 at this point. The Consumer Panel believes that most women would agree with the recommendation as there is no available evidence to suggest harm to mother or newborn.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for women and newborns without COVID-19.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are likely no important equity issues.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceptability of skin-to-skin contact between mothers with COVID-19 and their newborns is expected to vary and individual preferences should be considered. Clear communication from health professionals regarding the benefits and harms of skin-to-skin contact is essential to aid discussion around individual preferences and acceptability.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are likely no important feasibility issues as the recommendation reflects usual care.</td>
<td></td>
</tr>
</tbody>
</table>
### Clinical Question/ PICO

<table>
<thead>
<tr>
<th>Population</th>
<th>Women with COVID-19 who have given birth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Skin-to-skin contact</td>
</tr>
<tr>
<td>Comparator</td>
<td>No skin-to-skin contact</td>
</tr>
</tbody>
</table>

### Summary

No direct evidence for the risk of transmission of COVID-19 with skin-to-skin contact is available. However, important indirect evidence is available from an observational cohort study in the US of newborns whose mothers had confirmed COVID-19 [294]. While the number of newborns who received skin-to-skin care was not reported, the standard of care at all participating institutions was to initiate newborn skin-to-skin contact with mothers in the first hour of life if medically appropriate.

The Salvatore study reported on 106 newborns born to 116 mothers who were positive for COVID-19. Mothers could practice skin-to-skin care in the delivery room, during their hospital stay and after discharge, provided they were wearing a surgical mask and with proper hand hygiene. Newborns were tested for SARS-CoV-2 by nasopharyngeal PCR at 12-24 hours (n=106), 5-7 days (n=79) and 14 days (n=72) of life. All newborns returned negative test results for SARS-CoV-2 at all timepoints. There was no evidence that skin-to-skin contact increased the newborn infection risk for COVID-19.

### Outcome Timeframe

<table>
<thead>
<tr>
<th>Number of infected newborns</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Based on data from 106 patients in 1 studies.</td>
<td>See summary for details. Included 106 newborns born to 116 mothers with confirmed SARS-CoV-2 infection. Newborns were tested for infection at 12-24 hours, 5-7 days and 14 days of life. All newborns returned negative test results at all timepoints.</td>
<td>Very Low</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Number of infected neonates within 30 days of birth
### 12.5 - Breastfeeding

**Conditional recommendation**

Breastfeeding is supported irrespective of the presence of COVID-19. However, women with COVID-19 who are breastfeeding should use infection prevention and control measures (mask and hand hygiene) while infectious.

*There is currently no evidence to indicate that breastfeeding increases the risk of vertical transmission to the newborn. As there are substantial known benefits for breastfeeding, women should be supported to initiate or continue breastfeeding. If the baby is being fed with expressed breastmilk or formula, these same infection prevention and control measures should be used.*

#### Evidence To Decision

<table>
<thead>
<tr>
<th>Benefits and harms</th>
<th>Substantial net benefits of the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are substantial known benefits for breastfeeding for the health and well-being of mothers and newborns, which is supported as part of usual care. Breastfeeding reduces child mortality, promotes newborn development and reduces the risk of infectious and chronic disease. For mothers, breastfeeding reduces the risk of ovarian and breast cancer [292]. There is currently no evidence to indicate that a woman with a known COVID-19 infection should not breastfeed her newborn to prevent transmission, provided they use infection prevention and control measures (mask and hand hygiene).</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Certainty of the Evidence</th>
<th>Very Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certainty of the evidence is very low due to reliance on case reports and case series.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preference and values</th>
<th>Substantial variability is expected or uncertain</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no systematically collected information regarding the preferences and values of pregnant women with COVID-19 at this point. Breastfeeding is an individual decision based on consideration of individual preferences and values.</td>
<td></td>
</tr>
</tbody>
</table>

| The Consumer Panel believes that most women would agree with the recommendation as there is no available evidence to suggest harm to mother or newborn. The panel notes that some women might still choose not to breastfeed based on reasons unrelated to COVID-19. |

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit. However, there is not expected to be any substantial resource considerations for breastfeeding compared to not breastfeeding. Caring for pregnant women and newborns with COVID-19 (irrespective of breastfeeding) requires greater resources than for women and newborns without COVID-19.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>No important issues with the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are likely no important equity issues.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceptability of infant feeding practices by pregnant and postpartum women is expected to vary and individual preferences should be considered. Clear communication from health professionals regarding the benefits and harms of different feeding practices is essential to aid discussion around individual preferences and acceptability.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
<th>No important issues with the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>There are likely no important equity issues.</td>
<td></td>
</tr>
</tbody>
</table>
Rationale
There is currently no evidence to indicate that breastfeeding affects the risk of vertical transmission of COVID-19. Usual care practices regarding breastfeeding of newborns should be used.

No cases of newborn COVID-19 infection met the criteria for confirmed vertical transmission, and newborn infections did not differ substantively for different feeding practices, though evidence is currently limited.

Breastfeeding should be considered as per usual care, taking into consideration relevant clinical situation and a woman’s individual preferences.

Clinical Question/ PICO

| Population: | Newborns of mothers with confirmed COVID-19 |
| Intervention: | Breastfeeding or breast milk |
| Comparator: | No breastfeeding or breast milk |

Summary
There remains significant uncertainty whether SARS-CoV-2 transmission via breast milk is possible.

What is the evidence informing this recommendation?
Evidence comes from a living systematic review including 37 studies (28 case reports and nine case series) reporting newborn SARS-CoV-2 infection status and detection of SARS-CoV-2 in breast milk from mothers with confirmed SARS-CoV-2 infection [293]. The authors also identified a further 303 case reports and case series reporting newborn SARS-CoV-2 infection status by feeding practice where breast milk samples from mothers with confirmed SARS-CoV-2 infection were not available.

Additional evidence is available from an observational cohort study in the US of newborns whose mothers had confirmed COVID-19 [294]. This study reported on 106 newborns born to 116 mothers with confirmed COVID-19 infection and was not included in the living systematic review due to a later publication date.

Publication status
Update searches are planned as needed to keep the living systematic review current. In addition to our daily evidence surveillance processes, we follow up with the corresponding author every two months to request information on the review’s status.

Study characteristics
Living systematic review: SARS-CoV-2 infection status by feeding type was available from 37 studies for 77 newborns and infants where breast milk samples were available. Breast milk samples were tested for SARS-CoV-2 RNA using RT-PCR analysis. No studies attempted to culture the SARS-CoV-2 from breast milk isolates.

In the additional 303 studies, infection status by feeding type was available for an additional 917 newborns and infants where breast milk samples were not available.

Cohort study: comprised 106 newborns born to 116 mothers who were positive for COVID-19. Mothers could hold their newborns for feeding after appropriate hand hygiene, breast cleansing and placement of surgical mask, both during their hospital stay and after discharge. Newborns were tested for SARS-CoV-2 by nasopharyngeal PCR at 12-24 hours (n=106), 5-7 days (n=79) and 14 days (n=72) of life.

What are the main results?
Living systematic review: of the 37 included studies where breast milk samples were available, 14 out of 72 newborns had confirmed COVID-19, diagnosed either by viral RNA detection or by serology (Table 1).
Of the 27 newborns who were breastfed (n=23) or received mixed feeding (n=4), 10 had COVID-19 confirmed by viral RNA detection (Table 1).

Of the 303 included studies where breast milk samples were not available, 110 out of 917 newborns were diagnosed with COVID-19 by viral RNA detection. Of the 163 newborns who were breastfed or received mixed feeding, 19 were diagnosed with COVID-19 by viral RNA detection (Table 2).

Nine out of 68 breast milk samples collected from COVID-19 positive mothers tested positive for SARS-CoV-2 via RT-PCR assay. Of the six newborns and infants who were known to be exposed to breast milk with detectable viral RNA, four tested positive and two tested negative for SARS-CoV-2.

The authors make note of the following important considerations:

- The evidence of possible transmission through breast milk is still limited, particularly for older infants.
- The limited available breast milk samples were tested by RT-PCR assays. It is possible that viral RNA detection in breast milk was affected by the component of breast milk tested, as it has been shown to affect the assay sensitivity. The presence of viral RNA in breast milk does not necessarily indicate viral infectivity.
- Further research is needed to understand timing of maternal and infant exposure, breast milk viral load, duration of infection, and the presence of protective antibodies in breast milk and their effects on vertical transmission.

Additional cohort study: for 82 newborns with follow-up data, 64/82 (78%) were breastfed at 5-7 days and 45/53 (85%) were breastfed at 1 month of life. All newborns returned negative tests at all timepoints. There was no evidence that breastfeeding (with specified precautions) increased the risk of SARS-CoV-2 infection for newborns.

While the study describes the routine use of breast cleansing in participating hospitals, the Pregnancy and Perinatal Care panel noted there is no evidence that this practice is beneficial.

Our confidence in the results

Certainty of the evidence included in the living systematic review is very low for both outcomes due to the inclusion of case reports and case series likely to be at high risk of bias (including publication bias) and possible duplication of cases between studies.

Table 1 Studies where breast milk samples were available (N=37)

<table>
<thead>
<tr>
<th>Feeding type</th>
<th>Confirmed COVID-19</th>
<th>Negative COVID-19</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Newborns ≤ 28 days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast milk</td>
<td>8</td>
<td>15</td>
<td>23</td>
</tr>
<tr>
<td>Mixed feeding</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Formula</td>
<td>2</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>Not reported feeding practice</td>
<td>2</td>
<td>25</td>
<td>27</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>14</td>
<td>58</td>
<td>72</td>
</tr>
<tr>
<td><strong>Infants &gt; 28 days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast milk</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Mixed feeding</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Formula</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Not reported feeding practice</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>
### Table 2: Studies where breast milk samples were not available (N=303)

<table>
<thead>
<tr>
<th>Feeding type</th>
<th>Confirmed COVID-19</th>
<th>Negative COVID-19</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Newborns ≤ 28 days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast milk</td>
<td>14</td>
<td>137</td>
<td>153</td>
</tr>
<tr>
<td>Mixed feeding</td>
<td>3</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Formula</td>
<td>15</td>
<td>67</td>
<td>82</td>
</tr>
<tr>
<td>Not reported feeding practice</td>
<td>76</td>
<td>596</td>
<td>672</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>110</td>
<td>807</td>
<td>917</td>
</tr>
<tr>
<td><strong>Infants &gt; 28 days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast milk</td>
<td>12</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Mixed feeding</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Formula</td>
<td>6</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Not reported feeding practice</td>
<td>125</td>
<td>2</td>
<td>127</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>146</td>
<td>2</td>
<td>148</td>
</tr>
<tr>
<td>Outcome Timeframe</td>
<td>Study results and measurements</td>
<td>Absolute effect estimates</td>
<td>Certainty of the Evidence (Quality of evidence)</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------</td>
<td>---------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>No breastfeeding or breast milk</td>
<td>Based on data from 1,142 patients in 340 studies.</td>
<td>See summary for details.</td>
<td>Very Low Due to very serious risk of bias, and serious imprecision, indirectness, inconsistency and publication bias.</td>
</tr>
<tr>
<td>Breastfeeding or breast milk</td>
<td>Based on data from 72 patients in 37 studies.</td>
<td>See summary for details.</td>
<td>Very Low Due to very serious risk of bias, serious inconsistency, imprecision and publication bias.</td>
</tr>
</tbody>
</table>

1. Number of infected newborns within 30 days of breastfeeding or receiving expressed breast milk
2. Systematic review [293]. Supporting references: [294], 106 newborns.
3. Risk of bias: Very Serious. Evidence is derived from case studies and case reports.. Inconsistency: Serious. Variations in outcome definitions, disease severity of infected mothers and availability of different testing modalities.. Indirectness: Serious. Differences between the outcomes of interest and those reported. Testing of breast milk not reported.. Imprecision: Serious. Variations in outcome definitions, disease severity of infected mothers and availability of different testing modalities.. Publication bias: Serious. Due to case reports being more likely to report positive cases.
4. Systematic review [293].
5. Risk of bias: Very Serious. Evidence derived from case series and case reports. Inconsistency: Serious. Variations in disease severity of infected mothers and availability of different testing modalities.. Indirectness: No serious. Imprecision: Serious. Low number of breast milk samples tested.. Publication bias: Serious. Due to case reports being more likely to report positive cases.
12.6 - Rooming-in

**Conditional recommendation**

For women with COVID-19 who have given birth, support rooming-in of mother and newborn in the birth suite and on the postnatal ward when both mother and baby are well. However, women with COVID-19 should use infection prevention and control measures (mask and hand hygiene).

There is currently no evidence to indicate that a woman with a known COVID-19 infection should be separated from her newborn to prevent transmission. As there are substantial known benefits for keeping mother and newborn together postpartum, women should be supported to be with their newborn as per usual care.

Women with COVID-19 should be encouraged and supported in using good hand hygiene before and after handling their baby, and using a mask while in close contact with their baby. To the extent possible, these women should practice physical distancing when not feeding or caring for the baby.

---

**Evidence To Decision**

**Benefits and harms**

There are substantial known benefits for keeping mother and newborn together postpartum, which is supported as part of usual care. Rooming-in of mother and newborn promotes bonding and increases exclusive breastfeeding at discharge [295] as well as duration of breastfeeding [296]. There is currently no evidence to indicate that a woman with a known COVID-19 infection should be separated from her newborn to prevent transmission, provided they use infection prevention and control measures (mask and hand hygiene).

**Certainty of the Evidence**

Certainty of the evidence is very low due to reliance on case reports and case series.

**Preference and values**

There is no systematically collected information regarding the preferences and values of women with COVID-19 at this point.

The Consumer Panel believes that most women would agree with the recommendation as there is no available evidence to suggest harm to mother or newborn.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Caring for women and newborns with COVID-19 (irrespective of separation) requires greater resources than for women and newborns without COVID-19.

**Equity**

There are likely no important equity issues.

**Acceptability**

Acceptability of rooming-in is expected to vary and individual preferences should be considered. Clear communication from health professionals regarding the benefits and harms of rooming-in is essential to aid discussion around individual preferences and acceptability.
**Feasibility**

There are likely no important feasibility issues as the recommendation reflects usual care.

**Rationale**

There is currently no evidence to indicate that rooming-in affects the risk of vertical transmission of COVID-19. Usual care practices regarding rooming-in of newborns should be used.

No cases of newborn COVID-19 infection met the criteria for confirmed vertical transmission, and newborn infections did not differ substantively for different rooming-in practices, though evidence is currently limited.

Therefore, the use of rooming-in should be considered as per usual care, taking into consideration relevant clinical situation and a woman’s individual preferences.

**Clinical Question/ PICO**

<table>
<thead>
<tr>
<th>Population:</th>
<th>Women with COVID-19 who have given birth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention:</td>
<td>Rooming-in</td>
</tr>
<tr>
<td>Comparator:</td>
<td>No rooming-in</td>
</tr>
</tbody>
</table>

**Summary**

Evidence informing this recommendation comes from a systematic review that reported the number of newborns infected with COVID-19 whose mothers had confirmed or suspected COVID-19 [285]. The review included 49 case reports or case series comprising 666 newborns, of whom 28 had confirmed postnatal infection. Newborn infection status by rooming-in approach was reported for 159 newborns (see table).

<table>
<thead>
<tr>
<th>Rooming-in approach</th>
<th>Total newborns</th>
<th>Infected</th>
<th>Not infected</th>
<th>Not tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother-baby isolation</td>
<td>52</td>
<td>6</td>
<td>32</td>
<td>14</td>
</tr>
<tr>
<td>Rooming-in of mother and baby</td>
<td>107</td>
<td>6</td>
<td>100</td>
<td>1</td>
</tr>
</tbody>
</table>

Of the 28 newborns infected with COVID-19, six were isolated from their mother and six were cared for in the same room—for the remaining 16 newborns the approach taken was not reported. Overall, 52 newborns were isolated and 107 were cared for in the same room.

Additional evidence is available from an observational cohort study in the US of newborns whose mothers had confirmed COVID-19 [294]. The Salvatore study reported on 106 newborns born to 116 mothers who were positive for COVID-19. Newborns roomed-in with mothers (in closed Giraffe isolette) with the exception of 17 newborns who were separated from their mothers, either at parental request or due to a maternal or newborn medical condition (e.g. preterm). Newborns were tested for SARS-CoV-2 by nasopharyngeal PCR at 12-24 hours (n=106), 5-7 days (n=79) and 14 days (n=72) of life.

For 82 newborns with follow-up data, 68/82 (83%) roomed-in with their mother during their hospital stay. All newborns returned negative tests at all timepoints. There was no evidence that rooming-in (with specified precautions) increased the risk of SARS-CoV-2 infection for newborns.

<table>
<thead>
<tr>
<th>Outcome Timeframe</th>
<th>Study results and measurements</th>
<th>Absolute effect estimates</th>
<th>Certainty of the Evidence (Quality of evidence)</th>
<th>Plain text summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of infected newborns 1</td>
<td>Based on data from 666 patients in 49 studies.</td>
<td>See summary for details. Included newborns who had confirmed postnatal infection (28/666 newborns). Of the 28</td>
<td>Very Low</td>
<td>We are uncertain whether rooming-in increases or decreases</td>
</tr>
</tbody>
</table>
1. Number of infected neonates within 30 days of breastfeeding or receiving expressed breast milk

2. **Risk of bias: Very Serious.** Evidence is derived from case studies and case reports. **Inconsistency: Serious.** Variations in outcome definitions, disease severity of infected mothers and availability of different testing modalities. **Indirectness: Serious.** Differences between the outcomes of interest and those reported. Testing of breast milk not reported. **Imprecision: Serious.** Variations in outcome definitions, disease severity of infected mothers and availability of different testing modalities. **Publication bias: No serious.**

<table>
<thead>
<tr>
<th>Within 30 days of exposure</th>
<th>9 Critical</th>
<th>newborns infected, six were kept isolated from their mother, six were cared for in the same room as their mother and for 16 newborns the approach taken was not reported.</th>
<th>bias, and serious imprecision, indirectness and inconsistency</th>
<th>the number of infected newborns.</th>
</tr>
</thead>
</table>

- Within 30 days of exposure:
  - 9 Critical
  - newborns infected, six were kept isolated from their mother, six were cared for in the same room as their mother and for 16 newborns the approach taken was not reported.
  - bias, and serious imprecision, indirectness and inconsistency
  - the number of infected newborns.

---

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce

389 of 418
13 - Child and adolescent care

The primary panel for the recommendations in this section is the Paediatric and Adolescent Care Panel.

Recommendations are reviewed by the Guidelines Leadership Group and approved by the Steering Committee before being published. The remaining panels review recommendations when relevant to their specific population group. In addition, all our recommendations are reviewed by the Consumer Panel.

13.1 - Paediatric Inflammatory Multisystem Syndrome (PIMS-TS)

Since late April, clinicians have described a condition among severely ill children and adolescents of fever and significant inflammation, often with abdominal pain, rash or shock. This condition has occurred in settings with substantial community incidence of COVID-19 and these children often have evidence of prior SARS-CoV-2 infection. The condition has provisionally been named paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) by clinicians from the United Kingdom [300]. The US Centers for Disease Control and Prevention has named it multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C) [298]. WHO has also defined this condition and used the label MIS-C [299].

In Australia, the Acute Inflammatory Vasculitis working group, the Paediatric Active Enhanced Disease Surveillance (PAEDS) network and the Royal Australasian College of Physicians have issued a statement on PIMS-TS [297]. The Taskforce aligns with this statement, pending further evidence. In assessing the international literature on this condition, the Taskforce favours the PIMS-TS case definition from the Royal College of Paediatrics and Child Health (UK) [300] as we judge this to be most aligned with current Australian practice. The Taskforce will, however, review and include evidence to inform our recommendations from data using any of the three case definitions (listed below for comparison). Click here for a side-by-side comparison of the three definitions (adapted from [301]).

Royal College of Paediatrics and Child Health (PIMS-TS) case definition [300]

1. A child presenting with persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP) and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features*. This may include children fulfilling full or partial criteria for Kawasaki disease.

2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations

CDC MIS-C case definition [298]

* Additional features include:

** These assays are not widely available. CRP can be used as a surrogate marker for IL-6.

** These assays are not widely available. CRP can be used as a surrogate marker for IL-6.

1. SARS-CoV-2 polymerase chain reaction (PCR) testing may be positive or negative. All stable children should be discussed as soon as possible with specialist services to ensure prompt treatment (paediatric infectious disease / cardiology / rheumatology). There should be a low threshold for referral to paediatric intensive care using normal pathways.

Info Box

For recommendations on disease-modifying treatments, chemoprophylaxis and respiratory support in children and adolescents please see sections above. We are continually working on updating all recommendations to reflect special populations, including children and adolescents.
An individual aged under 21 years of age presenting with fever*, laboratory evidence of inflammation** and evidence of clinically severe illness requiring hospitalisation, with multisystem (> 2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological)

AND

No alternative plausible diagnoses

AND

Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

* Fever > 38.0°C for ≥ 24 hours or report of subjective fever lasting ≥ 24 hours

**Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin

Additional comments: some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C. Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection.

WHO MIS-C case definition [299]

Children and adolescents 0–19 years of age with fever > 3 days.

AND

Two of the following:

- rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet)
- hypotension or shock
- features of myocardial dysfunction, pericarditis, valvulitis or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP)
- evidence of coagulopathy (by prothrombin time (PT), partial thromboplastin time (PTT), elevated D-dimers)
- acute gastrointestinal problems (diarrhoea, vomiting or abdominal pain)

AND

Elevated markers of inflammation such as erythrocyte sedimentation rate, C-reactive protein or procalcitonin.

AND

No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

AND

Evidence of COVID-19 (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID-19.
The Taskforce endorses the PIMS-TS case definition from the Royal College of Paediatrics and Child Health (United Kingdom) [300].

1. A child presenting with persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP) and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features*. This may include children fulfilling full or partial criteria for Kawasaki disease.

2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).

3. SARS-CoV-2 PCR testing may be positive or negative. All stable children should be discussed as soon as possible with specialist services to ensure prompt treatment (paediatric infectious disease / cardiology / rheumatology). There should be a low threshold for referral to paediatric intensive care using normal pathways.

* Additional features include:

**Clinical**
- All: persistent fever > 38.5°C
- Most: oxygen requirement, hypotension
- Some: abdominal pain, confusion, conjunctivitis, cough, diarrhoea, headache, lymphadenopathy, mucus membrane changes, neck swelling, rash, respiratory symptoms, sore throat, swollen hands and feet, syncope, vomiting

**Imaging and electrocardiogram (ECG)**
- Echocardiogram and ECG: myocarditis, valvulitis, pericardial effusion, coronary artery dilatation
- Chest x-ray: patchy symmetrical infiltrates, pleural effusion
- Abdominal ultrasound scan: colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly
- Computed tomography (CT) chest: as for chest x-ray—may demonstrate coronary artery abnormalities if with contrast

**Laboratory**
- All: abnormal fibrinogen, absence of potential causative organisms (other than SARS-CoV-2), high CRP, high D-dimers, high ferritin, hypoalbuminaemia, lymphopaenia, neutrophilia in most – normal neutrophils in some
- Some: acute kidney injury, anaemia, coagulopathy, high IL-10 (if available)**, high IL-6 (if available)**, neutrophilia, proteinuria, raised creatine kinase (CK), raised lactic acid dehydrogenase (LDH), raised triglycerides, raised troponin, thrombocytopenia, transaminitis

** These assays are not widely available. CRP can be used as a surrogate marker for IL-6.

---

Consensus recommendation

Children and adolescents who have suspected or confirmed PIMS-TS should be managed by and discussed with a multidisciplinary team. Because of the potential for rapid deterioration, early consultation with experts and consideration of early transfer to a paediatric hospital with intensive care facilities to manage children are recommended for patients with suspected or confirmed PIMS-TS.
13.1.1 - Intravenous immunoglobulin

Consensus recommendation

Consider using intravenous immunoglobulin (2 g/kg per dose) in children and adolescents who meet PIMS-TS criteria or have features of Kawasaki disease related to COVID-19.

Practical Info

Primary classification of PIMS-TS should be based on the presenting phenotype (adapted from Harwood [302]):

1. Kawasaki disease-like: complete and incomplete, classified using the American Heart Association criteria [303]
2. Non-specific: children presenting with shock or fever (or both) and symptoms that might include abdominal pain, gastrointestinal, respiratory or neurological symptoms that do not meet the criteria for Kawasaki disease.

Evidence To Decision

Benefits and harms

There are proven benefits to using intravenous immunoglobulin in children and adolescents for other diseases, particularly in Kawasaki disease, which shares common characteristics and partially overlaps with PIMS-TS. Benefits outweigh the risks for using intravenous immunoglobulin in this population.

Certainty of the Evidence

No randomised trials have been identified assessing the use of intravenous immunoglobulin for the treatment of PIMS-TS.

Preference and values

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families or guardians. As intravenous immunoglobulin is a blood-derived product, some may decline this intervention.

Resources

We have no systematically collected evidence regarding cost-benefit. There may be potential issues accessing this treatment in certains areas.

Equity

There is a risk of creating inequity as people who live in rural and remote areas may have limited access to intravenous immunoglobulin.

Acceptability

Intravenous immunoglobulin is generally a well-accepted intervention, and there are no important issues regarding acceptability. However, some groups may decline this intervention as it is a blood-derived product.

Feasibility

There are no expected feasibility issues.
Rationale

Intravenous immunoglobulin is the standard first-line treatment for Kawasaki disease. Initial reports show it has been used to treat PIMS-TS patients. No randomised trials have been identified.

13.1.2 - Corticosteroids

Consensus recommendation

Consider using corticosteroids (irrespective of oxygen status) as a second-line agent or as adjuvant therapy for children and adolescents diagnosed with PIMS-TS.

_Intravenous corticosteroids should be considered as the next treatment option for children who remain unwell (tachycardia, need for vasoactive support) 24 hours after infusion of intravenous immunoglobulin, particularly if they have ongoing pyrexia._

_In certain cases, Intravenous corticosteroids may be indicated as a first-line option in combination with intravenous immunoglobulin._

Evidence To Decision

Benefits and harms

There are proven benefits to using corticosteroids in children and adolescents for other diseases, particularly in Kawasaki disease, which shares common characteristics and partially overlaps with PIMS-TS. Corticosteroids are generally considered safe in this population. However, there may be risks to consider, particularly with regards to unmasking other infections (e.g. strongyloidiasis).

Certainty of the Evidence

No randomised trials have been identified assessing the use of corticosteroids for the treatment of PIMS-TS.

Preference and values

We have no systematically collected information regarding preferences and values for children and adolescents, their parents, carers, families or guardians. However, we expect the intervention would be generally acceptable as it is occasionally used for the treatment of Kawasaki disease.

Resources

We have no systematically collected evidence regarding cost-benefit. There are unlikely to be issues as corticosteroids are widely available.

Equity

It is unlikely that the use of corticosteroids will create equity issues as they are widely available.

Acceptability

Corticosteroids are generally a well-accepted intervention, and there are no important issues regarding acceptability.
Corticosteroids are used for the treatment of several conditions and, in particular, in high risk of refractory cases of Kawasaki disease.

### 13.1.3 - Other immunomodulatory agents

**Consensus recommendation**

Additional immunomodulatory agents for PIMS-TS (anti IL-1, anti IL-6 or anti-TNF) should be considered as a third-line option in children and adolescents with PIMS-TS who do not respond to intravenous immunoglobulin and corticosteroids.

Before initiating additional immunomodulatory therapies, all PIMS-TS patients need to be discussed with a multidisciplinary team and interventions carefully considered. Immunomodulatory agents previously used that have an acceptable risk/benefit ratio include:

- Anakinra (IL-1 receptor antagonist)
- Infliximab (TNF inhibitor)
- Tocilizumab (IL-6 receptor antagonist)

Consider testing for infections that may be unmasked by the use of these agents.

**Evidence To Decision**

**Benefits and harms**

There are proven benefits of immunomodulatory therapy in children and adolescents for other diseases, but its effectiveness in treating PIMS-TS remains unknown. There are known harms of using immunomodulatory therapies, especially in relation to immunosuppression and the increased risk of infection (e.g. using these therapies in the context of undiagnosed bacterial sepsis). Depending on the agent used, a different ratio of risk and harms may be considered.

**Certainty of the Evidence**

No randomised trials have been identified assessing the use of immunomodulatory agents for the treatment of PIMS-TS.

**Preference and values**

We have no systematically collected information regarding children and adolescents and their families' preferences and values. However, we expect the intervention would be generally acceptable as it is regularly used for treating other conditions in this population.

**Resources**

We have no systematically collected evidence regarding cost-benefit. Depending on the agent used, the potential costs to be considered may vary as well as its availability.

**Equity**

There is a risk of creating inequity as people who live in rural and remote areas may have limited access to...
Immunomodulatory agents are routinely used to treat a range of rheumatological conditions in children and adolescents and may limit the hyperinflammatory state associated with this syndrome. Given the partial characterisation of PIMS-TS, immunomodulatory agents have occasionally been used for its treatment in international cohorts [304][305].

13.1.4 - Aspirin and antithrombotic agents

**Consensus recommendation**

Children who are treated for PIMS-TS with intravenous immunoglobulin or other agents should also be prescribed low-dose aspirin (3-5 mg per kg once daily for at least 6 weeks).

*Additional measures to be considered to prevent venous thrombosis associated with PIMS-TS include:*
- Anticoagulation therapy
- Compression stockings (in children older than 12 years of age)

**Evidence To Decision**

**Benefits and harms**

Aspirin is not routinely recommended in children due to the risk of Reye's syndrome. However, there are potential benefits of using aspirin in children and adolescents, particularly in Kawasaki disease, which shares common characteristics and partially overlaps with PIMS-TS. There are also other well-known harms to consider when administering aspirin at higher doses, such as increased risk of gastrointestinal bleeding, acute kidney injury, tinnitus or bronchospasm.

**Certainty of the Evidence**

No randomised trials have been identified assessing the use of aspirin or antithrombotic agents for the treatment of PIMS-TS.

**Preference and values**

We have no systematically collected information regarding children and adolescents and their families' preferences and values. However, we expect the intervention would be generally acceptable as it is regularly used for the treatment of Kawasaki disease.
### Rationale

Aspirin is used as an antithrombotic to prevent coronary artery thrombosis in Kawasaki disease.

<table>
<thead>
<tr>
<th>Resources</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>We have no systematically collected evidence regarding cost-benefit.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity</th>
<th>No important issues with the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is unlikely that the use of aspirin will create equity issues as it is widely available.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acceptability</th>
<th>No important issues with the recommended alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin is generally a well-accepted intervention, and there are no important issues regarding acceptability.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feasibility</th>
<th>Important issues, or potential issues not investigated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feasibility is affected by prompt diagnosis of PIMS-TS and access to a multidisciplinary team for discussion.</td>
<td></td>
</tr>
</tbody>
</table>
### 14 - Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>Angiotensin-converting enzyme</td>
</tr>
<tr>
<td>ACEIs</td>
<td>Angiotensin-converting enzyme inhibitors</td>
</tr>
<tr>
<td>AHPPC</td>
<td>Australian Health Protection Principal Committee</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>ANZICS</td>
<td>Australian and New Zealand Intensive Care Society</td>
</tr>
<tr>
<td>ANZPID</td>
<td>Australia and New Zealand Paediatric Infectious Diseases Group</td>
</tr>
<tr>
<td>ARBs</td>
<td>Angiotensin receptor blockers</td>
</tr>
<tr>
<td>ARDS</td>
<td>Acute respiratory distress syndrome</td>
</tr>
<tr>
<td>BiPAP</td>
<td>Bilevel positive airway pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body surface area</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease 2019 (disease caused by the virus SARS-CoV-2)</td>
</tr>
<tr>
<td>CPAP</td>
<td>Continuous positive airway pressure</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CXR</td>
<td>Chest x-ray</td>
</tr>
<tr>
<td>DMTs</td>
<td>Disease-modifying treatments</td>
</tr>
<tr>
<td>DOI</td>
<td>Digital Object Identifier</td>
</tr>
<tr>
<td>DVT</td>
<td>Deep vein thrombosis</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO</td>
<td>Echocardiogram</td>
</tr>
<tr>
<td>ECMO</td>
<td>Extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated glomerular filtration rate</td>
</tr>
<tr>
<td>FiO2</td>
<td>Fraction of inspired oxygen</td>
</tr>
<tr>
<td>GRADE</td>
<td>Grading of recommendations, assessment, development and evaluation</td>
</tr>
<tr>
<td>HCP</td>
<td>Healthcare professionals</td>
</tr>
<tr>
<td>HFNC</td>
<td>High-flow nasal cannula</td>
</tr>
<tr>
<td>HFNO</td>
<td>High-flow nasal oxygen</td>
</tr>
<tr>
<td>HFOV</td>
<td>High-frequency oscillatory ventilation</td>
</tr>
<tr>
<td>hUC-MSCs</td>
<td>Human umbilical cord mesenchymal stem cells</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IDSA</td>
<td>Infectious Diseases Society of America</td>
</tr>
<tr>
<td>IFN-κ</td>
<td>Interferon kappa</td>
</tr>
<tr>
<td>IHPS</td>
<td>Infantile hypertrophic pyloric stenosis</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IQR</td>
<td>Interquartile range</td>
</tr>
<tr>
<td>IU</td>
<td>International units</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low molecular weight heparin</td>
</tr>
<tr>
<td>MERS</td>
<td>Middle East respiratory syndrome</td>
</tr>
<tr>
<td>MET</td>
<td>Medical Emergency Team</td>
</tr>
<tr>
<td>MIS-C</td>
<td>Multisystem inflammatory syndrome in children</td>
</tr>
<tr>
<td>NC19CET</td>
<td>National COVID-19 Clinical Evidence Taskforce</td>
</tr>
<tr>
<td>NHMRC</td>
<td>National Health and Medical Research Council</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NIPPV</td>
<td>Non-invasive positive pressure ventilation</td>
</tr>
<tr>
<td>NIV</td>
<td>Non-invasive ventilation</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>NMBAs</td>
<td>Neuromuscular blocking agents</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Non-steroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>PaO2</td>
<td>Partial pressure of arterial oxygen</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PEEP</td>
<td>Positive end-expiratory pressure</td>
</tr>
<tr>
<td>PIMS-TS</td>
<td>Paediatric multisystem inflammatory syndrome - temporally associated with SARS-CoV-2</td>
</tr>
<tr>
<td>PPE</td>
<td>Personal protective equipment</td>
</tr>
<tr>
<td>rhG-CSF</td>
<td>Recombinant human granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>RR</td>
<td>Risk ratio</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse transcription-polymerase chain reaction</td>
</tr>
<tr>
<td>SAEs</td>
<td>Serious adverse events</td>
</tr>
<tr>
<td>SARS</td>
<td>Severe acute respiratory syndrome</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Severe acute respiratory syndrome coronavirus 2 (the virus that causes the disease COVID-19)</td>
</tr>
<tr>
<td>SOT</td>
<td>Supplementary oxygen therapy</td>
</tr>
<tr>
<td>SpO2</td>
<td>Oxygen saturation</td>
</tr>
<tr>
<td>TFF2</td>
<td>Trefoil factor 2</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumour necrosis factor</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>VA ECMO</td>
<td>Venoarterial extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td>VV ECMO</td>
<td>Venovenous extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
References


[5] Consumers Health Forum of Australia : What is Consumer-Centred Care?. Website


[10] Australian Commission on Safety and Quality in Health Care : National Safety and Quality Health Service (NSQHS) Standards. Website


[12] Institute for Patient and Family-Centred Care : Patient- and Family-Centred Care. 2010; Website


[14] First Affiliated Hospital, Zhejiang University School of Medicine : Handbook of COVID-19 Prevention and Treatment. 2020;


400 of 418


[37] European Medicines Agency: Remdesivir Gilead: summary on compassionate use EMEA/H/K/5622/CU. 2020; Website

[38] Remdesivir for COVID-19. 2020;


[42] US Food and Drug Administration: Emergency use authorization (EUA) of remdesivir (GS-5734). 2020; Website


[44] [Remdesivir study characteristics 09-09-20].


Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce


[99] Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; Pubmed Journal

[100] Lopinavir/Ritonavir for COVID-19.


[111] Therapeutic Goods Administration: Australian Product Information: Xofluza (baloxavir marboxil) tablets. 2020; Website


[113] [Bromhexine] for [COVID-19].


[129] [Convalescent plasma study characteristics 14-09-20].


[139] Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. 2020; Website


[143] Therapeutic Goods Administration: Regulation of stem cell treatments: information for practitioners. May 2020; Website


[158] Podder CS, Chowdhury N, Sina MI, UI Haque WMM: Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC Journal of Medical Science 2020; Website


Tocilizumab for COVID-19.


Tocilizumab for COVID-19.

Triazavirin for COVID-19.


Arbidol for COVID-19.


Ivermectin versus standard care for COVID-19.

Hydroxychloroquine pre-exposure prophylaxis for COVID-19.

Hydroxychloroquine pre-exposure prophylaxis for COVID-19.

Hydroxychloroquine pre-exposure prophylaxis for COVID-19.

Ivermectin plus Doxycycline for COVID-19.

Ivermectin plus Doxycycline for COVID-19.

HCQ pre-exp prophylaxis in HCW for COVID-19.

Grau-Pujol B, Camprubi D, Martí-Soler H: Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a
double-blind, placebo-controlled randomized clinical trial. Research Square 2020; Journal Website


[210] World Health Organization: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance. 2020; Website


[212] Institute of Tropical Medicine (Antwerp): Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium (version 4). 2020; Website

[213] Effectiveness, safety and risk of dispersion or aerosol generation and infection transmission with high flow nasal cannula use for acute hypoxemic respiratory failure in patients with COVID-19: two systematic reviews. 2020;


[219] Videolaryngoscopy versus Direct laryngoscopy for emergency intubation.


[229] Neuromuscular blockers versus No neuromuscular blockers for Mechanically ventilated adults with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation, or persistently high plateau pressures.


Forel J, Roch A, Marin V. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Critical Care Medicine 2006; [Pubmed]


Thrombosis and Haemostasis Society of Australia and New Zealand. Thromboprophylaxis and thrombosis in COVID 19 infected patients admitted to hospital. 2020; [Website]


VTE prophylaxis for COVID-19. [Website]


Lodigiani C, Iapichino G, Carenzo L. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Research 2020; [Pubmed]

Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce


[263] European Society of Cardiology Council on Hypertension: Position Statement of the ESC Council on Hypertension on ACE Inhibitors and Angiotensin Receptor Blockers. 2020; Website

[264] International Pharmaceutical Federation: FIP position statement on the association between the use of non-steroidal anti-inflammatory medicines (including ibuprofen), ACE inhibitors, angiotensin receptor blockers (ARBs) and corticosteroids, and an increased risk of coronavirus/COVID-19 infection or disease severity. 2020; Website

[265] Renal Association UK: Position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use. 2020; Website
[266] International Society of Hypertension: A statement from the International Society of Hypertension on COVID-19. 2020; Website


[268] Hypertension Canada: Hypertension Canada's Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. 2020; Website

[269] Canadian Cardiovascular Society: Guidance from the CCS COVID-19 rapid response team. 2020; Website


[271] Spanish Society of Hypertension: Comunicado Urgente COVID-19. 2020; Website

[272] American Heart Association, Heart Failure Society of America and American College of Cardiology: Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020; Website


[279] National Asthma Council: Managing asthma during the COVID-19 (SARS-CoV-2) pandemic. National Asthma Council 2020 (reviewed 22 June 2020); Website

[280] NICE: COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) [NG168]. 2020; Website

[281] NICE: COVID-19 rapid guideline: severe asthma [NG166]. 2020; Website

[282] Therapeutic Goods Administration: Australian Product Information: Dexamethsone (dexamethasone) tablets. 2018; Website


[284] Roberts D, Brown J, Medley N, Dalziel SR: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of
preterm birth. Cochrane Database of Systematic Reviews 2017;3 CD004454 Pubmed Journal


[300] Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS). Royal College of Paediatrics and Child Health 2020; Website


